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Abstract
Artemisinin and its derivatives provide faster clearance of parasitemia than any
other antimalarial drugs and these drugs are part of frontline combination therapies in
areas where drug-resistant Plasmodium falciparum exists. Clinical resistance to
artemisinins is emerging on the Thailand-Cambodia border, making it imperative to
investigate mechanisms of artemisinin resistance. Previous work in our laboratory
showed ring-stage parasites enter a dormant state after exposure to artemisinin. We
hypothesize that this period of dormancy is directly related to recrudescence and
prolonged parasite clearance times in patients, and possibly resistance. The target of
artemisinin is currently unknown, and potential resistance mechanisms are not well
described. Our laboratory previously selected artemisinin resistance in P. falciparum
clones D6 (Africa), W2 (southeast Asia), and a patient isolate from Thailand, TM91c235.
Studies were attempted in order to characterize artemisinin resistant phenotypes and
molecular mechanisms of resistance in these lines. W2 lines resistant to 40 ng/ml
artemisinin (W2.QHS40) and 80 ng/ml artelinic acid (W2.AL80) were exposed to AL
and transcriptionally profiled. Analysis of results found genes that were significantly
differentially expressed (such as pfmdr1, pfmdr2, PF11_0466, PFE1050w) in resistant vs.
parental lines. It was hypothesized that the differential expression of genes may be due to
novel single nucleotide polymorphisms (SNPs). Further studies found that the P.
falciparum multidrug resistance transporter-1 gene (pfmdr1) is involved in resistance in

xi

W2 and TM91, but not D6. Resistant parasites also exhibited resistance to other
artemisinin drugs than those used to originally select resistance in these strains. We
expanded on earlier selection of D6, W2, and TM91 artemisinin selection to produce high
level resistance to concentrations of artemisinin and artelinic acid that are considered
clinically relevant. Parental and resistant parasites were characterized for differences in
recovery after drug, growth rates, and in vitro susceptibility to antimalarial drugs. During
the generation of D6 resistant lines, it was determined that parental D6 could tolerate up
to 1500 ng/ml QHS, but D6.QHS340x3 tolerated 2400 ng/ml of artemisinin. Resistant
D6 parasites recrudesced before parental strains in these assays. Recovery assays also
found D6 and W2 resistant lines treated with 200 ng/ml dihydroartemisinin recrudesced
before parent strains after drug treatment. In vitro susceptibility testing with various
antimalarial drugs found that resistant D6, W2, and TM91c235 parasites all exhibited
reduced susceptibility to artemisinin drugs compared to parental parasites, with marked
resistance to QHS and AL. A novel hypoxanthine incorporation assay showed that
resistant progeny and parental lines of D6 and W2 both entered dormancy following
treatment with various artemisinin drugs, but resistant parasites tolerated higher drug
concentrations. These results have clinical relevance with artemisinin resistance that may
be occurring in patients. Analysis of merozoite number in resistant parasites found D6
and TM91c235 resistant progeny had significantly less merozoites than parent strains,
whereas W2 resistant progeny had significantly more. However, this only coincided with
a slower growth rate in the D6 resistant parasite, marked by a decrease in progression
from ring to trophozoite. Through these methods of characterization, we defined a
phenotype for artemisinin resistance and have made strides toward the relationship of

xii

dormancy, resistance, and recrudescence. We investigated potential molecular markers
of artemisinin resistance using a variety of drug selected lines. Next generation
approaches that included proteomics, whole genome sequencing, and microarrays
allowed us to identify putative resistance mechanisms in the highest artemisinin-selected
D6 and W2 lines. SNPs in D6.QHS2400x5 vs. D6 were identified and an amplification
event on chromosome 10 in QHS-resistant D6 and W2 were identified. Microarray
analyses found ring stage parasites of D6 and D6.QHS2400x5 were transcriptionally
arrested at ring stage, but the resistant parasite exited the transcriptional arrest before the
parent parasite. We also identified genes that were differentially expressed in both parent
and resistant parasites during dormancy, along with genes that were constitutively
expressed in resistant vs. parent strains before drug was added. Genes identified in the
amplification of chromosome 10 in D6.QHS2400x5 were up-regulated in the resistant
parasite before drug was added. Future studies will focus on validating transcriptional
data by real-time PCR and analyzing early selected parasites to determine when markers
of resistance accumulated. Our molecular analyses have identified high-probability
markers of artemisinin resistance in strains from different locations in the world which
may be useful in surveillance of artemisinin resistance.
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Chapter One:
Introduction
Malaria: Background
Malaria is the most important parasitic disease of man, causing considerable
mortality on four continents, and it is also a significant source of morbidity in endemic
areas. This disease is caused by one or more species of intracellular parasitic protozoans
of the Plasmodium genus (Superphylum Alveolata, Phylum Apicomplexa, Class
Aconoidasida, Order Haemosporida, Family Plasmodiidae). The Phylum Apicomplexa
encompasses other important intracellular pathogens of humans including Babesia spp.
(B. microti) and the Coccidians Toxoplasma spp. (T. gondii), Cyclospora cayetanensis,
and Cryptosporidium spp. (C. parvum). Apicomplexan organisms are defined by the
presence of the apicoplast, an apical polar ring (microtubule-organizing center), and a
specialized set of secretory organelles, termed micronemes and rhoptries, all of which
define the apical complex 1. The apicoplast is a non-photosynthetic plastid that functions
in fatty acid, isoprenoid and heme synthesis, and it is essential for survival. It is
theorized that plastids originated through a series of phagocytic events whereby
prokaryotes (e.g. cyanobacteria) entered primary and secondary endosymbiosis 2.
Laboratory research with human malaria has taken place relatively recently, if one
considers how long the disease has existed. Attempts at growing human malaria parasites
in vitro were first recorded in 1912, but it was not until some 60 years later that the

1

procedure was perfected 3. Two groups of scientists independently published methods
for the continuous culture of human malaria in 1976, but the method of Trager and Jensen
4

is considered the seminal procedure for cultivation of malaria. These scientists

revolutionized malaria research, making it possible to study various processes of malaria
parasites, and most importantly, unlock aspects of the most pathogenic species, P.
falciparum.
The genetic aspects of Plasmodium spp. have only recently been elucidated, and
more mysteries of the parasite continue to be uncovered. Research over the last decades
has determined that Plasmodium spp. have a total of three genomes (nuclear,
mitochondrial, and apicoplast). The nuclear genome of P. falciparum strain 3D7 (cloned
from isolate NF54, which was derived from a case of airport malaria in the Netherlands
presumed to be acquired from the bite of an infected African mosquito 5) was published
in 2002 and it was found to encode over 5000 genes 6. It is composed of approximately
23 mega bases (Mb) distributed among 14 chromosomes that range in size from
approximately 0.643 to 3.29Mb. The entire nuclear genome is unique in that it is
approximately 80% adenine+thymine and 20% guanine+cytosine, making it the most
A+T rich genome sequenced to date. The apicoplast contains a 35 kilobase (Kb) genome
that encodes only 30 proteins 6, but its proteome is supplemented by proteins encoded in
the nuclear genome that are targeted back to the apicoplast. The mitochondrial genome is
made up of tandem repeats of a 6 Kb element 7, making it the smallest reported
mitochondrial genome. It contains three open reading frames with homology to
components of the mitochondrial electron transport system.

2

The history of malaria is fascinating and many have worked through the years to
dissect the etiology of the disease. Malaria has been known since antiquity, as ancient
civilizations documented symptoms such as fever and splenomegaly that we now
recognize as classic signs of malaria. The name “malaria” stems from the medieval
Italian name for the disease, “mal‟aria”, which means “bad air”. This name was used to
describe the association of intermittent fevers and exposure to vapors from marsh areas.
The malaria parasite was discovered by the French physician Alphonse Laveran in 1880,
and he named it Oscillaria malariae. While working in North Africa, he found crescentshaped bodies containing pigmented granules inside red blood cells (RBCs) of soldiers
suffering from fevers. He subsequently found that these bodies were alive after he
observed filaments radiating from these microscopic bodies 8. Although his findings
were first met with criticism, Laveran was awarded the Nobel Prize in 1907 for
determining the role of protozoa in causing disease (he made considerable advancements
not only for malaria, but in trypanosome research as well). In 1897, Ronald Ross
conclusively showed that mosquitoes transmit malaria when he found parasites in the
stomach of mosquitoes after feeding them blood from a malaria patient. For this
momentous discovery, he was awarded the Nobel Prize in 1902.
Ronald Ross‟ discovery was vital for solving the mosquito part of the life cycle,
but he had not observed human malaria parasites completely develop in mosquitoes (he
did do this with avian malaria). The Italian neurophysiologist Camillo Golgi recognized
in 1885 that there were different forms of the disease, where fevers either occurred every
other day (tertian) or every third day (quartan) (see below). However, he did not realize
that more than one species of the malaria parasite was responsible for human disease. He

3

also found that the characteristic fever of malaria coincided with rupture of erythrocytes
and the liberation of parasites (merozoites). In 1890, the Italian researchers Giovanni
Grassi and Raimondo Filetti differentiated the malaria parasite into two species based on
Laveran‟s work, naming them Plasmodium vivax (tertian) and Plasmodium malariae
(quartan) 9. Later, the third human malaria species (Plasmodium falciparum) was named
by the American, William Welch (1897), and the fourth (P. ovale) named by John
Watson (1922). Plasmodium falciparum is the most lethal malaria parasite infecting
humans, responsible for most the mortality due to malaria each year. Grassi, Amico
Bignami, and other Italian researchers fed mosquitoes on malaria parasites, and by 1897,
this group described the development of P. falciparum, P. vivax, and P. malariae in
anopheline mosquitoes. The tissue stage of human malaria was not completely explained
until 1948, when H.E. Shortt, P.C. Garnahm, and others found malaria parasite
developing in livers of rhesus monkeys infected with P. cynomolgi. They later described
the complete life cycles of P. vivax and P. falciparum. A final, vital part about
Plasmodium spp. in humans concerns relapsing malaria, or the reappearance of
parasitemia in a sporozoite-induced infection following antimalarial therapy. This type
of malaria is due to stages of parasites called hypnozoites that lie dormant in hepatocytes
10

, and it only occurs with P. ovale and P. vivax. Research in this area of malaria biology

is limited, but should not be discounted, since these stages represent a serious obstacle for
vaccines against P. vivax. At present, an estimated 156 species of Plasmodium are
reported to infect a variety of animals 11 including rodents, birds, reptiles, and humans.
We now know there are four species of Plasmodium that exclusively infect man, which
include P. falciparum, P. vivax, P. ovale, and P. malariae. Plasmodium knowlesi has

4

recently emerged as a human pathogen, with reports of infections in Malaysia and other
countries in southeast Asia 12,13. This parasite, which was once confused with P.
malariae, naturally infects long-tailed macaques. It has not been shown to be transferred
from human to human via a mosquito, so it is classified as a zoonotic disease.
Plasmodium spp. Life Cycle
The life cycle of human malaria is pictured in Figure 1.1 11. The life cycle of P.
falciparum involves distinct stages, including exo-erythrocytic schizogony (asexual
reproduction) in human hepatocytes, a 48 hour cycle in human erythrocytes (erythrocytic
schizogony), and a cycle of development in female Anopheles spp. mosquitoes that
involved sexual reproduction (sporogonic cycle). The sporgonic cycle in mosquitoes,
consisting of maturation of ingested gametocytes to infective sporozoites, may range
from 10-18 days (extrinsic incubation period) depending on the species and relative
temperature 14.
Mosquito (definitive host). There exists over 400 species of Anopheles
worldwide, with 60 species capable of transmitting malaria, and approximately 30
species that are of major importance 15. The most efficient species of Anopheles for P.
falciparum transmission are A. gambiae complex and A. funestus. The normal life span
of an adult Anopheles female mosquito in nature is 1-2 weeks. Therefore, they must exist
longer than the extrinsic incubation period in order to transmit malaria to humans.
Considering that a small percentage of mosquitoes survive long enough for parasites to
become infective for humans, it is impressive that so many cases of malaria exist in the
world each year.
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Female Anopheles mosquitoes feed on infected humans and ingest gametocytes
with the blood meal. A gametocyte can be either male (microgametocyte) or female
(macrogametocyte), and in P. falciparum, they are in the characteristic shape of a
crescent or banana (the species name is from the Latin falcis= sickle). Male gametocytes
exflagellate and fertilize the female macrogametocyte, forming a zygote. The zygotes
become motile and elongated (ookinetes), and they invade the midgut wall of the
mosquito. Here, ookinetes transform into oocysts. Mature, segmenting oocysts divide
asexually (sporogony) into numerous sporozoites, which reach the salivary gland of the
mosquito.
Human (intermediate host). Humans become infected when a mosquito takes a
blood meal and injects sporozoites into the skin. Sporozoites are approximately 10μm in
length and are sickle-shaped. They are capable of invading multiple cells and they use
gliding motility for traversing various tissues 16. It has been estimated that a mosquito
carrying P. falciparum can inject 5-20 sporozoites upon taking a blood meal 17. For years,
it was thought that sporozoites travel to the liver and invade hepatocytes, with the process
occurring within minutes. However, a series of recent studies using rodent malaria
parasites have suggested that sporozoites may not leave the injection site immediately,
either remaining in the dermis, or invading blood or lymphatic vessels 18,19. It was found
that P. berghei and P. yoelii sporozoites inoculated by mosquitoes are released from skin
into blood circulation in a slow manner extending for 1-3 hours after a mosquito bite 19,20.
It appears that a proportion of sporozoites randomly find their way into the bloodstream,
although it is not known why some sporozoites exit the dermis, while others stay near the
site of inoculation 21. Once in the bloodstream, sporozoites must penetrate hepatocytes to
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continue development. The method in which this is accomplished is controversial, but it
is hypothesized that sporozoites pass through sinusoidal layer cells to access liver
parenchyma. It was recently shown in P. yoelii that sporozoites must pass through
Kupffer cells (resident macrophages in liver) before they reach hepatocytes 22.
Plasmodium sporozoites contain the circumsporozoite protein (CSP), which is essential
for attachment to liver cells 23. Once in hepatocytes, sporozoites divide and multiply,
becoming merozoites. Sporozoites of P. vivax and P. ovale may go through schizogony
like other Plasmodium spp., or become hypnozoites. These stages persist in hepatocytes
for years, and they are responsible for relapsing malaria. It has been estimated that
20,000-30,000 merozoites can be formed from one sporozoite 17. Merozoites are 1.52.5μm in length 24, and possess the necessary machinery for penetrating and invading
erythrocytes. It was recently found that P. berghei merozoites leave hepatocytes in
merosomes, or large membrane-bound vesicles in liver sinusoids, and the merosomes
help the release of merozoites into circulation 25. Regarding activities of Plasmodium spp.
while in the intraerythrocytic stage of development, perhaps the most is known about P.
falciparum. Therefore, some of what is described here is generalized to this species, but
these events may also occur in other Plasmodium species.
Merozoites enter the bloodstream and invade erythrocytes in a complicated and
organized process that involves a variety of interactions between the merozoite and
erythrocyte surface 26,27. Merozoites first bind to the erythrocyte surface receptors via
ligands such as merozoite surface proteins 1 (MSP-1 to 9), apical membrane antigen-1
(AMA-1), and erythrocyte binding antigen-175 (EBA-175), then they re-orientate
themselves to their apical pole. There is formation of a tight junction between host and
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parasite apical surface allowing the merozoite to invade, forming a parasitophorous
vacuole (PV). While P. falciparum uses various receptors to invade human erythrocytes
(above), erythrocyte invasion by P. vivax and P. knowlesi depend on the interaction with
Duffy blood group antigen displayed on young erythrocytes (reticulocytes) 28. Humans
lacking this antigen are not susceptible to infection, explaining why this parasite is not
present in West Africa, where the Duffy negative blood group is prevalent 29. After
invasion, the parasite develops in a PV through young (ring-stage) trophozoite (0–24
hours), mature trophozoite (24–36 hours) and schizont stages (40–48 hours) 30. The time
for completion of the life cycle may be strain-dependent, ranging from 44-48 hours 31.
Ring-stage trophozoites (named this way because of the appearance of thickened
cytoplasm and position of nucleus) begin feeding on contents of the RBC. Parasites
ingest hemoglobin via an endocytic feeding mechanism into a lysosomal compartment,
the digestive vacuole (DV). Here, hemoglobin is broken down into the moiety
ferriprotoporphyrin IX (free heme) 32,33. This molecule is toxic to the parasite, so it is
converted into non-toxic hematin and inert brownish-yellow crystals termed hemazoin
(also known as malaria pigment) 34. The trophozoite stage can be differentiated from the
ring stage based on size and shape of the developing parasite and the presence of darker
hemazoin granules.
Mature erythrocytic stages of P. falciparum (>24 h after development) display
knob-like structures on the erythrocyte membrane. The parasite is able to transport these
proteins (PfEMP1 [Plasmodium falciparum Erythrocytic Membrane Protein 1] and others)
to the surface of the erythrocyte through a tubovesicular membrane network (TVM) and
associated protein trafficking/sorting structures called Maurer‟s clefts 35. The
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development of a protein trafficking network and subsequent changes to the erythrocyte
surface parallel the increased selective adhesiveness of the parasitized erythrocyte
membrane, responsible for the sequestration of trophozoites and schizonts in deep
visceral blood vessels, and severe pathogenesis marked by obstruction of placental and
cerebral vasculature 32. The persistence of P. falciparum during blood stage proliferation
in its host depends on the variant expression of PfEMP1, which is a type of antigenic
variation used by the parasite. This variation is mediated by the differential control of
PFEMP1 encoded by approximately 60 var genes 36, and it allows the parasite to escape
the immune system. Early studies showed that sera from infected children and adults did
not recognize a common epitope (now thought to be PfEMP1) found on all infected
RBCs, but epitopes that are strain specific 37,38. Therefore, there is a lack of crossreactive epitopes and the presence of immunodominant variant epitopes on PfEMP1 may
explain how the immune response to PfEMP1 is kept variant-specific despite repeated
exposure to the pathogen.
The ligands displayed on erythrocytes by P. falciparum allow these cells to
adhere to venular endothelium (cytoadherence) 39. The ability to express different
PfEMP1 allows the parasite to sequester in deep blood vessels and avoid antibodies and
spleen-mediated clearance, thereby allowing transmissibility. Because of this
cytoadherence property, the only stages usually found in patient peripheral circulation are
ring-stage trophozoites and gametocytes, because infected red blood cells (IRBCs)
harboring these stages do not have these proteins on the cell surface. Schizonts are the
most mature forms in the asexual intraerythrocytic part of the life cycle, which are
characterized by nuclear division. In these stages, hemazoin continues to appear in the
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DV, and export of proteins from the parasite to the erythrocyte cytosol and beyond
continues as well 32. Interestingly, synthesis of proteins and other factors needed for
DNA replication and partitioning into merozoites is completed during the late trophozoite
phase 31. The final step is the liberation of merozoites from segmenting schizonts, and
these merozoites go on to infect other erythrocytes. A segmenting schizont of P.
falciparum may release 16–32 daughter merozoites 30. The number of merozoites is
typically greater in P. falciparum compared to other Plasmodium species (below). Some
merozoites do not develop through the normal intraerythrocytic cycle, but mature into
gametocytes. Mature gametocytes will be ingested by a mosquito upon taking a blood
meal, to complete the cycle.
Malaria: life cycle in relation to cell cycle. The development of erythrocytic
forms of Plasmodium spp. involves critical changes in gene expression, antigen
presentation, and processes that are important for research aimed at vaccination, drug
discovery, and cell biology. Because of the different stages of parasites in the life cycle
of malaria, it is difficult to make comparisons to the cell cycle of other cells (or
organisms) that exist in a normal format of G0-G1-S-G2-M. However, the part of the life
cycle of human malaria parasites that may best approximate this format is the
erythrocytic stage in humans. Studies on synchronized RBC stages have helped to
dissect the possible cell cycle of P. falciparum, the most important malaria parasite.
Based on microscopic studies and nuclear staining with flow cytometry, Arnot and Gull
(1998) 31 described a model of the relationship between asexual parasite development and
the cell-cycle. A merozoite, both free and in late segmenting schizonts, is essentially in a
G0-like state (resting phase), with condensed chromatin. After the haploid merozoite
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invades an erythrocyte, ring stage trophozoites develop into early trophozoites, which
represent pre-nuclear division stages where cell growth and preparation for DNA
replication occurs (probably analogous to G1 of cell cycle). Before DNA synthesis,
trophozoites accumulate high levels of RNA, a step in the preparation for proteins needed
for DNA synthesis. It appears that DNA synthesis starts about 28-31 hours after
merozoite invasion after the appearance of pigmented trophozoites (early-mid
trophozoites) and DNA content then increases for approximately 8-10 hours in late
trophozoites. This corresponds to S phase of the cell cycle, where DNA replication
begins. As trophozoites mature, subdivision of nuclear material (signaling onset of
schizogony) proceeds. DNA synthesis may continue in schizonts (defined as having
more than one nucleus) but it has not been established whether G2 (checkpoint between
DNA synthesis and mitosis) and then M (mitotic) phases occur during progression from
the haploid DNA content (1 merozoite) to the final genome complement of the mature
segmenter (which can reach a maximum of 32 merozoites). Merozoites are formed after
S phase, so if mitotic genome segregations occur, they must be very rapid, allowing
complete packaging and DNA segregation before the completion of the life cycle.
Unfortunately, transitions from one stage of the life cycle to the next are not clearly
separable biochemically or morphologically, so the relationship of schizogony to both the
DNA-synthetic cycle and the cell-cycle is poorly defined. Researchers have taken
advantage of similarities between the cell cycle and Plasmodium stages to exploit
potential drug targets and further understand gene expression.
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Malaria: Clinical Manifestations and Diagnosis
Uncomplicated malaria. All human malaria species can cause mild
(uncomplicated) malaria, with similar symptoms. However, the incubation period (time
between initial infection and appearance of symptoms) and pre-patent period (period
between sporozoite inoculation and detectable stages) varies. The incubation period may
range from 7-30 days 40, but it is usually shorter in the case of P. falciparum (9-14 days).
The incubation period of P. vivax and P. ovale (12-18 days) is almost similar to P.
falciparum, but that of P. malariae is significantly longer (18-40 days) 41. The minimum
pre-patent periods of P. falciparum (9-10 days), P. vivax (11-13 days), and P. ovale (1014 days) have similar ranges as well 42, but that of P. malariae can be much longer (1659 days) 43.
Uncomplicated malaria is defined as symptomatic malaria without signs of
severity or evidence (clinical or laboratory) of vital organ dysfunction 44. The first
symptoms of classical, uncomplicated malaria after the pre-patent period (period between
sporozoite inoculation and detectable stages) can be described as the primary attack, or
prodrome (symptom, or set of symptoms). It is usually atypical and may resemble any
febrile illness (marked by fever), but common symptoms are headache, myalgia, general
malaise nausea, and loss of appetite 40. The asexual intra-erythrocytic stages of
Plasmodium spp. cause all pathophysiological processes in humans. In uncomplicated
malaria, the hallmark of disease is episodes of chills (cold stage) and fever (hot stage).
The cold stage may last for 1 hour duration, followed by profuse sweating as the body
temperature decreases. A fever stage rapidly follows for 6-12 hours where patients
commonly experience nausea and vomiting. These episodes are caused by rupture of
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schizont-infected erythrocytes, where the massive release of hemazoin, toxins and RBC
components induce macrophages to secrete pro-inflammatory cytokines such as Tumor
Necrosis Factor-alpha (TNF-α) and Interleukin-1 (IL-1), common mediators of the
immune system (see below) induced by Plasmodium spp. 39,45.
The pattern of intermittent chills/fever is directly dependent on the synchronized
development of the infecting species of Plasmodium in the bloodstream. The appearance
of symptoms can be 48 or 72 hours depending on the species. This recurrence of
symptoms was noted by ancient Romans and they named the disease by measuring the
elapsed time from the beginning of the first episode to the end of the second episode 46.
When fevers recurred every third day, it was called tertian malaria, although only fortyeight hours separated the two attacks. A fever appearing every fourth day was called
quartan. Plasmodium vivax and P. ovale cause benign tertian malaria and P. falciparum
causes malignant tertian malaria. These parasites have 48 hour life cycles. Plasmodium
malariae causes benign quartan malaria (72 hour life cycle). Plasmodium knowlesi, a
fifth human malaria parasite has a 24-hour life cycle. If the disease is not treated
effectively, severe malaria can result in a few hours (mostly P. falciparum). There is
variability in the epidemiology and clinical manifestation of malaria due to factors such
as the species of parasite occurring in a given area, parasite susceptibility to antimalarial
drugs, environmental conditions, and the behavior and immune status of the host 47.
Severe malaria. Severe malaria occurs when P. falciparum infections are
complicated by serious organ failures or abnormalities in the patient's blood or
metabolism 40. This may occur in non-immune individuals, people who delayed
treatment, or those who were given sub-optimal antimalarial or ineffective antimalarial
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drugs. Severe malaria is life-threatening and it requires hospitalization, intravenous
antimalarial therapy (below), and management of various complications. The mortality
associated with severe malaria remains high, ranging from 10-50%, depending on the
setting 48. However, if left untreated, severe malaria is fatal in the majority of cases.
Severe malaria usually manifests with one or more of the following: coma (cerebral
malaria), metabolic acidosis, severe anemia, hypoglycemia, acute renal failure, acute
pulmonary edema, blackwater fever, acute respiratory distress syndrome (ARDS), among
others 44. The WHO defined criteria for severe malaria that includes one or more of a
clinical (prostration, impaired consciousness, respiratory distress, abnormal bleeding,
jaundice, hemoglobinuria, among others) or laboratory feature (severe anemia, acidosis,
renal impairment, hypoglycemia, hyperparasitemia) 49.
Cerebral malaria is the most common complication and cause of death in severe P.
falciparum infection (10% of all hospital admissions and 80% of deaths [falciparum
malaria] are due to Central Nervous System [CNS] involvement) 50. The disease is
typified by a sudden onset of headache, convulsions, body temperature reaching 106-108º
F, and rapid progression to death (24-72 hours Cerebral malaria is the result of
parasitized erythrocytes adhering to the cerebral microvasculature (a form of
sequestration) and parasite-induced inflammatory response. There is blockage of the
blood's pathway, leading to a shortage of oxygen (hypoxia) and nutrients to those areas of
the brain. A mentioned above, mature parasites induce the formation of knobs (formed
by PfEMP1 in association with KAHRP [knob-associated histidine-rich protein]) on the
surface of the erythrocyte 51. The cells expressing knobs will bind to host molecules such
as CD36, Intracellular Adhesion Molecule-1 (ICAM-1), E-selectin, and Vascular Cell
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Adhesion Molecule-l on vascular endothelium and uninfected erythrocytes 39. IRBCs
containing mature parasites can adhere to many uninfected RBCs, forming rosettes. This
is thought to be mediated by knobs such as PfEMP1, but also by various other parasitederived ligands such as rosettins and rifins 52. Like cytoadherence, rosettes have the
potential to block blood flow and contribute to cerebral malaria. Cerebral malaria must
be treated immediately, or death can result in a period of hours. Treatments for cerebral
malaria include quinine, quinidine gluconate, and artesunate (below). Because of
cardiotoxicity and advantages over quinine, intravenous artesunate may be the best option.
Blackwater fever is an acute, massive lysis of erythrocytes, marked by high levels of free
hemoglobin in the blood and urine. Hemoglobin and its products in the urine give it a
dark color, lending the name to the disease.
Global Impact of Malaria
Malaria affects almost half of the global population, which is represented by the
poorest countries in the world. There are at least 190 million cases of malaria per year
and the disease accounts for nearly one million deaths per year 53, covering four
continents of the world. A large percentage of malaria fatalities occur in Africa, but
malaria is endemic through most of Southeast Asia, sub-continental India, the South
Pacific, and parts of South America (Figs. 1.2, 1.3). Plasmodium falciparum causes the
majority of cases and deaths in Africa, where the most mortality and morbidity due to
malaria occurs in the world. A large portion of deaths due to malaria in Africa are in
children under five years old 53. It has been estimated that 85% of malaria deaths in the
world can be attributed to children under 5 years of age 54. A 2007 study found that 2.37
billion people (about 35% of the world's population) live in areas where there is some
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risk of P. falciparum transmission, and that 1 billion of these people live where there is a
low, but evident risk of malaria transmission 55. The study found that on a global scale,
nearly all the regions where prevalence of P. falciparum is more than 50% are in Africa,
although there are some African regions where few people are infected with P.
falciparum. Outside of Africa, the prevalence of P. falciparum is less than 5% 55.
Although P. falciparum is the most lethal and is concentrated in Africa, P. vivax is
actually more widely distributed in the world. It has been estimated that 70-80 million
cases of P. vivax occur each year, and greater than 50% of malaria cases (outside of
Africa) are caused by P. vivax 56. A more recent estimate of P. vivax risk by Guerra et al.
(2010) 57 estimated that 2.85 billion people were at risk for transmission in 2009, with
57.1% of them (1.63 billion) living in areas of unstable transmission. The vast majority
(2.59 billion, 91.0%) were located in central and southeast Asia, with the remainder
located in the Americas (0.16 billion, 5.5%) and Africa/Yemen/Saudi Arabia (0.10 billion,
3.5%). In all, a total of 95 P. vivax endemic countries and territories listed in
international travel and health guidelines were identified.
A variety of estimates as to the number of people affected by malaria and also the
number killed each year have been proposed in the literature. Breman (2001) 15 listed
annual malaria mortality estimates and stated that they range from 0.7-2.7 million. This
number is significantly higher than most report as it accounts for insufficient reporting
and clinical diagnosis. In 2006, the World Health Organization (WHO) estimated that
3.3 billion people are at risk for contracting malaria worldwide 54. The most recent
World Malaria Report 53 reported data for 2008 in 108 malaria-endemic countries, when
there was an estimated 243 million cases of malaria (5th-95th percentiles: 190–311
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million). The cases were predominantly in Africa (85%), followed by South-East Asia
(10%) and Eastern Mediterranean Regions (4%). For 2008, malaria was responsible for
an estimated 863,000 deaths (5th-95th percentiles: 708–1003 thousand), of which 89%
were in the African Region, followed by the Eastern Mediterranean (6%) and the SouthEast Asia Regions (5%). Hay et al. (2010) 58 recently estimated that 451 million (95%
credible interval 349–552 million) clinical cases of P. falciparum malaria existed in 2007
in 87 endemic countries. There were 271 (241–301) million cases estimated to have
occurred in Africa/Yemen/Saudi Arabia, 177 (89–270) million in central/south east Asia,
and 3 (1–7) million in the Americas. More than half of the world's estimated P.
falciparum clinical cases came from India, Nigeria, DRC, and Myanmar (Burma).
African populations suffered the largest proportion (60%) of the 451 million clinical
cases of P. falciparum. The reasons for discrepancies in disease burden between WHO
and other studies may stem from features of P. falciparum infection that confound
traditional measures of disease burden and disability 58. These may include the fact that
not all infections result in progression to disease, notably in areas of stable transmission,
where populations have acquired clinical immunity. Also, since symptoms of malaria
(principally fever) may overlap with other locally prevalent diseases in an area of stable
transmission, the routine reporting of malaria can overestimate disease rates by assuming
that most fevers are due to malaria. Many infected people elect to self-medicate after
experiencing a malaria-like syndrome, and they will not seek care from a health care
center that reports malaria cases. Finally, inaccurate diagnoses might be used to report
disease rates, and these errors may be compounded through inadequate and incomplete
national reporting systems.
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Malaria Public Health Control and Eradication Efforts
Malaria eradication seemed possible in the 1950s after the discovery of effective
antimalarials such as chloroquine and Paul Müller‟s finding that
dichlorodiphenyltrichloroethane (DDT) had insecticidal use. In 1955, the WHO
established the Global Malaria Eradication Program, with efforts focused on housespraying with DDT, antimalarial drug treatment (mainly chloroquine), and surveillance.
The program was designed to be carried out in 4 successive steps: preparation, attack,
consolidation, and maintenance 59. The program took place in many countries, regardless
of geography and epidemiology. A notable part of this program was the exclusion of
sub-Saharan Africa from this strategy 60. This approach failed to interrupt transmission
completely in many countries and malaria resurged to previous or even higher levels as
eradication programs crumbled and the strategy was abandoned. Successes included
eradication in nations with temperate climates and seasonal malaria transmission. Some
countries such as India and Sri Lanka had sharp reductions in the number of cases,
followed by increases to substantial levels after efforts ceased. The emergence of drug
resistance, widespread resistance to available insecticides, wars and massive population
movements, difficulties in obtaining sustained funding from donor countries, and lack of
community participation made the long-term maintenance of the effort unattainable59. By
1969, WHO admitted the failure of this campaign and the global eradication policy was
abandoned in favor of control programs. Malaria mortality and morbidity began to
increase again in the 1980s due to a combination of factors such as the increase in
parasite and vector resistance to available antimalarial drugs and insecticides, the
weakening of traditional malaria control programs, rapid decentralization and
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deteriorating primary health services, and the development of humanitarian crisis
situations in many malaria-endemic areas 61. This dramatic increase led to the adoption
of the Global Strategy for Malaria Control (GSMC) in 1992. GSMC was founded on
four technical elements, including early diagnosis and prompt treatment of malaria,
planning and implementation of selective/sustainable preventive measures (ex. vector
control), early detection/containment/prevention of epidemics, and strengthening of local
capacities in basic and applied research 62. A few years later, the Roll Back Malaria
Partnership (RBM) was created (1998) to coordinate global efforts in combating malaria.
The goal of most current national malaria prevention and control programs in
endemic countries is to reduce the number of malaria-related cases and deaths. RBM is a
global framework for coordinated action against malaria. RBM was launched by WHO,
the United Nations Children‟s Fund (UNICEF), United Nations Development Program
(UNDP), and the World Bank in an effort to provide a coordinated global response to the
disease 63. In 2009, the RBM Partnership comprised more than 500 partners, including
malaria endemic countries, developmental partners, the private sector, non-governmental
and community-based organizations, and research and academic institutions. Through
RBM partnership mechanisms, players in malaria control coordinate their activities at
global, regional and country level, while striving to achieve optimal use of resources.
RBM‟s overall strategy aims to reduce malaria morbidity and mortality by reaching
universal coverage and strengthening health systems. In 2008, key actors in malaria
control endorsed an ambitious plan to put an end to malaria as a global health problem.
The Global Malaria Action Plan (GMAP) consolidates the input of 30 endemic countries
and regions, 65 international institutions and hundreds of experts from a wide range of
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fields. The GMAP is supported by RBM and it aims for a substantial and sustained
reduction of malaria. The GMAP departs from other solutions that desire rapid results by
using strategies adapted to the specific ecology and epidemiology of malaria in a country
or region. Major goals of the GMAP include universal coverage of at-risk populations,
reducing global malaria cases from 2000 levels by 75% in 2015, and reducing global
malaria deaths to near zero in 2015 64. Malaria eradication is now being brought back to
the forefront as well. In 2008, the Bill and Melinda Gates Foundation called for malaria
eradication 65. They cited encouraging research into vaccines, vector control, and
antimalarial drugs as major factors that could lead to eradication. Also, a number of
collaborators have contributed significant energy and resources to the global effort to
control malaria, amounting in almost $4 billion for malaria control that will reach more
than 70 countries. Also, the GMAP lists eradication as an eventual goal where the global
incidence is reduced to zero through progressive elimination in countries. The GMAP
aims to eliminate malaria in 8-10 countries by 2015 and afterwards in all countries in the
pre-elimination phase today 64.
Malaria in the United States. Malaria was previously endemic in the United
States. The disease was a significant problem in the southeastern U.S., and Malaria
Control in War Areas (MCWA) was developed to prevent malaria on military bases and
prevent the spread to the general public from infected soldiers returning from endemic
areas 59. The MCWA became the Communicable Disease Center (now Centers for
Disease Control [CDC] and Prevention house in Atlanta) in 1946 and much of the CDC‟s
early work focused on malaria. The National Malaria Eradication Program commenced
operations in1947. The program consisted primarily of DDT application to the interior
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surfaces of rural homes or entire premises in counties where malaria was reported to have
been prevalent in recent years. By the end of 1949, over 4,650,000 house spray
applications had been made. By 1951, CDC gradually withdrew from active participation
in the operational phases of the program and shifted to its interest to surveillance. By
1951, malaria was considered eradicated from the U.S. Today, the majority of cases
diagnosed in the U.S. are acquired in endemic areas, although transmission via blood
transfusion has been reported 66. In addition, local mosquito-borne transmission
(autochthonous) has been implicated in outbreaks of P. vivax malaria in several states,
most recently Virginia (2002) and Florida (2003) 67. In 2006, CDC received 1,564
reports of cases of malaria occurring among persons in the U.S. and its territories. Of
these cases, the infecting Plasmodium species was identified in only 63.4%, and P.
falciparum and P. vivax made up the majority of infections (61.8% and 27.7%,
respectively) 68.
Current Malaria Control Programs
Control of malaria requires an integrated approach that targets vectors, allows
distribution of proper drugs, and access to prompt medical care. Since no antimalarial
drug is 100% protective, drug use should be combined with the use of personal protective
measures (i.e., insect repellent, long sleeves/pants, use of bed nets). Progress to control
malaria has been slow because of drug resistance, insecticide resistance, differences in
mosquito biology/ecology (breeding preferences/sites, flight/resting behavior) that
hamper universal vector control, and the cost of malaria control programs exceeds public
health resources in poor countries. The choice of interventions depends on the malaria
transmission level in the area (e.g. Intermittent Preventive Treatment in Pregnancy [IPTp]
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for pregnant women in areas of low transmission). The main components of malaria
control are case management (diagnosis and treatment) of patients with malaria and
prevention (Insecticide-Treated Nets [ITNs], IPTp in pregnant women [above], Indoor
Residual Spraying [IRS]) 69. In most malaria-endemic countries, these interventions are
packaged into public health programs. Other control measures include environmental
strategies to control mosquitoes and mass drug administration (this is not recommended
in order to discourage drug resistance). The current malaria control strategy calls for the
selection of those control measures which are most appropriate to local circumstances
and capabilities and malaria risk (Fig. 1.3).
Case-management of malaria involves accurate diagnosis and the use of proper
antimalarial drugs. Malaria infections can be diagnosed clinically and confirmed by
parasitological diagnosis with either microscopy or with rapid diagnostic tests (RDTs).
Importantly, RDTs are useful for diagnosis of malaria outside of health facilities where
equipment and diagnostic expertise may not be available. However, microscopic
diagnosis should be used to enhance case management of the patient. ACTs are the drug
of choice against uncomplicated P. falciparum malaria, but chloroquine and sulfadoxinepyrimethamine (now ineffective in many countries) are still the treatment of choice in
some areas for other Plasmodium spp. (more below). Thorough case management takes
into account the infecting Plasmodium species for correct antimalarial drug prescription,
patient tolerability of drug, and form of administration of drug. Some patients fail
antimalarial treatment and they must be handled carefully to ascertain if recrudescence of
infection or re-infection occurred 44. Most malaria patients in epidemics and emergencies
are non-immune, partially immune, or otherwise vulnerable to severe disease. Therefore,
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the WHO recommends an active search should be made for febrile patients to ensure that
as many patients as possible receive adequate treatment, rather than relying on patients to
come to a fixed clinic 44. Home-based management of malaria (HMM) is one of the
strategies recommended by WHO to improve access to prompt and effective treatment of
malaria episodes through trained community members living as close as possible to
where the patients live. HMM allows for coverage of the health services for malaria to
extend beyond the reach of health facilities. It requires that effective and appropriate
treatment with first-line ACTs, as well as guidance on referral criteria are provided at the
community level through trained community-based providers, such as community health
workers, mother coordinators and private vendors. Management of severe malaria is very
important, as death can occur rapidly after patients are admitted to a hospital or clinic.
The recommended steps to be taken for the management of severe malaria are clinical
assessment of the patient, specific antimalarial treatment (artesunate or quinine),
adjunctive therapy, and supportive care 44.
Vector control measures directed towards adult mosquitoes such as IRS and ITNs
are geographically broad and applicable compared to more ecology specific measures
directed towards larvae. Many important vectors of malaria bite indoors at night, and
may rest on indoor surfaces after biting, whereas larval habitats vary markedly among
anopheline species. IRS with an effective insecticide was a staple of early malaria
eradication programs, but the deterioration of IRS programs in some countries led to the
resurgence of malaria and the abandonment of the global campaign for eradication. IRS
is still used today, particularly in areas of seasonal transmission, including epidemicprone areas, and increasingly in more malaria-endemic areas. DDT was used primarily in
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early malaria eradication for IRS, but it was abandoned after reports of insecticide
resistance, and accumulation of DDT in the food chain, which can lead to long-term
toxicity in animals and humans. The production and use of DDT is restricted by the
Stockholm Convention on Persistent Organic Pollutants 70. There are currently 12
insecticides recommended for IRS, and DDT is one of them. The WHO recommends
DDT only for IRS in high transmission area, stressing that it is still useful for vector
control because there is no alternative of both equivalent efficacy and operational
feasibility 70. IRS is dependent on logistics such as adequate surfaces in the housing
structures that can be sprayed, the targeted mosquito must rest indoors before or after a
blood meal, and the mosquito must be susceptible to the insecticide. Because of the
problems with DDT, alternative insecticides classified as carbamates, organophosphates,
and pyrethroids were developed for vector control. Of these, pyrethroids are probably the
best since they have great utility in long lasting insecticidal nets (LLINs) reflected by
their low toxicity, ability to mosquitoes effectively, and affordance of personal protection
71

.
The development of pyrethroids with long residual action and very low

mammalian toxicity suggested that sub-optimal mechanical protection afforded by
mosquito netting could be paired with an insecticidal effect for greater protection.
Mosquitoes are positively attracted to individuals sleeping inside an ITN, making the ITN
work like a baited trap. Currently, there are two types of bed nets used for malaria
control, and only pyrethroids are allowed as treatment. Standard ITNs are cost-effective
but require re-treatment with insecticide every 6-12 months, which presents a barrier for
widespread use in endemic countries 72. LLINs are ITNs that maintain insecticide levels
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for up to 3 years. LLINs have been associated with sharp decreases in malaria in
countries where malaria programs have achieved high LLIN coverage. Mobilizing
resources to procure these nets remains a major challenge. After much debate, WHO
now recommends that LLINs be provided free, establishing universal coverage in
malarious areas. Donors and programs such as the Global Fund Against HIV/AIDs,
Tuberculosis, and the President‟s Malaria Initiative support the purchase of LLINs for
many countries. Making LLINs free to people has greatly increased bed net ownership
and encouraged their usage in endemic areas 73,74. A recent analysis estimated that
between 2008 and 2012, 327 million LLINs would be needed to achieve full coverage of
women and children in malaria-endemic countries of Africa, while 545 million LLINs
would be needed to achieve universal coverage in that same region 72.
ITNs are a form of malaria control that offers protection not only for the
individual, but for the community as well. There is much evidence that community-wide
use of ITNs leads to large-scale killing of mosquitoes and personal protection, indicated
by reduction of severe disease and mortality due to malaria in endemic regions 75-79. The
community-wide use of ITNs reduces the vector population and shortens the mean
mosquito lifespan, leading to a reduction of malaria 80. Apart from their killing effect,
ITNs also inhibit mosquito feeding, hence reducing the reproductive potential of vectors
and decreasing the number of potential mosquito bites in a community. A troubling fact
is that the mass use of ITNs or LLINs impregnated with pyrethroids may lead to
resistance, rendering this class of insecticides ineffective. Resistance (knock-down
resistance [kdr]) can be due either to detoxification of insecticide by enzymes or by
mutation on its target site: sodium channels for DDT and pyrethroids 81, and acetyl-
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cholinesterase for organophosphates and carbamates 82. Mutations in kdr genes were first
detected in A. gambiae from Africa in 1998, and mutations have been detected in other
African countries as well. However, reports have shown that mortality of wild
mosquitoes entering experimental huts areas of resistance remains high, and personal
protection from biting is still effective 80.
Vector control strategies have a proven track record of successfully reducing or
interrupting disease transmission when coverage is sufficiently high. However, vector
control also has proven weaknesses (insecticide resistance) that relate to technical and
managerial deficiencies and obstacles. Also, there may be differences in environmental
and societal determinants in parts of endemic areas, making one single vector control
approach unreasonable. Therefore, Integrated Vector Management (IVM) has emerged
as an adaptive and flexible approach of controlling mosquitoes in malarious areas that
uses a range of interventions. The approach encourages collaborations within health
sectors and communities, and seeks to improve the efficacy, cost-effectiveness,
ecological soundness, and sustainability of disease-vector control 83. The Round Four
Global Funds to fight Aids, Tuberculosis and Malaria submitted by Zambia in 2004
established key objectives and service areas pertinent to IVM that included scaling up
coverage for IRS, expanding environmental management and larviciding, and improving
the capacity for monitoring and evaluation 62. IVM selects proven vector control
methods based on knowledge of local vector biology and ecology, disease transmission
and morbidity. The application of IVM principles to vector control will contribute to the
judicious use of insecticides and extend their useful life, discouraging resistance 84. An
IVM approach takes into account the available health infrastructure and resources and
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integrates all available and effective measures, whether chemical, biological, or
environmental 83.
Vaccines
Pre-erythrocytic stage. Currently, vaccines that target pre-erythrocytic stages
focus on subunits of sporozoites, whole organism, or DNA-based approaches. Although
subunit vaccines (e.g. RTS,S below) show the most promise of malaria vaccines, they
actually have achieved lower efficacy than whole-parasite vaccines in phase IIa clinical
trials 85. The use of live, attenuated sporozoites for a whole parasite vaccine was
originally reported in the 1960s and subsequent work found that irradiated sporozoites
produce sterile and long-lasting protection in mice and humans 85. It appears that
immunity is mediated by specific antibody to the irradiated sporozoites (Radiation
Attenuated Sporozoites, RAS), but CD8+ T-cells are also necessary for the elimination of
infected hepatocytes. Although this method of vaccination seemed promising, the
vaccine must be totally protective against sporozoites since even one sporozoite can
initiate malaria infection. Also, a large number of sporozoites must be injected from the
bite of an irradiated mosquito (>1,000), which can cause logistical problems 86. In 2003,
scientists from Sanaria revisited the potential for a metabolically active and attenuated
whole parasite P. falciparum sporozoite (PfSPZ) vaccine. A preliminary study was
conducted in the U.S. in order to provide proof of safety, immunogenicity and protective
efficacy studies 87. A phase II/IIa clinical trial in non-immune healthy adults is being
conducted as a collaborative effort between Sanaria, PATH MVI, and the U.S. Military
Malaria Vaccine Program), and the Center for Vaccine Development at the University of
Maryland at Baltimore.
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The most effective malaria vaccine currently in clinical trials is the RTS,S vaccine
developed by Glaxo Smith Kline (GSK) in collaboration with the Walter Reed Army
Institute of Research (WRAIR). Clinical development of the RTS,S candidate vaccine
has continued in partnership with the Program for Appropriate Technology in Health and
the Malaria Vaccine Initiative (PATH MVI). The vaccine consists of a portion of CSP
(C-terminus amino acids 207-395) from P. falciparum fused to hepatitis B surface
antigen and mixed with free hepatitis B surface antigen. It also contains a GSK
proprietary adjuvant (ex. AS02) and the vaccine is expressed in the form of virus like
particles in Saccharomyces cerevisiae 88,89. Clinical evaluation of RTS,S began in adults
in the U.S. in 1992, and in Africa in 1998. A phase IIb trial with RTS,S/AS02A was
initiated in 2003 and it was conducted with more than 2,000 children aged 1-4 years in
southern Mozambique. There was confirmed vaccine efficacy (VE) during an initial 6month follow-up (30% against clinical malaria, 45% against infection, and 58% against
severe malaria), as well as sustained protection up to 21 months (35% clinical malaria, 49%
severe malaria) and 45 months (VE against clinical and severe malaria over entire follow
up= 31% and 38%, respectively; VE against all clinical episodes=26%) 90-92. A phase
II/IIb clinical trial in Mozambican infants found RTS,S/AS02D had VE of 66% over a
three-month follow-up period 93. Importantly, it displayed a promising safety and
tolerability profile and the trial was the first to show efficacy in infants of any malaria
vaccine candidate. The results of a RTS,S/AS02D phase IIb study in Tanzanian infants
found that VE against first infection of P. falciparum 6 months after last dose was 65.2%
94,95

. A study of children aged 5-17 months in Tanzania showed that RTS,S/AS01E
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reduced the risk of clinical episodes of malaria by 53% over an eight-month follow-up
period 95.
Based on these promising results, RTS,S is the first malaria vaccine candidate to
reach large-scale phase III clinical testing, the last stage of development before regulatory
file submission. A large-scale phase III multi-center efficacy trial in both infants and in
young children was launched in May, 2009. It is imperative to show effectiveness and
safety in these groups because they represent populations that are most vulnerable and
who would benefit most from an effective malaria vaccine. The multi-center trial is
underway in 11 sites in seven African countries (Gabon, Mozambique, Tanzania, Ghana,
Kenya, Malawi, and Burkina Faso). This trial, which will enroll up to 16,000 infants and
children, is expected to become the largest malaria vaccine trial to date 96. Pending
sufficient safety and immunogenetic profiles, general implementation of RTS,S for
infants 6-12 weeks of age may be possible within five years. The vaccine could be
available for specific use among young children 5-17 months old as early as 2013 96.
Other pre-erythrocytic vaccines that show efficacy in animal models are based on
genetically attenuated sporozoites (GAS) 97-100. DNA vaccine approaches for malaria
prevention have recently been described where different degrees of protection are
produced 88,89. There are a wide range of candidates being studied, some of which are in
clinical trials. A majority of these are plasmid DNA vaccines and live recombinant
vaccines that use differently prepared viruses (modified vaccinia Ankara (MVA) strain,
fowlpoxvirus (FPV), Adenovirus, Sindbis virus, yellow fever virus or a cold-adapted
attenuated influenza virus strain) as a vector.
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Erythrocytic stage. Vaccines against sporozoites such as RTS,S have been
designed to prevent infection, which theoretically should prevent disease. In contrast,
vaccines against the pathogenic asexual blood stages aim to prevent disease, but not
infection. Because merozoite attachment to RBCs is specific and essential for
progression of the erythrocytic cycle, antigens on the merozoite surface have been
targeted for vaccine development 85. Spf66, regarded as the first malaria vaccine, was the
first asexual blood-stage malaria vaccine developed. This vaccine is essentially a
synthetic protein consisting of amino acid sequences of three merozoite peptides linked
by repeat sequences of CSP from P. falciparum 101,102. The vaccine initially showed great
efficacy and promise 103,104, but testing in several phase III field trials involving
thousands of volunteers found that its efficacy was too low to warrant a role for malaria
control 89. Currently, the most promising asexual blood-stage vaccines are based on
immunogenicity to merozoite surface proteins such as MSP-1, MSP-2, MSP-3, AMA-1,
and GLURP (glutamate rich protein). Of the different merozoite proteins, MSP-1 has
been characterized the most. MSP-1 is present in all Plasmodium spp. and it has a
molecular mass of ~200 kDa 105. MSPs are not variant antigens, so they represent
suitable targets for antibody response. However, there is considerable polymorphism
within MSPs, and some are considered dimorphic with two major, conserved forms.
Although MSPs exhibit polymorphisms, each parasite clone expresses only one allele of
each MSP, indicating that a single clone cannot escape immune surveillance by switching
expression to a different variant form (as with VSAs) 106. A vaccine using a combination
of MSP 1/2 and ring stage infected erythrocyte surface antigen (RESA), called
Combination B vaccine, is the blood stage vaccine that has been characterized the most.
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This vaccine was used in a phase I/IIb clinical trial in 5–9 year old children in Papua New
Guinea and it provided 62% reduction in parasite density in vaccinees 107. However, the
vaccine preparation contained only the 3D7 allelic form of MSP-2 and subsequent
research found that vaccination with this formation led to a significant increase in
parasites with the FC27 allele genotype, the opposite dimorphic form of MSP-2 108.
Therefore, a new version of the vaccine is necessary that includes both variants of MSP-2
in order to target both genotypes. A vaccine using the MSP-1 42 kDa fragment in the
GSK AS02 adjuvant (used in RTS,S) was found to be safe and very immunogenic in
rhesus monkeys and humans in Kenya 109,110.
AMA-1 is a merozoite protein found in the micronemes and on the merozoite
surface, and it displays a high level of polymorphism 111. The vaccine potential of AMA1, like MSP-1, is also supported by the fact that antibodies inhibit invasion of RBCs in
vitro and that AMA-1 protein can induce species-specific protection against malaria in
rodent and non-human primate models 111-113. The level of polymorphism in AMA-1 has
been a variable in some studies, complicating the ability to design an effective vaccine.
However, AMA-1 vaccines have recently been reported to have efficacious results in
humans 114-116. There are also other antigens that are being investigated as vaccine
candidates. The merozoite proteins MSP-3 89,117-119, MSP-4 89, MSP-5 89, MSP-8 and
MSP-9 89, GLURP 89,120-122, and serine repeat antigen (SERA) 89,123-126 have shown
promise in animal and/or human models examples. EBA-175, which binds glycophorin
A on RBCs was shown to be antiparasitic in Aotus monkeys 127. A recent clinical trial
testing the safety and immunogenicity of EBA-175 RII-NG has just been completed in
the U.S. 128.
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Transmission blocking vaccines. Unlike the other classes of malaria vaccines,
the goal of transmission-blocking vaccines (TBVs) is not to prevent infection or
associated disease in the human host, but rather to prevent transmission of the parasite
once inside a mosquito. An effective transmission-blocking vaccine would not confer
protection from disease upon the individuals, but it would help to reduce disease
prevalence in the community. These vaccines intend to induce antibodies to sexual stage
antigens to prevent further fertilization and development of the parasite in the mosquito
host 129. Studies have shown they have been successful at preventing parasite
transmission in experimental animals and they are being investigated for stopping
transmission of P. falciparum and P. vivax 85. The targets of transmission blocking
antibodies include pre-fertilization antigens (Pfs230 and Pfs48/45) expressed in the
circulating gametocytes and post-fertilization antigens (Pfs25 and Pfs28) expressed
during mosquito stage ookinete development 130. Antibodies produced to pre-fertilization
antigens would have the added benefit of boosting immunity to blood stage infection as
well. A phase I clinical trial investigating Pfs25 and Pvs25 (P. vivax homolog of Pfs25)
found that significant levels of antibody were produced to Pfs25, which correlated with
transmission blocking activity. However, significant adverse skin reactions were
experienced by volunteers 131. Chowdhury et al. (2009) 130 showed that blocking
antibodies to Pfs48/45 could be produced in non-human primates and mice. Recently,
Dinglasan et al. (unpublished) found an Anopheles midgut protein (midgut alanyl
aminopeptidase [AnAPN1] that causes humans to produce antibodies, and this could be a
feasible TBV 132. Although TBVs have the potential to reduce malaria transmission and
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maybe contribute greatly to eradication, long-term studies must be conducted in order to
determine if malaria prevalence can be reduced over time.
Decades of research effort to develop malaria vaccines have seen many
candidates undergo preclinical trials, with a subset of these undergoing clinical trials.
Currently, only one vaccine has entered phase III clinical trials (RTS,S) and there are a
few in phase IIb trials. This reflects the difficulty and complexity of the malaria parasite
life cycle and vaccine development challenges. A major problem is that although
vaccines are efficacious, immunogenic, and safe, they do not provide complete protection
from infection (e.g. RTS,S). The Malaria Vaccine Technology Roadmap (2006) 133
established a landmark goal to develop and license a first-generation vaccine by 2015 that
has 50% protective efficacy against severe disease and death, with protection lasting at
least one year. Also, a strategic goal for 2025 was established: developing and licensing
a malaria vaccine that has a protective efficacy of more than 80% against clinical disease
and lasts longer than four years. The RTS,S vaccine is close to meeting the 2015 goal,
but it remains to be seen how the RTS,S vaccine performs outside of Africa where
different transmission dynamics and drug resistance profiles exist. It may be more
prudent for endemic countries to focus on sound and comprehensive malaria control
programs, as a fully efficacious vaccine may not be released for decades. Also,
improving the vaccine with different adjuvants or other components may be necessary in
order to achieve increased levels of efficacy.
A fundamental problem in regard to lack of complete efficacy lies in the fact that
even in endemic populations, natural immunity is slow to develop after repeated parasite
exposures. In fact, rapid immunity is never produced and it is only after several years,
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that a degree of „clinical‟ immunity develops. Partial immunity is manifested as reduced
morbidity, due to reduced parasitemia and possibly the development of an anti-toxic
response 111. Therefore, immunological memory is a problem that most malaria vaccines
meet with. The protective immune status acquired through repeated natural exposures
over years can be lost if continuous antigenic stimulation ceases. This suggests that lowlevel antigenic persistence will be required for immunity to malaria, and, therefore,
vaccines will need to simulate such a persistence to induce long-lasting protection 134.
Perhaps the use of prime-boost vaccination can circumvent this problem, but long-term
studies are required to ascertain this.
Despite the relative ineffectiveness of natural immunity, vaccine strategies aim to
induce the same type and specificity of immune responses as those that are induced by
natural exposure. Vaccines try to improve on host immune response by using highly
immunogenic antigens to produce antibodies and a CMI response. However, some of the
subunits (as discussed above) are polymorphic, in addition to containing a small number
of T-cell recognition sites. Furthermore, there are the complex relationships between the
parasite and immune system to deal with. Induction of immunity by vaccines can be
compromised by existing infection or the passage of maternal antibodies to infants.
Parasitized RBCs have been shown to suppress maturation of dendritic cells (DCs) and
also lead to apoptosis of parasite-specific T cells, memory B cells, and plasma cells 111.
Vaccine-induced immunity can be affected by the passage of maternal antibodies to
infants (occurs in measles). A study of P. yoelii showed that exposure of mother mice to
a malaria infection or a MSP-1 vaccine led to a diminished antibody response of her pups
to MSP-1. Passively acquired P. yoelii-specific antibodies most likely inhibited the
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development of an antibody response by blocking access to critical B cell epitopes 135.
Parasite biology is another problem as well. Erythrocytic vaccines using merozoite
antigens (MSP-1, AMA-1) do not confer high protection. Unlike P. vivax, P. falciparum
uses multiple redundant pathways to invade erythrocytes, complicating the effort to
develop anti-invasion vaccines 85. As mentioned before, P. falciparum encodes many
VSAs that make clearance of secondary malaria infections caused by different parasite
clones difficult. Clearance of a specific parasite clone appears to follow the development
of a VSA-specific antibody response. The new clone may have a slightly different
phenotype in terms of tissue adhesion, resulting in different pathology 106. Therefore, a
vaccine targeting PfEMP1 would need to incorporate a variety of antigens, perhaps to
common strains in a certain location, in order to elicit effective immunity. Finally, some
vaccine studies primarily use animal models and these may not be appropriate to
ascertain human immune responses and immunogenicity. Laboratory models cannot
replicate the intricacies of host-parasite interactions in nature. Therefore, vaccination
studies in animal models must be carefully designed to assure any beneficial effects can
correctly be related to human infection.
Antimalarial Drugs for Treatment
The complexities of the malaria parasite have made the malaria vaccine
development process arduous and a completely successful vaccine currently does not
exist. However, malaria is a curable disease if promptly diagnosed and treated correctly.
Antimalarial drugs are the most important global malaria intervention, responsible for
saving lives in many malaria-endemic countries. In general, there are only a few classes
of antimalarial medications, and most of the drugs currently available have been in use
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for decades. Those that are easily affordable for many malaria-endemic countries are
restricted to chloroquine, sulfadoxine/pyrimethamine, quinine and amodiaquine 136.
Their use is now severely limited by the emergence and spread of drug resistance,
primarily in P. falciparum, which exhibits resistance to almost every class of antimalarial
drug. Therefore, many endemic countries now face a situation in which there are no
affordable, effective antimalarial drugs available. The progress of drug discovery is not
keeping pace with the emergence of drug resistance, and there are problems such as
distribution, accessibility, and correct usage that have compounded the situation. Also, in
many malarious areas, a majority of the population may not receive reliable and
consistent information about malaria treatment and prevention, and drugs that are
available may be counterfeit or contain insufficient dosages to be completely effective
against local parasite strains 137. Drug resistance is a major problem where malaria is
endemic, described not only in P. falciparum, but for P. vivax as well 47. Drug resistant
parasites have appeared in areas almost as soon as new medications have been introduced,
making it important to understand the molecular mechanisms involved and to develop
strategies subverting the parasite‟s ability to survive in the presence of drug pressure. In
order to understand the mechanisms of resistance, it is important to first review the
history of antimalarial drugs and development, and to recognize the mechanisms of drug
activity.
Quinolines. Quinolines are aromatic nitrogen compounds characterized by a
central solid-ring structure, essentially benzene fused to pyridine at two adjacent carbon
atoms. However, there can be various functional groups on the main quinoline molecule
that add to solubility and specificity of drug activity. The main quinolines that are used
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as antimalarial drugs can be divided into groups based on chemical attributes. Type-1
quinolines (the 4-aminoquinolines chloroquine, amodiaquine, pyronaridine) are weak
bases, deprotonated, and hydrophilic at pH 7.0. Type-2 quinolines (the arylaminoalcohols quinine, mefloquine, halofantrine, lumefantrine) are weaker bases and
lipid soluble at neutral pH 138. Additional quinolines include the bis-quinoline
piperaquine and the 8-aminoquinoline, primaquine.
Quinine. The alkaloid quinine (QN) occurs naturally in the bark of the Cinchona
tree, which is native to South America. There is evidence that South American indians
used the bark as medicine, but not necessarily for the treatment of malaria 139. In the
1600s, the drug was brought to Europe by missionaries serving in Peru. It was not until
1820 that QN was isolated from the bark of the Cinchona tree by the French scientists
Joseph Pelletier and Jean Biename Caventou 140. Today, QN can be used for
uncomplicated malaria treatment, but it is not recommended for prophylaxis or routine
treatment because of toxicity (especially in children and pregnant women) and a
syndrome called cinchonism (dizziness, impaired hearing, nausea, vertigo) 49. Quinine
may be a useful first-line treatment in areas with multidrug-resistant malaria where P.
falciparum does not respond to chloroquine, sulfa drug-pyrimethamine combinations, and
mefloquine. It is usually combined with an antibiotic (doxycycline or tetracycline)
especially where some degree of quinine resistance may be present, such as in southeast
Asia 49. Quinine is a reasonable option for treatment in travelers returning to nonendemic areas who develop malaria, since the drug-resistance pattern of the parasite may
not be known and a fully efficacious drug is needed in non-immunes to prevent
progression of uncomplicated malaria to severe disease 137. Quinine is used to treat
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severe malaria because it can be administered intravenously (IV) and it is highly effective.
However, QN has been replaced by IV artemisinin drugs for the treatment of severe
malaria 44.
Quinine is principally active on mature trophozoites 141. It does not prevent
sequestration or further development of circulating rings, nor is it active against preerythrocytic stages of P. falciparum 49. Like other structurally similar antimalarials, QN
also kills sexual stages of P. vivax, P. malariae, and P. ovale, but not mature gametocytes
of P. falciparum. The exact mechanism of QN action is unknown, but it is postulated
that it may interfere with heme detoxification as with chloroquine 142-144 or nucleic acid
synthesis 145 in the malaria parasite. In some strains of P. falciparum, a decreased
amount of QN in the DV was associated with increased sensitivity to the drug, indicating
that it may target areas of the parasite other than the DV 146.
Chloroquine. In the 1920s, a German effort was conducted to find alternative
antimalarial drugs to quinine, which produced pamaquine and mepacrine 147. In the
1930s, synthetic drugs for malaria were introduced, as mepacrine was made widely
available for treatment. It replaced QN in routine treatment of non-severe malaria, as it
was a cheaper and less toxic alternative 148. Further German research produced
chloroquine (CQ) in 1934 149, and U.S./British scientists recognized CQ as an effective
and safe antimalarial in 1946 9. CQ replaced mepacrine in the late 1940s because it was
easier to use and the cost (total cost of treatment was less than 10 cents) enabled poorer
nations to treat more cases of malaria. Chloroquine, which has utility for treatment and
prophylaxis, has become the most widely used antimalarial drug in the world.
Historically, it has been the first-line drug of choice for treatment of uncomplicated
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malaria and chemoprophylaxis, but extensive resistance to the drug has made it quite
ineffective. CQ is a weak base that accumulates in the parasite‟s acidic DV. The
sequence of events related to heme degradation and CQ interference is complex, but
essentially CQ becomes deprotonated in the acidic DV (a membrane-impermeable form)
and trapped inside the DV 138. CQ acts to directly inhibit the polymerization of toxic
heme molecules (produced from hemoglobin degradation) into hemazoin, and monomeric
heme accumulates to levels in the DV that kill the parasite. CQ affects stages of the
erythroctyic cycle primarily, but there is some debate as to the specific stages it affects
150-152

. It is known that CQ is not active against pre-erythrocytic stages and it has low

activity against young gametocytes 44,147. Although CQ is ineffective in most areas of the
world where P. falciparum exists, it remains effective against P. falciparum in areas of
the Caribbean, Central America, and the Middle East 142. In most of the world, CQ is still
the first line of treatment for P. vivax malaria 153. Against P. vivax, CQ is well-tolerated
and affordable, and its long half-life provides protection from early relapses following
treatment. However, P. vivax is resistant to CQ in some parts of the world, most notably
areas of Papua, Indonesia; sporadic cases are reported from South America, Vietnam, and
Turkey 153.
Mefloquine, other aminoalcohols, and primaquine. Mefloquine (MQ) is also
effective against CQ or multi-drug resistant strains of P. falciparum. The U.S. Army
Antimalarial Drug Development Program (initiated in the 1960s), has screened over
200,000 compounds over 40 years for antimalarial activity. MQ was one of two licensed
drugs developed as a result of this effort 154. MQ was first synthesized in 1969 primarily
for the purpose of chemoprophylaxis in the military following the then recently
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discovered threat of CQ-resistant P. falciparum. It was first introduced for general use in
1977 (trade name Lariam) 155. It has been reported that MQ targets growing trophozoites,
but it also has activity against sexual stages 154,156. MQ is recommended for prophylaxis
when traveling in malarious areas were CQ resistance is prevalent, but there are areas of
the world (Thailand, Cambodia) where the drug is ineffective due to resistance 147,154.
MQ has a long half-life in the body, allowing it to be used in combination therapies. MQ
is known to cause neuropsychiatric episodes 49. The other important aminoalcohols are
halofantrine and lumefantrine. Halofantrine (HAL) is effective against CQ-resistant P.
falciparum. Because it is associated with cardiotoxicity, it has been taken off-market by
several countries 157. Lumefantrine (LUM) is active on blood stages 156 and it is only
available as a co-formulation with artemether (Coartem) 49. LUM has a shorter half-life
than MQ 147, but Coartem is still a useful ACT, with high activity against drug-resistant P.
falciparum. The mechanism of action of LUM is thought to be linked to heme
detoxification 158.
Primaquine was part of the search for antimalarial drugs that predated the
discovery of CQ 159. It was first deployed to prevent relapsing P. vivax malaria in U.S.
soldiers returning from World War II and the Korean War 156. Primaquine is the only 8aminoquinoline available for use currently, and it is effective against all stages of
parasites (except sporozoites) 156. It is used to provide radical cure of P. vivax and P.
ovale malaria, (elimination of relapse) in combination with a blood schizontocide for the
erythrocytic parasites 49. Primaquine (PQ) also kills P. falciparum gametocytes and it has
significant blood stage activity against P. vivax (and some against asexual stages of P.
falciparum). Primaquine is contraindicated in people that have severe glucose 6-
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phosphate dehydrogenase deficiency because of the risk of hemolytic anemia 49. The
drug also displays marked toxicity, preventing it from being a widely used antimalarial
drug. Tafenoquine is a new 8-aminoquinoline under development, and it has higher
antiparasitic activity than PQ 157. It is also tolerated better than PQ, but the risk of
anemia in glucose-6-phosphate people still remains. The exact mechanism of MQ and
PQ is unknown but it has been thought that these drugs inhibit membrane trafficking
events involved in uptake of metabolites in RBCs 33 or that they are involved in
hemoglobin degradation similar to the mechanism of CQ 160.
Amodiaquine and piperaquine. Amodiaquine (AQ) was discovered to have
antimalarial properties around the same time as CQ 147. AQ is metabolized to the primary
metabolite monodesethylamodiaquine, and it has a similar mode of action as CQ 49. AQ
is effective against some low-level CQ-resistant strains of P. falciparum, although there
is cross-resistance between the two drugs 44,157. AQ is used as monotherapy because it is
inexpensive in the developing world, but it is most commonly used in combination with
artesunate (as an artemisinin combination therapy, [ACT]) or in combination with
sulfadoxine-pyrimethamine (where efficacy of both is high) 49. Piperaquine (PIP) was
originally synthesized in the 1960s and it is approved for use in combination therapy with
dihydroartemisinin 44,157. It is thought to act on mature trophozoites and target heme
detoxification 161. PIP is a bisquinoline antimalarial drug that was first synthesized in the
1960s, and used extensively in China and Indochina as prophylaxis and treatment during
the next 20 years 162. This widespread use of PIP contributed to high levels of resistance.
However, during the next decade, PIP was rediscovered by Chinese scientists as one of a
number of compounds suitable for combination with an artemisinin derivative. The
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rationale for such artemisinin combination therapies (ACTs) was to provide an
inexpensive, short-course treatment regimen with a high cure rate and good tolerability
that would reduce transmission and protect against the development of parasite resistance.
It was used extensively in China after its development, and resistance to the drug
emerged. However, CQ-resistant isolates in Africa are susceptible to PIP, giving promise
to PIP+DHA in African countries 157.
Antifolates. Antifolates were developed as part of antimalarial research
programs during World War II. Most of the antifolates used for antimalarial treatment
today were developed in the 1940s and 1950s 163. These drugs result in decreased
pyrimidine synthesis, leading to reduced DNA, serine, and methionine formation. Type I
antifolates (sulfonamides, sulfones) compete for the active site of dihydropteroate
synthase (DHPS), preventing the formation of dihydropteroate. Type II antifolates
(pyrimethamine, biguanides) inhibit parasite dihydrofolate reductase (DHFR), preventing
H4 folate (necessary for biosynthesis of thymidylate, purines, amino acids) from being
formed 138. Because DHFR and DHPS inhibitors target DNA synthesis, they exert high
activity when DNA synthesis peaks (late trophozoites) in parasites 163. Resistance
developed to the drugs when used alone, but when used in combination (commonly
sulfadoxine+pyrimethamine [SP, Fansidar]), a synergy is observed which makes the pair
very effective in treating all types of malaria. Pyrimethamine is reported to be active
against all parasite stages (not sporozoites), whereas sulfadoxine displays blood stage
activity and activity against sexual stages 156. SP replaced CQ as first line therapy in
areas of CQ-resistance. SP is inexpensive and provides protection from new infections
for a prolonged period due to its long half-life 142. Resistance to SP emerged almost as

42

soon as it was introduced in the 1950s, and it is no longer effective for P. falciparum in
areas of Asia, Africa, and South American, and for P. vivax in many areas 49. SP is now
used in combination with artesunate as an effective ACT where SP resistance is low.
However, this is ineffective for P. vivax in some areas. Proguanil is a biguanide
compound that is metabolized to cycloguanil, which targets DHFR. The parent
compound, proguanil, has a separate target than cycloguanil and makes the drug dually
effective against parasites 164. Proguanil has slow schizontocidal action compared with
QN or mepacrine, and when it was used in the late 1940s as prophylaxis for plantation
workers in Southeast Asia and elsewhere, it provided an opportunity for widespread drug
selection pressure on the parasite and the subsequent development of resistance to this
drug 163. Proguanil is used in combination with atovaquone (below) as an effective
combination drug. Proguanil is reported to have activity against all parasite stages
(except sporozoites) 156. Chlorproguanil is a biguanide that has actions and properties
similar to those of proguanil. It is available only in combination with a sulfone such as
dapsone (co-formulated as Lapdap) 49. Studies indicate that Lapdap remains active
against the dhfr and dhps genotypes in Africa that cause SP failure, and there is
increasing discussion of replacing SP with Lapdap due to the latter combination‟s shorter
half-life of 12 h (thought to discourage selection of resistance) 163.
Atovaquone. Atovaquone (ATOV) is a naphthoquinone that was first introduced
for treatment in 1996 155. ATOV displays activity against all Plasmodium spp., and it
exerts its effects by collapsing mitochondrial membrane potential and inhibiting the
electron transport chain 49,165. ATOV can inhibit pre-erythrocytic development in the
liver, oocyst development in the mosquito, and it has blood stage activity 156. ATOV is
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not very effective when used alone, as resistance to the drug develops quickly. However,
there is a synergistic effect when ATOV is paired with proguanil (forming Malarone®) or
cycloguanil. Interestingly, the action of proguanil in Malarone® is not to inhibit DHFR
(as when used by itself), but it lowers the effective dose needed to cause mitochondrial
membrane potential collapse by ATOV 166. The double activity of proguanil reported by
Fidock et al. (1998) 164 gives triple-action to Malarone®. A short course of Malarone® is
very effective at curing multi-drug resistant malaria infections. However, ATOV is
expensive to manufacture, so the use of Malarone® is not practical for malaria-endemic
countries 147. Malarone® is a useful alternative to MQ for travelers from non-endemic
countries going to malarious areas.
Antibiotics. The apicomplexan plastid (apicoplast) arose by endosymbiosis of a
cyanobacterial-like prokaryotic cell 2. Antibiotics have antimalarial activity because they
can inhibit the prokaryote-like processes in Plasmodium spp., such as protein synthesis
and DNA/RNA replication. Interestingly, antibiotics do not immediately kill malaria
parasites, but they cause delayed death in the second erythrocytic cycle 157. The delay of
parasite killing equates to longer parasite clearance times and prolonged symptoms.
Therefore, antibiotics are used in combination (e.g. quinine) for non-immunes
experiencing acute malaria. Doxycycline (DOX), clindamycin (CLIN), and tetracycline
(TET) inhibit protein synthesis, and they are prescribed for malaria treatment. It is
reported that these drugs affect liver and blood stage parasites 156. Doxycycline has a
long elimination time, making it useable for prophylaxis when traveling to areas where
MQ is ineffective, or where multi-drug P. falciparum exists. However, it is
contraindicated in young children and pregnant women. CLIN is a safer alternative, but
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it has a short elimination time (unsuited for prophylaxis) and should be paired with a
faster acting antimalarial 157.
Artemisinins. The history of antimalarial drugs can be traced back thousands of
years with the use of the herb qinghao (Artemisia annua, sweet wormwood) for treatment
of fevers in traditional Chinese medicine. In 1967, the Government of the People‟s
Republic of China began a program to systematically identify remedies from plants in
response to Ho Chi Min‟s request for antimalarial drugs for Vietnamese troops 141,167. In
1971, Chinese scientists found that extracts of A. annua killed Plasmodium berghei in
mice and a year later, they identified the active ingredient. The Chinese called it
“qinghaosu”, but it is now known as artemisinin. In 1985, artemisinin (QHS) was
extracted at WRAIR in the U.S. 167. Today, artemisinin is still obtained by extraction
from A. annua, but there is a growing demand for high yields of the drug. Therefore,
methods are being developed for microbial and synthetic production of artemisinin
precursors and similar peroxides 168. Artemisinins are currently the most important class
of antimalarials, used in combination therapies for routine treatment, and also for
treatment of severe malaria.
Artemisinin is a sesquiterpene trioxane lactone (empirical formula C15H22O5) that
contains an endoperoxide ring that is critical for antimalarial activity 169. After QHS was
identified, it was determined that it was not soluble in oil or water and must be given
orally 170, so chemical modifications were introduced to improve solubility. The common
derivatives of artemisinin are dihydroartemisinin (DHA), oil-soluble artemether (AM)
and arteether (AE), and water-soluble artesunate (AS) and artilenate (artelinic acid, AL)
171,172

. The many derivatives of artemisinin also offer different routes of administration,
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which is beneficial for treating a variety of patients. The most clinically useful
artemisinins are metabolized to DHA after being absorbed, and then to inactive
metabolites via hepatic cytochrome P-450 and other enzyme systems 170. Artemisinin
itself is not converted to DHA, but to inactive metabolites.
The artemisinin class of compounds represents the most rapidly acting and
effective antimalarial drugs. The parent drug QHS and its derivatives all possess
remarkable activity against P. falciparum isolates, even those strains that are multiply
resistant to other antimalarial drugs. As a class the artemisinin drugs are active at low
nanomolar concentrations, with the primary human metabolite DHA being the most
active (50% Inhibitory Concentration [IC50] range 2.2-3.9 nM) (Kyle, Personal
Communication). In vivo artemisinin drugs produce faster parasite and fever clearance
times than any other antimalarial drug and reduce gametocyte carriage 141,173, thereby
effectively reducing transmission of malaria. Artemisinin‟s broad stage specificity
against blood stages 141,156 has important therapeutic consequences. It is believed that the
ability of artemisinins to kill young ring stages results in more rapid reduction in
parasitemia compared with other antimalarials 141 and reduces the number of parasites
that could mature and sequester in capillaries 174. Importantly, the rapid reduction of
parasites by artemisinins is a critical factor in treating severe malaria, as preventing
sequestration can prevent cerebral malaria. Artemisinin is better than QN for treating
severe malaria in this regard, as QN does not prevent sequestration. DHA has a half-life
of approximately 45 minutes, whereas AS is rapidly hydrolyzed (~10 minutes) to DHA
and its antimalarial activity is largely mediated by DHA 175. Artemether and arteether are
converted to DHA more slowly. Artemisinins have been linked to neurotoxicity and
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embryo death in animal models, and they have not been evaluated in the first trimester of
human pregnancy. Therefore, they are not recommended in first trimester patients with
uncomplicated malaria 49.
Perhaps the greatest benefit of artemisinin drugs is that they are effective in
treating severe malaria that is resistant to CQ and they can be incorporated with other less
effective drugs in combination therapies for high cure rates. ACTs take advantage of
pairing artemisinins, which have a short elimination time, with a longer eliminated drug.
The rapid action of the artemisinin component reduces the number of parasites for the
partner drug to remove and discourages parasites resistant to the partner drug from
emerging (protection) 174. In successfully treated patients, the partner drug also protects
the artemisinin component by removing all residual parasites originally exposed to the
drug; thus, there is low chance for the selection of artemisinin resistance. The
combination of AS+MQ exhibits these properties and it is very effective, even in areas of
MQ resistance. Because artemisinins have relatively short half-lives for elimination, the
selection for drug-resistant parasites is less likely. However, the relatively short halflives of artemisinin drugs may be responsible for the frequent recrudescence (~10%)
observed in patients after treatment with a single artemisinin drug 176. Also, a study
showed that over 90% of DHA is bound to plasma proteins is malaria patients and in
healthy volunteers 177. It is remarkable that these drugs are so active against parasites
although a majority of drug does not participate in killing.
Given the global adoption of ACTs, considerable research has been devoted to the
artemisinins and their effects on Plasmodium spp. However, the mechanism of action of
artemisinin and its derivatives on Plasmodium spp. remains unclear. The absolute
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requirement of the trioxane subunit of artemisinin for activity has led researchers to focus
on this for mode of action studies. It has been proposed that artemisinins can exert their
effect via the generation of reactive oxygen species, which can be enhanced in the
presence of free iron (heme) (Fe+2) that is found in parasites after hemoglobin digestion.
The Fe+2-catalysed reductive cleavage of the endoperoxide may give rise to O-centered,
or alkoxyl, radicals and then C-centered radicals and neutral products becoming activated
by free ferrous or heme iron. It is possible that these radicals may exert effects by
overwhelming parasite oxidative stress mechanisms 175. The peroxide pharmacophore
could also undergo ring-opening via protonation (H+), or formation of a complex with a
metal ion to generate an open hydroperoxide or metal peroxide. This may lead to
conversion into a peroxy radical, or the transfer of oxygen to oxidizable substrates, which
can have detrimental effects on biomolecules 178. Other studies found that artemisinin
can interfere with heme detoxification 179 in the DV or artemisinin derivatives localize to
neutral lipid bodies in the DV where they damage parasite membranes after oxidation
reactions 180. There may be a link between development of parasites and artemisinin
activity. Since more hemoglobin is metabolized by older trophozoites, one might think
that more mature stages is the main target of artemisinins due to the abundance of iron
that would be available in the DV and used in the above mechanisms. Indeed, this
appears to be how CQ works on older trophozoites where large amounts of ferrous heme
are produced and not detoxified due to the presence of CQ. The Kyle lab found that
trophozoites and schizonts are easily killed by artemisinins (Kyle et al., unpublished).
However, ring stages are also known to be susceptible to artemisinins 141, (Kyle et al.,
unpublished data), although we know ring stages enter dormancy and may recrudesce
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later to cause re-infection (below). Artemisinin and MQ can inhibit endocytosis in P.
falciparum, possibly indicating a role for these drugs in blocking intracellular
development 181. Artemisinins have also been found to target mitochondrial function in
Plasmodium spp. by interfering with the electron transport chain and by inducing reactive
oxygen species that cause mitochondrial membrane potential loss and disrupt the normal
function of mitochondria 182,183.
The most recent hypothesis for artemisinin mode of action is the inhibition of a
calcium-dependent ATPase that exhibits similarity to mammalian Sarco/endoplasmic
reticulum Ca+2 ATPase (SERCA), also known as PfATP6 184. The SERCA ortholog of P.
falciparum was expressed in Xenopus laevis oocytes and it was found that artemisinin
inhibited the protein with similar potency as thapsigargin (another sesquiterpene lactone
with high inhibition of Ca+2-transporting ATPases). Thapsigargin also competed with
artemisinin in terms of anti-parasitic activity and imaging of parasites with labeled
thapsigargin and artemisinin showed localization to the cytoplasm, and not the digestive
vacuole. Furthermore, after chelation of iron by desferrioxamine, the antiparasitic
activity was reduced. Taken together, the evidence suggests that artemisinins inhibit
PfATP6 outside the digestive vacuole after iron-activation. Molecular evidence also
suggests that mutations within pfatp6 are responsible for artemisinin resistance in P.
falciparum 185,186. All these studies point toward plausible, although somewhat
controversial, artemisinin action mechanisms, but none is generally accepted. The
question of the true mechanism of action has become more pressing and more
controversial as reports of emerging resistance to artemisinins have been published.

49

Antimalarial Drug Recommendations
Prophylaxis. Recommendations for drugs to prevent malaria differ by country of
travel and a good source is the CDC‟s country-specific tables of the Yellow Book
(http://www.cdc.gov/malaria/travelers/country_table/a.html) 187. It is imperative to
establish a clear potential for encountering drug resistance parasites in order to receive
the current antimalarial drug regimen. For all medicines, the possibility of interactions
with other medicines that the person is taking should be considered, as well as other
medical contraindications. For travelers leaving the U.S. to malarious areas, the CDC
recommends Malarone®, CQ (not where CQ- or MQ-resistance exists), DOX (not in
pregnant women and children <8 years old), MQ (not for MQ-resistant areas), and
Primaquine (where there is >90% P. vivax prevalence) 188. Because several different
drugs may be recommended for an area, it is critical to examine factors such as potential
side-effects, ease of use, contraindications, protection time, and time for activity.
Curative treatment. Treatment of malaria depends on many factors including
disease severity, the species of malaria parasite causing the infection, and the part of the
world in which the infection was acquired. It is crucial to determine the probability that
the organism is resistant to certain antimalarial drugs. Additional factors such as age,
weight, and pregnancy status may limit the available options for malaria treatment, as
well. Currently, the WHO recommends ACTs as front-line therapy for uncomplicated P.
falciparum malaria worldwide 44. Since 2001, at least 56 countries have adopted a WHOrecommended ACT, mostly as first-line treatment 189. The following ACTs are
recommended: AE+LUM, AS+AQ, AS+MQ, AS+SP, and DHA+PIP. The choice of
ACT in a country or region will be based on the level of resistance of the partner
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medicine in the combination. In areas of multi-drug resistance (east Asia and Africa),
AS+MQ, AS+AQ, AE+LUM, or DHA+PIP are currently recommended and being used
161

. In Africa where there is multidrug resistance, any of the ACTs including those

containing AQ or SP may still be effective. It is imperative that artemisinin and its
derivatives are not used as monotherapy, in order to discourage the emergence of
resistance. Any ACT should include a 3 day course of the artemisinin component in
order to eliminate at least 90% of the parasitemia. This allows cover up to three posttreatment asexual cycles of the parasite. This ensures that only about 10% of the
parasitemia is present for clearance by the partner medicine, thus reducing the potential
for development of resistance. Shorter courses (1–2 days) of the artemisinin component
would lead to a larger proportion of parasitemia for clearance by the partner medicine.
This is undesired because the artemisinin drug would be less efficacious (except when the
partner drug is highly effective), less effective on gametocyte carriage, and less protective
of the slowly eliminated partner antimalarial. For second-line therapies, an alternative
ACT known to be effective in a region, AS+TET/DOX/CLIN, or
QN+AS+TET/DOX/CLIN can be used. Any of these combinations should be given for 7
days. Pregnant women represent an exception for to these recommendations, as they
should take QN+CLIN for 7 days (AS+CLIN if treatment fails) during the first trimester
of pregnancy. During the second and third trimesters, an ACT known to be effective in
the country/region, AS+CLIN, or QN+CLIN can be given. Non-immune travelers
returning from endemic areas are recommended to be treated with Malarone®, AE+LUM,
DHA+PIP, or QN+DOX/CLIN (all drugs for 7 days).
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Severe malaria requires full doses of parenteral antimalarial treatment should be
started without delay with any effective antimalarial first available 44. For adults, IV or
intramuscular (IM) artesunate should be given on admission, then at 12 h, 24 h, then once
a day. Quinine is an acceptable alternative (IV or IM) if parenteral AS is not available,
but it has to be carefully administered (IV) in a rate-controlled fashion to avoid lethal
hypotension. For children, (especially in the malaria endemic areas of Africa), AS and
quinine are recommended as for adults, and IM artemether is available as an alternative.
Following initial parenteral treatment for 24 hours, once the patient can tolerate oral
therapy, it is essential to administer a full course of an effective ACT (any of five above).
In 2007, the U.S. Food and Drug Administration approved an investigational new drug
protocol for the use of IV Artesunate in the U.S. 190. This should replace quinidine
gluconate (cardiotoxicity) as the drug of choice for treating severe malaria in the U.S.
This protocol makes artemisinins available for malaria treatment in the U.S. for the first
time.
Antimalarial Drug Resistance
Drug resistance in relation to the malaria parasite was defined by the WHO in
1965 as the “ability of a parasite strain to survive and/or multiply despite the
administration and absorption of a drug given in doses equal to, or higher than, those
usually recommended but within the limits of tolerance of the subject” 149. The definition
was slightly changed decades later to reflect the fact that the drug must actually reach the
parasite or erythrocyte and act for the duration it takes for normal drug action. Drug
resistance has been attributed to the practice of constantly taking sub-curative doses of an
antimalarial drug, which only serves to eliminate the most sensitive parasites in the blood,

52

allowing resistant parasites to propagate. Longer half-life drugs such as CQ have an
extended elimination period from the body, during which time malarial parasites are
exposed to sub-therapeutic levels of the drug in the blood. The problem of taking subcurative doses is compounded by the availability of cheap drugs in many countries, which
can be problematic for adherence to regimens (side-effects) and the emergence of drug
resistance. There will always be a small number of parasites not eliminated by
medications, but host immunity can usually clear the infection. However, factors
decreasing the effectiveness of the immune system can increase the survivorship of
parasites, lending towards resistance. In certain malarious areas (Southeast Asia),
parasites will repeatedly cycle through non-immune populations, causing significant
morbidity and intensifying resistance. In addition, it has been reported that a synergistic
effect exists between P. falciparum and certain Anopheles spp., which can produce a
biological advantage favoring resistant parasites 47. The genetic events that lead to
resistance to an antimalarial drug are usually spontaneous mutations or changes in copy
number of genes relating to the drug target of the parasite 191. These events confer
reduced sensitivity to a particular drug, or a whole drug class. Over time, resistance
becomes stable in the population and it can persist even after drug pressure is removed.
Among the species causing human malaria, drug resistance has been reported and
characterized the most in P. falciparum, although resistance to antimalarials has been
documented for P. malariae and P. vivax, as well. In P. falciparum, resistance has been
observed in all currently used antimalarials (including artemisinin derivatives). The
geographical distributions and rates of spread have varied considerably (Fig. 1.4). P.
vivax has developed resistance rapidly to SP in many areas, while resistance to CQ is
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confined largely to Indonesia, Papua New Guinea, Timor-Leste and other parts of
Oceania. There are also reports of CQ resistance from Brazil, Peru, India, and Africa
(Fig. 1.4). However, P. vivax remains sensitive to CQ in most of South-East Asia, the
Indian subcontinent, the Korean peninsula, the Middle East, north-east Africa, and most
of South and Central America 44.
In vivo measures of drug resistance. Susceptibility of P falciparum to
antimalarial drugs is commonly assessed by therapeutic response (in vivo testing). The
WHO developed a scheme for estimating the degree of antimalarial drug resistance,
which involves studying patient parasitemia over 28 days. The in vivo response to drugs
was originally defined by WHO in terms of parasite clearance (sensitive [S] and three
degrees of resistance [RI, RII, RIII]) 137,155. Blood smears were taken on days 2, 7 and 28
after initiation of antimalarial treatment to grade the resistance as RI-RIII. Sensitivity
was classified as reduction of initial parasitemia by ≥75% on day 2 with smears negative
for malaria parasites from day 7 to 28 (end of follow up, but could be longer if drugs with
longer half lives are used [mefloquine]). RI response was classified as initial clearance of
parasitemia with negative smear on day 7, but recrudescence 8 or more days after
treatment started. RII response was classified as an initial clearance or substantial
reduction of parasitemia (<25% of the initial count on day 2) but with persistence or
recrudescence of parasitemia during days 4–7 after treatment. RIII was classified as no
significant reduction of parasitemia at 28 days after treatment. This scheme of
classification still remains valid for areas with low or no malaria transmission, but it is
difficult to apply to areas with intensive transmission, because of the chance that new
infection can be mistaken for recrudescences (which can also happen after 28 days).
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Other drawbacks of this method included the fact that RII was too broad of a category,
practical difficulties in following a patient for 28 days, and the intermittent nature of
parasitemia in the blood of infected patients. Therefore, WHO introduced a modified
protocol in 1996 based on clinical outcome targeted at a practical assessment of
therapeutic responses in areas with intense transmission, where parasitemia in the
absence of clinical signs or symptoms is common 137,155. The modified classification
established categories of Early treatment failure (ETF) (aggravation/persistence of
clinical symptoms in the presence of parasitemia during the first 3 days of follow-up),
Late treatment failure (LTF) (reappearance of symptoms in the presence of parasitemia
during days 4–14 of follow-up), and Adequate clinical response (ACR) (Absence of
parasitemia on day 14 irrespective of fever, or absence of clinical symptoms irrespective
of parasitemia, in patients not meeting ETF or LTF criteria). The WHO has continued to
update therapeutic efficacy protocols for high transmission areas and validate the
therapeutic efficacy protocol for low-to-moderate transmission areas on the basis of
feedback from countries and scientific recommendations. Recently, the WHO modified
the existing protocol to include applications of the same definitions of treatment
responses at all levels of malaria transmission, with slight adjustment of patient inclusion
criteria; administration of rescue treatment to patients with parasitological treatment
failure at all levels of malaria transmission; requirement for 28 or 42 days of follow-up as
a standard, depending on the medicine tested; and requirement for genotyping by PCR to
distinguish between recrudescence and re-infection. The 28-day follow-up is
recommended as the minimum standard to allow national malaria control programs to
capture most failures with most medicines, except mefloquine and piperaquine, for which
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the minimum follow-up should be 42 days 192. There are now set definitions of treatment
response that are used in all areas of malaria transmission. The ETF definition has been
modified to the following: danger signs or severe malaria on day 1, 2 or 3, in the presence
of parasitemia; parasitemia on day 2 higher than on day 0, irrespective of axillary
temperature; parasitemia on day 3 with axillary temperature ≥ 37.5 °C; and parasitemia
on day 3 ≥ 25% of count on day 0. Late clinical failure (LCF) is defined as: severe
malaria in the presence of parasitemia on any day between day 4 and day 28 (day 42) in
patients who did not previously meet any of the criteria of ETF; and presence of
parasitemia on any day between day 4 and day 28 (day 42) with axillary temperature ≥
37.5 °C in patients who did not previously meet any of the criteria of early treatment
failure. Late parasitological failure (LPF) is defined as the presence of parasitemia on any
day between day 7 and day 28 (day 42) with axillary temperature < 37.5 °C in patients
who did not previously meet any of the criteria of early treatment failure or late clinical
failure. Adequate clinical and parasitological response (ACPR) is defined as an absence
of parasitemia on day 28 (day 42), irrespective of axillary temperature, in patients who
did not previously meet any of the criteria of early treatment failure, late clinical failure
or late parasitological failure.
Quinolines.
Chloroquine. Resistance to CQ is a major problem because it remains the most
affordable and widely used antimalarial globally. Resistance was reported only a decade
after it was introduced and now widespread resistance has rendered it virtually useless
against P. falciparum infections in most parts of the world, although it still maintains
considerable efficacy for the treatment of P. vivax, P. ovale and P. malariae infections 44.
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It is theorized that P. falciparum resistance to CQ emerged in the epicenters of the
Thailand/Cambodia border in 1957 and in two foci in South America in 1960 (Columbia,
South America) 149,193 (Fig. 1.5). Resistance on the Thailand-Cambodia border can be
traced to the border town, Pailin. Malaria was hyperendemic at the time, and the most
prevalent species was P. falciparum (80%), transmitted by A. dirus and A. balabacensis.
In the late 1940s/early 1950s, many people migrated to the area for the business of
sapphire and ruby mining. Most of these migrants had not been previously exposed to
the parasite and consequently the low-immune population led to a cycle of epidemics.
Migrants would be repeatedly bitten by mosquitoes that bred in the damp mining pits
when gems were harvested. Chloroquine resistance was propagated by the practice of
taking medication until symptoms of malaria began to lessen. Resistance in Columbia
followed a similar pattern as in Pailin but P. falciparum was transmitted by A.
nuneztovari. In this case, emerald mining was implicated as encouraging drug resistance.
The spread of CQ resistance in the world is quite remarkable. From 1960-1970,
resistance was occurring more in South American countries than Southeast Asia. By
1970, it spread to Panama south of the Panama Canal, and by 1989, the drug resistance
distribution in South America, had become almost identical with the distribution of P.
falciparum. From the original focus of high-level CQ resistance first found in Thailand
in 1962, P. falciparum CQ-resistance spread gradually and contiguously throughout
Southeast Asia 163. Decreased susceptibility in Africa was noted in 1978, as cases were
reported in Kenya and Tanzania 149. As of 1985, resistance had spread from East Africa
throughout sub-equatorial Africa 148. It is theorized that resistance spread from Southeast
Asia to the African coast, then inland, as a result of population movements. White and
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Pongtavornpinyo (2003) 194 proposed that the genetic events conferring resistance to CQ
are so rare, that it is possible that resistance occurred in few foci globally, then spread as
a result of human or vector movements. This hypothesis was supported by Mehlotra et al.
(2001) 195, who conducted a population genetic survey showing similarity of parasites of
African and Asian origin.
Chloroquine-resistant parasites have the ability to limit the accumulation of the
drug in the digestive vacuole, but the mechanism leading to low drug concentration was
unknown for years. One approach to elucidating CQ resistance assumed an ATP
membrane transporter may be involved in changing the flux of CQ into the parasite
digestive vacuole 193. Pfmdr1 is the P. falciparum ortholog of mammalian Pglycoproteins that assist in multidrug resistance in cancer cells 196. Pfmdr1 (P.
falciparum multidrug resistance transporter-1) is encoded on chromosome 5, and is
located on the surface of the DV in mature parasites 197. Since this protein showed high
homology to mammalian P-glycoproteins known to be involved in drug efflux, it was
hypothesized that Pfmdr1 somehow modulated intracellular CQ concentrations 193,198.
Altered susceptibility to CQ was thought to be linked to point mutations in Pfmdr1, such
as the Asp-Tyr change at position 86 (N86Y) and to other mutations (Y184F, S1034C,
N1042D, and D1246Y) 155,193,199-203. However, some in vitro and in vivo studies showed
that there is not a significant relationship between pfmdr1 and CQ resistance 193,204-208.
Therefore, it appeared that CQ-resistance cannot be conferred by pfmdr1 alone and it
requires the presence of other genotypic changes.
In the late 1980s, two approaches were used to elucidate the genetic basis of CQ
resistance: genetic crosses and the observation of transporter homologs in mammalian
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tumor cells exhibiting a multi-drug resistance (mdr) phenotype 193. The identification of
the critical molecular determinant of CQ resistance was the result of a genetic cross
between CQ-resistant Dd2 (southeast Asia) and CQ-sensitive HB3 (Honduras) P.
falciparum clones, where it was found that a single genetic locus, localized to a 36 kb
segment on chromosome 7, segregated with inheritance of CQ resistance 208. Another
important finding of this study was that the CQ resistance phenotype was not attributed to
pfmdr1 (thought to be responsible for CQ resistance at the time). Subsequent studies
found a gene on the 36 kb segment coding for a 48.6 kDa protein with 10 predicted
membrane domains, and it was named PfCRT 209. Immunofluorescence and
immunoelectron studies 209,210 showed that the PfCRT protein is part of the digestive
vacuole, further implicating PfCRT in CQ resistance. Mutations in the pfcrt gene have
been linked to CQ resistance in isolates from around the world, and it is possible to map
certain mutations to specific countries. There is a specific mutation in resistant isolates at
amino acid (AA) position 76 (K76T) that has been found as critical for the resistance
phenotype 155,199,209,210. These in vitro results are largely consistent with in vivo findings
that document a strong association between the PfCRT K76T mutation and failure of CQ
treatment, leading to its widespread use as a molecular marker of CQ-resistance 196,211.
Interestingly, isolates from different countries that carry similar pfcrt mutant alleles
exhibit a wide range of CQ susceptibility, indicating the participation of additional genes
in modulating the level of response to CQ 201. It is possible that co-selection of pfcrt
amino acid T76 and pfmdr1 Y86 may occur as a result of CQ treatment, as has been
already reported 199,212, suggesting either that the two genes may work in concert in
determining CQ resistance levels or that the mutation at pfmdr1Y86 may compensate
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deleterious pfcrt mutations. Other studies have found that other genes, such as P.
falciparum multi-drug resistance-associated proteins 1 and 2 (pfmrp1, pfmrp2) 201,213,214
and a host of transporters 201 are associated with CQ resistance.
The pfcrt gene is polymorphic, reported to have mutations that can potentially
lead to 10 different amino acid changes 207. The K76T mutation is in a block of 5 amino
acids (normally CVMNK, #72-76) on the first transmembrane segment of PfCRT that are
strongly associated with geographic region-restricted evolution of P. falciparum
resistance to CQ 207,209. As mentioned above, CQ resistance is thought to have emerged
in Asia and South America separately. It appears that at least three foci were involved in
spreading CQ resistance worldwide. There was the focus at the Thai/Cambodia border,
two foci in South America, and a possible focus in Papua New Guinea, where CQresistance was reported in 1976 149. Therefore, the spread of CQ-resistant parasites
worldwide can be thought to have occurred from Asia to Africa, through South America
from a different origin, and through the Pacific islands from a different origin. This has
been verified by studies showing that nearly all resistant parasites in Southeast Asia and
Africa are of the CVIET type of PfCRT. Still, studies such as that by Chen et al. (2003)
215

in the Philippines make a case for more independent origins of CQ resistance in Asia.

Other PfCRT types have been described in Africa (SVMNT, commonly distributed in
South America and the Pacific; SVIET described in isolates from West Papua) 207.
Genotyping of pfcrt from isolates of the Pacific islands suggests a common lineage of CQ
resistance, as all CQ-resistant parasites harbored the SVMNT type in Papua New Guinea.
Another lineage of CQ resistance has been observed in the Philippines, where CQ
resistance was first described in the 1970s. In addition to the migration of the Papuan
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lineage (SVMNT), an indigenous lineage harboring a CVMNT type has also been
prevalent. The indigenous CVMNT type appears to have evolved into the SVMNT type.
In pfcrt, two distinct genotypes were initially identified in South America, the SVMNT
type and the CVMET type 207,209,216, consistent with the hypothesis based on
epidemiology that CQ resistance was generated from two foci. The most widely
distributed pfcrt genotype in South America is the SVMNT type, suggesting that the
SVMNT type (Venezuela origin), has been responsible for the emergence of CQ-resistant
isolates in South America 207. Another lineage, the CVMET type, has been observed
only in Colombia where CQ resistance was first reported 209,216. Other pfcrt genotypes
observed with less frequency in Brazil, Peru, and Ecuador are thought to have evolved
from the SVMNT type 207. Interestingly, the withdrawal of CQ in Malawi (1993) and in
China (1979) has correlated with a loss of both K76T in pfcrt and CQ resistance 217-220.
This may indicate that CQ has regained efficacy in these areas, and that CQ susceptible
parasites that dominate represent a re-expansion of the susceptible parasites that survived
in the population despite widespread drug pressure. This may also indicate that the Asian
and African CQ resistance alleles seem to confer a fitness cost, since CQ-resistant
populations did not flourish after the removal of drug pressure 196.
The association between mutations in PfCRT and reduced amount of CQ
accumulated by the parasite is somewhat controversial. It is now known that the majority
of intraparasitic CQ is concentrated within the DV, and since PfCRT is located in the DV
membrane, it seems plausible that mutations in PfCRT cause CQ resistance by reducing
the CQ concentration in the DV 196,221. Saliba et al. (1998) 222 showed that CQ-resistant
parasites had reduced CQ in the DV. Other studies found that CQ-resistant parasites
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initially accumulate CQ, but transport it out more efficiently than CQ-susceptible
parasites 223,224. This supports the idea that CQ resistance in P. falciparum is the result of
an inability of CQ-resistant parasites to accumulate CQ to toxic levels.
Amodiaquine and piperaquine. AQ is effective against some CQ-resistant
strains of P. falciparum in Africa, but it is more commonly used in combination with SP
or AS (as an ACT). In addition, it is used as monotherapy with effectiveness against P.
vivax 49. However, the drug exhibits poor efficacy against P. falciparum in regions of
India, Southeast Asia, the Philippines, South America, and Papua New Guinea 225.
Studies have found mutations (K76T and others) in pfcrt that are associated with AQ
resistance 211,226,227, and this corresponds to areas where CQ resistance has been reported
228,229

161

. However, other studies suggest AQ is still effective against CQ-resistant parasites

. AS+AQ is effective in Africa 230-234. A recent alarming study in Uganda found

resistance mediating alleles in pfcrt and pfmdr1 after AE+AQ therapy, indicating that
treatment selected for AQ resistance235. PIP was used for the treatment of CQ-resistant P.
falciparum since the 1960s, but its effectiveness declined in the 1980s due to resistance
162

. Recent studies showed introduction of mutant pfcrt had effects on sensitivity to PIP

in different strains 236 and disruption of pfmrp1 was associated with PIP susceptibility 214.
PIP is now packaged with DHA as an ACT recommended by the WHO. A study in
Cameroon found that PIP is highly active against CQ-sensitive and CQ-resistant P.
falciparum 237. Studies of DHA+PIP found it is a highly effective ACT in Africa and
Asia 233,238-242. One study found that DHA+PIP was more effective and better tolerated
than AS+AQ against multidrug-resistant P. falciparum and P. vivax infections in Papua
243

. Another study found that DHA+PIP and AE+LUM were both effective for treating P.
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vivax and P. falciparum in Papua, with low recrudescence of P. falciparum. However,
there was a significant level of P. vivax relapse and gametocyte carriage with AE+LUM
treatment compared to DHA+PIP 244. A recent report from Burkina Faso indicated that
patients infected with P. falciparum failed DHA+PIP therapy, and parasites that were
genotyped may have a different resistance mechanism as that mediating CQ resistance 245.
Also, DHA+PIP is reported to be less effective compared to AS+MQ for the elimination
of gametocytes, which is a tremendous drawback for controlling transmission 246.
Arylaminoalcohols.
Quinine. The earliest resistance to an antimalarial drug was reported for quinine
in 1910 (Brazil) and in 1938 (German railroad workers returning from Brazil/Bolivia
border) 163. It was not until the 1960s that successive observations of quinine resistance
were observed (Thai-Cambodia border) 155. Today, resistance exists globally, but the
highest levels of drug resistance are in Southeast Asia. This may be the result of
widespread use of QN in Thailand in the early 1980s as an interim therapy in the face of
declining SP efficacy 155. Resistance to quinine is not a serious problem and it still
remains an effective treatment (above) for multi-drug resistant strains.
The fact that QN resistance has been slow to evolve and disseminate in P.
falciparum indicates that there may be a multifactorial basis of resistance. The
mechanism of drug resistance is not clear, but certain genes have been implicated in
reduced susceptibility to quinine 247. These studies have indicated that there may be
overlap in mechanisms of resistance between QN and CQ/MQ. Early studies of field
isolates in Africa found an association between CQ and QN resistance 248,249. One gene
implicated is a P. falciparum Na(+)/H(+) exchanger (pfhne), as studies found increases in
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QN resistance as a result of pfhne-mediated pH perturbations, microsatellite
polymorphisms, or decreased expression 247,250-254. Studies found that mutations in the
Plasmodium falciparum CQ resistance transporter gene (pfcrt) were associated with
changes of QN sensitivity, but this may be dependent on the particular mutant allele as
well as the genetic background of the host strain 201,211,236,254-256. Research also found that
mutations 201-203,205,251,257-259 in Plasmodium falciparum multi-drug resistance transporter
(pfmdr1) or increase in its copy number 260-263 are linked to QN resistance. Other studies
implicated pfmrp1 in QN resistance 201,214. A recent study showed that QN may actually
inhibit pfmdr1, possibly establishing this as a parasite killing mechanism 264.
Mefloquine and other aryl-amino alcohols. Resistance to other antimalarial
aryl-amino alcohols been exhibited in areas where quinine is no longer effective (some
areas of Southeast Asia). Patients maintain sub-therapeutic levels of MQ for an extended
period following treatment because of its long half-life, which may promote the selection
of resistance in areas where persons are likely to be re-infected with malaria 154. An
alarming fact is that resistance to MQ was reported at the Thai-Cambodia border in 1982,
5 years after its introduction 149. Today, resistance is widespread in southeast Asia. As
stated above, early studies with pfmdr1 showed polymorphisms in pfmdr1 were linked to
CQ resistance. However, pfmdr1 was also been implicated in resistance to MQ and HAL.
Reed et al. (2000) 202 found that amino acid changes in pfmdr1 (S1034C, N1042D, and
D1246Y) in a CQ-sensitive strain doubled resistance for QN (with no effect on CQ
sensitivity). Interestingly, the opposite effect was found for MQ, HAL, and artemisinins
as sensitivity to these drugs was increased. However, changing AAs in a MQ, HALresistant strain to C1034S, D1042N, and Y1246D conferred resistance to MQ, HAL, and
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artemisinin. Notably, the single Y1246D mutation had a larger effect resistance for
MQ/HAL, suggesting that this amino-acid position is directly involved in MQ
accumulation. Resistance to MQ often correlates with CQ susceptibility, and vice-versa
248,261,265

. Other studies showed that point mutations in pfmdr1 either increased

susceptibility to MQ (HAL, LUM as well 259) 203,257-259,262,266 or decreased susceptibility
205

to MQ. These data emphasize that the pattern of mutations in any given field sample

may reflect a complex interplay of selection pressures arising from differing degrees of
exposure to the various quinoline-type drugs and differences in their precise mode of
interaction with the parasites 193. Lumefantrine is now paired with AE in the ACT
Coartem, and success at treating P. falciparum has reported in Asia and Africa 267. Some
recent studies have reported on the presence of AA residues in pfmdr1 (such as N86,
184F, 1246D) that may be associated with susceptibility/resistance to Coartem in Africa
268-271

. The selection of these mutations could be indicative of LUM resistance in the field.

Interestingly, the wild-type K76 pfcrt position was associated with LUM susceptibility in
some of those studies in Africa 245,272. Also, a recent study found that short term failure
of Coartem in Asia was associated with pfmdr1 amplification 273.
As well as polymorphisms arising from point mutations, variation in copy number
of the pfmdr1 gene has been associated with MQ resistance (and cross resistance to HAL,
QN, or LUM 206,261,263) in a number of studies, either in samples isolated from the field
205,260,262,266,274,275

, or arising through deliberate selection of highly resistant progeny of

laboratory strains 261,263,276-278. The presence (or lack) of copy number changes and/or
point mutations which influence levels of resistance to these inhibitors indicates that there
are several possible contributory factors and mechanisms involved in the acquisition of

65

resistance to these drugs. Still, these data have direct applicability to public health as a
predictor of resistance in clinical samples and can assist in assigning alternative treatment
regimens in MQ resistant areas. Another study reported that pfmrp2 expression was
associated with MQ treatment, implicating another transporter in possible MQ resistance
213

. A more recent study found that MQ is able to induce expression of pfmdr1, pfcrt,

pfmrp1 and pfmrp2, which may further indicate that additional transporter genes may be
involved in MQ resistance 279.
Mefloquine resistance in southeast Asia prompted the introduction of the ACT
AS+MQ in 1995 in Thailand and in Cambodia (2000) 280. Although MQ resistance is
widespread in southeast Asia, the addition of AS to MQ provides protection that allows
MQ to effectively eliminate parasites. The list of studies reporting on this ACT is
exhaustive. A group of studies in the early 1990s found that treating patients in Thailand
with MQ after an initial AS treatment produced high cure rates (even with a half dose)
and cured recrudescent infections 281-284. With the introduction of AS+MQ, malaria cure
rates increased in southeast Asia and the combination has been efficacious in general 285292

. However, there are reports of resistance to MQ after the introduction of this ACT

262,286

. AS+MQ has not been used at high levels beyond Asia, but some studies have

found it is highly efficacious and it should be recommended for treatment in Africa and
South America 293-295.
Although ACTs display high activity against multi-drug resistant parasites, they
are often used in an area where resistance already exists to the longer lasting component
of the ACT. Therefore, there is a risk that pre-existing resistance to these older partner
drugs could lead to drug failure. The case for this is becoming clear on the Thailand-
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Cambodia border 280. Wongsrichanalai and Meshnick (2008) 280 summarized three
studies that discussed the emergence of AS+MQ resistance based on the border of
Thailand/Cambodia or Thailand/Burma. Two of these were by Denis et al. (2006) 296
which focused on a group of 14 Cambodian efficacy studies from 2001-2004. In Pailin
(2002), AS+MQ response was 86% at day 28 follow-up, whereas a repeat study in Pailin
(2004), which used the same drug combination but more precise dosing and follow-up at
42 days, found efficacy to be 79%. Vijaykadga et al. (2006) 297 aimed to monitor the
efficacy of anti-malarial treatments in Thailand. This study took place in nine provinces
that bordered Cambodia and Burma. One group included the provinces Mae Hong Son
(NW border with Burma), Chiang Mai (NW border with Burma), Ratchaburi (W border
with Burma) and Ubon Ratchathani (E border with Cambodia). A second group included
patients from Kanchanaburi (W border with Burma). The third group had patients from
provinces with high-level mefloquine resistance (Tak [NW border with Burma], Ranong
[on border with S tip of Burma], Chanthaburi and Trat [both SE border with Cambodia]).
The percentage of adequate clinical and parasitological response to MQ was 62% in Mae
Hong Son, 75% in Chiang Mai, 94.0% in Ratchaburi and 90% in Ubon Ratchathani. In
Kanchanaburi, the percentage of adequate clinical and parasitological response to
AS+MQ was 94%. In the third group, this response exceeded 90%, except in Trat, where
it was only 79%.
Thus, evidence indicates that AS+MQ failures are occurring in different locations
in Thailand, but the ACT remains effective in others. Based on these data, it was
suggested that MQ monotherapy be replaced in Mae Hong Son and Chiang Mai. The
markedly reduced efficacy of the AS+MQ used in Trat raises questions about the future
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of this therapy on the SE border of Thailand with Cambodia. These studies as a whole
bring the prospect of widespread AS+MQ resistance to the forefront. In terms of
molecular mechanisms of resistance in AS+MQ therapy, it appears that treatment failures
most likely result from MQ resistance rather than artemisinin resistance because
increased pfmdr1 copy number has been linked with MQ resistance (or AS+MQ
resistance) 205,260,262,298,299. Indeed, recrudescence in the 2004 Pailin study above was
linked to amplification of pfmdr1 298 and pfmdr1 amplification was associated with
recrudescence after AS+MQ in NW Thailand in another study 274. Also, mutations
thought to be associated with artemisinin resistance (pfatp6) (below) have not been
detected in Cambodia, and no isolates resistant to artesunate in vitro have been found 280.
However, reports that link increased copy number of pfmdr1 to artemisinin and recent
reports of emerging artemisinin resistance in southeast Asia allude to the possibility of
artemisinin resistance as part of the resistance phenotype for ACTs (below).
The reason for emerging AS+MQ resistance is multifactorial. It may be that MQ
resistance in western Cambodia had already reached a level too extreme for the drug to
be further protected by AS. This is similar to what occurred when MQ+SP was
introduced in areas where there was already pre-existing SP resistance 154. The improper
use of antimalarial drugs may be a result of a number of reasons (i.e. misdiagnosis, lack
of adherence, taking substandard drugs, taking drugs for prophylaxis). A very recent
study found that a new fixed dose AS+MQ treatment was well-tolerated and effective,
making it a suitable replacement of AS+MQ non-fixed regimens 300. Perhaps finding
better ways to utilize existing components of ACTs can help maintain effectiveness of
drugs and protect the emergence of resistance. Another, more important, reason concerns
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pharmacokinetics of the drugs. The short half-life of the artemisinin component means
that if any parasites remained after an initial AS+MQ treatment, they may be selected for.
When patients become re-infected, tolerance to MQ may develop. Finally, malaria
parasites in southeast Asia are known to develop resistance to antimalarial drugs very
quickly 155,191, and one study found that parasites from this region are capable of
assuming an accelerated resistance to multiple drugs (AMRD) phenotype 301.
Resistance in southeast Asia to ACTs may not be limited to the Thai-Cambodia
region. Reduced efficacy of AS+MQ was reported in Kampot, a province in southern
Cambodia that borders Vietnam 280. Therefore, resistant parasites may be spreading and
an alternative ACT may be needed soon to replace AS+MQ. A disturbing possibility is
that emergence and spread of ACT resistance could occur in Africa, where the parasite
density is much greater, the transmission dynamics would ameliorate the spread of drug
resistance, drug use is inappropriate or uninformed, and the public health infrastructure is
weak 302. Although AS+MQ is not typically used in Africa, AE+LUM is a recommended
ACT that is used there. LUM is chemically related to MQ, which brings up the potential
for a situation that is like the one occurring in southeast Asia. The WHO is now
recommending ACTs to be first-line therapies in areas of falciparum malaria, and
because of this, presumptive treatment with ACTs may soon be commonplace in subSaharan Africa. This drug-use practice can only serve to promote the evolution of
resistance.
Antifolates. Resistance to the antifolate drugs first appeared in the 1950s with
the report of curative failures involved in the use of proguanil. Treatment failures were
observed with the once-effective pyrimethamine (PYR) shortly after it was introduced,
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rekindling interest in sulfonamides as antimalarials. The pairing of PYR with
sulfadoxine (SP) represented a first line drug for use in multi-drug resistant infections,
but the combination was found to exhibit adverse reactions and resistance emerged
shortly after it was introduced in Thailand and in Africa 155. High-level SP resistance is
found in many parts of South-East Asia, southern China and the Amazon basin, and
lower levels of resistance are seen on the coast of South America and in southern Asia
and Oceania. In eastern Africa, SP resistance has progressed westwards across Africa
over the last decade 49. Resistance to the antifolate antimalarials is well-established, and
it can be assigned to point mutations within DHFR (Pyrimethamine target) and DHPS
(Sulfadoxine target). Resistance to SP is attributable to parasites carrying mutations at
A16V, R50A, N51I, C59R, S108N, and I164L of the dhfr gene, and resistance is
augmented by point mutations at codons S436A, A437G, S436P, A581G, coupled with
A613T or A613S, and K540Q of the dhps gene 149,193,207,303. When mutations are found
together in an isolate, there is sometimes a synergistic effect on resistance. For example,
S108N is essential for in vitro PYR resistance. Additional mutation(s) in other
polymorphic sites synergistically increase the levels of resistance. Triple mutants
(N51I+C59R+S108N and C59R+S108N+I164R) show greater PYR resistance compared
to dhfr double mutants, and the quadruple mutant (N51I+C59R+S108N+I164R) shows
the highest resistance to PYR so far 207. The A437G mutation in dhps confers a 5-fold
increase in SULF resistance over wild-type parasites. Triple dhps mutants confer even
greater increases in sulfadoxine resistance: S436A+A437G+K540E (9.8-fold increase
over wildtype) and S436A+A437G+A613S (24-fold increase over wild-type) 207. The
effect of these point mutations is probably to alter the active binding site cavity where the
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drugs interact with the particular enzyme, thereby blocking drug action. As with CQ
resistance, it is possible to associate mutations in dhfr with geographical location of PYRresistant parasites. It appears that a resistant lineage having a double mutation in dhfr
(AA positions 59 and 108) was probably generated near the Thai-Cambodia border in the
1960s, and evolved to triple (positions 51, 59, 108; 59, 108, 64) and quartet (positions 51,
59, 108, 164) mutant types and spread to other regions in Asia and to Africa. In the
Pacific region, an indigenous lineage and a lineage that migrated from Southeast Asia
emerged. In South America, two distinct lineages of PYR resistance have been detected
in Venezuela (positions 50, 51, 108) and Peru (positions 51, 108, 164). These triple
mutant lineages sequentially evolved from different lineages of the same dhfr double
mutant (positions 51, 108) 207. Although SP may still retain some efficacy in areas of CQ
and MQ resistance, its repeated use will only serve to lower its efficacy due to the
accumulation of mutations in parasites, and this may compromise the efficacy of newer
antifolates even before they are brought into use. Because of this, SP is paired with AS
for ACT use. AS+SP has been effective in South America and Africa for treating P.
falciparum 304-306. AS+SP was reported to be very efficacious for P. vivax 307,308, but dhfr
mutations were detected in Papua after treatment 308. The WHO states that AS+SP is
ineffective at treating P. vivax in many locations in the world 44.
Atovaquone. ATOV is a relatively new drug that was developed in the 1980s,
but it was originally synthesized in the 1940s 309. When used as a single agent against
malaria, ATOV leads to high rates of recrudescence 310,311, and evidence suggests that
patients taking ATOV only may quickly develop resistance to the drug 311. ATOV
inhibits the cytochrome bc1 complex of the electron transport chain of malaria parasites,
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inhibiting electron transport and collapsing mitochondrial potential 165,309,312. Studies of
laboratory-generated ATOV resistant mutants and field isolates showed that mutations in
the cytochrome bc1 complex are linked to ATOV resistance 309,313-315. When ATOV is
combined with proguanil, cure rates are usually high 311,315. The effectiveness of this
combination then led to the inclusion of proguanil as a synergistic agent with ATOV
therapy. The recently introduced drug Malarone® (ATOV+proguanil) is used for
treatment and prophylaxis. Although Malarone® is a powerful combination, there is
potential for the emergence of drug resistance. There are reports of in vivo Malarone®
resistance in patients 315-319. These studies found that mutations at codon 268 in the
cytochrome b gene (within the region encoding the putative ATOV-binding domain) are
associated with Malarone® resistance. Currently, this appears to be the only genetic
change that is associated with Malarone® treatment failure in vivo. Therefore, these
mutations are considered useful tools for the surveillance of resistance to Malarone®.
Artemisinins. The potential emergence of artemisinin resistance is a major
concern given the fact that artemisinin is widely used as a monotherapy and it is part of
combination therapies utilized in areas where drug-resistant malaria is already prevalent.
The mechanism(s) of action of artemisinin drugs is controversial and not well-known, but
even less is known about potential resistance mechanisms to the drugs. Until recently,
resistance to artemisinin drugs had not been documented in the field. Several clinical
studies based in southeast Asia have classified artemisinin resistance as delayed parasite
clearance along with reduction of in vitro susceptibility to artemisinin drugs 320-322.
Although these authors acknowledge the potential of artemisinin resistance, they also
note that it is not a widespread phenomenon. Because artemisinin drugs are part of
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current recommended combination treatments for P. falciparum, it is critical to
investigate possible mechanisms of resistance to these drugs in Plasmodium spp.
Currently, there are a group of genes that have tentative associations with the site of
action or reduced susceptibility (or cross-resistance) to artemisinins.
As stated above, pfatp6 is reported to be the best candidate for the link to
artemisinin activity, and a recent report thoroughly discussed the reasoning behind this
and potential artemisinin resistance 323. However, there is a dearth of studies that have
reported on the involvement of this gene and artemisinin resistance. Uhlemann et al.
(2005) 186 reported that introducing a L263E mutation in transmembrane segment 3 in
pfatp6 abolished artemisinin activity, and it was theorized that this mutation existed in the
binding pocket for artemisinin. However, a study by Valderramos et al. (2010) 324 found
that parasites expressing engineered L263E variant PfATP6 did not have a significant
change in 50% inhibitory concentrations (IC50s) for QHS, DHA, or AS. In a study using
patient isolates from Cambodia, French Guiana, and Senegal, the S769N mutation was
found exclusively in French Guiana isolates (the double mutation A623E E431K was also
found in low prevalence), which correlated with resistance to AE 185. Further studies by
this group 325 of 100 isolates from sites in Africa, Asia, and South America found large
diversity in pfatp6 coding sequence including 32 SNPs (average of one SNP/115 bp), of
which 19 were novel mutations. The PfSERCA functional domains were very well
conserved, with non synonymous mutations located outside the functional domains,
except for the S769N mutation associated in French Guiana with elevated IC50 for AE.
The S769N mutation is located close to the hinge of the headpiece, which in other species
modulates calcium affinity and in consequence efficacy of inhibitors, possibly linking
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calcium homeostasis to drug resistance. Another study reported on pfatp6 diversity from
~400 samples from 17 countries (mainly Zanzibar and Tanzania). This resulted in the
identification of 33 SNPs, of which 29 had not been described previously. Three
mutations were found in high frequency in Zanzibar and Tanzania (E431K, N569K and
A630S). Interestingly, no variation was found in position 263 or in position 769 326.
Another study examined SNPs of pfatp6 in 87 P. falciparum samples from Niger and
found SNPs at positions 537, 561, 569, 630, 639, and 716. All the mutations found were
rare, except N569K, which was found in 17.2% of samples 327. A recent study with
Vietnam isolates reported mutations (N460N, N463S, N465S, C1031C) and one double
deletion (463-464) in pfatp6 that had not been reported before328. Others did not find
mutations within pfatp6 in Asia or Africa 276,320,321,329-331 or its homolog in P. chabaudi 332.
Price et al. (2004) 262 detected the I89T mutation in two isolates from NW Thailand that
had elevated IC50 to AS. A survey of a larger number of parasites did not associate this
mutation with an IC50 change, however. Toovey et al., 2008 333 reported that DHA, MQ,
and LUM inhibited mammalian SERCA at peri-physiological concentrations, further
implicating this gene type in artemisinin activity. Importantly, the prevalence of pfatp6
mutations may correspond to regions of ACT use 323,326,327. However, studies that
identified the SNPs did not attempt to associate mutations with altered susceptibility with
artemisinin drugs (except 262,324), indicating that a causal association between resistance
and mutations cannot be made at this time.
Studies have also found that artemisinin susceptibility can be influenced by
genetic changes in loci encoding pfmdr1and pfcrt. As discussed above, point mutations
and amplification of pfmdr1 can alter parasite susceptibility to different antimalarial
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drugs, leading to cross resistance to antimalarials in some cases. The study by Reed et al.
(2000) 202 found that amino acid changes in pfmdr1 (S1034C, N1042D, and D1246Y)
correlated with increase in MQ, HAL, and QHS sensitivity (the converse was true when
the residues were removed). Therefore, it appeared that there is cross resistance for these
drugs, possibly mediated by a common mechanism of resistance. Reports have justified
this assertion in different studies in Africa and Asia showing cross resistance between
QHS and QN/MQ/HAL 334, QHS and MQ/HAL 249, AS and MQ/QN 335, and
AS/DHA/MQ 336. It was recently found that genetic disruption of pfmdr1 led to
enhanced susceptibility of QHS/HAL/MQ 259 and decreased pfmdr1 copy number was
associated with susceptibility to QHS/MQ/LUM/HAL/QN 263. Increased copy number of
pfmdr1 in patient isolates or in vitro artemisinin- selected lines correlates with
recrudescence after AS+MQ treatment 298 and decreased susceptibility to QHS/MQ/HAL
206

, AS/MQ/HAL/CQ 266, AS/MQ 262,286, QHS/MQ/QN (but increased CQ) 205,

QHS/MQ/LUM/QN 260, and AL/QN/MQ/DHA/QHS (but increased CQ) 276. However,
other studies have reported a disassociation with pfmdr1 (or its homolog in murine
malaria) and artemisinin resistance 202,257-259,276,320,321,329,332,337. This may indicate that
depending on location in the world and the presence of other genetic alterations, drug
susceptibility profiles change.
PfCRT is usually not implicated in artemisinin resistance, but again, there are not
many studies attempted at making the association. Ngo et al. (2003) 258 reported on
isolates from Vietnam that were taken from patients before and after QHS therapy.
These isolates exhibited MQ resistance and CQ susceptibility (with concomitant SNPs in
pfcrt and pfmdr1), with no change in QHS sensitivity. This may indicate that AS+MQ
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treatment in the area selected for MQ resistance. Sidhu et al. (2002) 211 found that mutant
pfcrt haplotypes from Asia, Africa, and South America correlated with CQ-resistance, but
QHS susceptibility. The use of AE+LUM in Africa has been reported with susceptibility
to AE+LUM and wild-type K76 in pfcrt 245,272. It is unclear from these studies if the
presence of K76 is associated with any artemisinin activity. Very recently, Valderramos
et al., (2010) 236 placed CQ-resistance alleles from strain 7G8 (Brazil) into strains 3D7,
D10 (Papua New Guinea), and GC03 (Dd2xHB3cross). They found that QHS and LUM
susceptibility increased, but QN susceptibility was unchanged. In this study, the authors
also conducted susceptibility testing on isolates from French Guiana (originally reported
on in Jambou et al, (2005) 185 in study of pfatp6). They found that isolate H209 exhibited
elevated IC50 to QHS, AS, AE, LM, and QN. H209 carried a novel PfCRT mutation
(C350R) and this parasite was highly sensitive to CQ, yet demonstrated delayed
recrudescence. It remains to be seen if transfecting the C350R mutation into other
parasite lines will cause reduced artemisinin sensitivity in other strains. Chavchich et al.
(2010) 276 recently reported on the induction of artemisinin resistance in P. falciparum,
which did not associate with changes in pfcrt. Overall, it appears that pfcrt does not
correlate well with artemisinin resistance. However, the potential of a novel mutation for
artemisinin resistance is disturbing. Importantly, the strain carrying this mutation is from
French Guiana, an area where AE+LUM is actively used, and the presence of an
artemisinin-resistance mutation would be devastating. On the positive side, this could be
a potential marker for artemisinin resistance in the field.
Research on artemisinin resistance has intersected with several other genes
including pfmrp1, P. falciparum transitionally controlled tumor protein (pftctp), and
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murine homologs of P. falciparum ubiquitin protein 1 (pfubp-1) and pfmdr1. As
discussed above, pfmrp1 was previously found to be associated with QN and CQ
resistance. Disrupting this gene appeared to increase sensitivity to these drugs, and also
to QHS 214. PfTCTP was identified as a potential alkylated protein that may be acted on
by artemisinin activity 338. TCTP was found to be located in the DV and cytoplasm 339
and it was found to interact with QHS and bind hemin 338. Therefore, it is possible that
its position in the DV could provide a link to heme metabolism and artemisinin activity.
Studies in murine models of malaria have shed light on many facets of malaria,
including drug resistance, because these models are amenable to in vivo studies. An
artemisinin-resistant line of P. yoelii was described by Ferrer-Rodriguez et al. 2004 340
that had increased copy number of pymdr1. However, resistance was not stable,
preventing an association from being established between pymdr1 and artemisinin
resistance. Afonso et al. (2006) 332 reported on the induction of in vivo QHS and AS
stable resistance in P. chabaudi, which may be the first published work on the selection
of stable artemisinin-resistant malaria parasites. The QHS and AS-resistant parasites
were derived from CQ-resistant clones that were exposed to subcurative doses of QHS
and AS. Parasites that were resistant to artemisinins in this study had 6-15 fold increase
in the minimum curative dose. The parasites derived in this study have served for future
studies on artemisinin resistance in P. chabaudi. In this study, orthologs of pfatp6, pfcrt,
pfmdr1, and pftctp were analyzed in resistant and parental lines, and it was determined
that nucleotide sequences were similar and copy numbers were not elevated.
Interestingly, artemisinin resistance could not be induced in CQ-sensitive parasites. The
authors attributed the acquisition of artemisinin resistance in CQ-resistant parasites as a
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result of the parasites' ability to generate mutations in response to drug treatment (called
the ARMD phenotype) 301, which might have occurred during the generation of the CQresistant lines, or that the artemisinin resistance phenotype is expressed only in CQresistant clones. Although this would tend to suggest that there is some functional
interaction between the pathways underlying CQ and artemisinin resistance, studies have
shown that a CQ-resistance phenotype is associated with increased artemisinin
susceptibility in Asia and Africa 210,211,249. We and Chavchich et al. 2010 276 found that
artemisinin resistance can be induced in CQ-sensitive D6, and CQ susceptibility
decreased in D6 resistant lines. Clearly, the link between CQ and QHS resistance
warrants more attention in the future.
A study by Hunt et al. (2007) 341 employed the QHS-resistant version of P.
chabaudi from 332 and crossed it with a QHS-sensitive strain. This experiment identified
a locus on chromosome 2 that conferred in vivo ART resistance and revealed two point
mutations in a gene (pcubp-1) encoding a de-ubiquitin carboxyl-terminal hydrolase. One
of the mutations came as a result of crossing with the QHS strain (V739F), but the other
was in the CQ-resistant parent of the ART resistant strain to begin with (V770F). The P.
chabaudi ortholog of pfatp6 (pcatp6) also existed on chromosome 2, but no mutations
were detected in the gene. During this study, QHS resistance was also selected in P.
falciparum lines NF54 and 7G8, although it did not prove to be stable. However, in the
resistant parasite, pfcrt, pfmdr1, and the P. falciparum ortholog of pcubp-1 (pfubp-1) all
did not display mutations relative to the parental parasite. A subsequent study 342
implicated the V770F mutation as the sole indicator of shifting artemisinin response in
CQ and artemisinin resistant P. chabaudi parasites. Imwong et al., 2010 329 reported that
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P. falciparum isolates from Western Cambodia (where artemisinin resistance is reported
to be emerging) did not have putative mutations in pfubp-1 (those reported by Hunt et al.
2007 341). It remains to be seen how ubiquitin hydrolases relate to artemisinin resistance.
Because of the importance that pfmdr1 plays in drug resistance, researchers investigated
the relation of the P. chabaudi ortholog (pcmdr1). Cravo et al. (2003) 343 reported on the
induction of in vivo MQ resistance in P. chabaudi, and found that the sequence of both
copies of pcmdr1 in the genome of the resistant parasite were identical to that of the
parent sensitive clone. A cross between the MQ clone and a MQ-sensitive clone revealed
that duplication and over-expression of the pcmdr1 gene was an important determinant of
resistance. However, not all mefloquine-resistant progeny contained the duplicated gene,
showing that at least one other gene was involved in resistance. Rodrigues et al. (2010)
335

aimed to dissect factors influencing ACT resistance and its acquisition. Using the

QHS-resistant P. chabaudi described by 332, in vivo resistance to AS+MQ was achieved,
through prolonged exposure of parasites to both drugs over many generations. A stably
resistant parasite showed increased resistance to AS+MQ treatment and to AS or MQ
administered separately. Examination of putative artemisinin-resistance genes found a
duplication of pcmdr1 with concomitant increased levels of pcmdr1 transcripts and
protein. No point mutations were found in pcatp6 or pcubp1. This is the first report to
show selected resistance to a surrogate ACT, showing that resistance to ACTs may
evolve even when the two drugs within the combination are taken simultaneously and
amplification of an mdr1 gene may contribute to this phenotype. Walker et al (2000) 344
attempted to characterize QHS accumulation and the role of TCTP in a QHS-resistant P.
yoelii strain from Peters and Robinson (1999) 345. This study found that QHS-resistant
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parasites accumulated significantly less radiolabeled DHA compared to sensitive
parasites. Radiolabeled DHA bound to proteins in both parasites, but TCTP was
expressed about 2.5 times more as the sensitive strain. Based on these results, it appeared
QHS resistance is multifactorial in P. yoelii. However, these mechanisms of resistance in
murine malaria species may not be exhibited in human malaria species. A study by
Chavchich et al. (2010) 276 did not find sequence differences in pftctp, pfubp-1 or
expression of pftctp in in vitro selected artemisinin-resistant P. falciparum.
The above studies on artemisinin resistance have scratched the surface of what
may be a potentially emerging problem. Artemisinins were thought to be the one class of
drugs that were reliable as a last resort. However, studies from the field are now raising
fears that these drugs are no longer effective. What is concerning is that these drugs are
used in combination with other drugs that often have long half-lives and maybe suboptimal themselves at treating malaria. Therefore, it may be possible to select for
resistance to either part of the ACT. The biological basis of artemisinin activity is still
controversial, and molecular mechanisms of resistance cannot be causally associated with
patient treatment failure. As described above, it is only in the last few years that
researchers have attempted to examine these mechanisms, which may be imperative to
stopping spread of artemisinin resistance. Our laboratory has focused on dissecting
artemisinin-induced dormancy and molecular mechanisms of artemisinin resistance.
Preliminary Studies from the Kyle Laboratory
Dormancy. Artemisinin drugs and their derivatives are very effective for treating
malaria, but they are rapidly eliminated (approximately 1 hour, 346), which may be
responsible for the high number of patients that experience recrudescence following
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monotherapy treatment lasting less than 7 days 347. The recrudescent parasites remain
susceptible to artemisinin in vitro 282,284,288,348-351 (Kyle et al., 2010 unpublished),
suggesting that the high frequency of treatment failure is not due to conventional
resistance mechanisms.
Previous in vitro studies provide compelling evidence that the artemisinin drugs
are not completely cidal, but may produce a static effect on parasite growth. Studies
showed that after treatment with some antimalarials, parasites enter a survival state
before they recrudesce in culture. Reports of P. falciparum entering a dormant state have
been described after PYR and MQ treatment 352-354. It has been suggested that
recrudescence after artemisinin treatment is attributable to parasites surviving in a hidden,
protected state 355-358. The persistent suppression of parasite growth following short
exposures to artemisinins is similar to the postantibiotic effect (PAE) observed for
antimicrobial drugs 359. Although these studies observed effects on parasites after
antimalarial drugs, a causal association could not be made between drug activity and a
mechanism allowing parasites to survive and cause re-infection.
The apparently conflicting observations on the cidal mechanism of action for
artemisinin drugs and the frequency of recrudescence following treatment led our group
to investigate the stage specific activity of artemisinin drugs. Parasites were treated with
1 and 10 ng/ml of AS and 1 and 10 μg/ml QN for 6 hours. Development of the parasites
at 0, 4, 24, 28, and 44 hr was followed by using flow cytometry (Fig. 1.6). After
exposure to either 1 or 10 ng/ml of AS, the development of 8-12 hr old ring stage
parasites was abruptly halted, whereas QN-treated parasites continued to develop to
trophozoites. By 28 hours, there was a clear difference in the intensity of the observed
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fluorescence in the controls and the quinine treated parasites versus the AS groups. This
was indicative of parasite maturation to early schizonts in the control and quinine groups.
In contrast, the development of parasites was completely arrested in the presence of 10
ng/ml AS and very few parasites developed in the 1 ng/ml group. By 44 hours, the
control parasites had completely developed through schizogony and had initiated a new
cycle. In contrast, the AS-treated parasites still had not developed past the ring stage nor
had they synthesized DNA. Throughout the 44 hour experiment, the profiles observed
for the AS-treated samples remained similar to the control parasites at the beginning of
the experiment. Throughout the experiment, profiles observed for the AS-treated
samples remained similar to the control parasites at the beginning of the experiment.
Further experiments showed that treatment of ring stage parasites with DHA had a
significant effect on the subsequent development of the parasite to mature stages.
Treatment with 2 and 20 ng/ml DHA for 24 hours significantly delayed the growth of
parasites to trophozoites and schizonts, as parasites were arrested at ring-stage (Fig. 1.7).
This DHA-induced arrest was both dose and duration of exposure dependent. Although a
prolonged delay in growth was observed, in all cases the parasites eventually resumed
normal growth at a rate similar to that observed for untreated parasites. Microscopic
examination of blood smears revealed that the development of parasites was arrested at
ring stage during the “non-growth” period. Morphology of ring stage parasites exposed
to 2.0 ng/ml DHA for 6 hours revealed that for the first 48 hours, most parasites had
pyknotic nuclei and reduced cytoplasmic mass. By 72 hours, predominant forms seen
were parasites with densely stained nuclei with little or no cytoplasm. From 48-72 hours,
some parasites were more severely affected with the shape of the nuclei becoming less
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rounded and with clumps of more densely stained chromatin. There was no evidence that
parasites were developing to mature stages at either the 2 or 20 ng/ml doses by 72 hours.
In the 2 and 20 ng/ml groups normal ring stage parasites were seen at 72 hours and by
120 hours, morphologically normal mature stages were prevalent. Although the exact
proportions were not determined, there were many DHA-affected parasites still observed
at 144 hours, especially in the 20 ng/ml DHA group. Parallel experiments with QN also
produced a significant delay in development, but the effect upon the morphology of the
parasite was very different compared to parasites treated with DHA. Only DHA
produced the arrested development of ring stages. Subsequent experiments with
synchronous trophozoites and schizonts aimed to investigate stage-specific effects of
artemisinins. These results showed that trophozoites were severely affected by DHA,
with no formation of schizonts. The majority of parasites were shrunken, dead, and/or
extracellular. In contrast, schizonts exposed to DHA ruptured and produced merozoites
that were seen in newly invaded erythrocytes. The morphology of most young ring
stages observed in the DHA-treated group appeared normal. Some schizonts also
remained at 18 hour post-exposure to DHA, suggesting a delay in maturation of the
treated parasites. These parasites continued to develop normally. These data indicated
that schizonts were affected much less by equivalent DHA concentrations than other
erythrocytic stages of the parasites. Following the rupture of schizonts exposed to DHA,
morphologically normal rings and some forms that were similar to the ring stage
dormants were observed. The experiment could not be continued past 96 hours (due to
rapid growth of most parasites in the culture), but dormant ring stages were observed in
all slides from 24-96 hr. These results suggest the possibility that progeny of schizonts
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exposed to DHA may become dormant following invasion of a new erythrocyte.
Additional studies are required to determine the proportion of progeny from DHAexposed schizonts that continue to grow normally versus the proportion that may become
dormant.
These data that demonstrate recrudescence in vitro are similar in part to previous
observations by Witkowski et al. (2010) 360 and Nakazawa et al. 352,354. The study by
Witkowski et al. (2010) 360 detailed induction of artemisinin resistance in a P. falciparum
isolate from Tanzania. They noted that following QHS treatment, parasites were arrested
at ring-stage. However, they only noted this in the parental line (not resistant progeny),
and only reported on epifluorescence without thorough microscopic observations of the
arrested parasites. The studies by Nakazawa et al. reported on exposure of asynchronous
P. falciparum cultures to PYR or MQ in vitro, where recrudescence occurred up to 10
days after the end of treatment. Unfortunately, these excellent studies did not include any
observations on the morphological changes associated with drug treatment, stage specific
activity of PYR was not investigated, nor did the authors propose the mechanism that
allowed the parasites to recrudesce. Therefore, our lab compared the ability of other
commonly used antimalarial drugs to arrest ring stage development. Ring stages of
TM93c1546 (Thai isolate of P. falciparum) were exposed to CQ (500 nM), MQ (100 nM),
QN (1 M), HAL (100 nM), PYR (1 M), or DHA (100 nM) for 6 hours. Of the
antimalarial drugs tested, only DHA induced ring stage arrest and dormancy in >90% of
the parasites observed at 48 hr post-exposure. In contrast, the other drugs allowed a
significant proportion of the parasites to develop to more mature asexual stages, which is
consistent with reports that these drugs are most active against trophozoites. Although
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morphological abnormalities were observed in some ring stage parasites after treatment
with MQ and HAL, they were much different to that produced by DHA. These results
indicated that artemisinin drugs uniquely induce dormancy in ring stages, yet these data
do not exclude the possibility that other antimalarial drugs may induce dormancy in a
subsequent generation of the parasite. Previous studies suggest that some antimalarial
drugs have a significant effect upon the 2nd asexual generation following exposure to the
drug 361. Our data on the effect of DHA on schizonts are consistent with that hypothesis
and may help explain the data on recrudescence from PYR and MQ exposure in vitro
352,354

.
The preliminary data generated by our lab led to the intriguing hypothesis that

dormant ring stage parasites may be the forms that survive treatment with artemisinin
drugs and recover to initiate a recrudescent infection. To fully explore the hypothesis,
dormant forms were characterized at the cellular and molecular level. Our initial efforts
assessed if dormant ring stage parasites express proteins normally found in early ring
stages. We focused our attention on genes that would allow differentiation of rings from
other stages. One type of gene family is the early transcribed membrane proteins
(ETRAMPs), which are located on the parasitophorous vacuole membrane. ETRAMP2
is expressed only in ring stages, whereas ETRAMP4 is found only in trophozoites.
Exposure of synchronous ring stages of K1 and S99 (isolate from the Solomon Islands) to
10 or 400 nM DHA for 4-12 hours found that ETRAMP2 labeled ring stage parasites in
untreated control preparations, with fluorescence localized to the periphery of the parasite
(Fig. 1.8-A-C). ETRAMP2 antisera labeled dormant parasites with a fluorescence pattern
identical to normal early rings. In addition, many parasite nuclei were found without any
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associated staining by ETRAMP2 antisera (Fig. 1.8-D). In Giemsa-stained smears from
these same preparations, approximately 25% of the dormant parasites had intact nuclei
with evidence of cytoplasm. The rest of the dormant parasites had little or no cytoplasm
and many of the nuclei were irregularly shaped with uneven staining of the chromatin.
Interestingly, no signal was seen with the trophozoite-specific ETRAMP4 sera in either
the low or high dose DHA-induced dormant parasites. Parasites transformed with GFP
were also used to assess the effect of artemisinin-induced dormancy on protein
expression. Parasites exposed to DHA (100 nM) for 6 hours continued to fluoresce even
in the arrested ring stages (Fig. 1.8-E). GFP fluorescence was observed associated with
parasite nuclei during drug-induced dormancy and progeny from these cultures remained
fluorescent after they recovered from the drug effects. Similar to the data for ETRAMP2,
by 72 hr following drug exposure, many nuclei were found without any evidence of GFP
fluorescence. These data suggest that dormant parasites continue to express proteins
observed during normal ring stage development, but do not express trophozoite specific
proteins during artemisinin-induced dormancy. The intriguing finding of parasite nuclei
without corresponding protein expression > 72 hr post treatment may be indicative of
parasite viability, drug induced suppression of newly transcribed proteins, or both.
Continuation of these studies has enhanced our understanding of the physiological effect
of short-term drug exposures and lead to identification of markers that could be used to
enhance the detection of dormant parasites on blood smears (LaCrue et al., unpublished
data).
Our in vitro data demonstrate that in the early stages of dormancy the parasites
could easily be confused microscopically with tiny rings or newly invaded merozoites.
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Within 48-72 hr after dormancy is induced in vitro, many nuclei are found with little to
no blue-stained cytoplasm in giemsa stained smears. These forms could be easily missed
in thick or thin blood films since most experienced microscopists will not count a form as
a malaria parasite without evidence of typical purple-red nuclear and blue cytoplasmic
staining. With these limitations in mind, thick and thin blood smears were
retrospectively examined from two animal experiments with AL, an artemisinin
derivative that also induces dormancy. Retrospective examination of blood smears from
mouse studies with P. berghei and monkeys infected with P. falciparum provided
evidence that artemisinin-drug induced dormancy occurs in vivo. The search for dormant
parasites required prolonged examination of the smears and it was difficult to distinguish
between newly invaded merozoites and possibly dormant parasites. Interestingly, the
technician that reads the smears for routine antimalarial drug testing studies reported the
smears as negative. Clearly, there is a need to develop better tools or methods to
adequately examine the role of dormancy in in vivo recrudescence (and for in vitro
studies). Perhaps probing with sera to ETRAMP2 may lead to a better estimation of
some dormant forms, but the method may not be sensitive enough to identify parasite
nuclei (i.e., no cytoplasm). We have expanded on our immunofluorescence studies with
ETRAMPs, by assessing in situ hybridization methods to enhance the detection of
dormant parasites in vivo (LaCrue et al., unpublished data).
Our data on DHA-induced dormancy allowed us to draw some conclusions about
the relevance of this phenomenon to the clinic and also to propose experiments that
specifically address the most relevant questions. We hypothesized that ring stage
parasites exposed to artemisinins in vivo could have three fates: become dormant,

87

continue to grow at a slower rate, or be cleared by specific and non-specific immune
mechanisms (above). The drugs kill trophozoites efficiently, whereas cytoadherent
schizonts can either continue to produce viable progeny, or enter dormancy after
infecting a new erythrocyte (Fig. 1.9). If dormant parasites recover and resume growth
during the treatment period when the plasma drug level is above the MIC, they may enter
another cycle of dormancy or be killed. A recrudescence of infection will occur when
dormant parasites recover and resume growth when drug levels decline below the MIC.
Interestingly, our dormancy hypothesis is consistent with clinical observations of
recrudescence, yet remains at odds with proposals for artemisinin activity, focusing on
heme or iron-mediated mechanism of toxicity to parasites 175,178.
In contrast to a completely cidal mechanism of action, in vivo efficacy studies and
our in vitro dormancy data are more consistent with a specific protein target for the drug
class. As discussed above, several targets have been implicated. Perhaps the most
important implication of our data is that P. falciparum may survive exposure to
artemisinin drugs to a unique mechanism of drug resistance. As discussed above,
resistance to other antimalarial drugs is due to reduced binding affinity (antifolates and
ATOV), reduced accumulation of drug at the active site (CQ), or increased expression of
drug resistance associated proteins (MQ). Similar to these accepted mechanisms of
resistance, artemisinin induced dormancy possibly allows parasites to evade the action of
drugs and survive in the host long enough to reproduce. In previous studies we observed
that parasites from recrudescent infections were equally susceptible to AS and DHA as
the parasite collected prior to treatment 282,284,288,348-351. Since artemisinin drugs have
short effective half-lives (~2 hr), dormant parasites would not be under pressure to
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develop the more classical mechanism(s) of resistance to DHA as they may remain
dormant during the brief period these drugs persist in blood. It is important to determine
if the inherent susceptibility to artemisinin is reduced after multiple dormancy episodes or
if the recovery rate increases or duration of dormancy decreases. Either of these outcomes
would confirm a unique parasite survival mechanism to the most important class of
antimalarial drugs.
The use of artemisinin drugs is increasing worldwide and there is an ongoing
international effort to determine the most effective partner drug to prevent recrudescent
infections. One proposal suggests that ACTs utilizing AS should be used with all new
and existing drugs to prevent or slow the emergence of resistant malaria. The formation
of dormant parasites during treatment with AS could be an important factor in selecting
the best companion drug, especially since the second drug may be ineffective against a
dormant, metabolically quiescent parasite. Since AS+MQ is an ACT under heavy use in
Asia, we tested this theory by exposing ring stage K1 and FC27 parasites to 10 nM DHA
for 6 hours followed by mefloquine (50 nM) for an additional 18 hours. The FC27 rings
exposed to DHA alone produced dormant forms that did not begin to recover and grow.
Normal ring and trophozoites were first observed 172 hr after the experiment was begun.
Interestingly, rings exposed sequentially to DHA and then to MQ also recovered by 172
hours. In similar experiments with K1, there was a delay of 24 hours in the recovery of
the DHA+MQ treated group versus those only exposed to DHA. These results could
have significant implications for the use of artemisinin combinations. These data suggest
that a successful companion drug must have activity against dormant forms or have a
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long enough half-life to remain active in the blood when dormant forms revive to produce
recrudescent infections.
Based on the preliminary studies our laboratory has conducted, we hypothesize
that DHA and AS arrest the development of ring stages and induce a metabolically
quiescent or dormant parasite. These parasites can remain dormant and survive for a
minimum of 3 days after exposure to 10-100 fold concentrations above the MIC. These
data are consistent with previous observations in vitro and in vivo and for the first time,
provided evidence that the dormant ring stage parasites are the forms that survive to
produce recrudescent infections. The persistent suppression of parasite growth following
short exposures to DHA was similar to the PAE described above.
Another study from our group examined rates of recovery from dormancy, which
may be an important facet for uncovering why patients experience delayed clearance
times and recrudescence after treatment with a single artemisinin drug. Teuscher et al.
(2010) 362 exposed ring-stage parasites of several Plasmodium falciparum lines to
different doses of DHA alone or in combination with MQ. For each drug treatment series,
the proportion of recovering parasites was determined daily for 20 days with and without
the use of a magnetic column that would take out parasites unaffected by DHA. Parasite
development was abruptly arrested after a single exposure to DHA, with some parasites
remaining dormant for up to 20 days. Approximately 50% of dormant parasites recovered
to resume growth within the first 9 days. The overall proportion of parasites recovering
was dose dependent, with recovery rates ranging from 0.001% to 1.313%. Repeated
treatment with DHA or with DHA in combination with MQ led to a delay in recovery and
a ∼10-fold reduction in total recovery. Strains with different genetic backgrounds
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appeared to vary in their capacity to recover. These results imply that artemisinin-induced
arrest of growth occurs readily in laboratory-treated parasites and may be a key factor in
P. falciparum malaria treatment failure.
Studies relevant to this work. Investigators have attempted to establish
resistance models to artemisinin drugs, including P. falciparum and T. gondii in vitro and
rodent malaria in vivo 332,335,340,341,345,363-368 . Although all of these studied proved
artemisinin resistance can be induced in different models, some noted associated
problems with selection of resistance (unstable resistance, reversion to a sensitive
phenotype, parasites exhibiting a range of artemisinin sensitivity compared to the
sensitive strain, or lack of data on stability of resistance). However, some of these studies
have provided significant contributions toward dissecting putative molecular mechanisms
of artemisinin resistance.
Previous studies from our group found that multiple rounds of parasite exposure
to an artemisinin drug, followed by dormancy, recovery, and growth, selects for parasites
with reduced susceptibility to this class of antimalarial drugs. Studies have reported on
detailed selection of P. falciparum resistance to artelinic acid (AL) and QHS in vitro and
molecular changes occurring during the selection 276,337 (Gerena and Kyle, unpublished
data). Resistance was first induced to AL in P. falciparum strains in vitro by adopting the
methods Oduola et al. (1988) 369 used for MQ (W2Mef). Clones of W2 (Indochina) and
D6 (Sierra Leone) and a patient isolate from Thailand (TM91c235) were cultured under
increasing drug pressure in step-wise increments over 28 months 276 (Fig. 1.10). The
increments of AL used were 0.5, 1, 2, 4, 10, 20, 30, 40, 50, and 80 ng/ml, with each stage
of exposure lasting between 11-93 days. It is important to note that AL pressure was not
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applied continuously, even as parasites adapted to growth at higher AL concentrations. A
routine drug exposure cycle began with adding AL to asynchronous cultures at 4-8%
parasitemia. Drug pressure was removed when parasite morphology degraded so that
most of the parasites were abnormal or drug-affected (usually 2-3 days). AL pressure
was resumed when parasite growth and morphology became normal. A parasite was
considered adapted when the recovery phase occurred in 2-4 days. After W2 and D6
were adapted to 80 ng/ml AL, they were exposed to stepwise increments of
concentrations of QHS, starting from 20 ng/ml and extending up to a maximum of 200
ng/ml (W2 only). Overall, this procedure produced W2 progeny resistant up to 200
ng/ml AL and 200 ng/ml QHS, TM91c235 progeny resistant up to 80 ng/ml AL, and D6
progeny resistant up to 80 ng/ml AL and 80 ng/ml QHS 276.
Parasite susceptibility to the drugs was assayed by measuring the inhibition of [ 3H]
hypoxanthine uptake 276. Interestingly, parasite susceptibility to AL and other
antimalarial drugs shifted significantly in response to the increased drug pressure. In
general, as AL drug pressure increased, drug susceptibility decreased to other artemisinin
drugs (DHA, QHS), and MQ, whereas parasites under AL pressure became more
susceptible to CQ. In the W2 clone, a significant reduction in sensitivity to AL, QHS,
and MQ was observed when parasites became adapted to 40 ng/ml AL drug pressure and
this trend continued through the 80 ng/ml AL level. For D6, a significant reduction in
sensitivity to AL, MQ, and DHA was observed when parasites were adapted to 30 ng/ml,
but only AL resistance continued to increase as parasites were adapted to 80 ng/ml AL.
Interestingly, sensitivity to QHS was significantly decreased when D6 was adapted to 40
ng/ml AL and this trend continued to 80 ng/ml AL. For TM91c235, susceptibility to AL
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and QHS in TM91C235 decreased immediately and after exposure to 10 ng/ml AL, and
after 30 ng/ml AL, there was no noticeable change at higher levels. Susceptibility to
DHA significantly decreased as parasites tolerated 40 ng/ml AL, and this trend increased
up to 80 ng/ml AL. Parasites became noticeably less susceptible to MQ at 30 ng/ml AL,
but then parasites became more sensitive to MQ as AL tolerance increased.
Although long-term stability studies at these high levels of drug exposure have
not been completed, several important conclusions can be made from these observations.
Firstly, resistance to artemisinin derivatives (as indicated by the ability to survive
increasing concentrations of the drug) can be induced in P. falciparum in vitro. Secondly,
there is a significant degree of cross-resistance induced between various artemisinin
derivatives and to MQ. Finally, these artemisinin resistant parasites represent a unique
resource for the study of artemisinin resistance mechanism(s), mechanism of action
studies, and for determining the role of drug-induced dormancy as a mechanism of
recrudescence.
Molecular characterization of artemisinin resistance. It was previously
maintained that clinical resistance to artemisinins had not been observed 347,358.
Interestingly, data to support these claims ignore the frequent recrudescence of infection
following treatment with less than 7 days of an artemisinin derivative, with or without a
companion drug 347,370. It is important to note that confirmation of clinical resistance to
artemisinin will be difficult to discern from normal recrudescence infections. The
difficulty is amplified by the short half-life of the drug, which complicates therapeutic
drug monitoring confirmation of patient compliance with the proper regimen. Due to
these technical issues, it is likely that artemisinin resistance could emerge and spread
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rapidly before its occurrence is detected. Identification and development of molecular
markers, or other methods of identifying and tracking artemisinin resistant parasites, is
critically important. Recent reports of artemisinin resistance have emerged recently 320322

, but it remains to be seen if this will become a widespread phenomenon.
As discussed above, there is a paucity of data on possible mechanism(s) of

artemisinin resistance in P. falciparum, therefore our lab initially chose to characterize in
vitro selected artemisinin resistant parasites for global gene expression and analysis of
candidate resistance genes. Microarrays were conducted with early trophozoites of W2
vs. W2.AL80 and W2.QHS40, where transcriptional differences were measured after
treatment with DHA (unpublished data). Three-way ANOVA identified sets of genes
that were differentially expressed in the parent and resistant progeny or in response to
drug treatment. Overall, the most pronounced expression changes were observed for
pfmdr1 (PFE1150w), where there was a 4-fold increase in expression for W2.AL80 and
~2 fold increase in W2.QHS40 when compared to W2. A subset of putative ABC
transporters was under-expressed in the W2-resistant progeny (ex. pfmdr2). Genomewide screening of genes associated with drug resistant found 215 probesets whose values
of genotype effects were significant at P<0.01 level, and 40 probesets were significant at
P<0.001 level. Of these non-transporter genes, PFE1050w (S-adenosyl homocysteine
hydrolase, up-regulated) was the most significant. Targeted analysis of transporter genes
found that six were significant at P<0.05 level. Among 42 transporter genes, the most
significant gene to be differentially expressed was PF11_0466 (down-regulated). We
wondered if SNPs may occur within one or more of the 11 independent probe sets for a
particular gene that may contribute to a reduced signal due to reduced binding affinity.
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These results led us to hypothesize that differential expression of a subset of genes may
be associated with increased AL and QHS resistance.
More recent studies from our lab focused on three genes that have tentative
associations with the site of action or reduced susceptibility to this class of drugs (pftctp,
pfatp6, pfmdr1). Gene copy number, genotype, and expression of tctp, pfatp6, and
pfmdr1 were analyzed in parent/resistant progeny that survive pressure up to 80 ng/ml
AL (W2.AL80, D6.AL80, TM91c235.AL80), 200 ng/ml AL (W2.AL200) or up to 200
ng/ml QHS (W2.QHS200) 276. No differences in copy number, sequence, and
transcription profile between the parent lines and the resistant lines were observed for
tctp or pfatp6. Only one copy of tctp and pfatp6 was found in all lines tested and the
complete sequence of these genes confirmed they were similar to wild type. In addition,
there was no difference in stage specific expression of tctp or pfatp6 in resistant or parent
lines in the absence of drug pressure. Therefore, these data suggested that tctp or pfatp6
are not associated with AL or QHS resistance in P. falciparum. Although these genes are
not implicated in artemisinin resistance, there was an observed increase in pfmdr1 copy
number in W2 from a single copy in the parent clone to 3 copies in the W2.AL80 line.
The copy number was stable at three copies even up to 200 ng/ml AL in W2. Once the
W2.AL80 parasite was switched to pressure with a different artemisinin drug, QHS at 20
and then 40 ng/ml, the pfmdr1 copy number dropped to two. The copy number remained
stable at two, as this parasite was adapted up to 200 ng/ml QHS. In addition, expression
of pfmdr1 was increased ~ 2-fold in the resistant progeny; these data are consistent with
gene copy number increase. Consistent with pfmdr1 amplification in the W2 AL resistant
progeny was a concomitant increase in resistance to MQ and other artemisinin drugs, but
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not to CQ. These data are consistent with other reports showing that pfmdr1 amplification
is linked to MQ resistance and that MQ-resistant parasites exhibit a degree of crossresistance to artemisinin drugs (above). TM91c235 also had increase pfmdr1 copy
number (2 copies at 10ng/ml AL, up to 3 copies at 80 ng/ml AL). Again, this
corresponded to resistance to AL, QHS, MQ, and susceptibility to CQ. Conversely, the
same studies carried out for a parasite with a different genetic background (D6) and its
AL resistant progeny found no amplification of pfmdr1 or significant changes in
expression of pfmdr1 between the parent clone and the AL resistant line. The D6 lines at
all drug pressure levels only had one copy of pfmdr1. These data suggest that pfmdr1
amplification can be associated with stable resistance to AL and QHS in vitro, but clearly
pfmdr1 amplification is not the only mechanism involved in conferring artemisinin
resistance. The interesting de-amplification of pfmdr1 in W2 following a switch in
pressure from AL to QHS may indicate drug-specific mechanism(s) the parasite can
adopt to become resistant to different artemisinin derivatives.
Further studies on pfmdr1 from our lab have focused on examining the stability
and fitness of parasites having multiple copies of pfmdr1. The importance of these
factors on the artemisinin resistance phenotype in W2.AL80 (and clones originating from
W2AL80) was examined by Chen et al. (2010) 337. A rapid reduction in pfmdr1 copy
number was observed in the non-cloned W2.AL80 line (63% of this population reverted
to less than three copies of pfmdr1) when grown without drug pressure. Deamplification
of the pfmdr1 amplicon was then determined in three clones, each initially containing
three copies of pfmdr1. Interestingly, two outcomes were observed during three months
without drug pressure. In one clone, parasites rapidly emerged with fewer than 3 copies
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of the pfmdr1. In 2 other clones, the reversion was significantly delayed. In all subclones the reduction in pfmdr1 CN involved the de-amplification of the entire amplicon
(19 genes). Importantly, deamplification of the pfmdr1 amplicon resulted in partial
reversal of resistance to AL and increased susceptibility to MQ These results
demonstrate that multiple copies of the pfmdr1-containing amplicon in AL resistant
parasites are unstable when drug pressure is withdrawn, having practical implications for
the maintenance and spread of parasites resistant to artemisinin derivatives.
Dormancy, recrudescence, and artemisinin resistance. The preliminary data
from our lab suggested that artemisinin drugs induce dormancy in ring stage parasites and
that the effect is unique to this class of antimalarial drugs. Furthermore, it was
determined that there are stage specific effects of the artemisinin drugs and hypothesize
that the artemisinin-induced dormant rings are the form likely to survive to initiate
recrudescence in vivo. Parasites with different genetic backgrounds respond similarly,
which suggests that drug induced dormancy of rings is a universal phenomenon and that
it is not linked to any prior exposure or conventional mechanism of resistance to the
drugs.
The selection of resistance to AL and QHS in vitro allows a detailed study of
possible mechanism(s) of artemisinin resistance in P. falciparum and its association with
artemisinin-induced dormancy. These studies will define the relationship between
resistance and changes in the recovery rates or duration of dormancy. In addition, these
mechanism(s) can be examined directly with other possible mechanism(s) of resistance,
such as amplification of pfmdr1, mutations or amplification of other transporters (as with
CQ and QN resistance 201). Clearly, more studies are required to identify the
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mechanism(s) by which resistance to artemisinin emerges and to find molecular markers
that can be used for epidemiological studies to track the possible emergence of
artemisinin resistance.
Based on observations of dormancy and in vitro selection of artemisinin
resistance, it may be possible to implicate dormancy as an artemisinin-resistance
mechanism. We believe that multiple rounds of exposure to artemisinin drugs and
recovery from dormancy select for parasites with reduced susceptibility to artemisinin
drugs. It is possible that induction and selection of artemisinin resistant parasites could
enhance recrudescence rates (i.e., treatment failure) and explain a resistance mechanism
where an increased the proportion of parasites recover from dormancy following the
removal of drug pressure, by decreasing the duration of dormancy, or both. It is also
possible that this mechanism of dormancy and re-emergence is responsible for extended
parasite clearance times in patients where artemisinin resistance is reported to occur.
Focus of Study
In the present study, higher levels of artemisinin resistance in P. falciparum
strains was induced in order to further dissect artemisinin-induced dormancy and
mechanisms of artemisinin resistance. Because it was previously determined that various
strains of P. falciparum enter dormancy and recrudesce after artemisinin treatment, we
hypothesized that parasites could be treated with higher amounts of drug over a shorter
period. This process was continued in a stepwise manner in order to increase artemisinin
tolerance. However, during the induction of resistance procedure above, different
parasites were not characterized in terms of dormancy rates, rates of recovery, growth
rates, etc. Also, in regard to these methods of characterization, comparisons of parent vs.
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resistant parasites were not conducted. Strains W2 and TM91c235 (from Asia) have an
associated increase of pfmdr1 copy number with reduced susceptibility to artemisinin
drugs. However, D6 lines do not have amplification of pfmdr1, yet are still able to enter
dormancy and survive drug pressure. Since artemisinin resistance is most likely
multifactorial, we were interested in defining a phenotype for artemisinin resistance
based on different characteristics of resistant vs. parental strains. Furthermore, we
expanded on our previous molecular methods in order to identify potential new
mechanisms and markers of artemisinin resistance. We have generated a large amount of
data that can be used for future research on determinants of artemisinin resistance.
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Figure 1.1. Malaria Life Cycle 11. The malaria parasite life cycle involves an
intermediate host (man, where asexual stages of parasites develop) and a definitive host
(mosquito, where sexual stages of parasites develop). During a blood meal, a malariainfected female Anopheles mosquito inoculates sporozoites (infective stage [i]) into the
human host (1). Sporozoites infect liver cells (2) and mature into schizonts (3), which
rupture and release merozoites (4) (in P. vivax and P. ovale, a dormant stage [hypnozoites]
can persist in the liver and cause relapses by invading the bloodstream weeks, or even
years later). After this initial replication in the liver (exo-erythrocytic schizogony, [A]),
the parasites undergo asexual multiplication in the erythrocytes (erythrocytic schizogony,
[B]). Merozoites invade RBCs to initiate the erythrocytic cycle (5). Merozoites develop
into ring stage trophozoites and mature into trophozoites and segmenting schizonts,
which rupture releasing merozoites (6). Some invading merozoites differentiate into
sexual erythrocytic stages (gametocytes), which are the diagnostic stage (7). These blood
stage parasites represent diagnostic stages (d). In P. falciparum, only rings and
characteristic crescent-shaped gametocytes are found in peripheral blood (see text),
whereas all forms can be found in other species. The blood forms of Plasmodium spp.
are responsible for the clinical manifestations of the disease. The gametocytes, male
(microgametocytes) and female (macrogametocytes), are ingested by an Anopheles
female mosquito during a blood meal (8). The parasites‟ multiplication in the mosquito
is known as the sporogonic cycle (C). While in the mosquito's stomach, the
microgametes penetrate the macrogametes generating zygotes (9). The zygotes, in turn,
become motile and elongated (ookinetes [10]) which invade the midgut wall of the
mosquito where they develop into oocysts (11). The oocysts grow, rupture, and release
sporozoites (12), which make their way to the mosquito's salivary glands. Inoculation of
the sporozoites into a new human host perpetuates the malaria life cycle.
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Figure 1.2. Current Global Malaria Situation as of 2009 371. The map shows countries
where malaria transmission occurs (dark green) and where there is a limited risk of
transmission (light green). Areas where transmission does not occur are not colored.
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Figure 1.3. Countries in Phases of Malaria Control, Pre-elimination, Elimination, and
Prevention of Re-introduction 53. The map shows the global malaria situation as of 2008,
showing countries currently in different phases of elimination and control. White
indicates countries certified malaria-free and/or no ongoing transmission over a decade;
gray indicates countries in stages of prevention of re-introduction; light blue indicates
countries in phase of elimination; sky-blue indicates countries in phases of preelimination, dark blue indicates countries in control phase.
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Figure 1.4. Global Map of Antimalarial Drug Resistance as of 2005. 372. The map shows
areas where malaria transmission occurs (dark gray/light gray=high/low transmission), as
well as P. falciparum chloroquine (CQ) resistance (triangles), sulfadoxine-pyrimethamine
(SP) resistance (circles), and mefloquine (MQ) resistance (stars). Areas of P. vivax CQresistance are also showed (rectangles). Malaria free areas are not colored.
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Figure 1.5. Origin and Spread of Global P. falciparum Chloroquine Resistance 373.
Pockets of resistance were first noted within years of each other on Thailand/Cambodia
border and in Columbia, South America in the late 1950s. Resistance spread from
Southeast Asia to Africa, where CQ resistance was first noted in 1978. Since then, CQresistance has spread through virtually the whole African continent. Resistance spread
from foci in South America through much of the continent, as well (see text). The color
scheme (decreasing in shade intensity from magenta to light pink) indicates progression
of spread of CQ resistance from foci to other locations.
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Figure 1.6. Synchronous P. falciparum Ring Stage Parasites Exposed to Artesunate, but
not Quinine, are Arrested at Ring Stage. Parasites were treated with 1 and 10 ng/ml of
AS and 1 and 10 μg/ml QN for 6 hours. Development of the parasites at 0, 4, 24, 28, and
44 hr was followed by using flow cytometry. The top panel represents the flow
cytometric data for ring stage SHAM controls and parasites exposed to AS (left, 1 or 10
ng/ml) or QN (right, 1 or 10 μg/ml) 28 hours after the beginning of a 6 hr exposure to
drug. In the lower panel, the same groups are shown at 44 hr. Graphs are 3-dimensional
plots of P. falciparum infected erythrocytes stained with propidium iodide in which the
Y-axis represents cell number, the X-axis is the DNA content (or distribution), and the Zaxis represents the side scatter. AS arrested the development of ring stage parasites (8-12
hours post-invasion), whereas QN did not (parasites continued to develop to trophozoites).
Parasites continued to mature to early schizonts in the control and QN groups. In contrast,
the development of parasites was completely arrested in the presence of 10 ng/ml
artesunate and very few parasites developed in the 1 ng/ml group. By 44 hr the control
parasites had completely developed through schizogony and had initiated a new cycle. In
contrast, the artesunate treated parasites still had not developed past the ring stage nor
had they synthesized DNA.
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Figure 1.7. Treatment of Synchronized Ring Cultures of P. falciparum With
Dihydroartemisinin Produced Dormant Parasites That Recrudesced In Vitro. This figure
shows the duration of antimalarial activity following a 24 hour exposure of young rings
to Dihydroartemisinin (here, abbreviated DAR). Treatment with 0.2 ng/ml DAR
appeared to have no effect on parasite growth, but exposure to 2.0 and 20.0 ng/ml
induced a period of non-growth, or dormancy. After 72 hours, parasites exposed to 2.0
ng/ml DAR began to recrudesce and surpassed the starting parasitemia by 96 hours.
Treatment with 20.0 ng/ml produced a steady reduction of parasitemia up to 120 hours,
when parasites began to recrudesce. Parasites grew well beyond the starting parasitemia
at 192 hours post-drug. Microscopic examination of blood smears revealed that the
development of parasites was arrested at ring stage during the period of non-growth.
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Figure 1.8. Localization of Early Transcribed Membrane Protein-2 and Green
Fluorescent Protein in Dihydroartemisinin-Treated Ring Stage P. falciparum Parasites.
Images A-C show Early Transcribed Membrane Protein-2 (ETRAMP2) (red) is localized
around the periphery of the nuclei (blue) of dormant ring stages (S99 following a 12 hour
exposure to 10 nM dihydroartemisinin [DHA]). In contrast, ETRAMP2 staining was less
uniform and some parasite nuclei had little to no ETRAMP2 staining evident (*) 96 hours
after exposure to 400 nM DHA (D). Panel E shows a parasite expressing Green
Fluorescent Protein (GFP) (green) associated with the nucleus (orange) at 72 hours postexposure to DHA.
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Figure 1.9. Different Fates of Artemisinin-Treated Stages of P. falciparum. We have
shown that ring stage parasites can enter dormancy and recrudesce in vitro (this may lead
to recrudescence in patients). Trophozoites are most likely killed by artemisinins.
Schizonts may be unaffected and merozoites may enter dormancy or resist effects of
artemisinins, thereby allowing re-invasion of RBCs, and later recrudescence.
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Figure 1.10. Induction of Resistance to Artelinic Acid and Artemisinin in P. falciparum.
Two clones (W2 and D6) were included from the beginning of the study, whereas a
chloroquine (CQ) and mefloquine (MQ)-resistant isolate from Thailand (TM91c235) was
introduced at the 10 ng/ml artelinic acid (AL) level (left arrow). Parasites that were
adapted to grow in 80 ng/ml of AL (W2.AL80) were then transferred to pressure with a
different artemisinin derivative to examine the degree of cross-resistance induced. The
dashed line shows the point at which drug pressure was switched from 80 ng/ml AL to 20
ng/ml QHS (right arrow).
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Chapter Two:
Induction of High Level Artemisinin Resistance and
Phenotypic Characterization (Specific Aim 1)
Rationale for Study
There is a short history of induction of resistance to artemisinin in apicomplexan
parasites that has included in vivo and in vitro selection methods mechanisms of
resistance. However, these attempts to select stable resistance with increasing drug
pressure have led to various results, and only a few studies have reported on stable
artemisinin resistance induced in vitro for P. falciparum. Our laboratory has succeeded
in producing strains of P. falciparum that are stably resistant to levels of artemisinin
drugs that may be found in patients undergoing artemisinin treatment for malaria. Our
group reported detailed selection of P. falciparum resistance to artelinic acid (AL) and
artemisinin (QHS) in vitro, changes in antimalarial drug susceptibility, and molecular
changes occurring during the selection (Chapter One). Three families of parasites were
used and the highest levels reached were W2.QHS200 (also W2.AL80), TM91.AL80,
D6.QHS80 (also D6.AL80) 276. The induction of resistance methods described by
Oduola et al., (1988) 369 and Chavchich et al. (2010) 276 were cumbersome and lengthy,
so we hypothesized that it would be possible to use a selection procedure that induced a
higher degree of artemisinin resistance more rapidly. These parasites would be pressured
in a stepwise manner as before, but by using shorter pulses of drug exposure and larger
increments of drug at each treatment. Parasites would enter dormancy, recrudesce, and
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tolerate successive, increasing doses of QHS or AL in the procedure. We took parasites
that already tolerated 80 ng/ml of artemisinin (D6.QHS80 and TM91c235.AL80) and
attempted to adapt these parasites to increasingly higher levels of the respective drug they
were already resistant to. The most resistant W2 parasite on hand was W2.QHS200, but
we did not adapt this parasite to higher levels of resistance. Here, we report the induction
of a higher degree of QHS resistance in D6 and AL resistance in TM91c235. Parasites
were generated that tolerated concentrations of QHS that are beyond levels found in the
plasma of patients undergoing treatment for malaria. We hypothesized that by using a
variety of characterization methods, we could definitively show a difference in the
phenotypes of parental and artemisinin resistant lines. During the induction of resistance
procedure, we designed assays to quantitatively define differences between recovery rates
after drug exposure between resistant vs. parental strains. These drug recovery assays
also included analyses of the number of dormant parasites present in each strain. We
characterized resistant parasites in relation to parental strains by employing SYBR Green
antimalarial drug susceptibility testing for different artemisinin drugs and a few other
commonly used antimalarial drugs. While conducting these assays, we designed a novel
hypoxanthine incorporation assay to further determine viability of resistant vs. parental
parasites in a short window of time. This assay greatly helped to separate effects of drugs
on parent vs. resistant strains. Finally, we were also were interested in determining
growth rates of parent vs. resistant lines and concomitant merozoite development in order
to see the stepwise procedure of artemisinin resistance impaired the resistant parasites in
any way. Through these methods of characterization, we defined an artemisinin resistant
phenotype which will be useful for future resistance studies.
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The first attempts at molecular characterization of artemisinin resistance from our
group focused on transcriptional analysis of low level AL and QHS selected W2 strain
(W2.AL80, W2.QHS40) (see Chapter One). From these results, it was thought that
differential expression of a subset of genes may be associated with increased AL and
QHS resistance. We hypothesized that gene expression changes between resistant W2
parasites vs. W2 were an effect of actual transcriptional changes in parasites due to
artemisinin treatment. Alternatively, we hypothesized that SNPs in genes may also have
caused a change in oligo binding affinity, thereby leading to the appearance of
differential regulation. Although the microarrays were performed with lower-level QHSresistant W2 parasites, we aimed to test our hypotheses in the most resistant W2 parasite
on hand (W2.QHS200) in relation to the parental W2 parasite. We planned to sequence
pfmdr1, pfmdr2, and several of the most significant differentially expressed transporters
and non-transporters most from the microarrays (including PFE1050w and PF11_0466)
in order to determine if SNPs were involved in the array results. In tandem, we
conducted real-time PCR assays to examine copy number of these genes in parent and
resistant parasites to find any links between resistance and gene amplification. Our
laboratory previously found that in W2 and TM91c235 resistant lines, exposure to
increasing doses of AL or QHS resulted in the proportionate increase in the pfmdr1 copy
number as well as in its mRNA and protein expression 276. Therefore, we planned copy
number analyses for pfmdr1 to investigate if amplification changes might change from
what was previously found. We also planned on examining early artemisinin resistant
parasites and well as intermediate pressure levels to identify where amplification in genes
or SNPs may have occurred.
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Materials and Methods
Parasites and in vitro culture. Asexual stages of P. falciparum were maintained
in culture by using previously described methods 4. Parasites were cultured in complete
media which consisted of RPMI 1640 medium (Invitrogen, Carlsbad, CA.) supplemented
with 10% heat-inactivated A+ human plasma in anticoagulant/preservative Citrate
Phosphate Dextrose Adenine (CPDA-1) (Interstate Blood Bank, Memphis, TN), a final
concentration of 25 mM HEPES (Invitrogen), and 0.24% v/v sodium bicarbonate
(Invitrogen). Routine cultures were maintained in a total volume of 5-60 ml in 25 cm2,
75 cm2, or 150 cm2 sealed culture flasks. An inoculum of stock culture of each parasite
was cultured in a 4% suspension of type A+ human erythrocytes in CPDA-1 (Interstate
Blood Bank) (hematocrit changed for drug and hypoxanthine assays, below) at 1-15%
parasitemia. Cultures were synchronized using 5% (w/v) D-sorbitol (Sigma-Aldrich
Corp. St. Louis, MO.), following the method of Lambros and Vanderberg (1979) 374.
Synchronization of cultures was repeated 1-2 times before parasites were used for an
experiment. Media was changed every 48 hours or daily, depending on parasitemia.
Cultures were incubated at 37°C under a gas mixture of 5% O2, 5%CO2, and 90% N2.
For molecular analyses, pelleted cultures were saved for later genomic DNA extraction.
Development of resistant parasite lines in vitro. P. falciparum laboratory
clones W2 (Indochina), D6 (Sierra Leone) and a laboratory adapted field isolate
TM91c235 (Thailand) were previously selected for resistance to QHS or AL 276 (see
Chapter One) using a method developed by Oduola et al. (1988) 369. Discontinuous
exposure to AL produced W2, D6, and TM91c235 parasites that tolerated 80 ng/ml [191
nM] (W2.AL80, D6.AL80, TM91c235.AL80). W2.AL80 was subsequently cloned by
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limiting dilution and one clone was subjected to increasing pressure with QHS up to a
concentration of 200 ng/ml (709 nM). W2.AL80 was also pressured up to 200 ng/ml AL
(478 nM). D6.AL80 was subjected to QHS treatment up to 80 ng/ml (D6.QHS80)
(Gerena and Kyle, unpublished data).
In this work, the above method was modified to produce parasites resistant to
higher levels of QHS and AL. D6.QHS80 and TM91c235.AL80 were used as starter
parasites. Asynchronous cultures grown at 1.4-3.9% parasitemia were exposed to
particular drug levels as follows. D6.QHS80 was first exposed to 80 ng/ml QHS, and
then it was treated at increasing levels, each at 20 (70.8 nM) or 40 ng/ml (142 nM) QHS.
TM91c235.AL80 did not tolerate 80 ng/ml of AL after thawing from cryopreservation, so
40 ng/ml AL (95.6 nM) was applied to start. The level of increasing AL was applied in a
similar manner as for D6 (20-40 ng/ml increments). At 48 hours post-drug addition,
cultures were washed three times with stock RPMI to remove drug. After parasites
recrudesced to a point when parasite growth (≥1% parasitemia) and morphology became
normal, cultures were treated again at the current drug level (e.g. 80 ng/ml, recrudesce,
treat with 80 ng/ml again). Cultures were treated 2-4 more rounds at the current drug
level before being moved up in concentration as described above. Parasites were not
cloned at each level of resistance during the stepwise procedure. The last level of QHS
treatment using this method with D6 was 340 ng/ml and the last level of AL treatment for
TM91c235 was 280 ng/ml (669 nM). W2 resistant to 200 ng/ml QHS (W2.QHS200) was
treated with 200 ng/ml QHS once (similar manner) to maintain this resistance level.
After this parasite grew back to >3% parasitemia, it was cloned by limiting dilution.
These clones were then subjected to an additional round of 200 ng/ml QHS. One of these
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clones was picked for further analyses (C5), referred as W2.QHS200x2 in this work.
During this time, standard laboratory D6 and W2 parental lines were re-cloned and one
clone of each was chosen for further analyses (D6 clone C11, W2 clone D7). A clone of
TM91c235 (#23) (referred as TM91c235 in this work) (Gerena and Kyle, unpublished
data) was used as the parental strain in all experiments that involved comparisons with
TM91c235 parasites resistant to AL. Parasites were cryopreserved at each level of
resistance during the stepwise procedure (D6, TM91c235) and parasite pellets were saved
for later genomic DNA extraction.
Quantitative recrudescence assays.
W2 recovery assay. W2 (clone D7) and W2.QHS200x2 were synchronized to
ring-stage and split to 2% parasitemia in 5 ml volumes in 25 cm2 flasks. DHA (1 mg/ml)
was diluted 1:40 in complete media and added to each flask at a final concentration of
200 ng/ml (703 nM). DMSO was diluted 1:40 in complete media and a volume equal to
the 200 ng/ml drug amount was added to control flasks. At 6 hours post-drug addition,
parasites were washed three times with stock RPMI, resuspended in the original volume
of media, and transferred to new flasks. Thick and thin smears were made before drug
treatment and at every 24 hours after DHA was added. Culture media was changed every
day and parasite cultures were monitored until parasitemia of morphologically normal
parasites exceeded 2.5% (about 170 hours post-drug). For each time point, parasitemia
was determined by counting over 650 erythrocytes from at least four fields in each thin
smear. Parasites from thin smears were sorted into classifications of dead, dormant, ring,
trophozoite, or schizont. At each time point, parasitemia was calculated as the number of
total parasites counted/total number of erythrocytes counted. Recrudescence was
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expressed as the percentage of morphologically normal/total parasites and the percentage
of dormant/total parasites. Photomicrographs of W2 (clone D7) and W2.QHS200x2 were
taken from thick smears at 0, 24, 48, 72, 96, and 120 hours post-exposure to drug.
Initial D6 recovery assay. D6 and D6.QHS340x2 (treated twice at 340 ng/ml
QHS) were synchronized and split to 2% parasitemia in 5 ml volumes in 6-well microtiter
plates. QHS (1 mg/ml) was diluted 1:40 in complete media and added to final
concentrations of 28.2 ng/ml (100 nM), 80 ng/ml (283 nM), 120 ng/ml (425 nM), 160
ng/ml (567 nM), 200 ng/ml (709 nM), 240 ng/ml (850 nM), 280 ng/ml (992 nM), 300
ng/ml (1.06 μM), 340 ng/ml (1.20 μM). For D6, the concentration of QHS ranged from
28.2-300 ng/ml, but 80.0-340 ng/ml was used for D6.QHS340x2 because prior
experiments showed the parasite is not affected by 28.2 ng/ml QHS (data not shown).
DMSO was diluted 1:40 and an equivalent volume as the highest drug dilution was added
to parasites for a control well. In this experiment, QHS was applied for 48 hours, similar
to induction of resistance described above. At 48 hours post-drug addition, cultures were
transferred to conical tubes and centrifuged. Parasites were washed three times with
stock RPMI, resuspended in the original culture volume, and transferred to new 6-well
plates. Thick and thin smears were made before drug treatment and at every 24 hours
after. Culture media was changed every day. Parasites were followed to a point beyond
when normal growth and morphology had returned (over 300 hours post-drug). In this
experiment, recovery was monitored by inspecting thick smears. Because dormant and
dead parasites could not be separated in thick smears, they were scored together on each
smear. Parasites were counted from thick smears and classified as dead/dormant, ring,
trophozoite, or schizont. Most counts were based on 800 or more parasites, but it became
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difficult to count that many parasites for some time points (at least 400 total parasites
were counted in this case). Recrudescence was expressed as a percentage of the number
of morphologically normal/total parasites counted. Stocks of D6 that grew out of 300
ng/ml QHS and stocks of D6.QHS340x2 that grew out of 340 ng/ml QHS (named
D6.QHS340x3) were cryopreserved. Culture pellets were saved for these resistant levels
for later genomic DNA extraction.
Adapting D6 parasites beyond clinically relevant concentrations. In a separate
experiment, we aimed to determine the maximum concentration that both the D6 parent
and resistant D6.QHS340x3 (produced from the above experiment) could tolerate.
Concentration ranges were selected that included levels of drug that could typically be
found in plasma of malaria patients treated with artemisinin drugs (and beyond) 375. D6
and D6.QHS340x3 were synchronized to rings/early trophozoites and split to 2%
parasitemia in 1.5 ml volumes in 12-well microtiter plates. QHS (1 mg/ml) was diluted
as above and was added for a final concentration of 80 ng/ml, 160 ng/ml, 240 ng/ml, 500
ng/ml (1.77 μM), 800 ng/ml (2.83 μM), 1000 ng/ml (3.54 μM), 1500 ng/ml (5.31 μM),
2000 ng/ml (7.08 μM), and 2400 ng/ml (8.50 μM). DMSO was diluted 1:40 and an
equivalent volume as for the 2400 ng/ml drug addition was added to a control well
parasite suspension. After the drug was applied for 48 hours, cultures were transferred to
conical tubes and centrifuged. Parasites were washed as before and transferred to new
12-well plates. Thick and thin smears were made before drug treatment and at every 2224 (one gap of 43 hours) hours after. Culture media was changed every day. Parasites
were followed to a point beyond when normal growth and morphology had returned
(over 300 hours post-drug).The number of parasites present was calculated from thick
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smears as described above. D6.QHS2400 was treated three more times after this
experiment to maintain the resistance level, and then D6.QHS2400x4 was cloned by
limiting dilution. One of these clones (D6.QHS2400x4 clone C9) was treated with 2400
ng/ml QHS once more, referred to as D6.QHS2400x5 in this work. Stocks of D6 that
grew out of 300, 500, 800, 1000, and 1500 ng/ml QHS were cryopreserved. Stocks of
D6.QHS340x3 that grew out of 340, 500, 800, 1000, 1500, 2000, and 2400 ng/ml QHS
were cryopreserved. Culture pellets were saved for each resistant level and individual
clones for later genomic DNA extraction. Photomicrographs of D6 and D6.QHS340x3
exposed to 1500 ng/ml were taken from thick smears at 0, 22, 48, 235, 264, and 360
hours post-exposure to drug.
Growth assay. Parental and resistant parasites were synchronized to ring stage
and split to 0.1% parasitemia in 5 ml volumes in 25 cm2 flasks. These assays utilized D6
(clone C11), D6.QHS2400x5, W2 (clone D7), W2.QHS200x2, TM91c235 and
TM91.AL280x2. Thick and thin smears were made twice a day and both parasitemia and
percentage of stages were calculated every day for at least 97 hours. Media was changed
daily on each culture. Photomicrographs reflecting the most representative stages were
taken at each time point, and the number of merozoites in segmenting schizonts was
counted. Sixty segmenting schizonts (where individual merozoites could be
distinguished) were counted in blood smears for each strain over the complete time
course. The mean, median, mode, and standard deviation for number of merozoites in
segmenting schizonts was calculated, and an unpaired two-tailed student‟s t-test
(Microsoft Excel, Microsoft, Redmond, WA.) was used for testing of statistical
significance (α=0.05)
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In vitro drug susceptibility testing.
Antimalarial drugs. A collection of antimalarial drugs (n=11) was used to test
the susceptibility of P. falciparum strains in a 1:2 dilution scheme. The collection
included DHA, QHS, artesunate (AS), artemether (AM), artelinic acid (AL), chloroquine
(CQ), MQ, and atovaquone (ATOV), Lumefantrine (LUM), Halofantrine (HAL), and
Piperaquine (PIP). The types of drugs tested per strain varied and the entire collection
was not tested for certain strains. More than one assay was performed for each parasite.
Drugs were either dissolved in DMSO or 70% ethanol (CQ only), and stock solutions
were made at concentrations of 1 mg/ml or 10 mg/ml (CQ only). Stock concentrations
were then diluted in complete media to either 625 ng/ml (all Artemisinin drugs [QHS2.21 µM, AL-1.50 µM, AM-2.09 µM, AS-1.63 µM, DHA-2.20 µM], ATOV [1.70 µM],
HAL [1.16 µM]), 2500 ng/ml (MQ [6.03 µM], LF [4.73 µM], PIP [2.50 µM]), or 6250
ng/ml (CQ, 12.1 µM) as starting concentration for the serial dilution of drugs. The range
of concentrations after serial dilution were: artemisinins, ATOV, HAL (625-0.610 ng/ml);
CQ (6250-6.10 ng/ml); and MQ, LF, PIP (2500-2.4 ng/ml). A Biomek 3000 Laboratory
Automation Workstation (Beckman Coulter, Brea, CA.) serially diluted drugs 1:2 in
complete media in a 96 well assay “mother” plate, which could be frozen for later use.
This plate contained multiple drugs (up to four per plate). The robot then transferred 15
µl of each drug dilution in duplicate to a new 96 well plate that contained parasite culture.
In vitro SYBR green drug susceptibility assay. The procedure utilized here was
adopted from Bacon et al. (2007) 376. P. falciparum strains were synchronized (≥70%
rings) and grown until they reached parasitemias ranging from 4-10%. The same parent
and resistant pairs of D6, W2, and TM91c235 as described above were used for the
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growth assay. Using the Biomek robot, a parasite suspension was made that consisted of
a final parasitemia of 0.5% and the hematocrit was adjusted to 1.5%. A total of 135 μl of
this suspension was distributed to 96-well drug assay plates in duplicate containing the
aforementioned drugs using the Biomek robot. Once the parasites were added to the
assay plate, drugs were effectively diluted 1:10, giving final concentration ranges of:
artemisinins, ATOV, HAL (62.5-0.0610 ng/ml), CQ (625-0.610 ng/ml), MQ, LUM, PIP
(250-0.24 ng/ml). Negative controls included 25 µg/ml of QHS and DHA (88.6 µM,
87.9 µM, respectively) and cultures without drug were used as positive controls. Drug
susceptibility plates were incubated in a humidified modular incubator chamber (BillupsRothenberg, Del Mar, CA.) for 72 hours at 37°C under a mixture of gas (5% O2, 5% CO2,
90% N) with re-gassing every 24 hours. After the conclusion of incubations, the drug
susceptibility assay was stored at -80°C until the SYBR green assay was performed.
Drug susceptibility plates were thawed at room temperature for a minimum of 30 minutes.
A total of 100 µl/well of the drug susceptibility plate was transferred by the Biomek robot
into a new black 96-well plate, followed by the addition of 100 µl of SYBR green
(Invitrogen) lysis buffer376. The plates were covered and placed in the dark at room
temperature for 1 hour. Fluorescence intensity was measured with a Spectra Max-M2
plate reader. The mean concentration and standard deviation for inhibition of parasite
growth by 50% and 90% (IC50 and IC90) was determined for each parasite line.
IC50/IC90s were estimated based on linear and non-linear regression curves calculated
by DataAspects Plate Manager software (DataAspects Corporation, Glencoe, CA.). Data
was exported and analyzed in Microsoft Excel. The average IC50/IC90 and standard
deviation was calculated from replicate values for each strain tested.
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Ring stage viability in parental and resistant lines.
In vitro drug testing using a radioisotope microdilution technique. A procedure
similar to Webster et al. (1985) 377 was employed for testing. Synchronous ring-stage
parasites of W2 (clone D7), W2.QHS200x2, D6 (clone C11), and D6.QHS2400x5 were
treated with various artemisinin drugs to induce dormancy. Parasite cultures were grown
as described above, except they were cultured in complete media containing plasma
without added adenosine (to avoid altered growth kinetics). Cultures were synchronized
to 2-8% rings in 25cm2 flasks. After sorbitol treatment, cells were washed three times in
stock RPMI. A suspension consisting of 1% parasitemia/2% hematocrit was prepared for
each parasite prior to testing. The parent and resistant pair for each P. falciparum line
was tested on the same 96 well plate (Fig. 2.1) and plates were made for 24 and 48 time
points (post-drug exposure). In these assays, DHA, QHS, AL, and CQ were tested with
each parasite pair. Drugs were serially diluted in a 1:2 scheme covering 11
concentrations over a range from 8000 ng/ml- 7.8 ng/ml (DHA [28.1-0.0274 µM]), 1000
ng/ml-0.98 ng/ml (DHA [3.52-0.00345 µM], QHS [3.54-0.00350 µM ] AL [2.39-0.00234
µM]), or 6250 ng/ml-6.1 ng/ml (CQ [12.1 µM-0.0118 µM]) in a 96 well “mother” plate.
A Biomek robot transferred 10μl of each drug to the test plate and the robot transferred
90 μl parasite suspension to each well, diluting the drug 10-fold. Each concentration of
drug was run in triplicate per parasite tested. An extra row of parasite and drug was
included without hypoxanthine added for making smears. Each plate included parasitized
erythrocytes without drug and non-parasitized erythrocyte controls (NRBCs) (each was in
duplicate per strain tested). Immediately after parasites were added to drug,3[H]
Hypoxanthine monohydrochloride (equivalent to 1 µCi/well) (Perkin Elmer, Waltham,
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MA.) was added to each well of the test plate. Plates were then incubated in a modular
chamber at 37°C that contained a mixture of gas as above. After six hours, thick smears
were made for each concentration level for both parasite sets. At 24 hours and 48 hours
post-drug, thick smears were made from the respective plates, and plates from 24 and 48
hours post-drug were stored at -80°C until harvesting. Plates were washed and harvested
in a FilterMate cell harvester (Perkin Elmer). Next, 50 µl/well of OptiPhase scintillation
cocktail mix (Perkin Elmer) was added and plates were read in a TopCount NXT
scintillation counter (Perkin Elmer). Data (counts per minute [cpm]) from the
scintillation counter were imported into Microsoft Excel. For each parasite and time
point, the average cpm for each drug concentration (triplicate) was calculated. Data were
imported into TableCurve 2D (Systat Software, San Jose, CA.) for curve fitting analysis
and IC50 calculation. The percent parasite growth was plotted as a function of log drug
concentration and the logistic dose response was fitted using SigmaPlot (Systat Software).
DNA sequencing.
Genomic DNA extraction. A procedure similar to that of Beck 378 was used for
freeing parasites from erythrocytes. Cultures were centrifuged at 4,000 rpm for 5
minutes and the supernatant was aspirated. The cell pellet was measured, and 5x pellet
volume of 0.05% saponin was added. The mixture was placed on ice for 10 minutes,
centrifuged, and the supernatant was aspirated. Parasite pellets were washed twice with
1x PBS. Genomic DNA was extracted from the parasite pellets using a QiAmp DNA
Blood Mini Kit (Qiagen, Valencia, CA.). Purified genomic DNA was quantitated using a
NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA.).
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Sequencing for single nucleotide polymorphisms in candidate resistance genes
identified by preliminary microarrays. Genomic DNA was isolated as described above
from W2 and W2.QHS200 for sequencing of pfmdr2, PFE1050w, and PF11_0466.
Platinum Taq High-Fidelity DNA Polymerase (Invitrogen) was used in all PCR reactions
described here. The manufacturer‟s protocol was followed except for changing the
annealing temperature from 53-57°C, and using an extra extension step of 68°C. The
amount of genomic DNA for each reaction ranged from 50-200 ng. To sequence pfmdr2,
a 3294 bp segment was amplified that encompassed the 3075 bp coding sequence (CDS)
using pfmdr2 seqF-4 and pfmdr2 seqR-3 primers (Table 2.1). This fragment was then
subjected to PCR using seven different primer pairs (Table 2.1): pfmdr2 seqF-4/pfmdr2
seqR-4; pfmdr2 Cd F-2/pfmdr2 seqR-5; pfmdr2 seq F5/pfmdr2 seq R-6; pfmdr2 CdF4/pfmdr2 seq R-7; pfmdr2 seq F-6/pfmdr2 CdR-5; pfmdr2 CdF-6/pfmdr2 seq R-8; and
pfmdr2 Cd F-7/pfmdr2 seqR-3. Primer names containing “Cd” denote primer sequences
from Rosenberg et al. (2006) 379. PCR using these primer sets yielded overlapping
fragments ranging from 328-774 bp. Using the primer sets PFE1050w seq2 F/PFE1050w
seq2 R-1, the CDS of PFE1050w was amplified (1440 bp). The primers PF11_0466seq
F/PF11_0466 seq2 R-1 (Table 2.1), were designed to amplify polymorphic regions of
PF11_0466 that encompassed 2075 of the 2772 bp genomic sequence. Gene sequences
from individual forward and reverse reactions were assembled into contigs and aligned
using Vector NTI Advance 11.0 (Invitrogen). Multiple sequence alignments were
completed using an online version of ClustalW (located at http://align.genome.jp/).
Single nucleotide polymorphisms (SNPs) were detected by viewing sequence alignments
and verifying with sequence chromatograms.
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Real-time quantitative polymerase chain reaction.
Optimization of oligonucleotide sets for real-time quantitative polymerase chain
reaction. Sets of primers for pfmdr1 (PFE1150w), S-adenosyl-L-homocysteine
hydrolase (PFE1050w), and the putative transporter PF11_0466 were tested against 3D7
or D6 genomic DNA (isolated as described above) to determine optimal annealing
temperature and concentration for use in real-time quantitative polymerase chain reaction
(real time QPCR) assays. All primer sequences are listed in Table 2.1. To determine
optimal annealing temperature, 10-100 ng of genomic DNA was used as template for
standard PCR using a temperature gradient ranging from 50-65°C in a Biorad Mycycler
thermal cycler (Hercules, CA.). All primer sets were found to amplify equally well from
55-65°C. It was empirically found that ldh and pfmdr1 primers performed the best at
57°C (Peters, personal communication), so this annealing temperature was used for all
real-time PCR assays. A Stratagene (LaJolla, CA.) MX3000P real-time quantitative PCR
system was used for all QPCR assays. Optimal final primer concentration was
determined by designing primer matrices where the final primer concentration per
reaction (run in duplicate) ranged from 100-500 nM and genomic DNA template ranged
from 10-50 ng. Brilliant I/II QPCR SYBR Green 2x mastermix (Stratagene) and 30 nM
final concentration ROX was used for all real-time QPCR assays, and all reactions were
25 µl. The thermal profile for all reactions was as follows: segment 1 (95°C 10 minutes),
segment 2 (95°C 30sec, 57°C 1 minute, 72°C [repeat 40 cycles]), and segment 3
(dissociation curve: 95°C 1 minute, 55°C 30 sec, 95°C 30 sec). Fluorescent data were
collected at the end of each annealing step three times and averaged. The dissociation
curve was performed after the amplification cycles to verify that the correct products
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were produced. Text reports containing threshold cycle (Ct) values were produced in
Stratagene MXPro software and exported for further analyses in Microsoft Excel. The
concentration of primer that caused the lowest Ct value with high fluorescence intensity
was selected for subsequent assays. From this procedure, we found that the optimum
concentration for pfmdr1 and ldh primer pairs was 400 nM F/400 nM R. The optimum
concentration of 200 nM F/200 nM was identified for PFE1050w and PF11_0466.
Determination of gene copy number by real-time QPCR. The relative copy
numbers (CN) of pfmdr1, pfmdr2, PFE1050w, and PF11_0466 were determined for D6,
W2, TM91c235 parental and resistant lines by using ldh as normalizer. A variety of
pressure levels were selected from the stepwise selection of D6 and TM91c235 resistant
parasites, including intermediate pressure levels (D6 [80, 120, 200, 300, 340, 2400x2,
2400x4, 2400x5 ng/ml QHS]; TM91c235 [80, 240, 280 ng/ml AL, but 80 ng/ml not
included for chromosome 10 genes]). For the W2 series, we included W2, W2 (clone
D7), W2.QHS200, and W2.QHS200x2. QPCR assays were designed where the Ct value
was measured in triplicate for each template and primer set. In some cases, outlier values
were produced within a triplicate, which were disregarded. Each primer set included a no
template control (NTC) reaction so we could assess if primer dimers or other PCR
technicalities occurred. Copy number assays were run at least twice for each unknown
sample. In a given assay, the CN of a gene of interest was assessed for unknown
templates against ldh. A 96 well plate was used for each experiment that included a fivepoint standard curve using serial diluted uncloned D6 genomic DNA for the gene of
interest and for ldh (Fig 2.2). It was empirically found that serially diluting DNA
1:3/1:3/1:2/1:2 allowed us to achieve a standard curve where standards were only
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separated by 1-1.5 cycles. The amount of standard ranged from 20-0.036 ng of genomic
DNA (overall, not in a single experiment) in the 5-point standard curve (this varied per
experiment).For each standard curve dilution, it was necessary to determine the amount
of genomic DNA for unknown samples to use. It is imperative to have unknown Ct
values between the standard Ct values in order to assure the proper concentration of DNA
was used. The concentration of genomic DNA that allows unknown Ct values to occur
between standard was empirically determined. Either DNA was diluted to an equivalent
concentration, then diluted 1:100 before use in an assay, or each sample was diluted to
0.1 ng/µl. The components of each reaction mixture were the same as for primer
optimization above, but accounting for changes in diluted primer and water volumes to
make up a final volume of 25 µl reactions in each reaction. A master mix for ldh and the
gene of interest were made separately, then 23 µl was dispensed to wells in a 96 well
plate. The 96 well plate was split in half so that different DNA templates could be run
for ldh and the gene of interest on the same plate (Fig. 2.2). Two microliters of diluted
genomic DNA was added to make a final reaction volume of 25 µl. The thermal profile
for all reactions was the same as above.
After a QPCR run was completed, we verified that the gene of interest and ldh
had Ct values between the respective standards (Fig. 2.3). A standard curve equation
method (DNA concentration [log2] vs. Ct) was used to extrapolate copy number of
unknown samples relative to D6. Each unknown sample had a Ct value for the gene of
interest and ldh, so that the difference in Ct value (Fig. 2.4) could be calculated. Data
from the MX3000P system were exported into Microsoft Excel where the standard curve
equations were determined to calculate copy number of the gene of interest relative to ldh.
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Briefly, the average Ct per triplicate vs. log2 concentration D6 DNA for each standard
(ldh and target gene) was plotted and a slope and y-intercept for target gene and ldh were
determined from a trend line (Fig 2.5). The slope and y-intercept from the standard curve
trend lines were used to convert Ct of the various unknown templates to a relative copy
number with respect to the D6 standard ([Average Ct ldh-ldh y-intercept)/-(slope ldh)][Average Ct target gene-target gene y-intercept)/-(slope target gene)]). To calculate
primer efficiencies, log ng input DNA was plotted vs. average Ct for D6 standards of
target gene and ldh. The slope from the fitted line was used in the equation E=10(-1/slope)
380

to determine efficiency of each primer set. The average CN and standard deviation

were calculated from replicate assays for each parasite line and gene of interest and 95%
confidence intervals for mean CN were constructed (Microsoft Excel).
Results
Discontinuous drug pressure generated P. falciparum lines resistant to increased
levels of artelinic acid and artemisinin in vitro. Resistance was induced in parasite
lines by using two different methods. In the first method, D6 and TM91c235 strains that
already tolerated 80 ng/ml of QHS and AL, respectively 276, were exposed to increasing
concentrations of drug in a stepwise manner (Figs 2.6, 2.7; Tables 2.2, 2.3). Each round
of drug pressure consisted of a 48 hour exposure, then drug was washed out and parasites
were put back in culture. Each time QHS or AL was applied to a culture, a majority of
parasites had a morphology that was distinct from dead parasites beginning at 24 hours
post drug-addition. These dormant parasites were equivalent to what has been reported
previously (Kyle et al., 2010 unpublished; 362; Tucker et al., 2010 unpublished). They
were significantly smaller than normal parasites and resembled merozoites. Dormant
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parasites are small with a regular round outline on a Giemsa stained blood smear and
differ from the collapsed nuclei of pyknotic bodies in their retention of a small circle of
blue staining material that is cytoplasm and condensed red chromatin. These
characteristics separate dormant parasites from dead parasites which appear smaller and
globular with no distinct organization of chromatin and cytoplasm, appearing purplishpink when stained with Giemsa. However, it is very difficult in some cases to discern
dead parasites from dormant ones. After a few days, morphologically normal parasites
began to appear in cultures, which corresponded with the reduction of dormant forms. A
strain was considered recovered when the percentage of morphologically normal
parasites was ≥1%. After a parasite was treated with a specific concentration of drug, it
tolerated successive doses at the same concentration level. During the process of the
stepwise induction of resistance, high-quality photomicrographs were not taken of
parasites. However, in the experiments below detailing selection of higher resistance,
parasites enter dormancy and exhibit the same morphology after drug treatment and
recrudesce after a period of time. Therefore, you are referred to those photomicrographs
that reflect morphological observations of the original induction experiments. The
stepwise induction of resistance method produced parasites resistant to higher levels of
QHS and AL more rapidly than other experiments in our lab. In less than year using this
method, D6.QHS80 tolerated 340 ng/ml QHS (x2) (1205.7 nM) and TM91c235.AL80
tolerated 280 ng/ml AL (669 nM) in approximately a year (Tables 2.2, 2.3). We found
that parasites sometimes recrudesced faster after successive treatments at the same drug
level compared to recrudescence after the primary treatment. However, this was not
consistent during the procedure. The reason for this inconsistency may depend on

130

differences in starting parasitemia or differences in parasite stages in the culture.
W2.QHS200 was already produced 276, but throughout experiments described in this
paper, it was treated with 200ng/ml QHS to maintain the resistance level. After applying
200 ng/ml of QHS for 48 hours, the parasite recrudesced to 4% parasitemia by 7 days
(data not shown). This parasite was cloned by limiting dilution and clone C5 was then
treated with 200 ng/ml of QHS once more. The parasite grew back to ≥2% parasitemia
10 days after drug.
Resistant progeny of D6 and W2 recover faster than parent strains after
exposure to clinically relevant concentrations of artemisinin. After parasites were
adapted to certain levels of artemisinin drugs, we aimed to quantitatively dissect
differences in recrudescence between parent and resistant pairs of parasites. Recovery
rates of W2 (clone D7) and W2.QHS200x2 were determined by exposing parasites to
DHA for 6 hours and monitoring parasitemia over approximately a week. Parasitemia
was monitored for several days after drug exposure (Fig. 2.8-A). In both W2 (clone D7)
and W2.QHS200x2, the initial parasitemia decreased below 2% at 24 hours post drug
exposure, and all parasites observed were classified as dormant or dead. As noted before,
there is a distinct morphology for dormant parasites noted by small size and evidence of
chromatin and cytoplasm (Fig. 2.8-B). The dormant forms persisted through the end of
the assay for each parasite, but there was a greater percentage of dormant/total parasites
in W2.QHS200 vs. W2 (clone D7) up to 72 hours (24 hours, 41.7% vs. 27.3%, 48 hours,
31.3% vs. 23.1%, 72 hours, 20% vs. 25% ) (Fig. 2.8-C). The percentage of dormant/total
parasites in thin smears decreased more precipitously for the resistant parasite compared
to the parent. This decrease in dormant forms correlated with the appearance of
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morphologically normal parasites at 72 hours post-drug for W2.QHS200x2 (6.7% of
parasites counted) (Fig. 2.8-B, D). Morphologically normal parasites were observed at
96 hours for W2 (clone D7) (12.5% of parasites counted) (Figs. 2.8-B, D). The
percentage of normal parasites that appeared was initially greater for the resistant parasite
(from the time normal parasites appeared), but this equilibrated at 144 hours post-drug
(Fig. 2.8-D). The assay was terminated at 165.5 hours post drug after parasitemia of
normal parasites was ≥2.5%/
The process of discontinuous QHS pressure in D6 produced D6.QHS340x2. This
parasite was compared with D6 for differences in recrudescence. In this assay, both D6
and D6.QHS340x2 were exposed to a range of QHS that included clinically relevant
concentrations. Drug was applied for 48 hours in this assay and parasites were viewed in
Giemsa-stained thick smears 24-336 hours after drug pressure. At each drug
concentration, dormant parasites were observed in D6 and D6.QHS340x2 after 24 hours,
but some morphologically normal parasites persisted as well. At 48 hours post-drug, a
greater number of normal parasites persisted for D6.QHS340x2 vs. D6 at each
concentration (data not shown), but the majority of parasites observed were dormant or
dead. Figure 2.9-A shows a representative comparison of recovery rates (#normal
parasites/total parasites) for D6 vs. D6.QHS340x2 after exposure to 200 and 300 ng/ml of
QHS. At 24 hours, the percentage of morphologically normal parasites was greater for
D6.QHS340x2 vs. D6 (1.4% vs. 0.49%) after 200 ng/ml QHS. With 300 ng/ml QHS,
0.24% normal parasites were observed for D6 vs. 1.1% for D6.QHS340x2. After 48
hours with 200 ng/ml QHS, a higher percentage of normal parasites remained in
D6.QHS340x2 vs. D6 (0.49% vs. 0.12%). At the 300 ng/ml drug level, only dead or
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dormant parasites were observed in thick smears. After this time point with 200 ng/ml,
we only observed dead or dormant parasites in D6 and D6.QHS340x2 until the 120 hour
time point. At 120 hours, morphologically normal parasites (rings, trophozoites) were
observed for both strains, but a higher percentage of normal parasites were observed for
D6.QHS340x2 vs. D6 (0.25% vs. 0.13%) (Fig. 2.9-A). This trend continued up to the
last point where parasites were followed at 200 ng/ml (312 hours post-drug). Although
we observed morphologically normal parasites at later time points for D6, the percentage
of normal parasites did not reach high levels (only 10.2% normal parasites for D6 at 312
hours vs. 66.5% for D6.QHS340x2). With 300 ng/ml, normal parasites (rings,
trophozoites, schizonts) were observed at 144 hours post-drug for D6.QHS340x2 (0.61%
of total parasites counted), whereas morphologically normal parasites were not observed
until 240 hours (rings, trophozoites, schizonts) for D6 (0.86% of total parasites counted).
At the last point where parasites were followed for 300 ng/ml (336 hours post-drug),
67.4% of normal parasites were counted for D6.QHS340x3 and 38.3% for D6 (Fig. 2.9A). Therefore, it appeared that D6 recrudesced at a greater rate when compared to
D6.QHS340x3. However, a greater number of morphologically normal parasites existed
at each time point for D6.QHS340x3.
The assay described above produced D6.QHS340x3 (D6.QHS340x2 exposed to
340 ng/ml QHS), and this parasite was tested vs. D6 in another recovery assay aimed at
determining if the resistant parasite could tolerate levels of QHS that surpassed clinically
relevant concentrations. In a similar manner as reported above, D6 and D6.QHS340x3
were treated with QHS for 48 hours. This assay, also terminated at 360 hours, produced
D6 that tolerated a range of 80.0-1500 ng/ml QHS and D6.QHS340x3 that tolerated a
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range of QHS from 80.0-2400 ng/ml (Fig 2.9-B). A general trend from this assay was
that normal parasites either appeared in culture for D6.QHS340x3 before D6, or in cases
where parasites appeared for both D6 and D6.QHS340x3, a greater number of normal
parasites were observed in D6.QHS340x3. Figure 2.9-B shows D6 vs. D6.QHS340x3
exposed to 1500 ng/ml QHS, the maximum amount of drug D6 could tolerate. Much like
the first recovery assay, normal parasites persisted up to 48 hours for both D6 and
D6.QHS340x3 in thick smears (0.48% resistant vs. 0.23% parent), but the vast majority
of parasites observed were dead or dormant. Both D6 and D6.QHS340x3 remained dead
or dormant until 235 hours post drug, when normal parasites (rings, trophozoites,
schizonts) were observed (0.94% resistant vs. 0.37% parent). The number of dead and
dormant parasites in thick smears decreased methodically after 235 hours (Fig. 2.9-B).
At 235 hours and continuing to the last point where parasites were followed (360 hours
post-drug), there was a greater percentage of normal parasites for D6.QHS340x3 than D6
(68.2% D6.QHS340x3 vs. 58.4% D6). Figure 2.9-C shows the morphological
appearance of D6 and D6.QHS340x3 after treatment with 1500 ng/ml QHS at 0, 22, 48,
235, 264, and 360 hours (DMSO at 24, 48 hours). After 24 hours post-drug,
morphologically normal parasites were not observed in thin smears for D6, yet some
were observed for D6.QHS340x3. By 48 hours post-drug, all parasites observed in thin
smears were dead or dormant for each strain. At 235 hours (time when parasites were
observed in thick smears), normal parasites were observed in thin smears for both strains,
but they were present in greater numbers for D6.QHS340x3 (Fig. 2.9-B). Normal
parasites continued to appear in thin smears for both strains through 360 hours. At the
end of this experiment, the most resistant D6 line on hand was D6.QHS2400x1. This
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parasite was treated three more times at the 2400 ng/ml level (see Fig. 2.6), and each
time, parasites recovered to at least 2% parasitemia within 11 days. The parasite was
cloned after the fourth treatment of 2400 ng/ml QHS and one clone (D6.QHS2400x4 C9)
was treated a final time at 2400 ng/ml, yielding D6.QHS2400x5.
Analysis of growth rates and merozoite number reveals differences between
parental and resistant parasites. Data from experiments with D6 lines in our lab
suggested that earlier drug-selected D6 parasites grew slower than the parent strain (data
not shown). Based on these observations, we investigated growth and merozoite number
in parent and resistant parasites. In order to determine a difference in growth, pairs of
parent and the most resistant parasite for each line were synchronized, split to 0.1%
parasitemia, and allowed to grow for 2-3 cycles. Over a period of 105.5 hours (postsorbitol treatment), parasitemias of D6 (clone C11) and D6.QHS2400x5 were calculated
twice a day. At each time point beyond 25 hours post-sorbitol, parasitemia of
D6.QHS2400x5 was lower than D6 (clone C11) (Fig. 2.10-A). At 33 hours post-sorbitol,
parasitemias were D6 (clone C11): 0.5%, D6.QHS2400x5: 0.3%. This trend continued
up to the final time point where parasitemias were D6 (clone C11):12.3%,
D6.QHS2400x5: 10.9%. Furthermore, the resistant parasite lagged behind in
development during the erythrocytic life cycle. Sorbitol treatment left 10-16 hour rings.
At 51 hours post-sorbitol (equivalent to early-mid part of the 2nd cycle [61-67 hours into
life cycle]), there was a noticeable difference in the percentage of parasite stages. For D6
(clone C11), there were 42.9% rings, 57.1% trophozoites, but 90.9% rings, 9.1%
trophozoites in D6.QHS2400x5. The same experiment with W2 (clone D7) and
W2.QHS200x2 found that W2 initially reached a higher parasitemia (0.9% vs. 0.6% at 44
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hours) and this lasted until 92 hours, when the resistant parasite reached higher
parasitemia (4.1% W2 [clone D7] vs. 5.4% W2.QHS200x2) (Fig. 2.10-B). We did not
notice a difference in parasite development during the life cycles for the W2 pair. For the
TM91c235 series, a slightly less noticeable difference in growth was observed. Both the
parent and resistant parasite had similar growth up to 96 hours post-sorbitol, when the
parasitemia of TM91c235.AL280x2 spiked compared to TM91c235 (1.6% TM91c235 vs.
3.1% TM91.AL280x2) (Fig. 2.10-C). Based on parasite stages, it was not clear why the
resistant parasite grew faster at this point in the assay. The parasitemias of both strains
eventually equilibrated around 119 hours.
In order to determine if a variation in growth rates between the parent/resistant
pairs was related to invasion, the number of merozoites in segmenting schizonts for
parent vs. resistant strains were determined (Figs. 2.10-D). Sixty segmenting schizonts
were counted for each parasite, and we determined mean, minimum, and maximum
number of merozoites per schizont (Fig. 2.10-E; Table A-1, Appendix A). The mean
merozoite number for D6 (clone C11) (19.3±2.58) was significantly greater than
D6.QHS2400x5 (16.3 ±2.24) (P=3.8x10-10). In the W2 series, the mean number of W2
(clone D7) merozoites per schizont was significantly less (15.3±2.38) than that of
W2.QHS200x2 (19.7±2.66) (P=1.3x10-16). For the TM91c235 series, the parental strain
had significantly greater number of schizonts (20.7±2.26) than the resistant parasite
(19.7±2.16) (P=0.012). It was not clear why a lesser number of merozoites was
associated with reduced growth with D6.QHS2400x5 vs. D6 (clone C11), whereas
significantly more merozoites in W2.QHS200x2 was not associated with an increased
rate compared to W2 (clone D7). Also, TM91c235 had significantly more merozoites
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than TM91.AL280x2, but only a slight increase in growth compared to the resistant
parasite.
Resistant parasites exhibit reduced susceptibility to artemisinins and
mefloquine, but increased susceptibility to chloroquine. Standard measures of drug
resistance in Plasmodium are reported from in vitro susceptibility assays. Parent and
resistant pairs of cloned D6, W2, and TM91c235 lines were tested against five
artemisinin drugs and a group of six standard antimalarial drugs (Tables 2.4, 2.5). Assays
were repeated ≥2 times and the average IC50 and IC90 were calculated. Compared to D6
(clone C11), D6.QHS2400x5 showed a general decrease in susceptibility to all
artemisinin drugs (QHS, DHA, AS, AM, AL). D6.QHS2400x5 had the greatest tolerance
for AL compared to the parent (IC50 ~9-fold, IC90~2-fold), followed by QHS (IC50 ~8fold, IC90 ~5-fold). For the W2 parasites, there was a similar trend for reduction in
susceptibility, but W2.QHS200x2 was almost equally susceptible to DHA as W2 (clone
D7). W2.QHS200x2 had a greatest tolerance for AL compared to the parent (IC50, IC90
both ~6-fold), followed by QHS again (IC50, IC90 each ~3-fold). When
TM91c235.AL280x2 was compared to its parent, it showed a similar trend in
susceptibility as W2 (clone D7) vs. W2.QHS200x2 except it displayed a four-fold greater
IC50 for QHS, the degree of resistance to AM was greater, and the overall IC90 for AL
was greater. When comparing the parental lines to each other, the parental lines had
similar susceptibilities to artemisinin drugs, but TM91c235 exhibited greater resistance
compared to the other parental lines (especially with AL [IC90]). Testing of parent vs.
resistant parasites with CQ found there was only a remarkable reduction in susceptibility
with TM91c235.AL280x2. However, the resistant D6 and W2 lines showed a slight
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increase in susceptibility to CQ compared to respective parent parasites (more evident in
W2 series). Resistant lines of D6 and W2 had a moderate decrease in susceptibility to
MQ compared to respective parental parasites, except W2.QHS200x2 had a more
dramatic increase in IC90 (over 4-fold). The IC90 of the TM91c235 lines was greatly
increased compared to other tested strains, but the IC50 of parent and resistant strains of
TM91c235 were similar. For LF, HAL, and PIP, only the W2 lines were tested. We
found elevated IC50 of resistant parasites compared to the parent W2 for LF, but the
IC90s were similar. W2.QHS200x2 was more susceptible to PIP, but slightly more
resistant to HAL. For ATOV, all parent and resistant pairs for each line were equally
susceptible.
Ring-stage viability assay reveals that resistant parasites withstand greater
levels of drug compared to parental parasites. We postulated that potential reasons
why artemisinin-resistant parasites eventually recrudesce before parental parasites may
be that resistant parasites form a greater number of dormant forms after treatment with
artemisinin drugs, or that a greater percentage of resistant parasites are unaffected by
drug. Short term in vitro susceptibility assays may not be sufficient to quantify these
differences because of dormancy and the time of viability assessment. To quantitatively
assess these differences more accurately, we measured hypoxanthine incorporation in
cloned parent and resistant parasites (D6 and W2 pairs) directly after treatment with
drugs. Parasites were added to dilutions of artemisinin drugs, hypoxanthine was
immediately added, and the parasites were harvested at 24 and 48 hours post-drug to
quantify viability. The percent parasite growth as a function of log drug concentration
was plotted and IC50 was determined from dose response curves. A pilot experiment
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covering a range of DHA from 800-0.78 ng/ml in the D6 series found the resistant
parasite had higher percent growth than the parent at 24 and 48 hours (data not shown).
The parental parasite did not appear to incorporate a significant amount of hypoxanthine
compared to background levels at 24 and 48 hours. The resistant parasite tolerated at
least 6.25 ng/ml DHA at 24 hours, but at 48 hours, the resistant parasite tolerated at least
12.5 ng/ml DHA. Previous experiments in our lab showed that at higher levels of
artemisinin, it is difficult to measure a difference in drug tolerance (IC50 assays) between
parent and resistant parasites. We also expected that there a distinct difference between
parent and resistant parasites at lower levels of artemisinins based on in vitro
susceptibility data (Tables 2.4, 2.5). Therefore, this experiment did not include a low
enough concentration of drug that the parent parasite could tolerate. In subsequent
experiments, lower levels of drug were used so it would be possible to detect a distinct
difference in drug tolerance at lower levels. We also included W2 parasites to investigate
how parasites would respond that are different from D6 in terms of geographical location
and drug susceptibility profile. These experiments were similar to above, but the drugs
used were DHA, QHS, and AL (concentration ranged from 100-0.10 ng/ml), and CQ
(625-0.610 ng/ml) as a control drug. After each treatment with an artemisinin drug, the
resistant parasite in each pair tolerated more drug compared to parent strains at 24 and 48
hours (Fig. 2.11-A-C; E-G; Table 2.6). In addition, parental and resistant parasites both
tolerated more drug at 48 hours compared to 24 hours. Drug susceptibility data reported
here is for 24 and 48 hours post-drug, but Fig. 2.11 only shows data for 48 hours postdrug exposure. After D6 was treated with DHA, the IC50 was 0.23 ng/ml (24 hours) and
0.53 ng/ml (48 hours). The IC50 for D6.QHS2400x5 after DHA treatment at 24 hours
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was 1.39 ng/ml and at 48 hours it was 2.27 ng/ml (Fig. 2.11-A; Table 2.6). There
appeared to be a large separation between D6 and D6.QHS2400x5 after treatment with
AL and QHS (Fig. 2.11-B, C; Table 2.6). With AL treatment, the IC50 of D6 was 1.90
ng/ml at 24 hours and 5.76 ng/ml at 48 hours. The IC50 for D6.QHS2400x5 was 35.7
ng/ml at 24 hours and 57.8 ng/ml at 48 hours. For QHS, the IC50 for D6 was 2.05 ng/ml
at 24 hours and 3.26 ng/ml at 48 hours. The IC50 of D6.QHS2400x5 at 24 hours was
17.1 ng/ml at 24 hours and 25.0 ng/ml at 48 hours. After D6 strains were treated with
CQ, D6 tolerated more drug (IC50 24 hours=9.95 ng/ml; IC50 48 hours=17.8 ng/ml) than
D6.QHS2400x5 (IC50 24 hours=6.52 ng/ml; IC50 48 hours=8.35 ng/ml) (Fig. 2.11-D;
Table 2.6).
After the W2 strains were treated with DHA, the IC50 for W2 was 0.32 ng/ml at
24 hours and 0.48 ng/ml at 48 hours. The IC50 for W2.QHS200x2 was 0.53 ng/ml at 24
hours and 1.27 ng/ml at 48 hours (Fig. 2.11-E; Table 2.6). For AL (Fig. 2.11-F, Table 2.6)
and QHS (Fig. 2.11-G), there was not as much of a dramatic shift between parent and
resistant parasites as compared to the D6 pair. The AL IC50 for W2 was 1.17 ng/ml (24
hours) and 2.85 ng/ml (48 hours). The AL IC50 for W2.QHS200x2 was 4.81 ng/ml at 24
hours and 12.4 ng/ml at 48 hours. The QHS IC50 for W2 was 0.80 ng/ml at 24 hours and
1.55 ng/ml at 48 hours. The QHS IC50 for W2.QHS200x2 was 2.69 ng/ml at 24 hours
and 3.21 ng/ml at 48 hours. For CQ, problems arose during data analysis where 24 and
48 hour time points could not be used from individual experiments (low r2 produced from
logistic analyses). Therefore, 24 and 48 hour data were derived from separate
experiments (Fig. 2.11-H; Table 2.6). The IC50 for W2 was 158.5 ng/ml at 24 hours and
94.5 ng/ml at 48 hours. For W2.QHS200x2, the IC50 was 143.2 ng/ml at 24 hours 147.7
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ng/ml at 48 hours. Although the 24 hour data reflects greater tolerance of W2 for CQ
compared to W2.QHS200, the data from 48 hours (Fig. 2.11-H) probably more accurately
reflect tolerance to CQ. Overall, the results of artemisinin drug treatment indicate that
resistant parasites tolerate more drug than parent strains, possibly due to the increased
ability to enter dormancy and recover at a higher rate, or a greater number of parasites are
unaffected by drug.
Sequencing and real-time QPCR of genes implicated in prior molecular
studies. In this work, we conducted sequencing and QPCR on the differentially
expressed genes from the initial microarrays to investigate if these genes are involved in
resistance. The CN of pfmdr1 and other selected genes was also analyzed in higherselected parasites. A possible reason for differential expression of genes in resistant vs.
parent parasites could be that single nucleotide polymorphisms (SNPs) occur within these
genes that contribute to a reduced signal due to reduced binding affinity. Initially, genes
of interest were sequenced using W2 and W2.QHS200, as W2.QHS200 was the most
resistant parasite on hand at the time. Although the primary goal was to determine
differences between W2 vs. W2.QHS200, we also thought it would be interesting to
compare sequences of pfmdr2 (PF14_0455), PFE1050w, and PF11_0466 against other
strains with different drug sensitivities where SNPs have already been described
(PlasmoDB). We chose CQ and MQ-resistant Dd2 (also known as W2-mef) because it
descended from W2 369,381, so we could use Dd2 as a reference to validate our sequencing
and also to find any other differences. We also chose CQ-sensitive D10 (Papua New
Guinea) and included 3D7 as a reference strain. No SNPs were described in PlasmoDB
for PFE1050w.
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For pfmdr2, we assembled the complete CDS sequence (3075 bp) for
W2.QHS200 and W2 (only missing sequence for stop codon=TAA). We found that the
nucleotide sequences of W2 and W2.QHS200 were identical to each other (Fig. 2.12).
We searched PlasmoDB for SNPs of 3D7 vs. Dd2 or D10, and four were identified (but
all were of 3D7/D10 vs. Dd2 type). These non-synonymous SNPs were at chromosome
14 positions 1,956,996, changing codon AGT to AAT (Ser-Asn); 1,956,723, changing
codon GGT to GAT (Gly-Asp); 1,956,351, changing codon TTT to TAT (Phe-Tyr), and
1,956,168, changing codon ACA to ATA (Thr-Ile). Sequences of pfmdr2 from W2 and
W2.QHS200 were aligned against pfmdr2 sequences of 3D7 (NCBI Reference Sequence
Accession Number XM_001348593.1), Dd2 (Broad Institute locus PFDG_00251.1), and
D10 (NCBI GenBank Accession Number U04640.1). All four of the Dd2-like SNPs
were found in W2 and W2.QHS200. For the most part, our W2 lines looked very similar
to Dd2, with some exceptions. Further analysis of the results found a deletion of an ATA
codon in 3D7, Dd2, and W2 parasites just downstream from the SNP at position
1,956,723. When all strains were aligned, there was a single ATA codon deletion in 3D7,
but a double ATA codon deletion in Dd2 and W2 parasites. We also found a
synonymous SNP for D10 vs. the other strains (position 1367 in CDS, changing codon
GGT-GGA, Gly-Gly) that was not reported in PlasmoDB. This was located in between
the SNPs above at positions 1,956,351 and 1,956,168. Other observations included the
presence or absence of nucleotides in the Dd2 sequence from the Broad Institute that
were different from the other strains that were aligned, and a synonymous SNP for 3D7
vs. all other strains at position 2126 in CDS, changing codon ATA-ATC (Ile-Ile).
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Sequencing of PFE1050w in W2 and W2.QHS200 returned 1393/1440 bp of the
CDS sequence, just missing some nucleotides at the 3‟ end for both strains. Sequences
were aligned against the PFE1050w sequences of 3D7 (NCBI GenBank Accession
Number XM_001351731) and Dd2 (Broad Institute locus PFHG_03949.1). This analysis
found that the nucleotide sequences were similar for W2 vs. W2.QHS200, and sequences
were similar to all other strains (Fig. 2.13). There were a few missing nucleotides within
strings of adenosine (5‟end) or thymidine bases (3‟ end) in W2 and W2.QHS200
compared to 3D7 and Dd2. However, these were in areas of unreliable sequence and are
not likely to constitute actual missing bases.
For PF11_0466, we aimed to sequence the complete 2772 bp gene, but
sequencing returned erratic results that made it impossible to compare complete
sequences of W2 vs. W2.QHS200. We were able to align portions of sequences that
encompassed polymorphic regions of the gene. The obtained sequence from the strains
was similar to each other and also 3D7 (Genbank XM_001348097) and Dd2 (Broad
Institute locus PFDG_03578.1) in these regions (data not shown). A Dd2-like SNP (vs.
3D7) at chromosome 11 position 1,808,81, changing codon GTA to TTA (Val-Leu) was
found in the W2 lines. However, this only determined that sequence of W2 and
W2.QHS200 was most likely of Dd2 type, which is a descendant of W2.
QPCR was performed on a variety of parent and resistant strains of D6, W2, and
TM91c235. Results of QPCR on PFE1050w, PF11_0466, and pfmdr2 found all strains
had approximately one copy of each gene (Fig. 2.14 A-C; Table A-2, Appendix A).
QPCR for CN of pfmdr1 (Fig. 2.14-D, Table A-2, Appendix A) found a similar trend as
reported by Chavchich et al. (2010) 276. The CN of pfmdr1 was approximately 1 in all D6
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lines (ex. D6 CN, 1.01±0.015; 95% CI 1.00-1.01; D6.QHS2400x5 CN, 1.10±0.038; 95%
CI 1.06-1.15) (Fig. 2.14-D), a departure from what we found in other strains. W2 had
approximately 1 copy of pfmdr1 (CN, 1.18±0.114; 95% CI, 1.11-1.24) as did W2 (clone
D7) (CN, 1.21±0.101; 95% CI, 1.14-1.27). However, there was a noticeable increase in
pfmdr1 CN from 1 to >2 copies at 200 ng/ml QHS (W2.QHS200 CN, 2.24±0.166; 95%
CI, 2.12-2.35). There also was a slight increase after multiple treatments at 200 ng/ml
QHS (W2.QHS200x2 CN, 2.55±0.0740; CI 2.49-2.62) (Fig 2.14-D). The CN of pfmdr1
increased from approximately 2 copies in the parent TM91c235 (CN, 2.20±0.167; 95%
CI, 2.07-2.32) to almost 3 copies at 80 ng/ml (TM91c235.AL80 CN, 2.82±0.192; 95% CI,
2.63-3.01). As AL pressure increased to 240 ng/ml, the pfmdr1 CN increased beyond 3
(TM91c235.AL240x2 CN, 3.60±0.325; 95% CI, 3.31-3.88). The effect of increasing
concentration with concomitant increase in pfmdr1 CN appeared to taper off after
parasites tolerated 280 ng/ml (TM91c235.AL280x2 CN, 3.56±0.131; 95% CI, 3.413.71).The CN of TM91c235 resistant parasites were greater than any other strains we
measured. All of these data are in agreement with that reported in Chavchich et al. (2010)
in similar drug selected lines 276.
Discussion
Induction of resistance. In the study presented here, we expanded on previous
work from our lab that reported on the induction of resistance to artemisinin and its
derivatives in several clones and lines of P. falciparum. A stepwise procedure originally
produced parasites that could tolerate up to 200 ng/ml QHS (W2), 80 ng/ml QHS (D6),
and 80 ng/ml AL (TM91c235) 276. The current study details the induction of higher
resistance levels of these same parasites, but achieving resistance more rapidly. In less
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than a year, derivatives of D6 and TM91c235 were generated that tolerated 340 ng/ml
QHS and 280 ng/ml AL, respectively. The hallmark of the in vitro resistance for these
parasites is the ability for parasites to recover after increasing concentrations of
artemisinin derivatives over many generations. The parasites recover after treatment with
levels of drug which are equivalent to those found in plasma of patients taking
artemisinin drugs for antimalarial therapy. For certain artemisinin drugs, these parasites
display a striking decrease in susceptibility. Furthermore, when in vitro resistance to a
certain artemisinin drug developed, there was a significant degree of resistance to other
artemisinin derivatives not utilized in generation of resistance in a particular line. An
important note is that it is possible to select resistance in a sensitive background (D6)
compared to other studies where it was thought that multiple resistance phenotypes must
pre-exist 301,332. Rathod et al. (1997) 301 were unable to induce resistance to ATOV and 5fluoroorotate in D6 and HB3, but could induce resistance in W2. The authors of this
study named the ability of certain P. falciparum clones to readily develop resistance to
structurally and mechanistically unrelated compounds as the accelerated resistance to
multiple drugs (ARMD) phenotype.
Recovery assays. Recovery assays using sets of parent and resistant parasites of
W2 and D6 demonstrated that although parent and resistant parasites both enter
dormancy, resistant parasites recrudesce either before parent parasites or with a greater
number of parasites at the same time point. Parasite recovery was dependent on dose of
drug, where higher doses of QHS caused recovery at later times. Results similar to these
with other artemisinins were reported by Bwijo et al. (1997) 382 and Teuscher et al. (2010)
362

as well. An assay measuring recovery between D6 and D6.QHS340x3 included QHS
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concentrations beyond those considered clinically relevant. At the end of the assay (360
hours post-drug), D6.QHS340x3 tolerated the maximum concentration applied (2400
ng/ml) and D6 tolerated 1500 ng/ml. During recovery assays, the increase of normal
parasites coincided with the decrease of dormant (W2 recovery study) or dead-dormant
(D6 studies) parasites in resistant lines. These data indicate that resistant parasites
transitioned out of dormancy to normal growth before the parental parasite. This may be
because dormant resistant parasites have a higher survival rate from dormancy; if a
greater number of dormant parasites existed in resistant cultures, recrudescence would
occur earlier. Also, since the parental parasite did not exhibit the same type of
recrudescence, it may be possible that it is under more stress compared to the resistant
parasite.
Some variability was observed in recovery assays with sensitive and resistant
parasites. Although morphologically normal parasites sometimes were observed for
resistant strains before the parental strain, there was not much separation in time. In the
W2 experiments with 200 ng/ml QHS, only 24 hours passed between the appearance of
recrudescent parasites in W2.QHS200 and when they appeared for W2. This may
indicate that after 6 hours of drug exposure, the resistant parasite is capable of exiting
dormancy at a greater rate than W2. During the experiments with D6 and D6.QHS340x2,
parasites appeared for each strain at the same time after 200 ng/ml QHS, but more
parasites were present in D6.QHS340x2. However, with 300 ng/ml QHS, normal
parasites in D6.QHS340x2 appeared at 144 hours and D6 appeared at 240 hours.
Apparently, higher concentrations of QHS are required to observe a phenotypic
difference in recovery of resistant vs. susceptible parasites. Perhaps even higher levels of
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drug are required to surpass a critical threshold where differential recovery of D6
resistant vs. sensitive parasites can be determined.
The most interesting results were found from the high level recovery experiments
using D6 lines. D6 and D6.QHS340x3 tolerated 1500 ng/ml QHS and normal parasites
were observed at 235 hours for each parasite. However, there was a greater percentage of
normal parasites for resistant D6.QHS340x3. At subsequent time points, the number of
parasites increased more in D6.QHS340x3. To our knowledge, this study and Witkowski
et al. (2010) 360 are the only studies where P. falciparum artemisinin susceptible and
resistant lines generated in vitro survived levels of drug well beyond those typically
found in patient sera. Witkowski et al., 2010 360 showed that F32-Tanzania was induced
to 9 µM QHS, then it could tolerate 70 µM QHS after an initial 48 QHS treatment. The
parent survived 9 and 18 µM QHS after 48 hours. Although these levels are higher than
what we show here (D6 tolerated 5.3 µM, D6.QHS340x3 tolerated 8.5µM after 48h
QHS), drug levels greatly exceed the peak drug concentrations in treated patients. Also
intriguing is the ability of wild-type parasites, D6 (this study) and F32 360 to tolerate 5.318 µM QHS without any prior selection pressure. Both parasites are from Africa, which
is interesting since most previous successful in vitro resistance studies were
accomplished with Asian parasites (see Chapter One and below). Recent work from our
lab 362 reported on recovery rates of non-drug adapted W2, D6, S55, H3, and PH1 after
treatment with 200 mg/ml DHA. After a 6 hour exposure of DHA, parasites recovered at
similar rates from 4-25 days after drug exposure. D6, W2, and S55 had similar recovery
rates and all strains had majority of parasite recovery by day 15 post-drug. Another
experiment treating W2 for 6 hours with 20 , 200, 500 DHA for 6 hours found 50%
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recovery at day 9 at both 200 and 500 ng/ml, and day 5 for 20 ng/ml. Our recovery assay
that exposed W2 and W2.QHS200x2 to 200 ng/ml DHA for 6 hours showed that >40%
of morphologically normal parasites were present 6 days post-drug. It is difficult to
compare our D6 recovery results because of differences in exposure to drug (hours,
concentrations). However, their study did show reduced recovery after repeated exposure
up to 48 hours with DHA. Interestingly, by using a magnetic column, it was found that
parasite recovery was delayed. This delay in recovery indicated that there was a small
number of parasites that was either unaffected by the drug or had become dormant but
recovered in the first 3 days and had been removed by the columns. It would be
interesting to see how resistant parasites perform in this recovery assay, with and without
magnetic column. Again, these findings may reflect an intrinsic tolerability of P.
falciparum strains to artemisinin drugs.
In vitro susceptibility testing.
SYBR green assays. Testing with artemisinin drugs found resistant progeny had
reduced susceptibility compared to parental parasites as evidenced by IC50 and IC90. Of
the five artemisinin drugs tested, the resistant parasite in each pair showed the greatest
tolerance for AL, but it also exhibited a moderate degree of resistance to QHS. The
initial drug pressure experiments for all strains involved treatment with AL (to 80 ng/ml),
and D6 and W2 AL-resistant progeny were later switched to QHS pressure 276. Therefore,
we expected to find reduced susceptibility to drugs that were used in pressuring parasites
during these studies. Previous data from our lab also showed a degree of cross-resistance
276

to QHS, AL, and DHA with lower level drug selected parasites. These data showed a

marked reduction in sensitivity to AL and QHS for W2 resistant parasites when they
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became adapted to 40 ng/ml AL, and this continued up to 80 ng/ml AL. Susceptibility to
AL in TM91C235 decreased significantly after exposure to 10 ng/ml AL, but after
exposure to 30 ng/ml AL, there was no noticeable change at higher levels. The
susceptibility of D6 to AL decreased immediately after adaptation to 30 ng/ml of AL, and
this peaked after adaptation to 50 ng/ml AL. They did not report data for parasites
switched to QHS pressure after the original AL pressure. Although we did observe a
general decrease in susceptibility of resistant lines to QHS and AL, only D6.QHS2400x5
exhibited a substantial decrease in susceptibility to DHA (compared to D6). We found
that TM91.AL280x2 was equally susceptible to AL as reported for TM91.AL80 by
Chavchich et al. 276. Other reports on resistance selected with artemisinin drugs in
Plasmodium and Toxoplasma spp. also detailed cross resistance to artemisinins as well
332,368,383

. Furthermore, Chavchich, 2010 276 also reported that resistant lines became

more susceptible to CQ (except for higher selected TM91c235 parasites), but less
susceptible to MQ. Other studies found reduced susceptibility to artemisinin drugs
coincides with reduced susceptibility to MQ and increased CQ susceptibility in P.
falciparum 205,260,262,322. The resistant D6 and W2 lines in our study showed increased
susceptibility to CQ, but TM91c235.AL280x2 had a marked decrease in susceptibility to
CQ. Perhaps a threshold is passed in resistant TM91c235 parasites at some level where
CQ resistance is no longer displayed. We also found that TM91c235 parent/resistant
parasites were equally susceptible to MQ (by IC50), and that W2.QHS200x2 and
D6.QHS2400x5 showed a slight decrease in susceptibility to MQ compared to respective
parental parasites.
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Ring stage viability assays. It is possible that SYBR Green assays do not capture
true differences in parent vs. resistant parasites due to the formation of dormant parasites
after artemisinin treatment (more below). Therefore, a true measure of viability over the
first part of the life cycle may be missed if assessment is conducted at 48-72 hours postdrug. Indeed, Teuscher et al. (2010) 362 showed that after DHA treatment, parasites exist
for 3 days and can be removed by magnetic columns. This showed that recrudescence
before removal may be due to parasites that are unaffected, or those that go dormant and
recrudesce before removal. The addition of tritiated-hypoxanthine ([3H], Hx) as a
method to assess antimalarial drug susceptibility was pioneered by Desjardins et al., 1979
384

. Much like SYBR Green assays, this method is based on measuring the rate of

parasite growth via the incorporation of Hx into nucleic acid. However, this assay is
subject to variables such as starting parasitemia/hematocrit, isotope pulse time, and
duration in culture. Chulay et al. (1983) 385 examined the parameters influencing Hx
measurements used for parasite proliferation. This study found that Hx incorporation
was directly proportional to the number of infected erythrocytes in culture. It was found
that a steady 1.5% hematocrit level and 18 hour Hx pulse could maintain a linear
relationship between parasite numbers and Hx incorporation for initial parasitemia levels
of 0.4% or lower and this worked at different pulsings. If parasites are cultured for
longer periods or at hematocrit level greater than 1.5%, then the initial parasitemia must
be proportionally reduced to insure a linear relationship between the numbers of parasites
and hypoxanthine incorporation. There was a reduced rate of incorporation when
parasites were at higher initial parasitemia. This may be due to accumulation of acid
metabolites, depletion of nutrients during log phase growth.
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The outcome of an experiment using this method (IC50) is critical, and there can
be problems depending on when the hypoxanthine is added. Studies in the literature have
usually reported that hypoxanthine is added 18-24 hours after drug is added to parasites
384,386-388

. Basco (2004) 389 found that the time point when Hx was added (0 versus 18

hours) had no effect on the IC50 during a 42-hour incubation after CQ exposure. An
increase in Hx incorporation and CQ IC50 was observed when hematocrit increased from
1.0% to 2.5%. For the same isolates, CQ IC50 values were generally similar when the
initial parasitemia was between 0.1% and 0.5% but increased at higher (>0.75%)
parasitemias. Based on these results, it was recommended that assays should include a
42-hour incubation period, addition of Hx at the beginning of incubation, a 1.5%
hematocrit, and an initial parasitemia 0.1-0.5%.
Our studies pointed toward the fact that artemisinin-resistant parasites treated with
artemisinin drugs may produce a greater number of dormant parasites and/or exit
dormancy faster than parent parasites. Also, we knew that at high drug levels, it is
difficult to determine accurate differences in susceptibility after artemisinin exposure. At
low levels, some parasites may be unaffected or recrudesce during the assay. Therefore,
we investigated parasite viability during the first 48 hours after artemisinin treatment.
We chose to add Hx immediately after drug exposure because we theorized that IC50s
may be underestimated (due to dormancy) if Hx was added later. Also, we utilized 1%
parasitemia/2% hematocrit, which is in agreement with the above studies. We added a
lower range of artemisinin drug concentrations (than what parasites tolerate) and assessed
parasite viability at 24 and 48 hours. Dose-response curves for resistant and parent
parasites were produced and it was found that resistant parasites (D6, W2 lines) tolerate
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higher levels of AL, DHA, and QHS compared to parental parasites. Resistant parasites
tolerated AL the most (followed by QHS), much like we observed in SYBR Green drug
susceptibility assays. There was a greater degree of resistance between D6 and
D6.QHS2400x5 tolerance compared to W2 and W2.QHS200x2. This was also observed
in SYBR Green assays. Also, D6.QHS2400x5 exhibited higher tolerance for artemisinin
drugs compared to W2.QHS200x2. This is probably due to the fact that D6.QHS2400x5
was made resistant to much higher levels of QHS. Interestingly, it appeared that parental
D6 tolerated more drug than parent W2 (which was not as easily observed in SYBR
Green assays). The IC50 results from dose response curves were validated by blood
smears that showed levels of drug that parasites could not tolerate, and resistant parasites
were observed at higher drug doses than parent strains. We also used CQ as a control
drug and found CQ phenotypes of D6 (CQ-sensitive) and W2 (CQ resistant) were
reflected in this assay. We also observed that D6 was slightly more resistant to CQ
compared to D6.QHS2400x5 (as found in SYBR Green testing), but W2.QHS200x2 was
more resistant to CQ than W2 (at 48 hours post-drug exposure). This result for W2 is the
opposite of what we observed with SYBR Green testing (W2.QHS200x2 was more
susceptible vs. W2). This discrepancy in W2 results may be a factor of experimental
variability in the SYBR Green assay, due to the time of assessment (72 hours vs. 24/48
hours), or due to the fact that the CQ hypoxanthine results used different data for 24 and
48 hour time points. At 24 hours, W2 appeared to tolerate slightly more drug than
W2.QHS200x2. However, this result does not fit with other results we obtained where
higher IC50 values were observed while progressing from 24 to 48 hours post-drug
exposure. Overall, the reason for the higher drug tolerance in resistant vs. parent strains
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could be a greater number of dormant parasites incorporating Hx or unaffected parasites
that go through the life cycle as normal (saw by smear at low concentrations). Our
results with 1% parasitemia and 2% hematocrit seem to validate the results found by
Chulay et al. (1983) 385 and Basco (2004) 389. We were also able to detect a clear
separation of drug tolerance between susceptible and resistant parasites by using higher
parasitemia and hematocrit levels. Furthermore, a recent study showed a 48 hour Hx
assay (where Hx was added at time drug was added [Personal Communication]) detected
differences in AS, MQ, CQ, and QN susceptibility in western Cambodia vs. eastern
Cambodia 390.
We believe this assay is very useful for exploring artemisinin resistance (and
resistance to other antimalarials). This assay can utilize even lower hematocrit (1%) and
parasitemia (0.5%) when hypoxanthine is added at time zero (Sparks et al., unpublished
data). This assay would be suitable for ring stages which primarily exist in the
circulation of infected patients. It would also allow low parasitemias to be tested, making
it amenable to testing parasites grown for short periods in vitro after taken from patients.
This assay would also detect a suitable ring-trophozoite maturation period, indicating
parasites have reduced susceptibility to artemisinins and other drugs. The majority of Hx
incorporation occurs in the trophozoite stage and reflects the rapid increase in DNA
replication and transcription 151,384,385. Therefore, the assay may be useful for detecting
exit of dormancy or parasites unaffected by drug.
Our findings and those of others (Kyle et al., unpublished; 276,360) emphasize a
potential problem of short term in vitro growth studies for detection of artemisinin
resistance. As noted by us and Chavchich et al. (2010) 276, IC50/90 values of AL and

153

QHS for resistant lines generated were lower than the concentrations the parasites could
endure in vitro. A potential problem with current artemisinin susceptibility methods is
ring stage parasites enter dormancy and take an extended time to recover after exposure
to artemisinins. Standard 48-72 hour drug susceptibility assays may not be sufficient to
assess artemisinin resistance phenotypes. These tests assess viability based on the
presence or production of nucleic acid, which is maximal in mature trophozoites 31. As
we observed with SYBR Green methodology, there does not appear to be a difference
between the resistant and parental lines at 72 hours with some artemisinin drugs.
Dormant parasites do not contain high amounts of nucleic acid, and they persist beyond
the time that typical in vitro drug susceptibility assays assess viability (48-72 hours).
Although it is possible to detect differences in IC50 after artemisinin treatment, it is
essential to recognize that parasites will eventually recrudesce after an initial period of
dormancy after artemisinin treatment, so that parasite viability should be measured at a
later time. Reliance on the current IC50 is based in part on the assumption that parasites
cannot alter their developmental cycle period. In these assays, drug treated parasites are
compared to expected growth of untreated parasites given the same amount of time and
presumably number of cycles to grow. If a drug delays the developmental cycle then the
comparison is not as valid. However, we have shown that resistant parasites can tolerate
more drug than parental parasites at 24-48 hours by hypoxanthine incorporation.
Interestingly, a recent study showed that some CQ resistant parasites had identical IC50
values, yet recrudesced some time after treatment. This indicated that conventional in
vitro susceptibility testing (Hx incorporation in this case) is insufficient to detect strains
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that have low-level CQ resistance or manifest tolerance to CQ. These parasites had
elevated IC90 CQ values, a critical measure of CQ tolerance 236.
Growth rates and merozoite number. While inducing resistance in the various
parasite lines, we noticed that growth rates of resistant D6 strains were reduced and the
life cycle was shorter compared to the parental parasite. This was noted after parasites
recovered after drug treatment and subsequent recrudescence. Chavchich et al. (2010) 276
noted that in the absence of drug pressure, the selected progeny progressed normally
through the erythrocytic stages of the life cycle with no substantial growth differences
from the parent lines. During comparison of growth with synchronized parent and
resistant parasites, the most resistant D6 parasite (D6.QHS2400x5) was delayed in the
progression from rings to trophozoites. There was also a significant decrease in the
number of merozoites in segmenting schizonts compared to D6. These findings are
important because recent studies found that artemisinin-resistant parasites have prolonged
clearance times 280,286,320,321. It may be that the delayed parasite clearance times are due
to a delay in the life cycle of resistant parasites that are circulating in malarious areas
(White, Personal Communication). For the W2 parent/resistant pair, there was not much
separation in growth between parent and resistant parasite until later in the assay.
TM91c235.AL280x2 spiked in growth before TM91c235 shortly after the 3rd
cycle, but we did find convincing evidence of this growth difference being caused by
parasite development. We found that W2 had significantly less merozoites in segmenting
schizonts compared to W2.QHS200, but TM91c235 had significantly more merozoites
than TM91c235.AL280x2. Therefore, the association between growth and merozoite
development is less clear in these strains. It was surprising that the W2 parent had
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significantly less merozoites than the resistant parasite. Reilly et al. (2007) 391 reported
on the difference in proliferation rates, cycle time, merozoite number, and invasion rates
between Dd2 (descendent of W2) and HB3 (drug sensitive, Honduras). Compared to
HB3, Dd2 had a shorter cycle time (faster growth), more merozoites per segmenting
schizont (18 vs. 16), and a higher invasion rate. Interestingly, they found that the faster
growth of Dd2 was attributed to a decreased ring to trophozoite transition time. When
comparing these results to our studies, W2 had less merozoites (15.3) compared to Dd2,
although W2.QHS200x2 had more merozoites than Dd2 (19.7). These differences may
be a result of a number of things, but it is possible that drug pressure over time may have
caused genetic changes enabling a greater capacity to produce merozoites. However, the
increase in merozoites was not reflected in growth difference. We noticed an increase in
ring to trophozoite transition time for D6.QHS2400x5 which corresponded with reduced
merozoite number and slower growth. Perhaps long-term QHS pressure on this parasite
selected for genetic changes that manifested in growth inhibition. A recent study by Balu
et al. (2009) 392 found reduced growth rates in transposon-generated P. falciparum
mutants. The most attenuated mutants had insertions into the coding sequences of
MAL8p1.104 and PFF0770c, which encode a putative CAF1 family ribonuclease and a
protein serine/threonine phosphatase 2C, respectively. PP2Cs participate in many
cellular functions in eukaryotes, including growth factor dependent signal transduction,
transcription, pre-mRNA splicing, DNA replication and the DNA damage response.
These phosphatases also contribute to cell cycle and developmental check points 393. It is
possible that the D6 artemisinin resistant parasites we have generated display impaired
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growth due to genetic alterations in cell cycle checkpoints. However, this does not
appear to affect the ability of resistant parasites to exit dormancy.
Importance of artemisinin resistance and dormancy to patient studies.
Artemisinin resistance is a major concern given the fact that these drugs are still used as
monotherapies and they are part of combination therapies utilized in areas where drugresistant malaria is already prevalent. Recently, artemisinin resistance has emerged in
southeast Asia. Studies have reported on reduced susceptibility to both artemisinins and
ACTs in western Cambodia and eastern Thailand, characterized by prolonged parasite
clearance times (PCT), significant drug failure rates, and reduction of parasite
susceptibility to drugs in vitro 280,320-322,390,394,395. Importantly, resistance does not appear
to be mediated by polymorphisms or amplification of pfmdr1 (as with MQ resistance) or
selected pfatp6 or pfubp-1 polymorphisms 320,321,329. Studies from our groups have found
that these candidate genes for artemisinin resistance do not provide a reason for
artemisinin resistance. Therefore, another mechanism for extended PCT and changes in
drug susceptibility is responsible. Interestingly, the study by Dondorp et al. (2009) 320
found that resistance is characterized by slow parasite clearance in vivo without
corresponding reductions using conventional in vitro susceptibility testing. Therefore,
there is a discrepancy between in vitro and in vivo findings. Most reports of emerging
resistance to artemisinin report some elevation in IC50. A caveat to this is the use of in
vitro susceptibility tests for artemisinin. The tests do not properly assess resistance due
to the formation of dormant parasites, and it is possible that findings of similar
susceptibility patterns are misleading. An important conclusion that can be drawn from
recent studies is that although data point toward artemisinin resistance, it is likely still
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localized to the Thai/Cambodia border. Therefore, existing ACTs in use remain effective
in areas close to where artemisinin resistance is being reported.
Artemisinins clear parasites rapidly, an effect that is attributed to their unique
activity against young ring-stage parasites 141. However, it is well known that patients
experience recrudescence after treatment with a single artemisinin drug. Therefore, it is
recommended that artemisinin is avoided as a monotherapy, which may promote
resistance to this class of drugs 396. Studies with recrudescent parasites find that these
parasites do not differ from artemisinin resistant parasites that have been isolated from
similar locations or those from successfully treated infections (Looareesuwan et al., 1994
151 /id; Looareesuwan et al., 1997 100 /id). We report here and elsewhere (362; Kyle
unpublished) that artemisinin induces dormancy in ring stage parasites in vitro and a
proportion of these parasites recover to cause recrudescence. . We previously showed
that artemisinin induces dormancy in ring stage parasites in vitro and a proportion of
these parasites recover to cause recrudescence. The period of dormancy is marked by
shrunken parasites containing pyknotic nuclei and reduced cytoplasm. Our laboratory has
found that parasites enter a quiescent or dormant state after treatment with artemisinin
drugs 362 (Kyle et al., 2010 unpublished data) and these parasites are capable of resuming
growth after drug pressure is removed. Witkowski et al. (2010) 360 found that parasites
enter a quiescent state after exposure to high levels of artemisinin, and suggested that the
ability to enter the quiescent state was a hallmark of resistance. However, they only
observed that artemisinin resistant parasites enter dormancy. Our laboratory found that
dormancy occurs in artemisinin sensitive and resistant parasites 362 (Kyle et al., 2010
unpublished data; Tucker et al. 2010 unpublished data).
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We hypothesize that multiple rounds of exposure to artemisinin drugs and
recovery from dormancy select for parasites with reduced susceptibility to artemisinin
drugs. This process could enhance recrudescence rates (i.e., treatment failure) and
explain a resistance mechanism where an increased the proportion of parasites recover
from dormancy following the removal of drug pressure, by decreasing the duration of
dormancy, or both. If dormancy and recrudescence are related, and resistant parasites are
selected for, then these viable parasites could be responsible for increased PCT. Perhaps
in resistant parasites, higher dormancy and faster recovery allows recrudescence, then
prolonged PCT could result from more dormants lasting and not being eliminated. The
resistant parasites we have generated here and previously 276 display a noticeable
difference in vitro susceptibility. However, without prior drug pressure, we found that
dormant parasites that eventually recrudesce are equally sensitive to artemisinins as
control parasites. Therefore, repeated exposure to drug is key for accelerated exit from
dormancy and recrudescence. It may be too soon to make the correlation between what
we have found and what occurs in the field. An interesting study by Stepniewska et al.
(2010) 395 identified an indicator that could be used to screen for artemisinin resistance in
patients. They found that counting parasitemia from blood smears 3 days after drug
treatment is a useful predictor or therapeutic response. This takes into consideration that
most patients have cleared their peripheral parasitemia by day 3 (∼72 h) after the start of
treatment. However, some patients with hyperparasitemia have a proportion of parasites
that are not cleared, which may explain recrudescence and extended PCT. Another
interpretation based on our studies of artemisinin-treated ring stages is that parasites
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existing after day 3 may be dormant or recrudescent populations that came out of
dormancy.
There are several reasons why artemisinin induced dormancy has not been
observed previously, especially in vivo. Artemisinin drugs are known to rapidly reduce
peripheral parasitemia with the spleen playing a central role in removing artemisininaffected parasites 141. We hypothesize that late rings and early trophozoites will be easily
cleared by the spleen after therapy, whereas erythrocytes infected with early rings may
produce dormant forms that are less likely to be recognized by the spleen. The
population of dormant parasites may be difficult to detect microscopically, making it
appear that parasites have been cleared. Sequestered trophozoites would be killed by
drug action, whereas schizonts could produce additional dormant progeny. The
erythrocytes infected with dormant parasites could continue to circulate, or possibly even
sequester, until the parasites recover and begin to grow. Alternatively, artemisinintreated parasites may be cleared more effectively than other drugs. Newton et al. (2001)
reported that red blood cells that do not contain parasites (pitted RBCs) yet have ringinfected erythrocyte surface antigen (RESA) exist more after treatment with artemisinins
compared to quinine. The faster rise in RESA-RBC count after treatment with
artemisinins than after quinine reflects the greater efficacy of artemisinin derivatives in
killing or damaging circulating ring-stage parasites, since quinine is more active against
mature stages. It may be that dormant parasites still synthesize proteins after artemisinin
treatment and these parasites are pitted (removed from RBCs) by the spleen. Perhaps
peroxide damage induced by artemisinin to parasites help the spleen recognize dormant
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parasites or older rings change the architecture of RBCs so that they get picked out easier
compared to mature stages. This remains to be proven.
It was thought until recently that clinical resistance to artemisinin does not occur
in the world. Interestingly, data were ignored that showed frequent recrudescence of
infection following treatment with less than 7 days of an artemisinin derivative, with or
without a companion drug 347,370. It is important to note that confirmation of clinical
resistance to artemisinin will be difficult to discern from normal recrudescent infections.
The difficulty is amplified by the short half-life of the drug, which complicates
therapeutic drug monitoring confirmation of patient compliance with the proper regimen.
Due to these technical issues, it is likely that artemisinin resistance could emerge and
spread rapidly before its occurrence is detected. Identification and development of
molecular markers, or other methods of identifying and tracking artemisinin resistant
parasites, is critically important.
Our current understanding of the mechanism of action of artemisinin drugs is
limited, although many mechanisms are postulated. Similarly, little is known about
possible mechanism(s) of artemisinin resistance in P. falciparum. In order to study
mechanisms of resistance, investigators have attempted to establish in vitro and in vivo
resistance models for artemisinin drugs in apicomplexan parasites 332,335,340,344,345,363368,397,398

.

Studies based on previous microarray data. The in vitro resistance to
artemisinin drugs we and others 276 have reported on is different from resistance to other
conventional antimalarial drugs, such as CQ and MQ, where drug resistance mechanisms
are well-established 161. Genes linked to artemisinin resistance have been described
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previously (see above). Also, we previously reported that ring-stage dormancy occurs
only in parasites treated with artemisinin drugs (Kyle et al., 2010 unpublished).
Therefore, it appears that artemisinin resistance is unique in that parasites do not
continually grow under drug pressure. Previous data from our lab found W2 parasites
exposed to artemisinin display differential regulation of certain genes. We investigated
the most differentially regulated genes in hope to find SNPs or copy number differences
that may be responsible for resistance. Transporters PF11_0466 and pfmdr2 were underexpressed in the early microarrays. PF11_0466 is a member of the ATP binding cassette
(ABC) transporter superfamily and it contains a multidrug resistance domain 399. ABC
transporters are localized to the parasite food vacuole membrane or plasma membrane,
and they decrease intracellular drug accumulation by pumping out drugs, resulting in
drug resistance. Mu et al., 2003 201 investigated 49 known P. falciparum transporters and
assayed drug susceptibility and sequence of these transporters in various drug
resistant/susceptible strains (HB3, Dd2, D10, 7G8, and 3D7). Based on this analysis, five
non-synonymous SNPs were found in PF11_0466. Because of the close relation to
pfmdr1, PF11_0466 could be a candidate drug resistance gene 400. In addition, the WHOTDR drug target database classifies PF11_0466 with a druggability index of 0.5/1.0 401.
Our efforts to sequence PF11_0466 in W2 and W2.QHS200 did not produce reliable
sequence where we could determine SNPs between strains. We also did not find an
association between down regulation of PF11_04446 and copy number change (all strains
analyzed had approximately 1 copy). Therefore, PF11_0466 does not appear to be
important in artemisinin resistance at this point. However, its relation to pfmdr1 and
other transporters still makes it important to analyze in future assays. Pfmdr2 is another
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ABC transporter exhibiting similarities to Pfmdr1, and for some time it was thought to be
involved with antimalarial resistance 400. Over-expression of Pfmdr2 was purported to be
involved in CQ resistance 402, but other studies found that pfmdr2 was unassociated with
CQ resistance 403,404. Furthermore, a single genetic cross between CQ-resistant and CQsensitive P. falciparum parent found that pfmdr2 does not segregate with the CQresistance phenotype 208. This gene has recently been linked to heavy metal resistance in
a FCR3 strain of P. falciparum made resistant to cadmium chloride 379. The gene has a
druggability index of 0.7/1.0, indicating it has moderate potential as drug target 401. Like
PF11_0466, we did not detect SNPs in W2 lines, and there was no change in copy
number in all strains we tested. Based on these data, we do not believe pfmdr2 plays a
significant role in artemisinin resistance. But, like PF11_0466, it still may be interesting
to determine if this transporter plays any role in artemisinin resistance in future assays.
A group of non-transporter genes was found whose values of genotype effects
were also highly significant in the early microarrays, with PFE1050w (S-adenosyl
homocysteine hydrolase, up-regulated) being the most significant. This gene catalyzes
reversible hydrolysis of S-adenosyl homocysteine (SAH) to adenosine and homocysteine,
and it is necessary for active methylation of different biomolecules 405. Recent studies on
the inhibition of P. falciparum spermidine synthase (PfSpdSyn) with cyclohexylamine
and S-adenosyl methionine decarboxylase/ornithine decarboxylase (PfAdoMetDC/ODC)
with DL-α-difluoromethylornithine (DFMO)/MDL73811 found that genes of the
polyamine biosynthetic pathway were down-regulated (including PFE1050w) and
parasites were morphologically and transcriptionally arrested at early trophozoite stage
406,407

. A key finding of these studies was that there is significant transcriptional level
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control after drug treatment and drug-treated parasites displayed compensatory
mechanisms for the inhibition of certain pathways. Makanga et al. (2005) 408 reported
that late rings of P. falciparum (CQ-resistant strain K1, Thailand) treated with AE are
affected for a number of important biochemical processes. Genes encoding enzymes
involved in protein synthesis, nucleic acid metabolism (including PFE1050w), and
parasite respiration were down-regulated. Kidgell et al. (2006) 409 identified regions of
amplification in P. falciparum strains that included PFE1050w in strain FCR3 (CQresistant, Gambia) and PFE1115c (S-adenosyl methionine-dependent methyltransferase)
in strains FCB (CQ, QN resistant, Thailand), FCR3, and Dd2. Ribacke et al. (2007) 410
identified duplication in PFE1115c in patient isolates from Uganda. Gunasekera et al.
(2007) 411 identified PFE111c as a differentially regulated gene after 3D7 was treated
with CQ. Witkowski et al. (2010) 360 determined that PF10_0121, which encodes
hypoxanthine phosphoribosyltransferase) was down-regulated in QHS-selected P.
falciparum. Natalang et al. (2008) 412 also found PF10_0121 was down-regulated in a
study of AS-treated P. falciparum. These studies seem to implicate nucleic acid
metabolism in drug-resistant parasites. Although PFE1050w was up-regulated in W2
resistant parasites in early microarrays, we did not find any changes in CN or detect SNPs
in drug selected parasites. We find it interesting that PFE1050w was down-regulated in
these studies, whereas we found it to be up-regulated in our microarrays. It appears that
different compounds can arrest P. falciparum development (our data with rings and
trophozoites from the study above), yet PFE1050w is differentially regulated. Perhaps
nucleic acid metabolism can be affected in numerous ways by drugs, reflecting
transcriptional changes the parasite employs. At this point, we can state that PFE1050w
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does not appear to be involved in artemisinin resistance, but its potential as a drug target
should not be understated. The TDR drug target database lists the druggability index of
PFE1050w as 0.8/1.0, making it a high interest drug target. Studies have shown that
elevated levels of SAH are inhibitory for viruses and tumor lines 413, making SAHH an
intriguing antimalarial drug target. Early studies with SAHH in Plasmodium spp. found
that neplanocin A and 4„,5„-didehydro-5‟-fluoroadenosine inhibited parasite growth, but
the effect could not be attributed to inhibition of the parasite enzyme 405. A more recent
study showed that (6‟R)-6‟-C-methylneplanocin A (RMNPA) inhibits P. falciparum in
vitro, and P. berghei was inhibited in an in vivo assay 414. Therefore, nucleic acid
metabolism is an important drug target for ongoing antimalarial drug development.
The early microarrays demonstrated a role for pfmdr1 in resistance, and further
studies by our group have further implicated this gene in the resistance generated in vitro.
Pfmdr1 appears to involved in the AL and QHS resistance phenotypes of TM91c235 and
W2 276. Exposure to increasing doses of drug resulted in the proportionate increase in the
pfmdr1 copy number as well as in its mRNA and protein expression in the W2 and
TM91c235 resistant lines. Interestingly, the adaptation of parasites to 40 ng/ml of QHS
was associated with a decrease in pfmdr1 copy number from three to two copies. The
copy number remained stable at two, as this parasite was adapted up to 200ng/ml
QHS.Interestingly, D6 lines at all drug pressure levels only had one copy of pfmdr1. Our
results with higher drug-selected lines recapitulate these findings. These data suggest
that pfmdr1 amplification can be associated with resistance to artemisinin drugs in vitro,
but clearly pfmdr1 amplification is not the only mechanism involved in conferring
artemisinin resistance. Based on these analyses, artemisinin resistance appears
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multifactorial, but it can be enhanced by amplification of pfmdr1, which also confers
resistance to MQ 205,206,260-262,266,277. It is well known that pfmdr1 is associated with drug
resistance in Asia 205,260,262,286,298,415-417. However, few studies have reported on
amplification of pfmdr1 in Africa 275,418-421. Perhaps there is significant copy number
variation in Africa as we did not detect a pfmdr1 CN change in D6, which is from West
Africa. Also, there may be a unique mechanism for resistance in resistant lines we
generated since parasites tolerating 2400 ng/ml QHS still retained one copy of pfmdr1.
We are in the process of identifying genetic determinants of artemisinin resistance in D6
drug selected lines. As mentioned above, PFE1050w was up-regulated in W2 resistant
parasites in early microarrays, but we did not find any changes in CN. We hypothesized
that the up-regulation of PFE1050w was due to its presence on an amplicon including
pfmdr1 since these genes are near each other. Therefore, it was unexpected that
PFE1050w was up-regulated and there was not an increase in CN when pfmdr1 was upregulated and amplified. Chen et al. (2010) 337 showed amplification of 19 genes
(PFE1095 to PFE1180) that included pfmdr1 (PFE1150w) in W2.AL80 (three copies of
pfmdr1). When a decrease in CN of pfmdr1 occurred, so did the CN of other genes on
the amplicon. Perhaps PFE1050w is not part of a pfmdr1amplicon produced after
artemisinin pressure, but its up-regulation is still interesting.
Artemisinin resistance phenotype. Based our investigations with parental and
resistant pairs of parasites, we can begin to define an artemisinin resistance phenotype.
This phenotype can be defined by elevated IC50 by in vitro susceptibility testing with
artemisinins, marked by resistance to more than one artemisinin derivative. By
hypoxanthine incorporation, resistant parasites will show increased tolerance to lower
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levels of artemisinins compared to susceptible parasites- 48 hours after drug exposure.
Recovery assays document the level of drug parasites can tolerate without being selected.
We showed D6 tolerated 1500 ng/ml QHS and a line already induced to tolerate 340
ng/ml QHS could tolerate 2400 ng/ml QHS. Also, growth can be delayed through the
normal erythrocytic cycle with a noticeable extended transition from rings to trophozoites.
Resistance is not explained by candidate gene amplifications or mutations as Chavchich
et al. (2010) 276 reported that genes (pftctp, pfatp6, pfmdr1) with tentative associations to
artemisinin resistance have no changes in the gene coding sequences in resistant
progenies of W2, D6, or TM91c235 lines. Our molecular data fit with this assertion as
well.
Artemisinin drugs are essential tools for controlling the world‟s most important
parasitic disease. The recent WHO decision to introduce ACT combination therapy
globally makes the discovery of artemisinin resistance markers more important than ever
before. Subjecting P. falciparum to increasing amounts of artemisinin drugs has
produced resistant parasites that will serve as valuable reagents for molecular analyses
and other studies. Our data suggest that artemisinin resistance was selected for by
multiple pulse exposures to drug over time. Although long-term stability studies at these
high levels of drug exposure have not been completed, resistance to artemisinin
derivatives (as indicated by the ability to survive increasing concentrations of the drug)
can be induced in P. falciparum in vitro. An alarming fact is that parasites in the field
that are continually exposed to suboptimal levels of artemisinin drugs may begin to
tolerate high levels of these drugs, leading to a greater distribution of drug resistance.
The artemisinin resistant parasites we have generated represent a unique resource for
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molecular and cellular studies of artemisinin resistance mechanism(s) and markers,
mechanism of action studies, determining the role of drug-induced dormancy as a
mechanism of recrudescence, and optimizing ACT drug partners. We have used these
reagents to investigate dormancy and resistance and to define a resistance phenotype for
D6 parasites, exhibited by resistant parasites tolerating ≥1.5 µg/ml drug for > 48 hr, cross
resistance between artemisinin derivatives, and the fact that resistant parasites recover
faster than parental strains at low drug levels. Future research will focus on dissecting
whole genome sequence, transcription, and proteomic data of parental and resistant
parasites to further elucidate mechanisms of resistance to artemisinin drugs.
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Fig. 2.1. 96 Well Plate Setup for a Typical Hypoxanthine Assay. After a mother plate
was made with drugs from 1000 ng/ml-1.0 ng/ml, 10 µl of serially diluted drug was
transferred into wells containing 90 µl of parasite suspension. This made a 1:10 drug
dilution in the final plate (100 ng/ml-0.1 ng/ml). Each test plate had 11 drug
concentrations (representing 1:2 serial dilutions, left to right) in triplicate for each
parasite tested (each half of a plate contained one parasite). A fourth row of parasite and
drug was included, but hypoxanthine was not added in order to take material from wells
for smears. The final column contained controls (no drug and non-parasitized RBCs
[NRBCs]) for each parasite pair. The assay depicted here was for the initial DHA D6 and
D6.QHS2400x5 assay starting at 800 ng/ml. We also tested other drugs at lower
concentrations in a 1:2 dilution scheme (see text) and W2, W2.QHS200 were tested in a
similar manner as depicted here.
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Figure 2.2. 96 Well Plate Setup for a Typical QPCR Assay for Assessment of Copy
Number. Each half of a plate was set up the same way for the gene of interest (in this
example, PF10_0292) and the normalizer gene, ldh. Every sample on the plate was run
in triplicate. Each gene had the same serially diluted 5 point standard curve of D6
(replicate numbers 1-5 for PF10_0292 and 14-18 for 1dh). The unknown samples were
replicates 6-13 for PF10_0292 and 19-26 for ldh. Each primer set included a no template
control (NTC) reaction.
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Figure 2.3. Amplification Plots of Standards and Unknowns in a Typical QPCR Assay.
The y-axis indicates Fluorescence units and the x-axis indicates cycle number. Here, the
Ct value for each triplicate has been averaged and shown as a single plot for each
standard and unknown sample of pfmdr1 and ldh. There are separate thresholds
generated for pfmdr1 and ldh. The unknown Ct values (bulk of the amplification plots)
occur between the standard Ct values. Unknown Ct values in this experiment are very
close for pfmdr1 and ldh, so that the plots almost overlap for each sample (this varied per
experiment).
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Figure 2.4. Individual Amplification Plots of an Unknown Gene and Normalizer ldh. In
this pfmdr1 QPCR copy number assay, the average threshold cycle (Ct) for pfmdr1 and
ldh is shown for an unknown sample. The average Ct for ldh-pfmdr1 is calculated and
used in the standard curve equations calculated for the overall difference of ldh-pfmdr1
for the D6 standards (see text). Standards are not shown in this figure for clarity.
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Figure 2.5. Standard Curve Generation for a QPCR Assay. The Ct values (triplicate) of
each serial-diluted D6 standard (five total) for pfmdr1 and ldh are averaged and the
standard deviation is calculated. The average Ct value of each standard is plotted vs. log2
DNA concentration and a trendline is generated, giving a standard curve equation. The
slope and y-intercept of each equation is used to calculate the relative copy number of the
unknown samples (see text).
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Figure 2.6. Treatment of D6.QHS80 With Increments of Artemisinin Produced Parasites
That Tolerated 2400 ng/ml of Artemisinin. D6 adapted to 80 ng/ml artemisinin (QHS)
was treated with QHS with increments of 20-40 ng/ml QHS in order to increase drug
tolerance. After D6.QHS340 was treated one more time at 340 ng/ml QHS (x2), it was
subjected to a range of QHS and tolerated the maximum dose, 340 ng/ml. This parasite
(D6.QHS340x3) was then subjected to a range of QHS in a second recovery assay (802400 ng/ml), and it tolerated the maximum dose of 2400ng/ml. This parasite was treated
three more times with 2400 ng/ml QHS, and it was cloned by limiting dilution. Selected
clones were then treated one more time with 2400ng/ml QHS, yielding D6.QHS2400x5.
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Figure 2.7. Treatment of TM91c235.AL80 With Increments of Artelinic Acid Produced
Parasites That Tolerated 280 ng/ml of Artelinic Acid. TM91.AL80 was treated with
artelinic acid (AL) increments of 20-40 ng/ml AL in order to increase drug tolerance.
The parasite was first treated at 40 ng/ml, then 60 ng/ml before 80 ng/ml was applied,
then moved up to 280 ng/ml (x2). There is a long period of time between applications of
280 ng/ml because TM91c235.AL280x1 was cryopreserved for a while, then thawed, and
subjected to a second dose of 280 ng/ml AL.
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Figure 2.8. Recrudescence Assay With W2 and W2.QHS200 Clones Found the Resistant
Parasite Recrudesced Before the Parent Strain After Dihydroartemisinin Treatment.
Cloned parent W2 (clone D7) and resistant lineW2.QHS200x2 (clone C5) were exposed
to 200ng/ml dihydroartemisinin (DHA) and the parasitemia (A), pictures of parasites
during the time course (up to 120 hours post-drug exposure) (B), percentage
dormant/total parasites (C), and percentage normal/total parasites (D) was calculated at
each time point.
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Figure 2.9. Recovery Assays With D6 Parent and Resistant Lines Show Resistant
Parasites Recrudesced Before the Parent Strain After Artemisinin Treatment. Percentage
of Normal/Total Parasites for D6 and D6.QHS340x2 after exposure of 28.2-340 ng/ml
artemisinin (QHS) (showing 200 ng/ml and 300 ng/ml concentrations levels) (A.).
Percentage of Normal/Total Parasites for D6 and D6.QHS340 (x3) after exposure of 802400 QHS (showing representative example- D6+1500, D6.QHS340x3+1500) (B.).
Pictures of D6 and D6.QHS340x3 during the time course at 0, 22, 48, 235, 264, and 360
hours after treatment with 1500 ng/ml QHS (DMSO at 22 and 48 hours) (C.).
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Figure 2.10. Decreased Growth and Merozoite Number is Associated With D6 Resistant
Progeny but not All Resistant Strains. Growth curves of synchronized parental and
resistant strains of D6 (A.) (clonal pairs), W2 (B.) (clonal pairs), and TM91c235 (C.). In
(D.), the mean merozoite number in segmenting schizonts of cloned parent D6 cloned
resistant D6.QHS2400x5, cloned parent W2, cloned resistant W2.QHS200x2, cloned
TM91c235, and TM91.AL280x2 is shown. The number of merozoites was significantly
less in the resistant D6 parasite (*p=3.8x10-10) compared to the parent. The number of
schizonts was significantly greater in the resistant W2 parasite compared to the parental
W2 (**P=1.3x10-16). For the TM91c235 series, the mean number of schizonts was
greater in the parental strain compared to the resistant strain (***P=0.012). Pictures (E.)
of typical segmenting schizonts of D6, W2, and TM91c235 parasites, showing average,
minimum, and maximum (left to right) for each strain. D6 (clone C11): average-19.3,
min-14, max-24 merozoites/schizont; D6.QHS2400x5 average-16.3, min-12, max-22
merozoites/schizont;W2 (clone D7)-15.3, min-12, max-22 merozoites/schizont;
W2.QHS200x2 average-19.7, min-14, max-26 merozoites/schizont; TM91c235 average20.7, min-16, max-26 merozoites/schizont; TM91c235280x2 average-19.7, min-16, max24 merozoites/schizont.
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Figure 2.11. Ring Stage Viability Assay Determined That Resistant Parasites Tolerate
More Drug Than Parental Strains. Clonal D6 and W2 parent and resistant lines were
treated with drug and tritiated hypoxanthine was immediately added. Percent parasite
growth at 48 hours was compared to no drug controls for W2, D6 lines after exposure to
artemisinin (QHS), dihydroartemisinin (DHA), artelinic acid (AL), and chloroquine (CQ).
It is graphed as a function of drug concentration (ng/ml). The graphs depict logarithmic
dose response of parent (blue) and resistant (gray) parasites for each line after drug
treatment The graphs show D6/D6.QHS2400x5+DHA (A.), D6/D6.QHS2400x5+AL
(B.), D6/D6.QHS2400x5+QHS (C.), D6/D6.QHS2400x5+CQ (D.);
W2/W2.QHS200x2+DHA (E.), W2/W2.QHS200x2+AL (F.), W2/W2.QHS200x2+QHS
(G.), W2/W2.QHS200x2+CQ (H.).

187

W2.QHS200
Dd2
W2
3D7
D10

ATGGATGTATCAAATTACGAGTATTTAAGATCCTATGGAATTAAGAACGAACTGAAAAGG
ATGGATGTATCAAATTACGAGTATTTAAGATCCTATGGAATTAAGAACGAACTGAAAAGG
ATGGATGTATCAAATTACGAGTATTTAAGATCCTATGGAATTAAGAACGAACTGAAAAGG
ATGGATGTATCAAATTACGAGTATTTAAGATCCTATGGAATTAAGAACGAACTGAAAAGG
ATGGATGTATCAAATTACGAGTATTTAAGATCCTATGGAATTAAGAACGAACTGAAAAGG
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

AAAAGAACGCACAAGAAGATAATAATATATCACTTATTAGATATTATAATATTTTTCTTA
AAAAGAACGCACAAGAAGATAATAATATATCACTTATTAGATATTATAATATTTTTCTTA
AAAAGAACGCACAAGAAGATAATAATATATCACTTATTAGATATTATAATATTTTTCTTA
AAAAGAACGCACAAGAAGATAATAATATATCACTTATTAGATATTATAATATTTTTCTTA
AAAAGAACGCACAAGAAGATAATAATATATCACTTATTAGATATTATAATATTTTTCTTA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

TTATTTTTTAGTTGTTACAATTTTAATTTAGAATTATGTTATAAATATGAAAAGGCAATT
TTATTTTTTAGTTGTTACAATTTTAATTTAGAATTATGTTATAAATATGAAAAGGCAATT
TTATTTTTTAGTTGTTACAATTTTAATTTAGAATTATGTTATAAATATGAAAAGGCAATT
TTATTTTTTAGTTGTTACAATTTTAATTTAGAATTATGTTATAAATATGAAAAGGCAATT
TTATTTTTTAGTTGTTACAATTTTAATTTAGAATTATGTTATAAATATGAAAAGGCAATT
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

TTTTATAATTTTTTTAAATCATCAGTTGATTTATTTTTGTTGAATGTTATAAGAATAATA
TTTTATAATTTTTTTAAATCATCAGTTGATTTATTTTTGTTGAATGTTATAAGAATAATA
TTTTATAATTTTTTTAAATCATCAGTTGATTTATTTTTGTTGAATGTTATAAGAATAATA
TTTTATAATTTTTTTAAATCATCAGTTGATTTATTTTTGTTGAATGTTATAAGAATAATA
TTTTATAATTTTTTTAAATCATCAGTTGATTTATTTTTGTTGAATGTTATAAGAATAATA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

TACACCGTAATTTTATTTAGATTACATAAAAAGTTAACAGAATTGAATACATTAGGAAAG
TACACCGTAATTTTATTTAGATTACATAAAAAGTTAACAGAATTGAATACATTAGGAAAG
TACACCGTAATTTTATTTAGATTACATAAAAAGTTAACAGAATTGAATACATTAGGAAAG
TACACCGTAATTTTATTTAGATTACATAAAAAGTTAACAGAATTGAATACATTAGGAAAG
TACACCGTAATTTTATTTAGATTACATAAAAAGTTAACAGAATTGAATACATTAGGAAAG
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

GTGTATGTATTATCCAGACATATAACCGGTATCTTAGTTATATTGAATGTAATAAAGATG
GTGTATGTATTATCCAGACATATAACCGGTATCTTAGTTATATTGAATGTAATAAAGATG
GTGTATGTATTATCCAGACATATAACCGGTATCTTAGTTATATTGAATGTAATAAAGATG
GTGTATGTATTATCCAGACATATAACCGGTATCTTAGTTATATTGAATGTAATAAAGATG
GTGTATGTATTATCCAGACATATAACCGGTATCTTAGTTATATTGAATGTAATAAAGATG
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

ATAAATTATAGTTATGTAATAAAATCAGAAAATCCTCTTTATAATACTAACATGTATTTA
ATAAATTATAGTTATGTAATAAAATCAGAAAATCCTCTTTATAATACTAACATGTATTTA
ATAAATTATAGTTATGTAATAAAATCAGAAAATCCTCTTTATAATACTAACATGTATTTA
ATAAATTATAGTTATGTAATAAAATCAGAAAATCCTCTTTATAATACTAACATGTATTTA
ATAAATTATAGTTATGTAATAAAATCAGAAAATCCTCTTTATAATACTAACATGTATTTA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

ATAACACTCAAAGTTTTGTTTATGGTTTATAGTATGATTTCATCTATATATTATTATTTT
ATAACACTCAAAGTTTTGTTTATGGTTTATAGTATGATTTCATCTATATATTATTATTTT
ATAACACTCAAAGTTTTGTTTATGGTTTATAGTATGATTTCATCTATATATTATTATTTT
ATAACACTCAAAGTTTTGTTTATGGTTTATAGTATGATTTCATCTATATATTATTATTTT
ATAACACTCAAAGTTTTGTTTATGGTTTATAGTATGATTTCATCTATATATTATTATTTT
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

ATACAATTTAAATTATATAATATAAAGAAGAAATATATTATAGCTCGAGTTGAATTAGAA
ATACAATTTAAATTATATAATATAAAGAAGAAATATATTATAGCTCGAGTTGAATTAGAA
ATACAATTTAAATTATATAATATAAAGAAGAAATATATTATAGCTCGAGTTGAATTAGAA
ATACAATTTAAATTATATAATATAAAGAAGAAATATATTATAGCTCGAGTTGAATTAGAA
ATACAATTTAAATTATATAATATAAAGAAGAAATATATTATAGCTCGAGTTGAATTAGAA
************************************************************
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W2.QHS200
Dd2
W2
3D7
D10

AAAATATTAATAAATGATATTAAATCAAAAAAATATAACATATATAAATCTGATGAAAAT
AAAATATTAATAAATGATATTAAATCAAAAAAATATAACATATATAAATCTGATGAAAAT
AAAATATTAATAAATGATATTAAATCAAAAAAATATAACATATATAAATTTGATGAAAAT
AAAATATTAATAAATGATATTAAATCAAAAAAATATAACATATATAAATCTGATGAAAAT
AAAATATTAATAAATGATATTAAATCAAAAAAATATAACATATATAAATCTGATGAAAAT
************************************************* **********

W2.QHS200
Dd2
W2
3D7
D10

AGTGGCTTATTAGGAACAGATAATAATAGTACCATAATGAATAATGAATATTTAAACCTT
AGTGGCTTATTAGGAACAGATAATAATAGTACCATAATGAATAATGAATATTTAAACCTT
AGTGGCTTATTAGGAACAGATAATAATAGTACCATAATGAATAATGAATATTTAAACCTT
AGTGGCTTATTAGGAACAGATAGTAATAGTACCATAATGAATAATGAATATTTAAACCTT
AGTGGCTTATTAGGAACAGATAATAATAGTACCATAATGAATAATGAATATTTAAACCTT
********************** *************************************

W2.QHS200
Dd2
W2
3D7
D10

GATTATAAAAATTTATTAGATATGAATATATCATATAACAAATTAAATGAAAAAATAAAT
GATTATAAAAATTTATTAGATATGAATATATCATATAACAAATTAAATGAAAAAATAAAT
GATTATAAAAATTTATTAGATATGAATATATCATATAACAAATTAAATGAAAAAATAAAT
GATTATAAAAATTTATTAGATATGAATATATCATATAACAAATTAAATGAAAAAATAAAT
GATTATAAAAATTTATTAGATATGAATATATCATATAACAAATTAAATGAAAAAATAAAT
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

AATGATATTATAAATAATACTTCTGATGTTCAGGAGAAAAATATGGATTATAATGATATT
AATGATATTATAAATAATACTTCTGATGTTCAGGAGAAAAATATGGATTATAATGATATT
AATGATATTATAAATAATACTTTTGATGTTCAGGAGAAAAATATGGATTATAATGATATT
AATGATATTATAAATAATACTTCTGATGTTCAGGAGAAAAATATGGATTATAATGATATT
AATGATATTATAAATAATACTTCTGATGTTCAGGAGAAAAATATGGATTATAATGATATT
********************** *************************************

W2.QHS200
Dd2
W2
3D7
D10

CATAATTTTCAGAAAAAAAAAAAATCTTCTAATTTTGCTTATTTAAATTTTTTCCATAAA
CATAATTTTCAGAAAAAAAAAAAATCTTCTAATTTTGCTTATTTAAATTTTTTCCATAAA
CATAATTTTCAGAAAAAAAAAAAATCTTCTAATTTTGCTTATTTAAATTTTTTCCATAAA
CATAATTTTCAGAAAAAAAAAAAATCTTCTAATTTTGCTTATTTAAATTTTTTCCATAAA
CATAATTTTCAGAAAAAAAAAAAATCTTCTAATTTTGCTTATTTAAATTTTTTCCATAAA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

GAAAGTAAAGATAATAAAATTGATGTAAAAGAATCATTTTTAAATAAAAGATATGATAGT
GAAAGTAAAGATAATAAAATTGATGTAAAAGAATCATTTTTAAATAAAAGATATGATAGT
GAAAGTAAAGATAATAAAATTGATGTAAAAGAATCATTTTTAAATAAAAGATATGATAGT
GAAAGTAAAGATAATAAAATTGATGTAAAAGAATCATTTTTAAATAAAAGATATGGTAGT
GAAAGTAAAGATAATAAAATTGATGTAAAAGAATCATTTTTAAATAAAAGATATGGTAGT
******************************************************* ****

W2.QHS200
Dd2
W2
3D7
D10

AATAAACGTAGTAGTAAAATATATGATAATAATAATAATAATAATAATAATA------TA
AATAAACGTAGTAGTAAAATATATGATAATAATAATAATAATAATAATAATA------TA
AATAAACGTAGTAGTAAAATATATGATAATAATAATAATAATAATAATAATA------TA
AATAAACGTAGTAGTAAAATATATGATAATAATAATAATAATAATAATAATAATA---TA
AATAAACGTAGTAGTAAAATATATGATAATAATAATAATAATAATAATAATAATAATATA
****************************************************
**

W2.QHS200
Dd2
W2
3D7
D10

AACTCCAAAATTGATTATTTAGAAAATAATATAACATATACAGAATTCAAAAAAATACTT
AACTCCAAAATTGATTATTTAGAAAATAATATAACATATACAGAATTCAAAAAAATACTT
AACTCCAAAATTGATTATTTAGAAAATAATATAACATATACAGAATTCAAAAAAATACTT
AACTCCAAAATTGATTATTTAGAAAATAATATAACATATACAGAATTCAAAAAAATACTT
AACTCCAAAATTGATTATTTAGAAAATAATATAACATATACAGAATTCAAAAAAATACTT
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

TTACCATATTTGTGGCCAAGCAAAAGGATAGATATGAAAGGAAATAGCTCTATATTACGT
TTACCATATTTGTGGCCAAGCAAAAGGATAGATATGAAAGGAAATAGCTCTATATTACGT
TTACCATATTTGTGGCCAAGCAAAAGGATAGATATGAAAGGAAATAGCTCTATATTACGT
TTACCATATTTGTGGCCAAGCAAAAGGATAGATATGAAAGGAAATAGCTCTATATTACGT
TTACCATATTTGTGGCCAAGCAAAAGGATAGATATGAAAGGAAATAGCTCTATATTACGT
************************************************************
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W2.QHS200
Dd2
W2
3D7
D10

ACATATATTGTTCTAATATTTTTATTTATATTAGTATCAAAAGTATTTAGTGTAATTTCT
ACATATATTGTTCTAATATTTTTATTTATATTAGTATCAAAAGTATTTAGTGTAATTTCT
ACATATATTGTTCTAATATTTTTATTTATATTAGTATCAAAAGTATTTAGTGTAATTTCT
ACATATATTGTTCTAATATTTTTATTTATATTAGTATCAAAAGTATTTAGTGTAATTTCT
ACATATATTGTTCTAATATTTTTATTTATATTAGTATCAAAAGTATTTAGTGTAATTTCT
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

CCGATATATTTAGGTTGGGCATCAAATGAAGTATTAAAAAAGAGTTTATCTAGTTCAGTA
CCGATATATTTAGGTTGGGCATCAAATGAAGTATTAAAAAAGAGTTTATCTAGTTCAGTA
CCGATATATTTAGGTTGGGCATCAAATGAAGTATTAAAAAAGAGTTTATCTAGTTCAGTA
CCGATATATTTAGGTTGGGCATCAAATGAAGTATTAAAAAAGAGTTTATCTAGTTCAGTA
CCGATATATTTAGGTTGGGCATCAAATGAAGTATTAAAAAAGAGTTTATCTAGTTCAGTA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

TATTATTTAGGTTTATATGTAACATTTTTTTTTATATCTAAATTTTTAAAAGAGGTTTGT
TATTATTTAGGTTTATATGTAACATTTTTTTTTATATCTAAATTTTTAAAAGAGGTTTGT
TATTATTTAGGTTTATATGTAACATTTTTTTTTATATCTAAATTTTTAAAAGAGGTTTGT
TATTATTTAGGTTTATATGTAACATTTTTTTTTATATCTAAATTTTTAAAAGAGGTTTGT
TATTATTTAGGTTTATATGTAACATTTTTTTTTATATCTAAATTTTTAAAAGAGGTTTGT
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

GGTGTATTATATTCACAAGTACAACAATCAGCTTTTATAGAATTACAAGAATCTATATTT
GGTGTATTATATTCACAAGTACAACAATCAGCTTTTATAGAATTACAAGAATCTATATTT
GGTGTATTATATTCACAAGTACAACAATCAGCTTTTATAGAATTACAAGAATCTATATTT
GGTGTATTATTTTCACAAGTACAACAATCAGCTTTTATAGAATTACAAGAATCTATATTT
GGTGTATTATTTTCACAAGTACAACAATCAGCTTTTATAGAATTACAAGAATCTATATTT
********** *************************************************

W2.QHS200
Dd2
W2
3D7
D10

CAAACATTTCATAATTTATCATATGAATGGTATTCTAGTAAAAATTCGGGTGGTATCATG
CAAACATTTCATAATTTATCATATGAATGGTATTCTAGTAAAAATTCGGGTGGTATCATG
CAAACATTTCATAATTTATCATATGAATGGTATTCTAGTAAAAATTCGGGTGGTATCATG
CAAACATTTCATAATTTATCATATGAATGGTATTCTAGTAAAAATTCGGGTGGTATCATG
CAAACATTTCATAATTTATCATATGAATGGTATTCTAGTAAAAATTCGGGAGGTATCATG
************************************************** *********

W2.QHS200
Dd2
W2
3D7
D10

AGAATAGTTGATAGAGGTACCGAGAGTGCTAATAATTTGATGAGTTCTGTTTTAATGTAT
AGAATAGTTGATAGAGGTACCGAGAGTGCTAATAATTTGATGAGTTCTGTTTTAATGTAT
AGAATAGTTGATAGAGGTACCGAGAGTGCTAATAATTTGATGAGTTCTGTTTTAATGTAT
AGAATAGTTGATAGAGGTACCGAGAGTGCTAATAATTTGATGAGTTCTGTTTTAATGTAT
AGAATAGTTGATAGAGGTACCGAGAGTGCTAATAATTTGATGAGTTCTGTTTTAATGTAT
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

ATTATTCCGGCAATAATAGAAGGATTAATAACATGTATTATATTTATTTTTAAATATAAG
ATTATTCCGGCAATAATAGAAGGATTAATAACATGTATTATATTTATTTTTAAATATAAG
ATTATTCCGGCAATAATAGAAGGATTAATAACATGTATTATATTTATTTTTAAATATAAG
ATTATTCCGGCAACAATAGAAGGATTAATAACATGTATTATATTTATTTTTAAATATAAG
ATTATTCCGGCAACAATAGAAGGATTAATAACATGTATTATATTTATTTTTAAATATAAG
************* **********************************************

W2.QHS200
Dd2
W2
3D7
D10

AATAGTTTATTAGGTAGTGTATTATTTATAGGTTTAACTTTATATATATATTCAACAATA
AATAGTTTATTAGGTAGTGTATTATTTATAGGTTTAACTTTATATATATATTCAACAATA
AATAGTTTATTAGGTAGTGTATTATTTATAGGTTTAACTTTATATATATATTCAACAATA
AATAGTTTATTAGGTAGTGTATTATTTATAGGTTTAACTTTATATATATATTCAACAATA
AATAGTTTATTAGGTAGTGTATTATTTATAGGTTTAACTTTATATATATATTCAACAATA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

AAAATTACAAAGTGGAGAAAAAAAATTAGAACAAAAGCAAATGAGATGGATAATGTATAT
AAAATTACAAAGTGGAGAAAAAAAATTAGAACAAAAGCAAATGAGATGGATAATGTATAT
AAAATTACAAAGTGGAGAAAAAAAATTAGAACAAAAGCAAATGAGATGGATAATGTATAT
AAAATTACAAAGTGGAGAAAAAAAATTAGAACAAAAGCAAATGAGATGGATAATGTATAT
AAAATTACAAAGTGGAGAAAAAAAATTAGAACAAAAGCAAATGAGATGGATAATGTATAT
************************************************************
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W2.QHS200
Dd2
W2
3D7
D10

CATGATATAGCTCATGATTCATTAACAAATTATGAAAATGTGAAATATTTTAGTAATGAA
CATGATATAGCTCATGATTCATTAACAAATTATGAAAATGTGAAATATTTTAGTAATGAA
CATGATATAGCTCATGATTCATTAACAAATTATGAAAATGTGAAATATTTTAGTAATGAA
CATGATATAGCTCATGATTCATTAACAAATTATGAAAATGTGAAATATTTTAGTAATGAA
CATGATATAGCTCATGATTCATTAACAAATTATGAAAATGTGAAATATTTTAGTAATGAA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

AAATTTGAAATCAAAAAATTTTGTAATGCATTATCAAATTATCATAGATATAATTTAAAA
AAATTTGAAATCAAAAAATTTTGTAATGCATTATCAAATTATCATAGATATAATTTAAAA
AAATTTGAAATCAAAAAATTTTGTAATGCATTATCAAATTATCATAGATATAATTTAAAA
AAATTTGAAATCAAAAAATTTTGTAATGCATTATCAAATTATCATAGATATAATTTAAAA
AAATTTGAAATCAAAAAATTTTGTAATGCATTATCAAATTATCATAGATATAATTTAAAA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

ATATTAAATAGTTTAGGTATATTAAATACTGTTCAACAATTTATATTGAATGGTACCTTA
ATATTAAATAGTTTAGGTATATTAAATACTGTTCAACAATTTATATTGAATGGTACCTTA
ATATTAAATAGTTTAGGTATATTAAATACTGTTCAACAATTTATATTGAATGGTACCTTA
ATATTAAATAGTTTAGGTATATTAAATACTGTTCAACAATTTATATTGAATGGTACCTTA
ATATTAAATAGTTTAGGTATATTAAATACTGTTCAACAATTTATATTGAATGGTACCTTA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

TTCTTTACATTATTATGTGTAATATATATGATAGTTAAGGAAGGATCAGATCCAGGTACC
TTCTTTACATTATTATGTGTAATATATATGATAGTTAAGGAAGGATCAGATCCAGGTACC
TTCTTTACATTATTATGTGTAATATATATGATAGTTAAGGAAGGATCAGATCCAGGTACC
TTCTTTACATTATTATGTGTAATATATATGATAGTTAAGGAAGGATCAGATCCAGGTACC
TTCTTTACATTATTATGTGTAATATATATGATAGTTAAGGAAGGATCAGATCCAGGTACC
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

TTCATAAGTGTAGTTGTATATACATCTAATGTATTTGCTCCATTAAGTATATTAGGAACA
TTCATAAGTGTAGTTGTATATACATCTAATGTATTTGCTCCATTAAGTATATTAGGAACA
TTCATAAGTGTAGTTGTATATACATCTAATGTATTTGCTCCATTAAGTATATTAGGAACA
TTCATAAGTGTAGTTGTATATACATCTAATGTATTTGCTCCATTAAGTATATTAGGAACA
TTCATAAGTGTAGTTGTATATACATCTAATGTATTTGCTCCATTAAGTATATTAGGAACA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

TTATATGCTACTATTATTAAATCATTTACTGATATTAGTGATTTGATAGATATTTTAAGA
TTATATGCTACTATTATTAAATCATTTACTGATATTAGTGATTTGATAGATATTTTAAGA
TTATATGCTACTATTATTAAATCATTTACTGATATTAGTGATTTGATAGATATTTTAAGA
TTATATGCTACTATTATTAAATCATTTACTGATATTAGTGATTTGATAGATATTTTAAGA
TTATATGCTACTATTATTAAATCATTTACTGATATTAGTGATTTGATAGATATTTTAAGA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

GATAAAATTGATATATCAAATGATAAAAATTTGAAAAATTTTGATTTAACATCACAAGAA
GATAAAATTGATATATCAAATGATAAAAATTTGAAAAATTTTGATTTAACATCACAAGAA
GATAAAATTGATATATCAAATGATAAAAATTTGAAAAATTTTGATTTAACATCACAAGAA
GATAAAATTGATATATCAAATGATAAAAATTTGAAAAATTTTGATTTAACATCACAAGAA
GATAAAATTGATATATCAAATGATAAAAATTTGAAAAATTTTGATTTAACATCACAAGAA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

AAAAAATTCGGTGTTAGTATTGAATTTAATAATGTACATTTTAATTACCCAACACAACCA
AAAAAATTCGGTGTTAGTATTGAATTTAATAATGTACATTTTAATTACCCAACACAACCA
AAAAAATTCGGTGTTAGTATTGAATTTAATAATGTACATTTTAATTACCCAACACAACCA
AAAAAATTCGGTGTTAGTATTGAATTTAATAATGTACATTTTAATTACCCAACACAACCA
AAAAAATTCGGTGTTAGTATTGAATTTAATAATGTACATTTTAATTACCCAACACAACCA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

TTACATACATCATTAAAAGATATTAATATCTACATAAAACCAGGTACAACATGTGCTCTT
TTACATACATCATTAAAAGATAT-AATATCTACATAAAACCAGGTACAACATGT-----TTACATACATCATTAAAAGATATTAATATCTACATAAAACCAGGTACAACATGTGCTCTT
TTACATACATCATTAAAAGATATTAATATATACATAAAACCAGGTACAACATGTGCTCTT
TTACATACATCATTAAAAGATATTAATATCTACATAAAACCAGGTACAACATGTGCTCTT
*********************** ***** ************************
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W2.QHS200
Dd2
W2
3D7
D10

GTAGGTCATACAGGTTCTGGAAAAACAACAATTTCGAAATTGTTA-TATCGATTCTATGA
---------------------AAAACAACAATTTCGAAATTGTTAATATCGATTCTATGA
GTAGGTCATACAGGTTCTGGAAAAACAACAATTTCGAAATTGTTA-TATCGATTCTATGA
GTAGGTCATACAGGTTCTGGAAAAACAACAATTTCGAAATTGTTA-TATCGATTCTATGA
GTAGGTCATACAGGTTCTGGAAAAACAACAATTTCGAAATTGTTA-TATCGATTCTATGA
************************ **************

W2.QHS200
Dd2
W2
3D7
D10

TTCAAAAGGAGAGATTAAAATTGGAGGACGTAATATAAATGAATATACCAGAAACTCCAT
TTCAAAAGGAGAGATTAAA-TTGGAGGACGTAATATAAATGAATATACCAGAAACTCCAT
TTCAAAAGGAGAGATTAAAATTGGAGGACGTAATATAAATGAATATACCAGAAACTCCAT
TTCAAAAGGAGAGATTAAAATTGGAGGACGTAATATAAATGAATATACCAGAAACTCCAT
TTCAAAAGGAGAGATTAAAATTGGAGGACGTAATATAAATGAATATACCAGAAACTCCAT
******************* ****************************************

W2.QHS200
Dd2
W2
3D7
D10

TAGAAATATTATAGGTATAGTACCACAAGATACCATATTATTTAATGAATCTATAAAATA
TAGAAATATTATAGGTATAGTACCACAAGATACCATATTATTTAATGAATCTATAAAATA
TAGAAATATTATAGGTATAGTACCACAAGATACCATATTATTTAATGAATCTATAAAATA
TAGAAATATTATAGGTATAGTACCACAAGATACCATATTATTTAATGAATCTATAAAATA
TAGAAATATTATAGGTATAGTACCACAAGATACCATATTATTTAATGAATCTATAAAATA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

TAATATTTTATACGGAAAATTAGATGCCACTGAAGAAGAATTAATACAAGCTGTTAAATC
TAATATTTTATACGGAAAATTAGATGCCACTGAAGAAGAATTAATACAAGCTGTTAAATC
TAATATTTTATACGGAAAATTAGATGCCACTGAAGAAGAATTAATACAAGCTGTTAAATC
TAATATTTTATACGGAAAATTAGATGCCACTGAAGAAGAATTAATACAAGCTGTTAAATC
TAATATTTTATACGGAAAATTAGATGCCACTGAAGAAGAATTAATACAAGCTGTTAAATC
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

GGCTCAGTTATATGATTTTATACAATCTCTTCCAAAAAAATGGGACACTTTAGTTGGTGA
GGCTCAGTTATATGATTTTATACAATCTCTTCCAAAAAAATGGGACACTTTAGTTGGTGA
GGCTCAGTTATATGATTTTATACAATCTCTTCCAAAAAAATGGGACACTTTAGTTGGTGA
GGCTCAGTTATATGATTTTATACAATCTCTTCCAAAAAAATGGGACACTTTAGTTGGTGA
GGCTCAGTTATATGATTTTATACAATCTCTTCCAAAAAAATGGGACACTTTAGTTGGTGA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

TAAAGGAGTCAAATTATCAGGAGGAGAACGACAAAGAATATCTATAGCAAGATGTTTATT
TAAAGGAGTCAAATTATCAGGAGGAGAACGACAAAGAATATCTATAGCAAGATGTTTATT
TAAAGGAGTCAAATTATCAGGAGGAGAACGACAAAGAATATCTATAGCAAGATGTTTATT
TAAAGGAGTCAAATTATCAGGAGGAGAACGACAAAGAATATCTATAGCAAGATGTTTATT
TAAAGGAGTCAAATTATCAGGAGGAGAACGACAAAGAATATCTATAGCAAGATGTTTATT
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

GAAAGATCCTAAAATTGTTATATTTGATGAAGCAACCAGTTCATTAGATTCAAGAACCGA
GAAAGATCCTAAAATTGTTATATTTGATGAAGCAACCAGTTCATTAGATTCAAGAACCGA
GAAAGATCCTAAAATTGTTATATTTGATGAAGCAACCAGTTCATTAGATTCAAGAACCGA
GAAAGATCCTAAAATTGTTATATTTGATGAAGCAACCAGTTCATTAGATTCAAGAACCGA
GAAAGATCCTAAAATTGTTATATTTGATGAAGCAACCAGTTCATTAGATTCAAGAACCGA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

ATATCTTTTCCAAAAAGCTGTAGAAGATTTAAGAAAAAATAGAACCATTATTATTATAGC
ATATCTTTTCCAAAAAGCTGTAGAAGATTTAAGAAAAAATAGAACCATTATTATTATAGC
ATATCTTTTCCAAAAAGCTGTAGAAGATTTAAGAAAAAATAGAACCATTATTATTATAGC
ATATCTTTTCCAAAAAGCTGTAGAAGATTTAAGAAAAAATAGAACCATTATTATTATAGC
ATATCTTTTCCAAAAAGCTGTAGAAGATTTAAGAAAAAATAGAACCATTATTATTATAGC
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

ACATAAACTATGTACTATCACAACCGCTGAATTAATTATCTTATTGAACAAAGGAAAAAT
ACATAAACTATGTACTATCACAACCGCTGAATTAATTATCTTATTGAACAAAGGAAAAAT
ACATAAACTATGTACTATCACAACCGCTGAATTAATTATCTTATTGAACAAAGGAAAAAT
ACATAAACTATGTACTATCACAACCGCTGAATTAATTATCTTATTGAACAAAGGAAAAAT
ACATAAACTATGTACTATCACAACCGCTGAATTAATTATCTTATTGAACAAAGGAAAAAT
************************************************************
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W2.QHS200
Dd2
W2
3D7
D10

TATAGAAAGAGGAACACATCTAGATTTATTAAAATGTAATGGAGAATACACAGAAATGTG
TATAGAAAGAGGAACACATCTAGATTTATTAAAATGTAATGGAGAATACACAGAAATGTG
TATAGAAAGAGGAACACATCTAGATTTATTAAAATGTAATGGAGAATACACAGAAATGTG
TATAGAAAGAGGAACACATCTAGATTTATTAAAATGTAATGGAGAATACACAGAAATGTG
TATAGAAAGAGGAACACATCTAGATTTATTAAAATGTAATGGAGAATACACAGAAATGTG
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

GAATATGCAATCAAAATCAAATGAACCACATACTGAAACAAATTCATCAATTGATAAAGA
GAATATGCAATCAAAATCAAATGAACCACATACTGAAACAAATTCATCAATTGATAAAGA
GAATATGCAATCAAAATCAAATGAACCACATACTGAAACAAATTCATCAATTGATAAAGA
GAATATGCAATCAAAATCAAATGAACCACATACTGAAACAAATTCATCAATTGATAAAGA
GAATATGCAATCAAAATCAAATGAACCACATACTGAAACAAATTCATCAATTGATAAAGA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

CGATGTAAATAAAAATAATAACAAAAATAATGATGTCATACTTAATACATGTAAAAATGA
CGATGTAAATAAAAATAATAACAAAAATAATGATGTCATACTTAATACATGTAAAAATGA
CGATGTAAATAAAAATAATAACAAAAATAATGATGTCATACTTAATACATGTAAAAATGA
CGATGTAAATAAAAATAATAACAAAAATAATGATGTCATACTTAATACATGTAAAAATGA
CGATGTAAATAAAAATAATAACAAAAATAATGATGTCATACTTAATACATGTAAAAATGA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

TATCACCACAAGTTTTAGATCGAACAGTGAAAAAAGTAGTCAAGAATTTAGTGACGCAAG
TATCACCACAAGTTTTAGATCGAACAGTGAAAAAAGTAGTCAAGAATTTAGTGACGCAAG
TATCACCACAAGTTTTAGATCGAACAGTGAAAAAAGTAGTCAAGAATTTAGTGACGCAAG
TATCACCACAAGTTTTAGATCGAACAGTGAAAAAAGTAGTCAAGAATTTAGTGACGCAAG
TATCACCACAAGTTTTAGATCGAACAGTGAAAAAAGTAGTCAAGAATTTAGTGACGCAAG
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

TAATCATATTAAGCAATCGAAAACTTCTAATGACCATAATAATAATATTAACGTACACAA
TAATCATATTAAGCAATCGAAAACTTCTAATGACCATAATAATAATATTAACGTACACAA
TAATCATATTAAGCAATCGAAAACTTCTAATGACCATAATAATAATATTAACGTACACAA
TAATCATATTAAGCAATCGAAAACTTCTAATGACCATAATAATAATATTAACGTACACAA
TAATCATATTAAGCAATCGAAAACTTCTAATGACCATAATAATAATATTAACGTACACAA
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

AAAAAATGAACAAGAACAACTTTTTTTAACAAATGATAAAACAGATATGGATGATAATAT
AAAAAATGAACAAGAACAACTTTTTTTAACAAATGATAAAACAGATATGGATGATAATAT
AAAAAATGAACAAGAACAACTTTTTTTAACAAATGATAAAACAGATATGGATGATAATAT
AAAAAATGAACAAGAACAACTTTTTTTAACAAATGATAAAACAGATATGGATGATAATAT
AAAAAATGAACAAGAACAACTTTTTTTAACAAATGATAAAACAGATATGGATGATAATAT
************************************************************

W2.QHS200
Dd2
W2
3D7
D10

GAATAACAAAAAAAAATAG
GAATAACAAAAAAAAATAG
GAATAACAAAAAAAAA--GAATAACAAAAAAAAATAG
GAATAACAAAAAAAAATAG
****************

Fig. 2.12. Alignment of pfmdr2 Nucleotide Sequences in W2 Lines did not Identify
Dissimilarities. ClustalW Alignment of pfmdr2 sequences from 3D7, D10, Dd2, W2, and
W2.QHS200. The CDS of pfmdr2 is 3075 bp. Similar bases in the alignment are
denoted by an asterisk in the last row of the alignment, whereas SNPs or missing bases
can be detected by a gap in continuous asterisks. There was a gap in the middle of the
Dd2 sequence (highlighted) that caused missing asterisks, but in that part of sequence,
there is similarity between W2 strains, 3D7, and D10.
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3D7
Dd2
W2
W2.QHS200

ATGGTTGAAAATAAGAGTAAGGTCAAAGATATCAGTTTGGCCCCCTTTGGAAAAATGCAG
ATGGTTGAAAATAAGAGTAAGGTCAAAGATATCAGTTTGGCCCCCTTTGGAAAAATGCAG
ATGGTTGAAA-TAAGAGTAAGGTCAAAGATATCAGTTTGGCCCCCTTTGGAAAAATGCAG
ATGGTTGAAA-TAAGAGTAAGGTCAAAGATATCAGTTTGGCCCCCTTTGGAAAAATGCAG
********** *************************************************

3D7
Dd2
W2
W2.QHS200

ATGGAAATTTCTGAAAATGAAATGCCGGGATTAATGAGAATAAGAGAAGAATACGGAAAA
ATGGAAATTTCTGAAAATGAAATGCCGGGATTAATGAGAATAAGAGAAGAATACGGAAAA
ATGGAAATTTCTGAAAATGAAATGCCGGGATTAATGAGAATAAGAGAAGAATACGGAAAA
ATGGAAATTTCTGAAAATGAAATGCCGGGATTAATGAGAATAAGAGAAGAATACGGAAAA
************************************************************

3D7
Dd2
W2
W2.QHS200

GATCAACCATTAAAAAATGCTAAAATTACTGGTTGTTTACATATGACTGTTGAATGTGCT
GATCAACCATTAAAAAATGCTAAAATTACTGGTTGTTTACATATGACTGTTGAATGTGCT
GATCAACCATTAAAAAATGCTAAAATTACTGGTTGTTTACATATGACTGTTGAATGTGCT
GATCAACCATTAAAAAATGCTAAAATTACTGGTTGTTTACATATGACTGTTGAATGTGCT
************************************************************

3D7
Dd2
W2
W2.QHS200

TTATTAATTGAGACTTTACAAAAATTAGGAGCTCAGATTAGGTGGTGTTCATGTAATATT
TTATTAATTGAGACTTTACAAAAATTAGGAGCTCAGATTAGGTGGTGTTCATGTAATATT
TTATTAATTGAGACTTTACAAAAATTAGGAGCTCAGATTAGGTGGTGTTCATGTAATATT
TTATTAATTGAGACTTTACAAAAATTAGGAGCTCAGATTAGGTGGTGTTCATGTAATATT
************************************************************

3D7
Dd2
W2
W2.QHS200

TATTCAACAGCTGATTATGCTGCAGCAGCAGTAAGTACATTAGAAAATGTAACGGTTTTT
TATTCAACAGCTGATTATGCTGCAGCAGCAGTAAGTACATTAGAAAATGTAACGGTTTTT
TATTCAACAGCTGATTATGCTGCAGCAGCAGTAAGTACATTAGAAAATGTAACGGTTTTT
TATTCAACAGCTGATTATGCTGCAGCAGCAGTAAGTACATTAGAAAATGTAACGGTTTTT
************************************************************

3D7
Dd2
W2
W2.QHS200

GCTTGGAAAAATGAAACTTTAGAAGAATACTGGTGGTGTGTTGAAAGTGCCCTTACGTGG
GCTTGGAAAAATGAAACTTTAGAAGAATACTGGTGGTGTGTTGAAAGTGCCCTTACGTGG
GCTTGGAAAAATGAAACTTTAGAAGAATACTGGTGGTGTGTTGAAAGTGCCCTTACGTGG
GCTTGGAAAAATGAAACTTTAGAAGAATACTGGTGGTGTGTTGAAAGTGCCCTTACGTGG
************************************************************

3D7
Dd2
W2
W2.QHS200

GGTGATGGAGATGATAATGGTCCAGATATGATTGTAGATGATGGGGGTGATGCAACCTTA
GGTGATGGAGATGATAATGGTCCAGATATGATTGTAGATGATGGGGGTGATGCAACCTTA
GGTGATGGAGATGATAATGGTCCAGATATGATTGTAGATGATGGGGGTGATGCAACCTTA
GGTGATGGAGATGATAATGGTCCAGATATGATTGTAGATGATGGGGGTGATGCAACCTTA
************************************************************

3D7
Dd2
W2
W2.QHS200

TTAGTTCATAAAGGTGTTGAGTATGAAAAATTATATGAAGAGAAAAATATATTACCTGAT
TTAGTTCATAAAGGTGTTGAGTATGAAAAATTATATGAAGAGAAAAATATATTACCTGAT
TTAGTTCATAAAGGTGTTGAGTATGAAAAATTATATGAAGAGAAAAATATATTACCTGAT
TTAGTTCATAAAGGTGTTGAGTATGAAAAATTATATGAAGAGAAAAATATATTACCTGAT
************************************************************

3D7
Dd2
W2
W2.QHS200

CCAGAAAAAGCAAAAAA-TGAAGAAGAACGATGTTTTCTAACTTTATTAAAAAATTCCAT
CCAGAAAAAGCAAAAAA-TGAAGAAGAACGATGTTTTCTAACTTTATTAAAAAATTCCAT
CCAGAAAAAGCAAAAAAATGAAGAAGAACGATGTTTTCTAACTTTATTAAAAAATTCCAT
CCAGAAAAAGCAAAAAAATGAAGAAGAACGATGTTTTCTAACTTTATTAAAAAATTCCAT
***************** ******************************************

3D7
Dd2
W2
W2.QHS200

ATTAAAAAATCCAAAGAAATGGACAAATATTGCAAAGAAAATTATAGGTGTATCTGAAGA
ATTAAAAAATCCAAAGAAATGGACAAATATTGCAAAGAAAATTATAGGTGTATCTGAAGA
ATTAAAAAATCCAAAGAAATGGACAAATATTGCAAAGAAAATTATAGGTGTATCTGAAGA
ATTAAAAAATCCAAAGAAATGGACAAATATTGCAAAGAAAATTATAGGTGTATCTGAAGA
************************************************************
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3D7
Dd2
W2
W2.QHS200

AACTACTACAGGAGTATTAAGATTAAAAAAAATGGACAAACAAAATGAATTATTATTTAC
AACTACTACAGGAGTATTAAGATTAAAAAAAATGGACAAACAAAATGAATTATTATTTAC
AACTACTACAGGAGTATTAAGATTAAAAAAAATGGACAAACAAAATGAATTATTATTTAC
AACTACTACAGGAGTATTAAGATTAAAAAAAATGGACAAACAAAATGAATTATTATTTAC
************************************************************

3D7
Dd2
W2
W2.QHS200

TGCTATTAATGTAAATGATGCTGTCACTAAACAAAAATATGATAATGTGTATGGATGTAG
TGCTATTAATGTAAATGATGCTGTCACTAAACAAAAATATGATAATGTGTATGGATGTAG
TGCTATTAATGTAAATGATGCTGTCACTAAACAAAAATATGATAATGTGTATGGATGTAG
TGCTATTAATGTAAATGATGCTGTCACTAAACAAAAATATGATAATGTGTATGGATGTAG
************************************************************

3D7
Dd2
W2
W2.QHS200

ACATTCCTTACCTGACGGATTAATGAGAGCTACCGATTTTTTAATATCTGGAAAAATCGT
ACATTCCTTACCTGACGGATTAATGAGAGCTACCGATTTTTTAATATCTGGAAAAATCGT
ACATTCCTTACCTGACGGATTAATGAGAGCTACCGATTTTTTAATATCTGGAAAAATCGT
ACATTCCTTACCTGACGGATTAATGAGAGCTACCGATTTTTTAATATCTGGAAAAATCGT
************************************************************

3D7
Dd2
W2
W2.QHS200

TGTCATATGTGGATATGGTGACGTAGGTAAAGGATGTGCTTCTTCTATGAAAGGTTTAGG
TGTCATATGTGGATATGGTGACGTAGGTAAAGGATGTGCTTCTTCTATGAAAGGTTTAGG
TGTCATATGTGGATATGGTGACGTAGGTAAAGGATGTGCTTCTTCTATGAAAGGTTTAGG
TGTCATATGTGGATATGGTGACGTAGGTAAAGGATGTGCTTCTTCTATGAAAGGTTTAGG
************************************************************

3D7
Dd2
W2
W2.QHS200

TGCAAGAGTATATATAACAGAAATTGATCCCATATGTGCTATACAAGCTGTAATGGAAGG
TGCAAGAGTATATATAACAGAAATTGATCCCATATGTGCTATACAAGCTGTAATGGAAGG
TGCAAGAGTATATATAACAGAAATTGATCCCATATGTGCTATACAAGCTGTAATGGAAGG
TGCAAGAGTATATATAACAGAAATTGATCCCATATGTGCTATACAAGCTGTAATGGAAGG
************************************************************

3D7
Dd2
W2
W2.QHS200

ATTTAATGTTGTTACTTTAGATGAAATTGTAGATAAAGGAGATTTTTTTATTACTTGTAC
ATTTAATGTTGTTACTTTAGATGAAATTGTAGATAAAGGAGATTTTTTTATTACTTGTAC
ATTTAATGTTGTTACTTTAGATGAAATTGTAGATAAAGGAGATTTTTTTATTACTTGTAC
ATTTAATGTTGTTACTTTAGATGAAATTGTAGATAAAGGAGATTTTTTTATTACTTGTAC
************************************************************

3D7
Dd2
W2
W2.QHS200

AGGTAATGTTGATGTTATTAAATTAGAACACTTACTTAAAATGAAAAATAATGCTGTTGT
AGGTAATGTTGATGTTATTAAATTAGAACACTTACTTAAAATGAAAAATAATGCTGTTGT
AGGTAATGTTGATGTTATTAAATTAGAACACTTACTTAAAATGAAAAATAATGCTGTTGT
AGGTAATGTTGATGTTATTAAATTAGAACACTTACTTAAAATGAAAAATAATGCTGTTGT
************************************************************

3D7
Dd2
W2
W2.QHS200

TGGAAACATTGGTCATTTTGATGATGAAATACAAGTAAATGAACTTTTTAATTATAAAGG
TGGAAACATTGGTCATTTTGATGATGAAATACAAGTAAATGAACTTTTTAATTATAAAGG
TGGAAACATTGGTCATTTTGATGATGAAATACAAGTAAATGAACTTTTTAATTATAAAGG
TGGAAACATTGGTCATTTTGATGATGAAATACAAGTAAATGAACTTTTTAATTATAAAGG
************************************************************

3D7
Dd2
W2
W2.QHS200

AATACATATAGAAAATGTAAAACCACAGGTTGATAGAATTACTTTACCTAATGGAAATAA
AATACATATAGAAAATGTAAAACCACAGGTTGATAGAATTACTTTACCTAATGGAAATAA
AATACATATAGAAAATGTAAAACCACAGGTTGATAGAATTACTTTACCTAATGGAAATAA
AATACATATAGAAAATGTAAAACCACAGGTTGATAGAATTACTTTACCTAATGGAAATAA
************************************************************

3D7
Dd2
W2
W2.QHS200

AATTATTGTTTTAGCTAGAGGGAGATTATTAAATCTAGGATGTGCAACAGGACATCCAGC
AATTATTGTTTTAGCTAGAGGGAGATTATTAAATCTAGGATGTGCAACAGGACATCCAGC
AATTATTGTTTTAGCTAGAGGGAGATTATTAAATCTAGGATGTGCAACAGGACATCCAGC
AATTATTGTTTTAGCTAGAGGGAGATTATTAAATCTAGGATGTGCAACAGGACATCCAGC
************************************************************
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3D7
Dd2
W2
W2.QHS200

ATTTGTTATGTCCTTTTCATTTTGTAATCAAACCTTTGCTCAATTAGATTTATGGCAAAA
ATTTGTTATGTCCTTTTCATTTTGTAATCAAACCTTTGCTCAATTAGATTTATGGCAAAA
ATTTGTTATGTCCTTTTCATTTTGTAATCAAACCTTTGCTCAATTAGATTTATGGCAAAA
ATTTGTTATGTCCTTTTCATTTTGTAATCAAACCTTTGCTCAATTAGATTTATGGCAAAA
************************************************************

3D7
Dd2
W2
W2.QHS200

CAAGGATACAAACAAATATGAAAATAAAGTTTATTTGTTACCTAAACATCTTGATGAAAA
CAAGGATACAAACAAATATGAAAATAAAGTTTATTTGTTACCTAAACATCTTGATGAAAA
CAAGGATACAAACAAATATGAAAATAAAGTTTATTTGTTACCTAAACATCTTGATGAAAA
CAAGGATACAAACAAATATGAAAATAAAGTTTATTTGTTACCTAAACATCTTGATGAAAA
************************************************************

3D7
Dd2
W2
W2.QHS200

GGTTGCTCTTTATCATTTGAAAAAATTGAACGCTTCCTTGACAGAATTGGATGACAATCA
GGTTGCTCTTTATCATTTGAAAAAATTGAACGCTTCCTTGACAGAATTGGATGACAATCA
GGTTGCTCTTTATCATTTGAAAAAATTGAACGCTTCCTTGACAGAATTGGATGACAATCA
GGTTGCTCTTTATCATTTGAAAAAATTGAACGCTTCCTTGACAGAATTGGATGACAATCA
************************************************************

3D7
Dd2
W2
W2.QHS200

ATGTCAATTTTTGGGAGTCAACAAAAGTGGTCCCTTTAAGAGTAACGAATACAGATATTA
ATGTCAATTTTTGGGAGTCAACAAAAGTGGTCCCTTTAAGAGTAACGAATACAGATATTA
ATGTCAATTTTTTG---------------------------------------------ATGTCAATTTTTTG---------------------------------------------************ *

3D7
Dd2
W2
W2.QHS200

A
A
-

Fig. 2.13. Alignment of PFE1050w Nucleotide Sequences in W2 Lines did not Identify
Dissimilarities. ClustalW Alignment of PFE1050w sequences from 3D7, Dd2, W2, and
W2.QHS200. The CDS of PFE1050w is 1440 bp. Similar bases in the alignment are
denoted by an asterisk in the last row of the alignment, whereas SNPs or missing bases
can be detected by a gap in continuous asterisks. Sequence from the 3‟ end of the gene
for W2 and W2.QHS200 was not returned from sequencing efforts. Sequences of W2
and W2.QHS200 are identical to each other and 3D7 and Dd2 except for a few missing
nucleotides within strings of adenosine (5‟end) or thymidine bases (3‟ end). However,
these were in areas of unreliable sequence and are not likely to constitute actual missing
bases.
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Figure 2.14. Real-Time QPCR Assays for Copy Number Found PFE1050w, PF11_0466,
and pfmdr2 Were not Amplified in Resistant Parasites, but pfmdr1 was Amplified in W2
and TM91c235 Lines. Average copy number of PFE1050w (A.), PF11_0466 (B.),
pfmdr2 (C.), and pfmdr1 (D.) in parental and resistant strains (D6, W2, TM91c235)
relative to D6 as determined by SYBR Green real-time QPCR.
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Table 2.1. Oligonucleotides Used in Analyses of PFE1050w, PF11_0466, pfmdr2, and
pfmdr1
Primer Name
Sequencing
pfmdr2 seqF-4
pfmdr2 seqR-4

Sequence 5'-3'

Source/Reference

TGAGACATTTATTCTATTCCGA
CATTCAATATAACTAAGATACCG

This work
This work

pfmdr2 Cd F-2

GAATACATTAGGAAAGGTGT

pfmdr2 seq R-5

GCTATTTCCTTTCATATCTATC

Rosenberg et al.,
2006 379
Rosenberg et al.,
2006 379

pfmdr2 seq F-5
pfmdr2 seq R-6

GCAAAAGGATAGATATGAAAGG
GAACTCATCAAATTATTAGCACT

This work
This work

pfmdr2 Cd F-4
pfmdr2 seq R-7

TTTTAAAAGAGGTTTGTGGTGT
CTTATGAAGGTACCTGGATCT

Rosenberg et al.,
2006 379
This work

pfmdr2 seq F-6

GATCAGATCCAGGTACCTTCA

pfmdr2 Cd R-5

GTATGACCTACAAGAGCACATG

This work
Rosenberg et al.,
2006 379

pfmdr2 Cd F-6
pfmdr2 seq R-8

CATAAAACCAGGTACAACATGT
GAATCTAATGAACTGGTTGCT

Rosenberg et al.,
2006 379
This work

pfmdr2 Cd F-7
pfmdr2 seq R-3

AAATGGGACACTTTAGTTGG
CGAAGAATTTTGGATATGATTA

Rosenberg et al.,
2006 379
This work

PFE1050w seq2 F
PFE1050w seq2 R-1

GTATCATACCCATCGGCATATAA
CGTTACTCTTAAAGGGACCAC

This work
This work

PF11_0466 seq F
AACGATTGAGAATGGTACGTTTT
PF11_0466 seq2 R-1 GCGTTTCATATCTCTTTCTTAATC

This work
This work

Real-Time QPCR
LDH-T1F

AGGACAATATGGACACTCCGAT

LDH-T1R

TTTCAGCTATGGCTTCATCAAA
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Chavchich et al.,
2010 276
Chavchich et al.,
2010 276

Table 2.1 Continued
Primer Name
Real-Time QPCR

Sequence 5'-3'

Source/Reference

MDR-T1F

TATGCATTTGTGGGAGAATCAG

MDR-T1R

CTCCTTCGGTTGGATCATAAAG

Chavchich et al.,
2010 276
Chavchich et al.,
2010 276

pfmdr2 rt F-3
pfmdr2 rt R-3

ACAAGCTGTTAAATCGGCTCAG
TCTTTGTCGTTCTCCTCCTGA

This work
This work

PFE1050w RT-1 F
PFE1050w RT-1 R

GAAATGCCGGGATTAATGAG
ATCTCCATCACCCCACGTAA

This work
This work

PF11_0466 RT-1 F
PF11_0466 RT-1 R

GGATAAGCAATTTTTCGAATGG
CCACCACCACTTTTCCCTATT

This work
This work
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Table 2.2. Stepwise Induction of Artemisinin Resistance in D6
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Strain

Date QHS Added

Days Post
Original Drug
Addition

D6.QHS80

8/27/2007

0

80

283.7

D6.QHS80x1

8/31/2007

4

80

283.7

D6.QHS80x2

9/6/2007

10

120

425.5

D6.QHS120x1
D6.QHS120x2

9/14/2007
10/2/2007

18
36

120
160

425.5
567.4

D6.QHS160x1

10/10/2007

44

160

567.4

D6.QHS160x2

10/16/2007

50

200

709.2

D6.QHS200x1

10/26/2007

60

200

709.2

D6.QHS200x2

11/9/2007

74

200

709.2

D6.QHS200x3

11/15/2007

80

240

851.1

D6.QHS240x1

11/19/2007

84

240

851.1

D6.QHS240x2

11/21/2007

86

280

992.9

D6.QHS280x1

12/3/2007

98

280

992.9

D6.QHS280x2

12/10/2007

105

300

1063.8

D6.QHS300x1

1/4/2008

130

300

1063.8

D6.QHS300x2
D6.QHS300x2,
200x1

3/7/2008

193

200

709.2

3/14/2008

200

300

1063.8

D6.QHS300x3

4/7/2008

224

300

1063.8

D6.QHS300x4

5/5/2008

252

340

1205.7

D6.QHS340x1

5/28/2008

275

340

1205.7

D6.QHS340x2

7/24/2008

332

340

1205.7

D6.QHS340x3

8/29/2008

368

2400

8510.6

QHS Concentration
(ng/ml)

QHS Concentration
(nM)

Notes

D6.QHS300x2 was exposed to 200 ng/ml
before a cloning attempt

D6.QHS340x2 to recovery assay 80-340
ng/ml QHS=D6.QHS340x3
D6.QHS340x3 to recovery assay 80-2400
ng/ml QHS=D6.QHS2400x1

Table 2.2 Continued
Strain

Date QHS Added

Days Post
Original Drug
Addition

D6.QHS2400x1

9/24/2008

394

2400

8510.6

D6.QHS2400x2

11/26/2008

457

2400

8510.6

D6.QHS2400x3
D6.QHS2400x4
clone C9

2/16/2009

539

2400

8510.6

10/28/2009

793

2400

8510.6

QHS Concentration
(ng/ml)

QHS Concentration
(nM)

Notes

D6.QHS2400x4 to cloning
D6.QHS2400x4 (clone C9) treated with
2400 ng/ml for 5th time
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Table 2.3. Stepwise Induction of Artelinic Acid Resistance in TM91c235
Date AL
Added

Days Post
Original AL
Addition

AL
Concentration
(ng/ml)

AL
Concentration
(nM)

Notes

TM91c235.AL80
TM91c235.AL80
(40x1)
TM91c235.AL80
(40x2)
TM91c 235.AL80
(40x2, 60x1)

11/26/2007

0

40

95.6

40 ng/ml applied because it did not tolerate 80 ng/ml

1/14/2008

49

40

95.6

1/23/2008

58

60

143.4

1/28/2008

63

80

191.2

TM91c 235.AL80x1

3/5/2008

100

80

191.2

TM91c 235.AL80x2

3/25/2008

120

120

286.8

TM91c235.AL120x1

4/1/2008

127

120

286.8

TM91c235.AL120x2

4/15/2008

141

160

382.3

TM91c235.AL160x1

4/30/2008

155

160

382.3

TM91c235.AL160x2

5/28/2008

184

180

430.1

TM91c235.AL180x1

6/18/2008

205

180

430.1

TM91c235.AL180x2

6/23/2008

210

200

477.9

TM91c235.AL200x1

8/11/2008

259

200

477.9

TM91c235.AL200x2

9/1/2008

280

200

477.9

TM91c235.AL200x3

9/21/2008

300

240

573.5

TM91c235.AL240x1

10/6/2008

315

240

573.5

TM91c235.AL240x2

11/26/2008

366

280

669.1

TM91c235.AL280x1

10/23/2009

697

280

669.1

Strain
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thawed out to continue pressure much later- 280 for 2nd time

Table 2.4. In Vitro Susceptibility Testing of Parental and Resistant Lines: Artemisinin Drugs
DHA

QHS

AS

AM

AL
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Parasite line

IC50

IC90

IC50

IC90

IC50

IC90

IC50

IC90

IC50

IC90

W2

0.69±0.34

1.6±0.95

1.3±0.71

3.2±0.80

0.40±0.16

0.94±0.50

0.73±0.38

1.5±0.56

2.0±0.75

3.3±1.2

W2.QHS200x2

0.89±0.33

2.3±0.70

4.2±2.0

9.6±4.1

1.2±0.36

2.2±0.58

1.6±0.42

3.4±1.4

12.3±3.35

18.4±5.93

D6

0.15±0.028

0.34±0.19

0.92±0.10

4.1±0.75

0.28±0.080

0.68±0.17

0.50±0.070

1.3±0.44

2.8±0.66

11.5±4.80

D6.QHS2400x5

1.4±0.30

4.0±0.44

8.8±1.0

19.3±2.95

1.2±0.040

2.0±0.13

2.7±0.30

5.8±0.27

18.0±1.56

22.2±4.32

TM91c235

1.2±0.78

2.7±0.81

2.2±1.8

5.7±2.1

0.93±0.77

1.4±0.57

0.91±0.73

2.3±0.67

3.2±1.5

22.3±15.9

TM91c235.AL280x2

1.7±1.2

3.7±1.2

8.7±5.4

16.5±6.2

1.7±0.82

4.0±2.1

3.5±2.1

6.0±2.1

16.0±12.0

37.6±19.7

DHA=Dihydroartemisinin
QHS=Artemisinin
AS=Artesunate
AM=Artemether
AL=Artelinic Acid
IC50=50% Inhibitory Concentration (in ng/ml)
IC90=90% Inhibitory Concentration (ng/ml)

Table 2.5. In Vitro Susceptibility Testing of Parental and Resistant Lines: Common Antimalarial Drugs

Parasite line
W2
W2.QHS200x2

CQ
IC50
140.1±43.68
101±7.44

IC90
193.3±46.99
142.6±10.28

MQ
IC50
2.7±0.94
5.9±1.3

D6
D6.QHS2400x5

2.6±0.26
1.8±0.19

4.3±0.72
2.8±0.31

0.93±0.17 3.1±1.2
3.8±0.37 7.8±0.77

TM91c235
TM91c235.AL280x2

23.2±5.54
66.5±40.4

51.3±10.6
126.1±74.10

8.0±3.0
8.7±4.5
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Parasite line
W2
W2.QHS200x2

HAL
IC50
0.28±0.10
1.1±0.68

IC90
0.84±0.39
2.0±0.95

PIP
IC50
115.6±12.66
94.2±5.45

LF
IC90
IC50
5.7±1.7
26.0±12.7
22.3±4.36 98.8±17.3

IC90
169.1±89.44
144.5±25.98

91.3±37.9
51.7±22.0
ATOV
IC90
IC50
158.6±56.90 0.21±0.0904
123.5±15.56 0.21±0.067

IC90
1.3±0.96
0.75±0.31

D6
D6.QHS2400x5

0.022±0.0040 0.11±0.045
0.041±0.0050 0.25±0.044

TM91c235
TM91c235.AL280x2

0.26±0.15
0.29±0.19

2.0±1.2
1.9±0.88

CQ=Chloroquine, MQ=Mefloquine, LF=Lumefantrine, HAL=Halofantrine, PIP=Piperaquine, ATOV=Atovaquone
IC50=50% Inhibitory Concentration (in ng/ml)
IC90=90% Inhibitory Concentration (ng/ml)

Table 2.6. Ring Stage Viability Assay Utilizing D6 and W2 Parental and Resistant Strains at 24 and 48 Hours Post-Drug Exposure
DHA

AL

QHS

CQ
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Parasite line

24 hours

48 hours

24 hours

48 hours

24 hours

48 hours

24 hours

48 hours

D6

0.23

0.53

1.9

5.76

2.05

3.26

9.95

17.8

D6.QHS2400x5

1.39

2.27

35.7

57.8

17.1

25

6.52

8.35

W2

0.32

0.48

1.17

2.85

0.8

1.55

158.5

94.5

W2.QHS200x2

0.53

1.27

4.81

12.4

2.69

3.21

143.2

147.7

DHA=Dihydroartemisinin, AL=Artelinic Acid, QHS=Artemisinin, CQ=Chloroquine
Values in ng/ml

Chapter Three:
Proteomic, Whole Genome, and Transcriptional Approaches for Dissecting
Artemisinin Resistance (Specific Aim 2)
Rationale for Study
Given the global adoption of ACTs, considerable research has been devoted to the
artemisinin drugs; however, the mechanism of action of the class of drugs on
Plasmodium spp. remains controversial. Perhaps equally controversial is the debate on
the emergence of artemisinin resistance and molecular determinants associated with the
resistance phenotype. Considering that recent studies have documented the emergence of
clinical artemisinin resistance, it is imperative to discover the true mechanism of action
and potential drug resistance mechanisms. Prior molecular characterization of
artemisinin resistant parasites in our lab focused on early drug-selected parasites for the
most part. The results from our initial microarrays (W2 vs. W2.AL80 and W2.QHS40)
determined that a subset of genes was differentially expressed in low-level artemisininselected W2 lines after exposure to DHA. Further molecular studies that focused
primarily on pfmdr1 used parasites that only tolerated a maximum of 80 ng/ml AL (W2,
D6, TM91c235) or up to 200 ng/ml AL/QHS (W2) 276,337. Chavchich et al. 276 reported
on genes (tctp, pfatp6, pfmdr1) that have tentative associations with the site of action or
reduced susceptibility to this class of drugs. No changes in the putative resistance gene
coding sequences were detected in resistant progenies of the W2, D6, or TM91c235 lines.
This study found different results than others in regard to pfatp6 and tctp (see Chapter
210

One), but the pfmdr1 results were in agreement with many studies that showed this gene
can be involved in modulating drug resistance to other drugs (mostly MQ), and possibly
artemisinins. Chen et al. found pfmdr1 can be deamplified in drug resistant W2 lines
when grown off drug pressure. Based on these analyses, artemisinin resistance appears
multifactorial, but it can be enhanced by amplification of pfmdr1.
Based on these results, we performed similar molecular analyses in the current
study on parasites with higher tolerance to QHS and AL, and we went even further to
investigate putative molecular markers for resistance. The high-level QHS-resistant D6
progeny we selected in vitro (up to 2400 ng/ml) represented parasites that, at the time of
selection, had never been described before. These parasites tolerate levels of artemisinin
beyond those typically found in patients taking artemisinin therapy for malaria. We
hypothesized that genetic determinants of artemisinin resistance (SNPs, copy number
variations) accumulated over the process of selecting these parasites. By comparing
parent vs. resistant strains, novel molecular markers of artemisinin resistance would be
revealed, and possibly markers of dormancy. Therefore, we utilized next-generation
molecular technologies to dissect differences between parent and resistant lines that were
pressured to artemisinin resistance levels beyond that which were originally obtained.
We used a proteomic approach combined with whole-genome DNA sequencing and
transcriptional analyses to dissect potential artemisinin resistance mechanisms in resistant
parasites we generated in vitro. If any interesting gene amplifications, SNPs, or
differentially regulated genes were found, we planned to investigate low and intermediate
level resistant parasites to see where these changes occurred. We also aimed to verify
transcriptional changed by reverse transcriptase (RT) real-time QPCR, conduct copy
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number assays to verify amplifications from sequencing, and sequence individual genes
that contained SNPs for confirmation. In addition, we thought it would be interesting to
correlate proteomic data with newer microarrays we would perform. We also
hypothesized that transcriptome analysis would allow us to characterize dormancy in ring
stages of resistant and sensitive strains after treatment with artemisinin drugs. We
theorized it would be possible to identify genes that were over-expressed during
dormancy that we could use as markers to allow identification of dormant parasites in
future assays.
Materials and Methods
Parasites and in vitro culture. Asexual stages of P. falciparum were maintained
in routine culture by using previously described methods 4. Parasites were cultured in
complete media which consisted of RPMI 1640 medium (Invitrogen, Carlsbad, CA.)
supplemented with 10% heat-inactivated A+ human plasma in anticoagulant/preservative
Citrate Phosphate Dextrose Adenine (CPDA-1) (Interstate Blood Bank, Memphis, TN).
CPDA-1 preservative), a final concentration of 25 mM HEPES (Invitrogen), and 0.24%
v/v sodium bicarbonate (Invitrogen). Routine cultures were maintained in a total volume
of 5-60 ml in 25 cm2, 75 cm2, or 150 cm2 sealed culture flasks. An inoculum of stock
culture of each parasite was cultured in a 4% suspension of type A+ human erythrocytes
in CPDA-1 (Interstate Blood Bank) (hematocrit changed for drug and hypoxanthine
assays, below) at 1-15% parasitemia. Cultures were synchronized using 5% (w/v) Dsorbitol (Sigma-Aldrich Corp. St. Louis, MO.), following the method of Lambros and
Vanderberg (1979) 374. Synchronization of cultures was repeated 1-2 times before
parasites were used for an experiment. Media was changed every 48 hours or daily,
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depending on parasitemia. Cultures were incubated at 37°C under a gas mixture of 5%
O2, 5%CO2, and 90% N2. Pelleted cultures were saved for later genomic DNA extraction.
When culture conditions required different modifications, these methods are listed in
individual sections below.
Proteomics.
Parasites. We used parent and resistant pairs of D6 and W2 for analysis of
protein expression. In the process of adapting D6 to high levels of resistance, it was
treated with 2400 ng/ml multiple times (above). Once D6.QHS2400x2 was produced, it
was treated with 2400 ng/ml QHS (a third total treatment) and allowed to recover until
normal growth returned (parasitemia>6% 12 days after treatment). This parasite was
grown in culture for about 2 months to increase volume of culture and reach high
parasitemia (proteomic analysis protocol called for microgram quantities of protein). W2
and W2.QHS200 were grown in tandem as well around this time, but W2.QHS200 was
not placed under drug pressure. D6/D6.QHS2400x3 and W2/W2.QHS200 were
synchronized together during this process. Parasites were grown to 60 ml in 150 cm2
flasks at 4% hematocrit. The last sorbitol treatment before cultures were frozen for
subsequent proteomic analysis synchronized them to late rings/early trophozoites. Final
parasitemia counts were D6 (5.6%), D6.QHS2400x3 (6.4%), W2 (3.8%), W2.QHS200
(7%). Pelleted cells were treated with 0.05% (w/v) saponin to free parasites from RBCs
and culture lysates were incubated on ice for 10 minutes. The lysates were centrifuged
and the resulting parasite pellets were washed three times with 1x PBS to remove RBC
components. Washed parasite pellets were frozen at -80°C until shipping for proteomic
analysis.
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Two dimensional fluorescence difference gel electrophoresis. Two Dimensional
Fluorescence Difference Gel Electrophoresis (2D-DIGE) and protein identification was
performed by Applied Biomics, Inc (Hayward, CA). Essentially, protein extracts of
resistant/parent pairs are labeled with different dyes, mixed together, a SDS-PAGE gel is
run with labeled extracts, differential excitation of resistant/parent proteins is performed
enabling fold changes of identical proteins, and proteins are isolated and identified.
Parasite pellets were washed with Washing Buffer (10 mM Tris-HCl, 5 mM magnesium
acetate, pH 8.0) three times, then 150 µl of 2-D cell lysis buffer (30 mM Tris-HCl, pH
8.8, containing 7 M urea, 2 M thiourea and 4% CHAPS) was added to each sample. The
mixture was sonicated at 4oC followed by shaking for 30 minutes at room temperature.
The samples were then centrifuged for 30 minutes at 14,000 rpm and the supernatant was
collected. Protein concentration was measured using a Bio-Rad protein assay method.
For each sample, 30 µg of protein was mixed with 1.0 µl of diluted CyDye, and
kept in the dark on ice for 30 min. Cy2 and Cy5 have different excitation/emission
wavelengths (Cy2 [489 nM/506 nM; Cy5 [625-650 nM/670 nM]), enabling differential
analysis of labeled proteins. Parental and resistant parasites from each pair were labeled
with Cy2 (green) and Cy5 (red) dyes, respectively. The labeling reaction was stopped by
adding 1.0 µl of 10 mM Lysine to each sample, and incubating in the dark on ice for an
additional 15 min. The labeled samples were then mixed together. The 2X 2-D Sample
buffer (8 M urea, 4% CHAPS, 20 mg/ml DTT, 2% pharmalytes and trace amount of
bromophenol blue), 100 µl Destreak solution and Rehydration buffer (7 M urea, 2 M
thiourea, 4% CHAPS, 20 mg/ml DTT, 1% pharmalytes and trace amount of bromophenol
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blue) were added to the labeling mix to make the total volume 250 µl. This solution was
mixed well and centrifuged before loading the labeled samples into a strip holder.
Isoelectric focusing and sodium dodecyl sulfate polyacrylamide gel
electrophoresis. After loading the labeled samples, Isoelectric focusing (IEF) was run
following the protocol provided by Amersham BioSciences (Sweden). Upon finishing
the IEF, Immobilized pH Gradient (IPG) strips were incubated in freshly made
equilibration buffer-1 (50 mM Tris-HCl, pH 8.8, containing 6 M urea, 30% glycerol, 2%
SDS, trace amount of bromophenol blue and 10 mg/ml DTT) for 15 minutes with gentle
shaking. Then the strips were rinsed in freshly made equilibration buffer-2 (50 mM TrisHCl, pH 8.8, containing 6 M urea, 30% glycerol, 2% SDS, trace amount of bromophenol
blue and 45 mg/ml DTT) for 10 minutes with gentle shaking. Next, the IPG strips were
rinsed in SDS-gel running buffer before transferring into 13.5% SDS-gels. The SDS-gels
were run at 15oC until the dye front running out of the gels.
Image scan and data analysis. Gel images of each resistant/parent parasite pair
were scanned immediately following the SDS-PAGE procedure using Typhoon TRIO
(Amersham BioSciences). Since each dye produced different excitation, individual gel
images could be made for each fluor, then merged. The scanned images were then
analyzed by Image Quant software (version 6.0, Amersham BioSciences), followed by
in-gel analysis using DeCyder software version 6.0 (Amersham BioSciences). The fold
change of the protein expression levels was obtained from in-gel DeCyder analysis.
Protein identification by mass spectrometry. The above analysis identified 29
spots for D6/D6.QHS2400x3 and 33 for W2/W2.QHS200 comparisons based on
positioning on gel images (Fig 3.1) and the degree of over-expression/under-expression.
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We selected 13 spots for each D6/D6.QHS2400x3 or W2/W2.QHS200 comparison (overexpressed and under-expressed) for further analysis. The spots of interest were picked up
by Ettan Spot Picker (Amersham BioSciences) based on the in-gel analysis and spot
picking design by DeCyder software. The gel spots were washed a few times then
digested in-gel with modified porcine trypsin protease (Trypsin Gold, Promega). The
digested tryptic peptides were desalted by Zip-tip C18 (Millipore, Billerica, MA.).
Peptides were eluted from the Zip-tip with 0.5 µl of matrix solution (α-cyano-4hydroxycinnamic acid [5 mg/ml in 50% acetonitrile, 0.1% trifluoroacetic acid, 25 mM
ammonium bicarbonate] and spotted on the Matrix-Assisted Laser Desorption/Ionization
(MALDI) plate (model ABI 01-192-6-AB).
MALDI-Time of Flight (TOF) MS and TOF/TOF tandem MS/MS were
performed on an ABI 4700 mass spectrometer (Applied Biosystems, Framingham, MA).
MALDI-TOF mass spectra were acquired in reflectron positive ion mode, averaging 4000
laser shots per spectrum. TOF/TOF tandem MS fragmentation spectra were acquired for
each sample, averaging 4000 laser shots per fragmentation spectrum on each of the 10
most abundant ions present in each sample (excluding trypsin autolytic peptides and other
known background ions).
Database search. The resulting peptide mass and the associated fragmentation
spectra were both submitted to a GPS Explorer workstation equipped with MASCOT
search engine (Matrix Science, Boston, MA.) to search the National Center for
Biotechnology Information non-redundant database (NCBInr). Searches were performed
without constraining protein molecular weight or isoelectric point, with variable
carbamidomethylation of cysteine and oxidation of methionine residues, and with one
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missed cleavage also allowed in the search parameters. Candidates with either protein
score C.I.% or Ion C.I.% greater than 95 were considered significant.
Whole genome sequencing.
Parasites and DNA isolation. Initially, we sequenced uncloned D6 and
D6.QHS2400x2. Cultures at 4% hematocrit were scaled up to 10 ml (D6) and 25 ml
(D6.QHS2400x2). Parasites were asynchronous, but consisted of majority trophozoites.
Subsequent sequencing focused on W2 (clone D7), W2.QHS200x2, D6 (clone C11), and
D6.QHS2400x5. Parasites were grown to highly synchronous rings/early trophozoites in
large volume cultures at 4% hematocrit and >3% parasitemia. Cultures were centrifuged
and pellets were saved for later DNA extraction. A procedure similar to that of Beck 378
was used for freeing parasites from erythrocytes. Cultures were centrifuged at 4,000 rpm
for 5 minutes and the supernatant was aspirated. The cell pellet was measured, and 5x
pellet volume of 0.05% saponin was added. The mixture was placed on ice for 10
minutes, centrifuged, and the supernatant was aspirated. Parasite pellets were washed
twice with 1x PBS. Genomic DNA was extracted from the parasite pellets using a
QiAmp DNA Blood Mini Kit (Qiagen, Valencia, CA.). Purified genomic DNA was
quantitated using a Nano Drop spectrophotometer (Thermo Fisher Scientific, Waltham,
MA.).
Paired end library preparation. At least 1 µg of genomic DNA was used for
Illumina Solexa sequencing. Samples for sequencing of artemisinin sensitive (D6, D6
[clone C11]; W2, W2 [clone D7]) and resistant strains (D6.QHS2400x2, D6.QHS2400x5;
W2.QHS200x2) were prepared using the Illumina paired end sample kit (Illumina, Inc.
San Diego, CA.). The procedure called for the nebulizatoin of 2-5 µg of genomic DNA
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at 32 psi for 6 minutes and purification of DNA using Zymo-Spin Columns (Zymo
Research Corporation, Orange, CA.). End repair, ligation of adapters, and PCR
enrichment were performed as described in the Illumina Paired End Sample Kit protocol.
Ligation products were purified on a 2% TAE agarose gel, extracting a range of 250-350
bp fragments using an Invitrogen PureLink Gel Extraction Kit. Validation of sequencing
libraries was performed by TOPO cloning (Invitrogen) 4 µl of the PCR enriched library
and sequencing of 30 clones. A final library concentration of 8 pM was loaded into a V4
flow cell and clusters were generated using the Illumina Cluster Generation Kit and
sequenced on the Illumina Genome Analyzer GAII.
Downstream analysis. Base calling was run using the standard Illumina pipeline.
Reads were then aligned to the P. falciparum genome (PlasmoDB version 6.3) using the
Bowtie short read aligner. Using MegaBLAST, reads were pre-filtered through the
human genome to remove reads that result from culture growth conditions before
aligning to the P. falciparum genome. Since the published genome is based on the 3D7
reference strain, we allowed for two read mismatches due to possible strain specific SNP
differences with D6 and W2. Any reads with more than 2 mismatches were not further
analyzed. We also required that reads were unique such that reads that mapped to
multiple loci were not used. We calculated coverage per base pair throughout the entire
genome and created wiggle (WIG) files to view the sequenced genomes on the UCSC
genome browser. Binary alignment/map (BAM) files were also created using sequence
alignment/map (SAM) tools to view the aligned reads on the Broad Institute‟s Integrative
Genome Viewer.
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Sequencing for verifying single nucleotide polymorphisms from whole
genome sequence data. Genomic DNA was isolated from D6, D6 (clone C11),
D6.QHS2400x2, D6.QHS2400x4, D6.QHS2400x4 (clone C9), D6.QHS2400x5 (clone
C9), W2, W2 (clone D7), W2.QHS200, W2.QHS200x2, and 3D7 for sequencing of
PF13_0238 (kelch protein, putative) and PFF0275c (nucleoside diphosphate kinase,
putative). Not every gene was sequenced for each parasite sample. The primer
sequences used for these genes are listed in Table 3.1. As in Chapter Two, the optimal
annealing temperature was determined by temperature gradient PCR. Promega (Madison,
WI.) GoTaq was used in all PCR reactions described here. The manufacturer‟s protocol
was followed except for changing the annealing temperature from 53-62°C, changing the
extension temperature to 68°C, and using an extra extension step of 72°C for 5 minutes.
Each reaction used 15 ng of genomic DNA as template for standard PCR using a
temperature gradient ranging from 53-62°C in a Biorad Mycycler thermal cycler. All
primer sets were found to amplify equally well from 56-60°C. The optimum annealing
temperature was determined to be 57°C and 200 nM F/200 nM R was the optimal primer
pair concentration. The PCR products of PF13_0238 1F new/1R new, PFF0275c 1F/1R,
PFF0275c 3F/3R, and PFF0275c 4F/4R were 668 bp, 687 bp, 491 bp, and 400 bp,
respectively. Gene sequences from individual forward and reverse reactions were
assembled into contigs and aligned using Vector NTI Advance 11.0 (Invitrogen).
Assembled sequences were searched for presence of SNPs and verified in sequence
chromatograms.
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Real-time QPCR for copy number assessment of chromosome 10 genes.
Optimization of oligonucleotide sets. Sets of primers for PF10_0275
(protoporphyrinogen oxidase), PF10_0277 (nucleolar rRNA processing protein EBP2,
putative), PF10_0278 (nucleolar preribosomal assembly protein, putative), PF10_0279
(conserved Plasmodium protein, unknown function), PF10_0285 (conserved Plasmodium
protein, unknown function), PF10_0286 (conserved Plasmodium protein, unknown
function), PF10_0292 (conserved Plasmodium protein, unknown function), PF10_0294
(RNA helicase, putative), PF10_0295 (conserved Plasmodium protein, unknown
function), PF10_0296 (conserved Plasmodium protein, unknown function), PF10_0299
(glycoprotease, putative), and PF10_0300 (RNA methyltransferase, putative) were tested
against 3D7 or D6 genomic DNA to determine optimal annealing temperature and
concentration for use in assays. All primer sequences are listed in Table 3.1. The
procedure for primer optimization was the same as that detailed in Chapter Two. The
concentration of primer that caused the lowest Ct value with high fluorescence intensity
was selected for subsequent assays. The optimum concentration of 200nM F/200nM R
was identified for PF10_0277, PF10_0278, PF10_0279, PF10_0285, PF10_0294,
PF10_0295, PF10_0296, and PF10_0300 primer sets. The combination of 500 nM F/500
nM R was identified as optimal for PF10_0286, PF10_0292, PF10_0299 primer sets.
Determination of gene copy number by real-time QPCR. The relative copy
numbers (CN) of the chromosome 10 genes listed above were determined for D6, W2,
TM91c235 parental and resistant lines by using ldh as normalizer. The procedure was
similar to that described in Chapter Two for QPCR of pfmdr1, pfmdr2, PFE1050w, and
PF11_0466. A variety of pressure levels were selected from the stepwise selection of D6
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and TM91c235 resistant parasites, including intermediate pressure levels (D6 [80, 120,
200, 300, 340, 2400x2, 2400x4, 2400x5 ng/ml QHS]; TM91c235 [80, 240, 280 ng/ml AL,
but 80 ng/ml not included for chromosome 10 genes]). For the W2 series, we included
W2, W2 (clone D7), W2.QHS200, and W2.QHS200x2. Patient isolates from Thailand
(#3, 6) and Cambodia (#3, 5, 6, 8, 10, 18, 26, 32, 33) were also tested for a few genes
within the amplification. Each assay was performed more than once (except for ThaiCambodia isolates). The amount of standard ranged from 3.3-0.036 ng of genomic DNA
(overall, not in a single experiment) in the 5-point standard curve (this varied per
experiment). Mean copy number relative to D6, standard deviation, and 95% confidence
intervals were calculated as in Chapter Two.
Measurement of the rate of recovery from dormancy for D6 parasites. To
determine the rate of recovery from dormancy, D6 (clone C11) and D6.QHS2400x5 were
synchronized to mid-late ring stages and split to 2.5±0.15 parasitemia/4% hematocrit in
15 ml volumes in 75 cm2 culture flasks. DHA (1 mg/ml) was diluted 1:40 in complete
media and was added to each flask to a final concentration of 200 ng/ml (703.3 nM).
This dose was chosen because previous experiments (data not shown) showed that this
concentration of drug was high enough to induce dormancy in both parent and resistant
parasites, yet low enough to allow parasites to recrudesce over a period of approximately
a week after treatment. Control flasks containing the same parasite suspensions also were
made. DMSO was diluted 1:40 in complete media and a volume equal to the 200 ng/ml
drug amount was added to control flasks. Six hours post-treatment, cultures were
transferred to conical tubes and centrifuged. Parasites were washed three times with
stock RPMI, resuspended in the original volume, transferred to new flasks, and incubated
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at 37°C. Thick and thin smears were made before drug treatment (time zero), after drug
was washed out (T6), and every 24 hours post-treatment up to 192 hours. Culture media
was changed every day and parasites were monitored until parasitemia of normal
parasites in drug-treated cultures exceeded 4% (192 hours post-drug). For each time
point, parasitemia was determined by counting over 800 erythrocytes from five fields in
each thin smear. Parasitemia was calculated as the number of total parasites /total number
of erythrocytes. The ratio of normal/total parasites and dormant/total were calculated at
each time point.
Microarrays.
Culture for microarray experiments. For the pilot studies with W2, synchronized

parasites were exposed to 28.4 ng/ml (100 nM) DHA for six hours, washed with stock
RPMI, and put back into culture. Samples representing parasites six hours post-treatment
(T6) and 27 hours post-treatment (T27) were collected for microarray analysis.
For the transcriptional studies with D6 parasites, D6 (clone C11) and
D6.QHS2400x5 were divided into four groups: parent synchronized (PS), parent
unsynchronized (mixed) (PM), resistant synchronized (RS), and resistant mixed (RM)
(Fig. 3.2). To obtain highly synchronized cultures, parasites were synchronized 7 times
over a 192-hour period. Approximately 26 hours following the seventh synchronization,
cultures were monitored for maximum invasion (the time when the number of rings=the
number of schizonts counted in Giemsa stained blood smears). Two hours postmaximum invasion, parasites were subjected to a final round of synchronization and
cultures (mixed and synchronous) were split to 3.47±0.97% parasitemia and 4%
hematocrit. Eight hours post-invasion, time zero (T0, untreated samples) were collected
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and 200 ng/ml DHA (703 nM) was added to selected cultures (making parent treated
synchronized [PTS], parent treated mixed [PTM], resistant treated synchronized [RTS],
and resistant treated mixed [RTM]). An equivalent amount of diluted DMSO was added
to control cultures (making parent untreated synchronized [PUS], parent untreated mixed
[PUM], resistant untreated synchronized [RUS], and resistant untreated mixed [RUM]).
Six hours post-treatment (T6), parasites were washed with fresh media and put back into
culture as described in the previous section. At this point, there were eight sample groups.
Samples were collected from DHA-treated cultures over 189 hours post-drug (time points
were 6, 12, 18, 24, 32, 40, 48, 57, 69, 81, 93, 105, 129, 141, 153, 165, 177, 189).
Samples from PTM and RTM were collected from 6-153 hours post-drug, and samples
from PTS and RTS were collected from 6-189 hours post-drug. Samples from PUS,
PUM, RUS, and RUM were collected for the first 48 hours of the time-course and then
discontinued. All samples were snap-frozen in liquid Nitrogen for later RNA extraction
and subsequent transcriptional analysis.
Microscopy and smear counts. For parasitemia quantification, thin smears were
taken at each time point (out to 189 hours for PTS, RTS) and were independently
examined in a blinded fashion by three people. Each person analyzed at least three fields
per slide and counted between 300-900 total cells per slide. Parasitemia was calculated
as the number of parasites per total number of erythrocytes counted. Average parasitemia
(and standard deviation) for the independent counts for each time point and treatment
group were plotted. Parasites from thin smears were sorted into classifications of dead,
dormant, ring, trophozoite, or schizont. For DHA-treated cultures, only data from two of
three microscopists was used because one of the labs in the joint project could not assess

223

time points beyond 48 hours. Also, time points after 117 hours were only assessed by
one microscopist. Analysis of blood smears by microscopy allows the efficient
quantification of normal morphological forms as compared to dormant parasites, but it is
very difficult to discriminate between dead and dormant parasites. Also, in some
instances, discrimination of dormant vs. dead was not performed during counting of
parasites. Therefore, a separate category was developed that grouped dead and dormant
parasites together (dead-dormant). The ratios of dead-dormant parasites in relation to
total parasites and normal/total parasites were calculated for each time point of the drug
treated groups (PTM, PTS, RTM, and RTS).
RNA extraction and amplification. Total RNA used for microarray analysis was
isolated from experimental samples using Trizol (Invitrogen), per the manufacturer‟s
instructions. Briefly, 10 ml Trizol (55°C) and 2 ml chloroform were added to frozen cell
pellets (approximately 250 µL) on ice, mixed, and centrifuged to obtain the aqueous
phase. The aqueous phase was isopropanol/sodium acetate precipitated overnight at 80°C, centrifuged, washed with 70% ETOH, and the resulting RNA pellet was resuspended in RNAase-free water prior to amplification. Next, 110 ng of total RNA was
amplified and aminoallyl-labeled using the Amino Allyl MessageAmp II aRNA
Amplification kit (one round, oligo dT priming, 14 hr IVT, Ambion, Austin, TX). As
much total RNA as possible was used for amplification when samples contained <110 ng
total RNA. An amplified 3D7 RNA pool representing transcripts expressed throughout
the intraerythrocytic development cycle (IDC) was compiled as a reference.
Cy dye labeling and microarray hybridization. Aliquots of amplified and pooled
reference RNA (2 µg) were coupled to Cy3 and 2 µg amplified experimental RNA was
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coupled to Cy5 using Amersham post-labeling reactive dye packs (GE healthcare,
Piscataway, NJ). Prior to hybridization, microarrays were printed and post-processed as
described in Bozdech et al (2003). Cy3 reference pool and Cy5 samples were
competitively hybridized at 65˚C on a spotted microarray containing 8159 70-mer oligos
that map to 5338 ORFs as annotated in PlasmoDB release 6.3. Samples were hybridized
against the pooled reference instead of against each other, to avoid the confounding
effects of differential growth rates noted by others 412. In total, 89 arrays were used.
Following an 18 hour hybridization, microarrays were washed in 65˚C 0.6x SSC, 0.03%
SDS, and then washed in room temperature 0.06x SSC. After spinning dry, arrays were
scanned on an Axon 4000B scanner using Axon Genepix software, taking care to balance
the intensities of the two dye channels (version 6.0 and 6.1, Molecular Devices, Union
City, CA). Several arrays have technical replicates. For subsequent calculations the
results of replicate arrays without large artifacts were averaged together.
Array analysis. Microarrays were manually gridded and Cy3 and Cy5 intensity
of each spot was extracted using Genepix software. Arrays were uploaded to Nomad v2.0
(http://ucsf-nomad.sourceforge.net/) where the data was normalized in bins of pixel
intensity R2, and then filtered to remove spots with “bad” or “missing” manual flags
added during gridding, as well as spots with sum of median intensities less than 500. The
resulting ratio Cy5/Cy3 intensity tables were log2 transformed and re-centered about zero.
Re-centered arrays were compared with all time points of the HB3 IDC by Pearson‟s
correlation (after filtering out surface antigen genes that are very strain-specific, 422).
The lists of genes up-regulated and down-regulated in the 48 hours after drug
treatment in treated PTS and RTS groups were generated by averaging the log2 ratios for
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the 6 through 48 hr time points and subtracting the time zero log2 ratios. Those results
were considered our measure of induction and the data were sorted for genes consistently
up-regulated or down-regulated in both strains (114 genes). We also were interested in
gene inductions that differed between the two strains. Therefore, we sorted for oligos
with measures of induction that had opposite signs in D6 (clone C11) versus
D6.QHS2400x5 synchronized cultures with absolute distance between the two inductions
greater than an arbitrary cutoff of 1.8. To compare the transcriptomes of PTS and RTS at
baseline, we calculated the residual between the time zero array signals of the
synchronized resistant parasites and a linear regression of its relationship with
synchronized resistant parasites. By this measure of differential baseline transcription
after taking our variable antigen oligos, we arrived at the list of the 100 most different
oligos (this is the top 1.2% of the data).
Results
Proteomics identified differentially expressed proteins in artemisinin
resistant vs. parent parasites. Proteomic analyses of D6 parasites focused on uncloned
strains D6 vs. D6.QHS2400x3 and W2 vs. W2.QHS200. D6.QHS2400x2 was treated
with 2400 ng/ml QHS to produce D6.QHS2400x3, and this parasite was grown up to
large volume to have enough material to send for proteomics. However, this process took
about two months after parasites recovered from the drug treatment. W2.QHS200 was
not treated with QHS before growing up for proteomics. Pairs of D6 and W2 parasites
were synchronized to ring/early trophozoite stages in parallel. Comparison of 2D gels of
D6 vs. D6.QHS2400x3 and W2 vs. W2.QHS200 found some protein spots that were
under-expressed/over-expressed in resistant vs. parental parasites (Table 3.2). We picked
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13 spots from 2D-DIGE of D6 vs. D6.QHS2400x3 and W2 vs. W2.QHS200 for mass
spectrophotometry and protein identification (in red, Table 3.2). The ratio of proteins
expressed in resistant/parental strains was determined for D6.QHS2400x3/D6 and
W2.QHS200/W2. Computer analysis measured protein peaks and ratios were calculated.
An example of down-regulation and up-regulation in D62400x2/D6 is displayed in Fig
3.3. Spot 1594 had decreased ratio of 1.53 in the resistant vs. parent parasite, whereas
spot 2300 had increased ratio of 2.05 in the resistant parasite. We were confident the
results were valid as surrounding protein peaks looked similar in the protein pairs. For
the W2 series (Fig. 3.4), examples of differential regulation are spot 439, which was
decreased 2.75 fold in W2.QHS200 compared toW2, whereas spot 788 was increased
1.88 fold in the resistant parasite. For D6.QHS2400x3/D6, the highest scoring proteins
that were differentially regulated included PF11_0098 (endoplasmic reticulum-resident
calcium binding protein, down-regulated, ratio= -1.41), PFI0265c (RhopH3 rhoptry
protein, up-regulated, ratio= +1.57), PF14_0425 (Fructose bisphosphate aldolase, downregulated, ratio= -1.53), and PFI1270w (conserved Plasmodium protein unknown
function, up-regulated, ratio= +1.74) (Table 3.2). For W2.QHS200/W2, the highest
scoring proteins that were differentially regulated included PFI0875w (Heat shock
protein 70 [HSP70] homologue, up-regulated, ratio= +1.62), PFI1475w (MSP-1
precursor, up-regulated, ratio= +1.88), PFL2215w (actin I, up-regulated, ratio= +1.38),
PF13_0197 (MSP-7 precursor, up-regulated, ratio= +1.54) (Table 3.3)
Whole genome sequencing identified single nucleotide polymorphisms and
copy number amplifications in artemisinin resistant parasites. D6 and
D6.QHS2400x2 were the first set of parent/resistant parasites for sequencing. We aimed
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to detect SNPs and/or amplifications in parent vs. resistant strains. At the point
D6.QHS2400x2 was submitted for sequencing, it had been grown for about 2 weeks
since the last pulse of 2400 ng/ml. A second set of sequencing was conducted with
D6.QHS2400x5, W2, W2 (clone D7), and W2.QHS200x2.
Single nucleotide polymorphisms identified in resistant D6 strains. To search
for high-likelihood SNPs in the first set of sequencing, a tool was developed to measure
the percentage of reads for a particular base in the parent or resistant strain. This analysis
also took into account differences between parent and resistant parasites caused by
antigenic variation genes between the strains. We expected that a causative mutation for
artemisinin resistance would likely be present in an exon at nearly 100% of the reads in
D6.QHS2400x2, so SNPs that are heterogeneous (i.e. 40% have one base, 60% have
another) are not likely to be very important. This was a way to reduce noise while
analyzing the data. Another important factor was that SNPs could only be credible if
there were sufficient reads for both the parent and the selected strain (more is better).
Our initial analysis focused on at least three reads for a base either for D6 or
D6.QHS2400x2. As a result of the analysis, it was possible to find high likelihood SNPs
based on the number of reads for a base/total number of reads (ex. 100 reads of A in 100
total reads=100%). This was done for a particular base in both D6 and D6.QHS2400x2 (%
parent SNP or % resistant SNP). After removing the antigenic variation genes, the actual
number of SNPs affecting coding regions was fairly small (Table 3.4). In this initial
analysis, SNPs were divided into two groups where D6/3D7 were similar vs.
D6.QHS2400x2, and where D6.QHS2400x2/3D7 were similar vs. D6. The results of this
analysis found an overall trend of a greater number of reads for D6 bases compared to
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D6.QHS2400x2. Based on a high number of reads for both D6 and D6.QHS2400x2
while having a high percentage of a single base /total reads, PF13_0238, PFC0320w
(encodes a conserved Plasmodium protein of unknown function), PFF0275c, PFE1155c
(encodes a putative mitochondrial processing peptidase alpha subunit), MAL13P1.298
(encodes a conserved Plasmodium membrane protein of unknown function) contained
high-quality SNPs for D6/3D7 vs. D6.QHS2400x2. A similar analysis of
D6.QHS2400x2/3D7 vs. D6 found high quality SNPs in PF14_0419 (encodes a
conserved Plasmodium protein of unknown function) and PFA0315w (encodes a
conserved Plasmodium protein of unknown function). More coverage was gained from
additional rounds of sequencing, allowing us to define the most promising SNPs. We
further defined criteria for true SNPs where 80% of reads for a particular base
corresponded to a nucleotide difference between D6 and D6.QHS2400x2 (Table 3.5).
These SNPs all came from genes from the original D6/3D7 vs. D6.QHS2400x2 group, so
all associated amino acid changes are in the resistant parasite. Based on this analysis, a
small list of high quality reads was produced for SNPs in D6 vs. D6.QHS2400x2. As
before, the highest quality SNPs were in PF13_0238, PFF0275c, MAL13P1.298,
PFC0320w, and PFE1155c. The SNPs caused non-synonymous amino acid changes in
codons for PF13_0238: GAA-AAA (Glu-Lys) at position 1726407 in chromosome 13;
PFF0275c: GAT-CAT (Asp-His) at position 230387 in chromosome 6; PFC0320w:
AAT-ATT (Asn-Ile) at position 323233 in chromosome 3; PFE1155c: AGT-GGT (SerGly) at position 963839 in chromosome 5; and MAL13P1.298: GGT-GAT (Gly-Asp) at
position 2394027 in chromosome 13.
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A potential problem we noted with the initial sequencing with the uncloned
parasites was heterogeneity of bases for a given number of reads. Because of this, we
attempted a second set of sequencing using D6 (clone C11), D6.QHS2400x5, W2 (clone
D7), W2.QHS200x2, and another parental W2 strain from the MR4 depository. The
results of whole genome sequencing of the clonal parasites are currently being analyzed,
and we are trying to assess the same high-probability non-synonymous SNPs reported
above in D6.QHS2400x5 and W2.QHS200x2, and also non-synonymous SNPs in the
same gene for these pairs of parasites.
Single nucleotide polymorphisms verified in resistant D6 strains. The initial
sequencing of D6 vs. D6.QHS2400x2 found high probability SNPs between the strains,
and these SNPs were located in PF13_0238, PFC0320w, PFE1155c, PFF0275c, and
MAL13P1.298. We sought to verify some of these SNPs by sequencing a few genes
using genomic DNA we had for these parasites and parasites that had been exposed to
additional rounds of 2400 ng/ml (D6.QHS2400x4, D6.QHS2400x4 [clone C9], and
D6.QHS2500x5). We used D6, D6 (clone C11), W2, W2 (clone D7), and 3D7 as control
parasites. We chose two genes in an attempt to independently verify the SNPs separating
D6 vs. QHS-selected D6 strains. Sequencing of PF13_0238 and PFF0275c (using
PFF0275c-1 primers) found that D6, D6 (clone C11), W2, W2 (clone D7), and 3D7
possessed the wild-type nucleotide, but D6.QHS2400x2, D6.QHS2400x4,
D6.QHS2400x4 (clone C9), and D6.QHS2400x5 (clone C9) had the nucleotide change
(Table 3.6). We noticed that for a few genes (PF13_0238, PFF0275c-1, MAL13P1.298),
SNP data for D6 vs. 3D7 were deposited in PlasmoDB. We were interested in verifying
if all the D6 parasites we were using at the time all were the same genotypically and
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different from W2 (which had same base as 3D7). We had some concern at the time
since multiple strains were being cultured as at the same time. These SNPs were in
regions of DNA that could be amplified using primers that we used for SNP detection of
D6 vs. QHS-selected D6 parasites (for PF13_0238) or with new primers we designed
(PFF0275c-3, PFF0275c-4). The SNP separating D6 vs. 3D7/W2 in PF13_0238 was at
position 1,726,463 in chromosome 13, changing codon AAA to ACA (Lys-Thr). Primer
set PFF0275c-3 amplified a region of DNA containing a SNP at position 229836 of
chromosome 6, changing codon AAA to AAG (Lys-Lys). Primer set PFF0275c-4
amplified a region of DNA containing a SNP at position 229481 of chromosome 6,
changing codon AAA-CAA (Lys-Gln). For this round of sequencing, 3D7, D6, D6
(clone C11), D6.QHS2400x2, D6.QHS2400x4, W2, W2 (clone D7), W2.QHS200, and
W2.QHS200x2 were used as templates. We did not have genomic DNA for
D6.QHS2400x4 (clone C9) or D6.QHS2400x5 (clone C9) at the time these sequencing
reactions were performed. The results of the sequencing showed that 3D7 and W2
parasites contained similar wild-type nucleotide, but D6 strains were different (Table 3.6).
Also, all D6 strains contained the same nucleotide when compared to each other.
Amplifications identified in chromosome 10 in artemisinin resistant D6 and W2
lines. We scanned for differences in readings between D6 and D6.QHS2400x2 by
looking at output signals that changed between the two parasites. There was a clear
increase in signal for D6.QHS2400x2 in a region of chromosome 10. An initial analysis
confined the amplification region to PF10_0279 through PF10_0299. It appeared that
each gene within this amplification was amplified 2-fold compared to D6. The genes
interior of these boundaries included: PF10_0278 (nucleolar pre-ribosomal assembly
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protein, putative), PF10_0279, PF10_0280 (both conserved Plasmodium proteins of
unknown function), PF10_0281 (merozoite TRAP-like protein), PF10_0282, PF10_0283,
PF10_0284, PF10_0285, PF10_0286, PF10_0287, PF10_0288 (all conserved
Plasmodium proteins of unknown function), PF10_0289 (adenosine deaminase, putative),
PF10_0290 (conserved Plasmodium protein, unknown function), PF10_0291 (RAP
protein, putative), PF10_0292 (conserved Plasmodium protein, unknown function),
PF10_0293 (transcription factor, putative), PF10_0294 (RNA helicase, putative),
PF10_0295 (conserved Plasmodium protein, unknown function), PF10_0296 (conserved
Plasmodium protein, unknown function), PF10_0297 (conserved Plasmodium protein,
unknown function), PF10_0298 (26S proteasome subunit, putative), and PF10_0299
(glycoprotease, putative).
A second round of sequencing with D6 (clone C11), D6.QHS2400x5, W2 (clone
D7), W2.QHS200x2, and W2 (MR4 reference strain) strains found that the chromosome
10 amplification existed in D6.QHS2400x5 (PF10_0279-PF10_0299), similar to what we
reported for D6.QHS2400x2 (data not shown). Also, a subset of genes within the D6
amplification was found in the clonal W2 parent and resistant strains (PF10_0288
through PF10_0297). In both W2 and W2.QHS200x2, it appeared that there were three
copies of each gene within the amplification. These results are interesting because they
showed that two sets of geographically different parasites contain amplified genes in a
similar region. Interestingly, the amplification was not found in the MR4 reference W2
strain. Although the presence of the amplification in W2 (clone D7) makes the results for
W2 lines less clear, we believe this is a technicality (see below).
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Copy number amplification was verified in D6 and W2 artemisinin resistant
strains by QPCR. To verify the amplification on chromosome 10, primers were designed
to assess copy number of genes within the amplicon (Table 3.1). We chose a subset of
genes within the amplicon for copy number assessment and a few outside of the amplicon.
These genes were PF10_0275, PF10_0277, PF10_0278, PF10_0279, PF10_0282,
PF10_0285, PF10_0286, PF10_0292, PF10_0293, PF10_0294, PF10_0295, PF10_0296,
PF10_0299, and PF10_0300. During primer optimization, it was determined that primers
for PF10_0282 and PF10_0293 did not perform well in our assay, so these genes were
discontinued from further analyses. Based on the results, some general trends were noted.
We determined the boundaries of the amplification in QHS-resistant D6 parasites to be
PF10_0279 and PF10_0299. It was found that all D6 parasites had approximately 1 copy
of PF10_0275, PF10_0277, and PF10_0300 (Fig. 3.5-A, Table A-3, Appendix A). For
the resistant D6 parasites, CN of genes from PF10_0279 to PF10_0299 was
approximately two across the amplification. The minimum CN was for D6.QHS2400x5
in PF10_0286 (CN, 1.82±0.0812, 95% CI 1.74-1.90) and the maximum CN was for
D6.QHS80 (CN 2.49±0.060, 95% CI, 2.43-2.55) and D6.QHS2400x2 (CN, 2.50±0.20, 95%
CI, 2.30-2.69), both in PF10_0292 (Fig. 3.5-A, Table A-3, Appendix A). The overall
mean of average CN for resistant parasites from PF10_0279-PF10_0279 was 2.09 ±0.112,
95% CI 2.06-2.12. In the W2 series, there was a smaller region of amplification within
the large amplification detected in resistant D6 parasites (Fig. 3.5-B, Table A-3,
Appendix A). This region was from PF10_0292 to PF10_0296, and parts of this region
were found in W2, W2 (clone D7), as well as resistant W2 progeny. However, the
amplification in W2 and W2 (clone D7) was only in PF10_0292 and PF10_0294. We
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also found that CN differed between W2 (CN, 3.46±0.52 95% CI, 3.34-3.59) and W2
(clone D7) (CN, 2.18±0.069 95% CI, 2.12-2.24) for PF10_0292 and for PF10_0294 (W2
CN, 3.05±0.302 95% CI, 2.75-3.34; W2 [clone D7], CN 2.17±0.085 95% CI, 2.08-2.27).
The amplification in W2 and W2 (clone D7) was not found in any other gene we
analyzed. The resistant W2 parasites had amplification in PF10_0292 (W2.QHS200 CN,
2.97±0.18, 95% CI 2.72-3.22; W2.QHS200x2 CN, 3.58±0.021 95% CI 3.55-3.60),
PF10_0294 (W2.QHS200 CN, 2.87±0.150, 95% CI 2.70-3.03; W2.QHS200x2 CN,
3.07±0.028 95% CI 3.03-3.11), PF10_0295 (W2.QHS200 CN, 2.96±0.35 95% CI, 2.663.27; W2.QHS200x2 CN, 3.50±0.0071 95% CI, 3.49-3.50), and PF10_0296
(W2.QHS200 CN, 3.07±0.21 95% CI 2.89-3.25; W2.QHS200x2 CN, 3.61±0.042 95% CI,
3.55-3.67) (Fig. 3.5-B, Table A-3, Appendix A). These data for W2.QHS200x2 validate
the sequencing results reported above where the copy number of PF10_0292-PF10_0296
inW2.QHS200x2 was increased over 3 copies. Currently, it is not known why W2 and
W2 (clone D7) contained amplification in PF10_0292 and PF10_0294 at all, or why only
these genes were amplified (more in Discussion). Also, sequencing determined that W2
(clone D7) had amplification in PF10_0295 and PF10_0296, but we did not detect
amplification in these genes. Furthermore, sequencing found that there were 3 copies of
amplified genes in W2 (clone D7), yet we found they were amplified only ~2-fold.
In the TM91c235 series, copy number of chromosome 10 genes was
approximately 1 for all strains that we analyzed (Fig. 3.5-C, Table A-3, Appendix A).
The lowest value in the set was for TM91.AL280x2 in PF10_0286 (CN, 0.945±0.0071 95%
CI, 0.935-0.955). The highest copy numbers in chromosome 10 were for PF10_0279 in
TM91c235 (CN, 1.36±0.035 95% CI 1.31-1.40) and TM91c235.AL240x2 (CN,
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1.39±0.038 95% CI, 1.35-1.44). We also observed CN ≥1.2 for other genes (PF10_278,
PF10_0294). We also examined patient isolates from Thailand and Cambodia for some
of the genes within the amplification, but not all. These isolates were from another study
where our laboratory performed in vitro susceptibility testing on isolates from this region
of Asia. It was found that a few of these (including Cambodia 18) had reduced
susceptibility to artemisinins. All isolates that were assayed had approximately 1 copy of
the particular gene tested within chromosome 10 (genes tested were PF10_0275,
PF10_0279, PF10_0292, PF10_0294, PF10_0295, PF10_0296) (Fig 3.5-D, Table A-3,
Appendix A).
Dihydroartemisinin treatment is associated with the appearance of dormant
forms prior to recrudescence. Before microarrays were conducted on D6 resistant
strains, we performed an experiment to determine the rate of recovery from dormancy
after D6 (clone C11) and D6.QHS2400x5 were treated with 200 ng/ml DHA. This dose
was chosen because previous experiments (data not shown) showed that this
concentration of drug was high enough to induce dormancy in both parent and resistant
parasites, yet low enough to allow parasites to recrudesce over a period of approximately
a week after treatment. Recovery rates of parent and resistant D6 parasites were
determined by exposing parasites to DHA for 6 hours and monitoring parasitemia over
eight days (Fig 3.6). For the untreated parasites, parasitemias spiked at 48 hours, then
decreased as parasites started becoming stressed and dying. In both D6 and
D6.QHS2400x5, the total parasitemia did not decrease below 2% after drug exposure
(Fig. 3.6-A); however, the number of normal parasites decreased markedly after DHA
was added (Fig 3.6-B). At 24 hours, the majority of parasites observed in DHA-treated
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D6 were classified as dormant or dead, with 4.2% of parasites identified as
morphologically normal. In contrast, a higher percentage of morphologically normal
parasites were noted for the resistant parasite (21.1%) (Figs 3.6-B, C [for pictures at 24
hours]). At 48 hours post-drug, again the majority of parasites were classified as dead or
dormant, but normal parasites were still detected in each strain (Figs 3.6-B, C). The
percentage of normal parasites observed was greater for the resistant parasite compared to
the parent (8.0% vs. 3.8%). At 72 hours post-drug, normal parasites were not counted for
D6, although after thorough examination of the smear, very few normal parasites were
observed (Fig. 3.6-C). A greater number of normal parasites were observed in
D6.QHS2400x5 (23.5% of total parasites counted). The percentage of normal parasites
was consistently greater after 72 hours in the resistant parasite compared to the parent
until the end of the assay (Fig. 3.6-B). At 96 hours, normal parasites were observed for
the parent strain (Fig. 3.6-C), but the percentage was less than the resistant parasite (9.5%
vs. 31.6%) (Fig. 3.6-B). Overall, dormant forms persisted until 144 hours in thin smears
for each strain (Fig. 3.6-C), but there was a greater number of dormant parasites in the
resistant strain at every time point (after 24 hours) (Figs. 3.6-D). The assay was
terminated at 192 hours post drug after parasitemia of normal parasites was ≥4%. The
parasitemia of morphologically normal parasites was greater for the resistant parasite
(6.3%) compared to the parent (3.9%) at the end of the assay.
Transcriptional analysis of dihydroartemisinin treated parental and resistant
parasites reveals transcriptional arrest and differences in gene expression.
Dihydroartemisinin induces transcriptional arrest at ring stage in W2 parasites.
In a pilot microarray experiment, synchronized rings of wild-type W2 parasites were
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exposed to 100 nM DHA for 6 hours, and RNA was isolated at 6 (T6) and 27 (T27) hours
post-drug treatment. For untreated parasites, a 21 hour separation in the IDC would
constitute a huge change in the transcriptome 422-424 and be expected to have a negative
correlation of -0.69 (calculated from the HB3 dataset). However, these studies revealed
that following treatment with DHA, samples taken 21 hours apart had surprisingly similar
transcriptomes with a Pearson correlation of 0.63 and correlated best with 12 and 13 hour
post invasion (hpi) (Fig. 3.7) in transcriptome data from the normal IDC of HB3 422.
These data suggest there is an arrest in ring-stage development following treatment with
DHA. Unfortunately, these data contained numerous gaps for expression of genes and it
only involved DHA-treated parental W2 (without relative untreated controls) over a
limited time. Therefore, a study with a longer time course was conducted with QHS
sensitive and resistant parasites to probe DHA-induced dormancy over a prolonged
period of time. The experimental design is illustrated in Fig. 3.2.
Dihydroartemisinin induces arrest with a ring-like transcriptome in artemisinin
sensitive and resistant D6 parasites. Clones of D6 (artemisinin sensitive) and
D6.QHS2400x5 (artemisinin resistant) were grown into highly synchronous cultures for
microarray analysis. Approximately 8 hours after merozoite invasion, one half of each
strain was treated with 200 ng/ml DHA, while the other half was treated with DMSO as a
negative control. Drug or DMSO was washed out of cultures at six hours after treatment
(T6). Starting at the time of drug treatment (T0), samples were taken from both treated
and untreated cultures every six hours for the first 24 hours, then every 8 hours until 48
hours after drug treatment. After T48, untreated control cultures were discontinued, but
samples from treated cultures were taken at 57 hours and then every 12 hours thereafter
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until the cultures recrudesced beyond measurable parasitemia (treated synchronized
cultures were terminated after 189 hours, treated unsynchronous [mixed] cultures were
terminated after 153 hours). After RNA isolation and linear amplification in parallel,
dye-labeled samples were hybridized to 89 P. falciparum expression arrays. The array
results were analyzed as described for the W2 pilot microarrays, comparing results from
each array to every hour of the IDC from normally growing HB3 parasites (data from 422).
In Figure 3.8, DMSO-treated control parasites present a drifting sine wave of correlation
whose peak correlation (0.73±0.05 for D6 and 0.64±0.07 for D6.QHS2400x5) shifts
across the IDC as expected (Fig 3.8-A, C). In stark contrast, D6 and D6.QHS2400x5
synchronized treated parasites failed to progress their transcriptome past a state most
closely resembling a normal ring at 8-11 hours post invasion (hpi). This period of
transcriptional arrest lasted for 86 hours post-drug for DHA-treated D6 and 62 hours
post-drug for DHA-treated D6.QHS2400x5 (Fig 3.8 B, D). Peak correlations to the IDC
stalled at 8-11 hpi (0.63±0.02) for D6 and stalled at 9-11 hpi (0.55±0.02) for
D6.QHS2400x5. These results confirm and significantly extend our observation of a
DHA-induced dormancy and transcriptional arrest in the W2 pilot experiment (Fig. 3.7).
Importantly, both parental and QHS resistant clones exhibited transcriptional arrest
consistent with a 8-11 hpi ring stage parasite. The data suggest the period of dormancy
was shorter for the resistant clone compared to the drug sensitive parent and the
correlation of the DHA treated to the normal IDC ring transcriptome did not appreciably
diminish across the prolonged period of dormancy. We believe this unique observation is
consistent with the morphological observation of dormant rings at the same time points
(below).
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Recovery following exposure to dihydroartemisinin: artemisinin resistant
parasites exit dormancy earlier than parental parasites. The recovery of parasites from
dormancy was evaluated by morphological and transcriptional analysis. Parasitemia of
the untreated groups was followed up to 48 hours and the treated groups were followed
for up to 189 hours (Fig. 3.9-A, B). Figure 3.9-A shows parasitemias of the untreated
groups (PUM, PUS, RUM, RUS). Figure 3.9-B shows parasitemias of the treated groups
(PTM, PTS, RTM, RTS). In the untreated cultures, the mixed groups reached greater
parasitemias before the synchronized groups, with the PUM group eventually reaching
highest parasitemia. There fact that the different untreated groups grew to different
parasitemias is a factor of starting parasitemia, which we attempted to standardize. In the
treated groups, parasitemias of all groups declined after drug treatment, but parasitemias
of PTM, PTS, and RTM spiked at 57 hours before declining again. This may indicate a
greater number of dead and dormant parasites were counted at this time point for those
groups. The untreated groups also reached greater parasitemias compared to the treated
groups over the time course.
As noted previously (Kyle et al., 2010 unpublished; 360,362), there was a
predominant shift in morphology from rings to dormant forms after synchronized cultures
were treated with DHA (see Fig. 3.6-C for dormant morphology in D6 recrudescence
assay). As stated before, dormant parasites are small with a regular round outline on a
Giemsa blood smear and they differ from the collapsed nuclei of pyknotic bodies in their
retention of a small circle of blue staining material that is cytoplasm and condensed red
chromatin. These characteristics separate them from dead parasites which appear smaller
and globular with no distinct organization of chromatin and cytoplasm, appearing
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purplish-pink when stained with Giemsa. By 24 hours after DHA exposure, most of the
parasites observed had ring-stage dormant morphology. Much like the D6 recrudescence
assay before the microarrays, the period of dormancy after treatment preceded eventual
recrudescence of morphologically normal parasites. Although overall parasitemia in
treated groups did not change significantly (Fig 3.9-B), the proportion of parasites with
normal morphology (rings, trophozoites, schizonts) dropped dramatically, which
corresponded with an increase in dead-dormant stages in all treated groups. Figures 3.9C and 3.9-D show the percentage of dead and dormant/normal parasites for the treated
groups (asynchronous and synchronous, respectively), which increased greatly 12 hours
after drug pressure. The majority of parasites observed were classified as dead rather
than dormant at this point. In the treated synchronized groups, the ratio of dead and
dormant/total parasites was similar after 12 hours post-drug up to a point. Analysis of
parasite morphology in synchronous cultures revealed that morphologically normal
parasites appeared earlier in resistant parasites. There was a sharper decrease for the
resistant parasite (starting at 57 hours post-drug) indicating an increasing prevalence of
parasites with normal ring, trophozoite, or schizont morphology later in the time course
(Fig. 3.9-E, which is inverse of Fig. 3.9-D). In addition, a greater percentage of parasites
with normal morphology were evident in the resistant strain at time points after parasites
appeared in culture. Although the synchronized treated parent culture reached higher
overall parasitemia before the resistant treated parasite (Fig. 3.9-B), the percentage of
normal/total parasites was lower for the parent strain during the majority of the time
course (Fig. 3.9-E). Like the D6 recrudescence assay above, the period of recrudescence
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did not differ significantly between parent and resistant strains. Normal parasites were
observed in PTS at 69 hours post-drug.
Dormant forms were observed from 12 hours to 141 hours post drug exposure in
both PTS and RTS. Generally, there were more dormant parasites observed in PTS
compared to RTS (data not shown) throughout the time course. This is different from the
initial D6.QHS2400x5 recrudescence assay that showed more dormant parasites present
in the resistant parasite throughout the experiment. Perhaps experimental variability
between the two assays played a factor. Although there appeared to be a lower
percentage of dormant parasites in the resistant strain in the arrays, those parasites
recrudesced before the susceptible parent strain. This may indicate that resistant parasites
are more capable of emerging from dormancy compared to the parent strain.
Interestingly, time points starting at 68 hpi revealed the resistant parasites resume
a progressing transcriptome earlier that the parental parasites. Fig 3.8-D illustrates that
the DHA-treated resistant parasites‟ transcriptome at 68 starts to shift away from the
stalled transcriptome and at 80 hours is clearly shifted later in the IDC (peak Pearson
correlation 0.61 with 23 hpi). We noticed a strange effect of the progression of the
transcriptome of the resistant parasite after leaving dormancy. At 68 hours, it appeared
that the transcriptome started to resemble that of late rings and early-trophozoites.
Another 12 hours later (80 hours total), the transcriptome resembles mid-trophozoites.
Strangely, at 92 hours, the transcriptome again resembles early ring stages. We do not
completely understand how rings could appear after drug at 68 hours, then appear again
only 24 hours later (one would expect to observe late trophozoites and schizonts in a
normal 48-hour P. falciparum life cycle). Perhaps some parasites that released early
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from dormancy died as they progressed at 80-92 hours. Maybe some of the rings that
originally exited dormancy were stalled in progression so that they still remained at 92
hours. Also, it may be that another population of rings emerged from dormancy at 92
hours. Taken together, there were unexpected effects on progression of the life cycle
after leaving dormancy. This will be followed up by more detailed studies. In contrast,
the parental lines‟ transcriptome remains stalled in the ring-like state through at least 92
hpi (Fig 3.8-B). The parental transcriptome at 104 hpi had progressed out of the ring-like
state, around 24 hours or half a replicative cycle after the matched resistant parasite clone.
The time points subsequent to the exit from dormancy have reduced peak correlations in
the transcriptome probably due to the loss of synchrony as individual parasites exit
dormancy at different times and create a combined asynchronous population. This is
consistent with observations on recovery from dormancy by Teuscher et al (2010) 362.
Asynchronous cultures exposed to dihydroartemisinin become dominated by a
ring-like transcriptome. An alternative to the ring stage dormancy hypothesis is this
transcriptional arrest in ring-treated parasites might simply reflect a pause relative to their
stage of development at the time of drug treatment or that signal captured on the
microarrays could represent residual RNA from dead or dying rings in the synchronized
culture. Therefore, simultaneously with the synchronized culture experiment, we exposed
asynchronous cultures of the same D6 and D6.QHS2400x5 parasites and harvested
samples for microarray analysis. If the transcriptional arrest was due to dead parasites or
to the developmental stage of each parasite, then we would expect the asynchronicity of
the cultures to be maintained over the time course following drug exposure. In contrast,
we found that DHA induced a similar arrest at ring stage in asynchronous cultures of
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parental and resistant parasites. Time points after drug treatment showed increased
correlation to a normal ring in the IDC (0.40±0.10 for D6 and 0.37±0.07 for
D6.QHS2400x5) (Figure 3.10-B, D). DMSO treated controls produced low peak
correlations (0.18±0.07 for parental and 0.16±0.02 for resistant) that reflected normal
asynchronous growing cultures (Fig 3.10-A, C). Importantly, the transcriptome of
asynchronous DHA treated parasites converged and paused consistent with a dormant
state in both resistant and parental clones (peak correlation at 15±1.3 hpi for D6 and
11±2.3 hpi for D6.QHS2400x5, p=0.0017). The slight difference between the hpi of peak
correlation during stall might be due to differences in the mix of populations at time zero,
with the parental asynchronous sample most closely resembling 21 hpi and the resistant
sample most closely resembling 9 hpi. The fact that the period of transcriptional arrest
across time points is tight, but across cultures is more broad suggests that there is a
window of time in the IDC in which parasites can go dormant. The data demonstrate the
ring stage is the only point in the IDC where DHA arrests transcription. In addition, the
pause in the transcriptome may indeed be relative to the parasites‟ current transcriptional
state at the time DHA is added. This might also explain why the peak correlations for the
asynchronous transcriptome peak correlations are not as high as those of the originally
synchronized dormant parasites (i.e. more developed stages are killed and not able to
enter dormancy). In the parental culture the 6 and 12 hpi time points exhibit lower peak
correlations than subsequent time points suggesting a recruitment of more parasites into
the dormant state. Perhaps the resistant parasites are able to enter dormancy more
quickly than sensitive parasites, yet this remains to be confirmed.
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Dihydroartemisinin-induced dormancy is characterized by unique gene
expression in parental and resistant strains. Although the overall transcriptome of these
dormant parasites most closely matches ring stage, the data provided an opportunity to
identify those genes that were reproducibly up-regulated or down-regulated following
drug exposure in both parasites. For this purpose we used the expression data from the
treated synchronized cultures of D6 and D6.QHS2400x5. The time zero expression data
was subtracted from the dormant state expression data averaged across all post-drug time
points for each gene. This analysis provides a measure of gene induction (or downregulation) from baseline expression. The data were filtered for spots with more than 17
total data points that passed previous quality control filters, and spots with a measure of
induction < -1.0 or > 1.0. In Table 3.7, the top 113 oligo hits most different from time
zero are displayed. The most up-regulated gene in the data set was PFE0065w (skeleton
binding protein, chromosome 5), expressed 15-fold (3.92 log2) in D6.QHS2400x5 and
165-fold (7.37 log2) in D6. Thioredoxin reductase (PFI1170c, chromosome 9) was upregulated 9-fold (3.16 log2) in D6.QHS2400x5 and 23-fold (3.16 log2) in D6 in the first
48 hours after drug treatment. P. falciparum thioredoxin reductase (PfTrxR) is a
NADPH-dependent disulphide oxidoreductase which catalyses the reduction of
thioredoxin (Trx) 425. PF14_0017 (chromosome 14) was up-regulated 7.3-fold in both
strains at 48 hours after DHA treatment (log2 D6:2.86, log2 D6.QHS2400x5: 2.87). This
gene encodes a lysophosopholipase, which belongs to a family of alpha/beta hydrolases.
PF14_0183 (encodes a putative signal recognition particle RNP) was up-regulated 22fold in D6 (log2: 4.43) and 2.5-fold in D6.QHS2400x5 (log2: 1.31). Also, PFF0510w
(encodes a histone H3 protein) was up-regulated 5-fold in D6 (log2: 2.34) and 7.4-fold in
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D6.QHS2400x5 (log2: 2.89). PF14_0010 (encodes a glycophorin family binding protein)
was up-regulated 19-fold in D6 (log2: 4.25) and 6.2-fold in D6.QHS2400x5 (log2: 2.63).
Interestingly, up-regulation of a longevity-assurance (LAG1) domain gene (PFE0405c)
was observed in both D6 and D6.QHS2400x5. The gene was up-regulated to a higher
degree in the resistant parasite, with large differences at baseline and in the first few time
points after DHA was added (data not shown). Conversely, PF10_0327 was downregulated 2.8-fold in both parasites (log2 D6:-1.53, log2 D6.QHS2400x5: -1.50), and
PF13_0088 was down-regulated 2.1-fold in D6 (log2:-1.08) and 3.3-fold in
D6.QHS2400x5 (log2:-1.73). These genes both encode PfMyb domain proteins. Two
genes (MAL7P1.19 and PF08_0020) that encode a putative ubiquitin transferase and a
ubiquitination mediated degradation component, respectively were also down-regulated
in both PTS and RTS. MAL7P1.10 was down-regulated 2.8-fold in PTS (log2: -1.50) and
3.3-fold in RTS (log2: -1.71). PF08_0020 was down-regulated 2.5-fold in PTS (log2: 1.35) and 2.1-fold in RTS (log2: -1.09).
Dihydroartemisinin induces differential expression of genes in artemisinin
resistant and sensitive parasites. Genes involved in DHA-induced dormancy or QHS
resistance could potentially be up-regulated in resistant parasites during dormancy or
only after drug treatment. To explore this possibility, the microarray data were analyzed
for genes that showed a different direction of regulation from baseline after drug
treatment. We sorted for oligos with measures of induction that had opposite effects in
the D6 versus D6.QHS2400x5 synchronized cultures with absolute distance between the
two inductions greater than an arbitrary cutoff of 1.8 (Table 3.8). There appears to be
differential regulation of cytochrome c complex genes after DHA treatment, as three
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genes of this complex had various expression effects. MAL13P1.55 was down-regulated
1.7-fold (log2:-0.766) in D6, but up-regulated 2.8-fold in D6.QHS2400x5 (log2: 1.51).
PF14_0038 was down-regulated 2.8-fold in D6 (log2:-1.47) and up-regulated 2.6-fold in
D6.QHS2400x5 (log2: -1.38). PF10_0252 was up-regulated 3.1-fold in D6 (log2:1.63),
but down-regulated 3.3-fold in D6.QHS2400x5 (log2: -1.73). The differential induction
of two zinc finger proteins PF11_0357 and PFC0510w was also identified. PF11_0357
was down-regulated 3.3-fold in D6 (log2: -1.71) and up-regulated 3.7-fold in
D6.QHS2400x5 (log2:1.87). PFC0510w was up-regulated 1.6-fold in D6 (log2: 0.69) and
down-regulated 2.2-fold in D6.QHS2400x5 (log2:-1.14).
Constitutive transcription differences were identified between artemisinin
resistant and sensitive strains. The genetic determinant of dormancy or resistance might
induce constitutive up-regulation or down-regulation of some transcripts in resistant
parasites. Therefore, we queried the data from time zero synchronized parasites, looking
for differences in expression in the absence of drug. To compare the transcriptomes of
D6 and D6.QHS2400x5 at baseline, the residual between the time zero array signals of
the synchronized resistant parasites and a linear regression of its relationship with
synchronized resistant parasites was calculated. By this measure of differential baseline
transcription after removing variable antigen oligos, a list of almost 200 differentially
expressed oligos was generated (Table 3.9, represents the top 1.2% of the data). Notable
in the genes that are higher expressed in the resistant strain are a few from a relatively
tight physical location on chromosome 10. PF10_0281 was down-regulated 2.6-fold in
D6 (log2: -1.39) and up-regulated 2.8-fold in D6.QHS2400x5 (log2:1.47). PF10_0282
was down-regulated 2.3-fold in D6 (log2: -1.18) and up-regulated 2.8-fold in
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D6.QHS2400x5 (log2:1.51). PF10_0291 was down-regulated 2.3-fold in D6 (log2: -1.21)
and up-regulated 2.7-fold in D6.QHS2400x5 (log2:1.45). PF10_0296 was expressed at
baseline for D6 (log2: -0.051), but up-regulated 4.5-fold in D6.QHS2400x5 (log2:2.17).
The putative role of these genes in artemisinin resistance is described below. PfMDR1
(encoded by PFE1150w), known to be involved in resistance to some drugs and a
possible compensatory protein for artemisinin resistance, had lower expression in
D6.QHS2400x5 (7.2-fold, log2: -2.85), compared to D6 (1.4-fold, log2: -0.483).
Discussion
Studies in this specific aim have thoroughly examined artemisinin resistant
parasites and identified putative molecular markers of resistance, while characterizing
artemisinin-induced ring-stage dormancy. We utilized next-generation sequencing
technology and found high-probability polymorphisms between D6 and D6.QHS2400x2
that also existed in parasites treated additional times with 2400 ng/ml QHS. Sequencing
also identified amplifications in chromosome 10 for resistant D6 and W2 QHS-selected
parasites. We believe the SNPs and amplifications we identified represent great promise
for public health efforts, possibly representing markers that can be used to analyze field
isolates in areas where artemisinin resistance is reported to be emerging. An assay
measuring recrudescence of D6 vs. D6.QHS2400x5 after DHA treatment found the
resistant parasite produced more dormant parasites and recrudesced earlier than the
parental strain. Importantly, D6.QHS2400x5 represents the highest selected artemisininresistant parasite we have, and it tolerates drug levels beyond those typically found in
patients taking artemisinin therapy for malaria. We also used transcriptional analysis to
dissect molecular mechanisms of artemisinin-induced dormancy and identify genes
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linked to artemisinin resistance in highly QHS-resistant D6 parasites. As we expected,
both D6 and D6.QHS2400x5 exposed to DHA entered a dormant state in ring stage.
Interestingly, the dormant parasites continually expressed a ring like transcriptome for
68-92 hours after drug treatment before recovering, growing normally, and reverting to a
normal transcriptome as parasites progressed through development. In addition,
transcriptional analysis revealed 113 genes that were up- or down-regulated during
dormancy. Furthermore, genes were identified that were differentially expressed in
artemisinin resistant versus susceptible parasites. These data provided new insight into
artemisinin-induced developmental arrest in the IDC and revealed novel candidate genes
associated with dormancy and resistance to the most important antimalarial drug.
Proteomics. The proteome of Plasmodium spp. changes as parasites progress
through different stages of the life cycle. Researchers have studied the proteome of
various stages of P. falciparum, enabling a systematic cataloging of protein expression.
Prior studies provided functional profiles of thousands of proteins encompassing protein
expressed in gametocytes, asexual stages, and sporozoites 426,427. Significant proteomic
changes occur in the erythrocytic stage of the life cycle, where parasites express and
display numerous, variable proteins on the surface of the red blood cell. Although studies
have thoroughly characterized functionality of proteins in relation to stage, there is a
significant lack of studies regarding proteomic changes after treatment of parasites with
antimalarial drugs. Therefore, we attempted to use proteomic analysis to characterize
molecular mechanisms of artemisinin resistance by focusing on comparisons of highly
synchronous (ring/early trophozoite) parental/resistant parasites (D6 vs. D6.QHS2400x3
and W2 vs. W2.QHS200). An important fact to consider when analyzing the data is that
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D6.QHS2400x3 was culture for months after the last pulse of 2400 ng/ml. Also,
W2.QHS200 was thawed from cryopreservation and grown for some time in culture
before proteomic analysis. The time since the last drug pulse in W2.QHS200 is unknown.
Since these parasites were grown without drug pressure or off drug pressure for a period
of time, it may be difficult to make valid comparisons to other studies.
In the D6 series, the most significantly differentially regulated proteins were
PF11_0098, PFI0265c, PF14_0425, and PFI1270w. PF11_0098 encodes an endoplasmic
reticulum-resident calcium binding protein (PfERC) 428. It was down-regulated (1.4 fold)
in D6.QH2400x2. In a study comparing proteomes of P. falciparum strain FCR3 and
progeny (ring stage) that were made resistant to a synthetic endoperoxide (N-89), it was
found that PfERC was up-regulated 1.5-fold 429. Makanga et al. (2005) 408 reported on
protein expression of P. falciparum strain K1 (ring stage) after treatment with AE or
LUM, and found PfERC was up-regulated in both drug treatments. Also, Nirmalan et al.
(2004) 430 characterized proteins expressed in strain Dd2 (rings) without drug pressure,
and found PfERC was expressed (no data on levels). The gene encoding this protein is
minimally expressed in merozoites, but maximally expressed in gametocytes. It is also
up-regulated in later blood stages, but down-regulated in rings (PlasmoDB). Perhaps in
the absence of drug pressure, this gene is under-expressed in ring stages, and
endoperoxide drugs including artemisinins cause the over-expression of the protein.
D6.QHS2400x2 was grown for some time without drug pressure, so expression of PfERC
may have returned to basal levels in ring-stages we assessed. As stated previously, it is
hypothesized that artemisinins target a sarco-endoplasmic reticulum ATPase and these
drugs are reputed to alter calcium homeostasis 323. Interestingly, the studies that detailed
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protein expression after artemisinin drug treatment above did not find differential
regulation of pfatp6 itself. It may be that these drugs cause the expression of
compensatory calcium-regulatory mechanisms when pfatp6 is inhibited. Since the
parasites we assessed were grown without drug pressure or off drug pressure for a period
of time, this may be a reason we did not find up-regulation of calcium-related proteins.
Fructose bisphosphate aldolase (FBA, encoded) was also down-regulated (1.5fold) in D6.QHS2400x2. FBA is an enzyme of the glycolytic pathway. It is minimally
expressed in gametocytes and maximally expressed in merozoites. However, other
studies found steady-state expression of FBA throughout the life cycle (PlasmoDB). The
study by Aly et al. (2007) 429 found FBA was up-regulated in resistant parasites, whereas
Makanga et al. (2005) 408 reported that FBA (and a host of other glycolytic enzymes)
were both down-regulated after AE treatment, but up-regulated after LUM treatment.
Natalang et al. (2008) 412 described the transcriptional changes that occur in trophozoite
parasites in response to AS. This study described dying stages 3 and 10 hours after drug
treatment. This study found PF14_0425 was down-regulated in AS-treated P. falciparum.
It is not known how antimalarial treatment would affect enzymes of glycolysis, but it is
theorized that enzymes of this pathway could be good antimalarial targets since malaria
parasites rely on this pathway for energy production while inside the RBC 431. Also, it is
not known why this protein would be under-expressed in resistant D6.QHS2400x2, but
not differentially expressed in W2.QHS200.
RhopH3 rhoptry protein (encoded by PFI0265c) was up-regulated (~1.6 fold) in
D6.QHS2400x2. Also, MSP-1 precursor (PFI1475w) and MSP-7 precursor (PF13_0197)
were up-regulated (~1.9 fold and 1.5 fold, respectively) in W2.QHS200x2 compared to
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W2. Other than being found on merozoites, these proteins are also associated with upregulation in trophozoite and schizont stages, as merozoites are being packaged for the
next invasion cycle 426,427. The study by Aly (2007) 429 found MSP-7 was up-regulated in
endoperoxide-resistant parasites, but Makanga et al. (2006) 408 did not report any
significant differences in regulation of MSPs in their study with AE or LUM-treated
parasites. Jiang et al. (2008) 432 found PFI0265 was up-regulated at the transcriptional
level in both CQ-resistant (>4-fold) and CQ-sensitive (>11-fold) P. falciparum parasites
(trophozoites) after exposure to CQ. Gunsakera et al. (2003) also found CQ-treated
parasites (trophozoites) over-expressed genes encoding RBC invasion proteins (including
MSP-1). It is unclear why a merozoite-associate protein would be up-regulated in
artemisinin-resistant parasites and after CQ-treatment. In the CQ studies, it may be that
trophozoites already express a certain amount of merozoite proteins, and drug effects
may cause even more expression or maybe not contribute that much (it would depend on
basal expression of these proteins). Perhaps merozoite proteins such as these have dual
roles. The proteins may be expressed maximally during invasion, then non-expressed in
the erythrocytic cycle until artemisinin drug treatment caused up-regulation. Another
reason we may have found MSPs in W2 parasites is that perhaps the cultures contained a
minority population of mature schizonts. However, these proteins were not found in the
D6 parasites, which were synchronized in the same fashion.
Actin I (encoded by PFL2215w) was up-regulated (~1.4 fold) in W2.QHS200.
Actin I is a motor protein that is associated with merozoite invasion and up-regulated in
late trophozoites and schizonts (PlasmoDB, 427), but Actin II is found in sexual stages and
ring stages (PlasmoDB, 426). Actin I was down-regulated in endoperoxide resistant
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parasites in the study by Aly et al. (2007) 429. Makanga et al. (2005) 408 did found Actins
I and II in their study, but did not state if they were significantly differentially regulated
in AE or LUM treated parasites. We cannot definitely state why Actin I was up-regulated
in W2.QHS200. Actin appears to be present in many proteome analyses of parasites, but
its role in artemisinin resistance is not clear. It may be that this protein is constitutively
expressed in W2 parasites and artemisinin exposure caused the parasite to up-regulate the
protein, where the effect was maintained even after long periods of culture. Nirmalan et
al. (2004) 430 identified Actin I and Actin II in their analysis of Dd2 ring-stage proteins.
Since Dd2 is a descendant of W2, these results may fit with what we found. Also, since
Actin I is expressed in late stage asexual parasites, perhaps some contaminating late stage
parasites remained after synchronization in our cultures, leading to the detection of this
protein.
The heat shock protein 70 (HSP70) homolog (encoded by PFI0875w) was upregulated in W2.QHS200 (1.6-fold). PFI0875w is reported to be minimally expressed in
gametocytes, but maximally expressed in schizonts (PlasmoDB). HSPs are stress-related
proteins that have been reported to be expressed during drug pressure. However, the
resistant W2 parasite was not grown in presence of drug. Perhaps this protein is
continually expressed after the original artemisinin pressure to induce resistance in W2.
HSP70 was up-regulated in endoperoxide resistant parasites in the study by Aly et al.
(2007) 429. Witkowski et al. (2010) 360 determined that PF08_0054, which encodes
HSP70 was down-regulated in QHS-selected P. falciparum. Natalang et al. (2008) 412
found a variety of genes encoding HSPs or related proteins that were differentially
expressed after AS treatment of P. falciparum strain FCR3 (trophozoites). Makanga et al.
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(2005) 408 found HSPs were up-regulated in both AE and LUM treated parasites.
PFI0875 was up-regulated in the study of CQ-resistant parasites by Gunasekera et al.
(2003) 433. The fact that HSPs are up-regulated in drug-treated parasites and in
W2.QHS200 reveals that proteins of the general stress response in response to drugs are
active. Interestingly, these were found in W2.QHS200, which had not undergone QHS
pressure for some time after thawing. Nirmalan et al. (2004) 430 identified a variety of
HSPs in their analysis of Dd2 ring-stage proteins, so perhaps these proteins are
constitutively expressed by W2 parasites, and pressuring of QHS lead to up-regulation.
The second-highest differentially regulated protein in our analysis was the conserved
Plasmodium protein of unknown function, PFI1270w. It was up-regulated almost 1.7fold in D6.QHS2400x2. Unfortunately, little is known about this protein in the literature
and it is not possible at this time to hypothesize why this protein would be up-regulated in
artemisinin-resistant parasites.
Interestingly, Prieto et al. (2008) 434 performed a large scale proteomic analysis of
3D7 (trophozoites) exposed to either QHS or CQ, and they did not report differential
regulation of any of the genes we present here. Their study found subunits of vacuolar
ATP synthase (encoded by PF13_0130) were down-regulated after QHS treatment. This
may go along with the reported effect of artemisinin on pfatp6. Several processes also
had slight up-regulation after QHS-treatment including proteins involved in nucleotide
and nucleic acid metabolism, transport and secretion as well as the expected response to
stimuli. There were many hypothetical proteins or conserved, undescribed Plasmodium
proteins that were significantly up-regulated or down-regulated as well. It may be
difficult to compare our results to those of Prieto et al. (2008) 434 because of different
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stages of parasites used and the fact that we did not expose parasites to drug prior to
proteomic analysis. One of the most important observations of Prieto et al. (2008) 434 is
that pfmdr1 was found to be up-regulated under CQ and QHS pressure, indicating that
pfmdr1 indeed mediates resistance to a number of unrelated classes of agents. Studies
from our lab have shown the role of Pfmdr1 in artemisinin resistance in W2 lines 276 and
it is well known that it factors into MQ resistance and modifies susceptibility to other
drugs (see Chapter One).
Whole genome sequencing.
Single nucleotide polymorphisms. The first attempt at whole genome sequencing
focused on D6 and D6.QHS2400x2. Results from initial analysis of sequencing data
found a relatively small list of SNPs that could be potentially involved in artemisinin
resistance. After applying further SNP filters and criteria, there were five highprobability SNPs identified in D6.QHS2400x2 vs. D6: MAL13P1.298, PF13_0238,
PFC0320w, PFE1155c, and PFF0275c. We conducted follow-up sequencing of various
strains to verify these SNPs in D6-resistant lines (3D7, W2 as controls). SNPs in
PF13_0238 and PFF0275c that separated D6 vs. D6.QHS2400x2 were found in all D6QHS resistant lines we assayed. Unfortunately, we did not assay earlier-selected D6 lines,
any QHS-resistant W2 progeny, or any AL-resistant TM91c235 progeny. It would be
interesting to see at what QHS-selection level these SNPs became present in the genome
of D6 lines, and also if these SNPs exist at all in W2 and TM91c235 artemisinin-resistant
parasites. If these SNPs are present in W2 and TM91c235 resistant parasites, it would
also be interesting to find at what drug concentration level they appeared in the genome.
Future studies will focus on these analyses.
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MAL13P1.298 (CDS=6381 bp) encodes a conserved Plasmodium membrane
protein of unknown function (PlasmoDB). This gene is expressed in merozoites and
shows steady state levels in other erythrocytic stages as well. The SNP in MAL13P1.298
is located 1720 bases downstream from the start codon, changing the codon GGT-GAT
(Gly-Asp). The protein contains an alpha/beta hydrolase domain toward the C-terminus,
but the SNP we identified is not in the region of the gene encoding this portion of the
protein. PlasmoDB lists a variety of SNPs in the gene, found in isolates around the world
(including D6), so it appears to exhibit a high degree of diversity. The SNP found in our
sequencing analysis is not listed in PlasmoDB, but it appears to exist between regions
with polymorphisms. The gene is not described in the literature, and we currently do not
have a reason why this SNP may be involved in artemisinin resistance.
PF13_0238 (CDS=2181 bp) encodes a putative kelch protein, which is a protein
formed of multiple kelch sequence motifs, each corresponding to a 50-amino acid motif
that forms a beta-sheet blade. Several of these repeats can associate to form a superbarrel structural fold (beta propeller) 435. PF13_0238 is minimally expressed in
gametocytes and maximally expressed in merozoite. The protein also contains a motif
that is related to voltage-gated potassium channel complexes, which are responsible for
potassium ion transport. The SNP we identified in D6.QHS2400x2 vs. D6 is located 621
bp from the start codon, changing codon GAA to AAA (Glu-Lys). The SNP we found is
also upstream of regions with high polymorphic character. PlasmoDB does not have a
record of the SNP we detected, but this SNP is near (57 bases) another SNP that is found
in D6/HB3 vs. 3D7/Dd2/D10 (AAA-ACA [Lys-Thr]). However, these SNPs are located
outside of any functional domains of the protein, including potassium transport. It is
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tempting to implicate SNPs in this gene with artemisinin resistance, possibly showing a
link between a conformational change in the protein and potassium transport. It is
already theorized that artemisinin may affect calcium homeostasis, and SNPs in pfatp6
may affect susceptibility to these drugs.
PFC0320w is located on chromosome 3 (genomic sequence=2241 bp) and it
encodes a conserved Plasmodium protein of unknown function. The gene is minimally
expressed in early ring stages and maximally expressed in gametocytes. The SNP we
identified occurred 636 bp from the 5‟ end of the gene, changing codon AAT to ATT
(Asn-Ile). PlasmoDB lists only a few SNPs for this gene. Like MAL13P1.298, we
cannot state a reason why this nucleotide change may exist in D6.QHS2400x2.
PFE1155c (genomic sequence=1818 bp) is located on chromosome 5 and encodes
a putative mitochondrial processing peptidase alpha subunit. It a component of
mitochondrial electron transport (Complex III / Ubiquinol-cytochrome c oxidoreductase /
cytochrome bc1) 436. The gene is minimally expressed in gametocytes and maximally
expressed in early trophozoites. The protein has domains that exhibit activities ascribed
to metalloendopeptidases, proteolysis, metal ion binding, zinc ion binding, catalysis, and
metallohydrolases. The SNP we detected is located 1200 bp from the 5‟ end of the gene,
in the codon AGT-GGT (Ser-Gly). There are only four SNPs described in the gene in
PlasmoDB, and they exist more upstream in the gene than the one we found. Proteins of
key mitochondrial processes (including PFE1155c) have been proposed as antimalarial
drug targets 436. Atovaquone is an antimalarial drug that is known to inhibit
mitochondrial electron transport at the cytochrome bc1 complex and collapses
mitochondrial membrane potential 165,436. Mutations in this cytochrome complex are
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responsible for ATOV resistance in P. falciparum 309,313-315. Although ATOV and
artemisinins are structurally unrelated, artemisinins have also been theorized to target
mitochondria 182,183. The molecular target in mitochondria has not been described for
artemisinin, but perhaps mutations in mitochondrial genes could be responsible. Further
research into this possibility is necessary. Interestingly, Jiang et al. (2008) 437 described
copy number variations (CNVs) in different P. falciparum strains and found
amplification of a region within chromosome 5 that contained a total of 20 genes. These
genes included PFE1065w-PFE1155c that were amplified ~2–3 copies in FCR3 and 14
genes (PFE1095w-PFE1160w [including PFE1155c]) amplified ~4–5 copies in Dd2.
Perhaps this gene may play a role in antimalarial drug resistance in both CNV and SNPs
much like pfmdr1.
PFF0275c (genomic sequence=6704 bp) encodes a putative nucleoside
diphosphate kinase that is minimally expressed in gametocytes and maximally expressed
in merozoites. The protein appears to be steadily expressed throughout the IDC. The
protein contains domains with ATP binding activity and it is active in UTP, CTP, and
GTP biosynthetic processes. The SNP we detected is located 4445 bp from the 5‟ end of
the gene and it is a codon GAT-CAT (Asp-His). The SNP is not reported in PlasmoDB.
The SNP exists in between regions of high polymorphic character, and it is located 16 bp
from a SNP (GAA-GTA, Glu-Val) found in D6/3D7/D10/Dd2 vs. Senegal3404. There
are a number of other SNPs in this gene (including D6) in PlasmoDB. There are not any
reports in the literature about this gene, but nucleic acid metabolism is theorized to be an
important antimalarial drug target 438,439 Makanga et al. (2005) 408 found nucleic acid
metabolism genes in proteomic analysis under AE and LUM exposure, with up-
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regulation of one protein (PGC0250c). Witkowski et al. (2010) 360 determined that
PF10_0121, which encodes hypoxanthine phosphoribosyltransferase) was downregulated in QHS-selected P. falciparum. Natalang et al. (2008) 412 also found this gene
was down-regulated in AS-treated P. falciparum. PF10_0121 encodes an enzyme
involved in purine biosynthesis, which is essential for DNA synthesis. We found that
PFE1050w, involved in nucleic acid metabolism, was up-regulated in microarrays but we
did not find SNPs in artemisinin-resistant W2. Therefore, PFF0275c may be one of gene
of many nucleic acid-related genes that could be implicated in drug resistance.
A potential problem we noted with the initial sequencing that used uncloned
parasites is heterogeneity of bases for a given number of reads. The heterogeneity could
be attributed to two sources: error rates in the sequencing and true heterogeneity at the
base. While both sources exist in our data, some bases have high coverage and clear
heterogeneity (for example, 100 reads covering a base with only 60% showing the major
base). A clear argument could be made that the sample is heterogeneous at these
positions. Therefore, we aimed to repeat the sequencing with a sample from a clonal
population of each parasite in order to eliminate these types of SNPs. This second set of
sequencing used D6 (clone C11), D6.QHS2400x5, W2 (clone D7), W2.QHS200x2, and
another parental W2 strain from the MR4 depository. SNP analysis is pending for this
second round of sequencing.
Chromosome 10 amplification. The initial sequencing we performed with D6
and D6.QHS2400x2 identified a clear region of amplification on chromosome 10 in
D6.QHS2400x2. The region of amplification was determined to be from PF10_0279
through PF10_0299. Each gene appeared to be amplified 2-fold compared to the parent
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D6. These data were substantiated by QPCR data that we accumulated on various D6
resistant strains. It was determined that each gene in the amplification had approximately
two copies, and the amplification existed in D6 parasites that tolerated 80 ng/ml up to
2400 ng/ml (treated five times). It is interesting that the amplification occurred relatively
early in the selection of QHS-resistant D6 parasites, indicating that this may represent a
necessary resistance mechanism in D6 lines. Further research will focus on D6 lines that
were selected prior to the 80 ng/ml QHS level to determine when the amplification
originally occurred.
In the TM91c235 series, copy number of chromosome 10 genes was
approximately 1 for all strains we analyzed. There were instances where the CN
exceeded 1.2 for some genes (PF10_0278, PF10_0279, PF10_0294). But, in these cases,
the parent and resistant progeny both had elevated CN, so we do not think these findings
are significant for artemisinin resistance.
We also discovered a region of amplification from PF10_0288-PF10_0297 in
both W2 (clone D7) and QHS-resistant W2 (W2.QHS200x2) during a second round of
whole genome sequencing. Genes within this part of chromosome 10 have also been
identified as amplified in other artemisinin resistant W2 progeny by our colleagues in
Australia (Kyle, Personal Communication). When we assessed copy number by QPCR,
amplification of this region was verified in PF10_0292 to PF10_0296 in QHS-resistant
W2 lines (≥ 3 copies). Strangely, amplification also existed in W2 parent lines (W2, W2
[clone D7]), but found only in PF10_0292 and PF10_0294. Also, the magnitude of
amplification differed in W2 parental lines in these genes (≥3 copies in W2, but
approximately 2 copies of W2 [clone D7]). These results are different than what was
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determined from sequencing which found 3 copies of each gene in W2 (clone D7) from
PF10_0288-PF10_0297. Furthermore, sequencing of a reference MR4 W2 strain did not
find amplification in chromosome 10 genes. A key remaining issue to resolve in the W2
series is why amplification of genes in chromosome 10 was also found in W2 parental
lines. It may be difficult to explain why parental W2 lines contained amplified genes,
and how to relate this to resistant W2 lines. The W2 parent line we routinely used for
culture in our lab (and from what W2 [clone D7] was cloned from) was once thought to
have originated from the first W2 clones isolated 381 that are now in the MR4 depository
(Kyle, personal communication). W2.QHS200 is believed to have descended from this
W2 parent. In regard to the amplification of chromosome 10 genes in parent W2 strains,
we theorize that parent W2 was probably mixed with an AL or QHS-resistant W2 line,
making it appear that the parental line has amplification in genes. The W2 parent that
was submitted to MR4 has no amplification and the W2 parent our colleagues in
Australia work with (again from Dr. Kyle‟s collection) has no amplification (Kyle,
Personal Communication). Another interesting fact is that the W2 parent parasites that
have amplification in chromosome 10 genes also have approximately one copy of pfmdr1.
If the parent W2 was somehow mixed with an artemisinin-resistant W2 line, we should
have found amplification of pfmdr1 (our QPCR results found ≥2 copies in W2.QHS200
lines). However, this logic is complicated by the fact that W2 lines resistant to artelinicacid lose copies of pfmdr1 when grown without drug pressure 337. Also, we found that
AL-resistant TM91c235 lines had increased pfmdr1 copy number, yet no amplification of
chromosome 10 genes. Therefore, the link between the genes is not very strong. Perhaps
W2 parasites are capable of de-amplifying genes other than pfmdr1, and the parasite that
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resulted from a mixture of parent and resistant line lost a few genes of the amplification.
Alternatively, it may be that earlier selected W2 lines do not contain all the genes of the
amplification (and mixing with parent W2 made it seem that only a few were amplified).
It is unclear why the parent W2 parasites only had amplification of two genes on
chromosome 10 (by QPCR), whereas the resistant W2 parasites had a larger region of
amplification. If the parent W2 was mixed with resistant W2, then we should have found
more amplified genes. We will resolve this issue by targeting the earliest artemisininselected W2 lines we have. If it is determined that the original W2 line that started the
artemisinin-selection process has only a single copy of the genes in the amplification,
then this will conclusively show that amplification only exists in artemisinin-resistant W2.
Also, we do not currently have a reason for the discrepancy between CN estimated by
sequencing for W2 (clone D7 ~ 3 copies) and that determined by QPCR (~2 copies). An
important point to take away from amplifications in chromosome 10 (and pfmdr1) is that
once the amplification appeared in parasites, it remained a stable CNV through multiple
cycles in culture. Therefore, we believe these amplifications are probable markers of
resistant parasites.
In addition to laboratory strains that were selected for resistance to artemisinin
drugs assayed patient isolates from Cambodia and Thailand. These regions represent
areas where artemisinin is thought to currently be occurring. We had some evidence that
some strains had reduced artemisinin susceptibility, so these strains were included with
others for chromosome 10 analysis. Our results found that all isolates had approximately
one copy of the genes we assayed. It is interesting that strains D6 and W2 had
amplifications, whereas other patient isolates (TM91c235 and Thai-Cambodia isolates)
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did not have amplifications. This may indicate that QHS-selected progeny of only certain
backgrounds will amplify strains, or that laboratory lines are unique in some manner.
Alternatively, it is possible that field isolates may only have one type of genetic
amplification that affords artemisinin resistance, as with pfmdr1 amplification in
TM91c235. We did not examine pfmdr1 copy number in the isolates from Cambodia and
Thailand, but it will be interesting to assay these in the future.
The detection of amplification in chromosome 10 may be a unique resistance
mechanism that possibly exists in two parasite strains from different parts of the world.
In the field of malaria research, copy number amplifications have been linked to MQ
resistance and artemisinin resistance (Chapter One) in P. falciparum. However,
amplification in chromosome 10 has only been described in a few studies, and never
described in D6 parasites in relation to drug resistance. Jiang et al. (2008) 437 reported on
a number of CNVs and SNPs from Dd2 (CQ-resistant, Asia) 7G8 (CQ-resistant, Brazil),
FCR3, and HB3 (CQ-sensitive, Honduras) strains of P. falciparum. Within chromosome
10, only a few a genes were amplified (HB3: PF10_0005-PF10_0008, PF10_0323; Dd2:
PF10_342, PF10_0382, PF10_0382; PF10_0404, PF10_0405; 7G8: PF10_0014,
PF10_0190, PF10_0374). They did not detect any of the chromosome 10 gene
amplifications that we observed. Cheeseman et al., 2009 5 investigated CNVs in a variety
of P. falciparum strains from Africa (including D6), South East Asia (including Dd2 and
W2mef), Papua New Guinea (including D10), South America (7G8), Central America
(HB3), and 3D7. Genes that were deleted or amplified included PF10_0007, PF10_0008,
PF10_0074, PF10_0353, PF10_0383, PF10_0388, PF10_0390, PF10_0394, PF10_0398,
and PF10_0399. Most significant to our study, PF10_0074 was amplified in D6 and W2-
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mef. It is not known why genes were not found to be amplified in D6 and W2 that we
identified in these strains. The fact that D6 did not contain many amplifications seems to
justify our results that amplifications were observed only in resistant parasites. For W2mef, the same may be true for our findings in W2 resistant strains. However, it is
possible that MQ resistance may not induce the same type of chromosome 10
amplifications as artemisinin does. Some other studies 409,410,440 found amplifications in
chromosome 10 in P. falciparum strains known to exhibit drug resistance (ex. CQ, QN,
PYR). Of these studies, the one by Mackinnon et al. (2009) 440 is most significant in
relation to our work. This study investigated genomic and transcriptional changes in P.
falciparum patient isolates from Kenya vs. long-term adapted laboratory isolates. CNVs
were determined by comparing to 3D7 and other field strains (P<0.001, >1.5-fold
difference from 3D7 in at least 2 field strains). This study showed that much of the
biological variation in transcription among field isolates and between field/lab strains is
due to genes near CNVs. Gene copy number in the CNVs associated strongly with
expression level of these genes. Many of the CNV genes encode proteins that are:
exported to the RBC surface, transcriptional regulation factors, involved in nutrient
biosynthesis, transmission, involved in colonization of pregnant women, and proteins
involved in metabolic pathways in drug resistance. One of the most up-regulated genes
was PF10_0350, which is suppressed in pregnancy-associated malaria. This study also
identified other CNVs in chromosome 10, from PF10_0016 to PF10_0392. Within the
region of amplification we investigated, this study found PF10_0281 was down-regulated
in at least 5 strains; PF10_0282 and PF10_0285 were down-regulated in at least 7 strains;
PF10_0283, PF10_0286, PF10_0288, PF10_0291, PF10_0292, PF10_0294, PF10_0295,
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and PF10_0296. were down-regulated in at least 8 strains; PF10_0284 and PF10_0287
were down-regulated in at least 6 strains; PF10_0293 was down-regulated in at least 3
strains; and PF10_0290 was not differentially regulated. It is unclear why these genes
would be down-regulated in various parasite strains, when we found amplification of
genes and constitutive over-expression of genes within the amplification in resistant D6
(from Africa) (microarrays).
Proteomic and transcriptome studies have also identified genes of chromosome 10.
Nirmalan et al. (2004) 430 found proteins within chromosome 10 (PF10_0065 [conserved
hypothetical protein], PF10_0155 [Enolase AE down, LUM up], and PF10_0289) were
abundantly present in Dd2. PF10_0289 is part of the amplification we identified in QHSresistant D6 and W2 lines. Aly et al. (2007) 429 also identified PF10_0155 as a downregulated protein in their study. Makanga et al. (2005) 408 described proteins in P.
falciparum strain K1 that were differentially regulated under AE or LUM treatment.
PF10_0153 (HSP60 up AE, up LUM), PF10_0155 (not diff regulated), PF10_0345
(MSP-3 not diff regulated), PF10_0344 (glutamate rich protein, down AE), PF10_0203
(ADP ribosylation factor up AE, up LUM), and PF10_0141 (MO15 related protein kinase,
not diff regulated) were identified on chromosome 10. Witkowski et al. (2010) 360
conducted transcriptome analysis of a Tanzanian P. falciparum isolate that was selected
for QHS resistance in vitro. They identified PF10_0121 (hypoxanthine phosphoribosyl
transferase) as a down-regulated gene (compared to parent). Prieto et al. (2008) 434 found
PF10_0043 (ribosomal protein L13), PF10_0111 (20S proteasome beta subunit),
PF10_0031 (hypothetical protein), and PF10_0170 (hypothetical protein) were upregulated proteins in artemisinin-treated 3D7. Natalang et al. (2008) 412 reported that
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genes within chromosome 10 are differentially regulated after exposure of P. falciparum
to AS. Genes that were highly up-regulated included PF10_0026 (Tryptophan-rich
antigen 3, putative), PF10_0378 (DNAJ protein), PF10_0186 and PF10_0046
(hypothetical proteins that probably encode transcription factor), PF10_0374 (Pf11-1
protein), PF10_0345 (MSP-3), and PF10_0046, PF10_0319 (hypothetical proteins).
Those that were down-regulated included PF10_0121 (above), PF10_0016 (acyl CoA
binding protein, putative), PF10_0097, PF10_0211 (hypothetical proteins), PF10_0019
(early transcribed membrane protein 10.1 [ETRAMP 10.1]), and PF10_0285. The downregulation of PF10_0285 is interesting, since we did not detect differential regulation of
this gene in our microarrays. Also, we found the gene was amplified in QHS-resistant
D6 and W2, indicating the gene may be important for artemisinin resistance.
Taking all this into consideration, it appears that genes within chromosome 10 are
fairly variable in terms of copy number. The studies above identified CNV in
chromosome 10 from different strains around the world, but these reports did not focus
on drug-selected lines. However, some of these isolates may exist in areas where
artemisinin pressure is constant, making it possible to compare with our studies.
Interestingly, the study by Mackinnon et al. (2009) 440 found under-expressed genes in
multiple parasites in Africa that are in the region we found in QHS-resistant D6. Our
arrays found constitutive up-regulation of PF10_0281, PF10_0282, PF10_0291, and
PF10_0296 in D6.QHS2400x5 vs. D6 throughout the life cycle. Therefore, these genes
seem to be important for parasites even when drug pressure is not involved. Our data are
in opposition to Mackinnon et al. (2009) 440, indicating that these genes are differentially
regulated in different strains from Africa. Outside of Africa, amplification of these genes
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as a marker of artemisinin resistance may not be clear either. Although we found
amplification in W2 lines, we did not find it in AL-resistant TM91c235 lines. However,
pfmdr1 is clearly linked to artemisinin resistance in these parasites. Interestingly, a
section that was down-regulated in at least 8 strains in Mackinnon et al. (2009)
encompassed the region of amplification that overlaps between D6 and W2 QHSresistant strains. Perhaps these genes are the most variable within the amplification and
could be the most likely markers of artemisinin resistance in field isolates. Therefore, we
provide more evidence that artemisinin resistance may be multifactorial.
Recrudescence assays with D6 vs. D6.QHS2400x5. The goal of this experiment
was to verify that a 6-hour exposure of 200 ng/ml DHA is high enough to induce
dormancy in both D6 and D6.QHS2400x5, but low enough to allow recovery of both
strains in less than 10 days. Much like we found in experiments reported in Chapter Two,
a greater number of morphologically normal parasites were observed in the resistant
parasite compared to the parent. Interestingly, we found that a greater number of
dormant parasites were found in the resistant strain, and also that normal parasites were
observed at some level throughout the entire assay for each strain (except 72 hours for
D6). This seems to contradict what we reported in Chapter Two for D6 vs.
D6.QHS340x2 exposed to 200 ng/ml QHS. In that experiment, both parent and resistant
parasites entered dormancy and did not appear to recrudesce until 120 hours (more
normal parasites in resistant strain). Also, the resistant parasites were adapted to different
levels of drug in the two assays and the more resistant parasite seemed to tolerate lower
levels of drug better than D6.QHS340x2. However, this experiment involved a different
drug than DHA and the drug was applied for 48 hours. Therefore, this comparison may
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be inappropriate. We exposed W2 and W2.QHS200x2 to 200 ng/ml DHA for 6 hours
and found that both strains entered dormancy. The resistant parasite recrudesced 24
hours before the parent strain, and there were a greater number of dormant parasites in
the resistant strain during the first few time points of the assay. Again, it may be
inappropriate to compare this assay to the D6.QHS2400x5 assay due to strain differences
and resistance levels. A more appropriate comparison of this assay is the results from
microarrays discussed below. The same strains and drug dosage were used to induce
dormancy and monitor recrudescence in the microarrays as the initial recrudescence
assay. However, the microarray experiment found both parent and resistant strains
recrudesced later in time (57 hours resistant parasite, 69 hours parent) compared to the
initial experiment where morphologically normal parasites remained even at early time
points. The reason for this is probably due to experimental variability and the fact that
starting parasitemias for the different groups were different. Importantly, resistant
parasites recrudesced before the parent (or a greater percentage of normal/total parasites
were present compared to the parent) in these assays.
Transcriptional analyses of D6 and D6.QHS2400x5. Here we have described
in molecular detail a long-lasting developmental arrest in P. falciparum induced by DHA.
The induction of dormancy at the ring stage was confirmed microscopically and by
transcriptional analysis. Both dormancy and transcriptional arrest were qualitatively
similar for QHS sensitive and resistant clones, yet important differences were observed.
As stated above, results of the recovery experiments showed that the parent and resistant
D6 parasites both tolerated the drug as parasites recrudesced after a period of dormancy.
However, D6.QHS2400x5 recrudesced 12 hours prior to the parent strain (57 hours vs. 69
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hours). Perhaps the most intriguing result was the transcriptional arrest at ring stage in
DHA treated parasites (W2 and D6 strains). The transcriptome of DHA-treated parasites
was similar to early-mid rings and coincided with morphological observations of arrest at
early ring stage. This result is remarkably different from the effect of other antimalarial
drugs that have no demonstrated effect on progression through the IDC.
By using expression microarrays we compared the transcriptomes of DHA-treated
cultures of an in vitro selected artemisinin resistant clone D6.QHS2400x5 and its
artemisinin sensitive parent clone, D6. By correlating each transcriptome snapshot to
historical datasets of the transcriptome of normally growing parasites, we found that
DMSO-treated parasites continue progressing through the IDC, whereas both artemisininresistant and -sensitive parasites exposed to DHA arrest in a dormant, ring-like state for
3-4 days. The timing of this transcriptional pause correlates with the observance of
dormant ring stage parasites, which we (Kyle et al., unpublished results; 362) and others
360

have previously observed after artemisinin treatment. Witkowski et al. 2010 360

suggested the ability to enter a quiescent state was a hallmark of resistance, yet they
suggested only artemisinin resistant parasites enter dormancy. Our studies have
demonstrated that dormancy occurs in both QHS sensitive and resistant parasites, which
our laboratory already had determined prior to this study (362; Kyle and Tucker,
unpublished data). Interestingly, previous work on expression profiling the response to
AS in sensitive trophozoite stage parasites 412 also indirectly noted growth rate effects
that complicated analysis of later time points under their experimental design.
Although the transcriptional arrest we observed at ring stages is most likely due to
effects of DHA, the phenomenon of transcriptional arrest could be due to other causes. It
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is unlikely that leftover mRNA from dead parasites could account for a paused ring-like
transcriptome since previous studies have found that cidal antimalarials typically do not
disturb the normal progression through the IDC 441,442. These published data suggest
parasites killed by other means do not exhibit a developmental arrest, either
morphologically or transcriptionally when assayed by expression microarrays.
Additionally, Shock et al. (2007) 443 demonstrated that P. falciparum mRNA decay rates
are relatively rapid, with the average half-life of ring-stage transcripts being 9.5 minutes.
Correlations such as those are illustrated in decay to noise data in the absence of active
transcription. Furthermore, if the transcriptional arrest observed only reflected the
mRNA of dead parasites, then it would be difficult to explain the observed convergence
upon a ring-like state in the originally asynchronous cultures. This is because dead
parasites from several stages would contribute to the signal and therefore it should
continue to have no correlation to any specific hour of the IDC. Thus far the
preponderance of the data suggests that DHA induces a cell cycle arrest at the ring stage
characterized by dormant rings and a ring stage transcriptome.
The possibility that artemisinins induces cell cycle arrest has precedence in
studies with human carcinoma cell lines. Morrisey et al. (2010) 444 concluded that
artemisinin disrupts transcription at the promoter of CDK4 in prostate cancer. In
pancreatic cancer, T cells, and hepatoma cells, artemisinins have been shown to disrupt
cyclin levels and induce G1 arrest 445-447. Additionally, Efferth et al. (2001) 448 reported
that a yeast strain with a defective mitosis spindle checkpoint gene showed increased AS
sensitivity and another strain with a defective gene that encodes a cyclin (involved in the
G1 to S phase transition) showed increased AS resistance over the wild-type strain.
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These results suggested that cell-cycle checkpoints that regulate growth are important in
mediating artemisinin sensitivity, as uncontrolled proliferation (no DNA replication
checkpoint prior to S phase) leads to artemisinin resistance and functional mitosis
regulation is necessary for tolerating artemisinin. Although Plasmodium spp. are known
to encode cell cycle regulatory genes, there has been doubt over the existence of any
inducible checkpoint or arrest.
The observation that the resistant parasites released from dormancy earlier than
sensitive clones stimulates speculation about the nature of the dormant state as it relates
to artemisinin resistance. Interestingly, morphological and correlogram analysis suggest
resistant parasites exit dormancy before the parental parasites. Perhaps the mechanism of
resistance involves an increased ability to recover from dormancy following exposure to
drug. Also, a greater proportion of parasites might survive drug pressure long enough to
enter dormancy. We showed that a greater percentage of parasites enter dormancy and
there were a greater ratio of normal/total parasites in resistant vs. parent strains. Also,
hypoxanthine assays (Chapter Two) showed that resistant parasites tolerate more drug in
a 48 window than parent strain indicating resistant parasites have the ability to enter
dormancy and recover at a higher rate, or a greater number of parasites are unaffected by
drug. This suggests the intriguing possibility that dormancy is a natural phenomenon that
enables parasites to cope with environmental stressors. Regardless of the mechanisms
involved, our data suggest dormancy and resistance are linked, yet may be separate
phenotypic responses to drug.
Differentially expressed genes in parental/resistant strains during dormancy. A
subset of genes (>100) were strongly induced or suppressed during artemisinin-induced
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dormancy (Table 3.7). A skeleton binding protein (encoded by PFE0065w) was highly
up-regulated in both D6 and D6.QHS2400x5, but the magnitude of regulation was much
greater in D6. This protein is required for transport of PfEMP1 to the RBC surface. It
functions at the parasitophorous vacuole membrane to load PfEMP1 into Maurer clefts
during formation of these structures 449. This protein is unlikely to be involved in drugrelated effects, but perhaps it assists in the secretion of other proteins that assist in
remodeling parasite structure during dormancy (more below). A gene encoding P.
falciparum thioredoxin reductase (PFI1170c) was induced in both D6 and
D6.QHS2400x5, but the degree of up-regulation in the parent parasite was much greater.
Thioredoxin reductase (PfTrxR) and thioredoxin (PfTrx) are components of an efficient
antioxidant system for P. falciparum while in RBCs. This system is involved in a variety
of cellular functions including the reduction of deoxyribonucleotides (DNA synthesis),
regulation of transcription by interacting with transcription factors, and reducing
hydrogen peroxide 425,450. It is possible that this enzyme plays a role in the detoxification
of the oxidative stress induced by DHA. PfTrx is involved in one of two functional redox
systems in P. falciparum (the other involving glutathione). Both are part of enzymatic
redox cascades, which transfer electrons from NADPH to acceptor molecules such as
hydrogen peroxide and alkyl hydroperoxides but also proteins like ribonucleotide
reductase and a number of transcription factors 450. Interestingly, PlasmoDB lists PfTrxR
as minimally expressed in ring stages and maximally expressed in gametocytes. The
strong induction of PfTrxR in dormant rings implicates the gene in parasite defense
against artemisinin induced oxidative stress. Currently, we do not know the reason why
PfTrxR was up-regulated much more in the parent strain. Perhaps over multiple rounds

271

of artemisinin drug pressure, the resistant parasite developed other tolerance mechanisms
so that its reliance on PfTrxR decreased over time. This could involve a multitude of
regulatory factors in the resistant parasite that enable it to up-regulate other proteins. The
fact that Plasmodium-infected erythrocytes are under enhanced oxidative stress together
with their susceptibility to exogenous oxidative challenge (artemisinin treatment) is a
reason to believe that the antioxidant systems of the parasite are important for the
survival of the parasite during their erythrocytic life stages. PfTrxR may be a potential
target for the development of new antimalarials. One study found PfTrxR is essential for
survival of the erythrocytic stages of P. falciparum 450. Because functional antioxidant
and redox systems are necessary for parasite survival (normally and maybe in response to
drugs), inhibitors that target this enzyme would be effective antimalarials. Indeed,
compounds that target this enzyme in have been described. Andricopulo et al. 2006 451
identified three nitrophenyl derivatives that inhibit PfTrxR, and they were active against
P. falciparum strain K1 (CQ resistant). Importantly, an inhibitor selective for PfTrxR
might be an ideal partner drug for future ACTs in controlling malaria in regions of multidrug resistant P. falciparum.
Other up-regulated genes that may have important roles during dormancy
included PF14_0017 (lysophosopholipase), PF14_0183 (signal recognition particle,
RNP), PFF0510w (Histone H3), and PF14_0010 (glycophorin binding protein), and
PFE0405c (Longevity Assurance [LAG-1] domain-containing protein). PF14_0017
encodes a lysophospholipase that is a member of a 9 member family of genes encoded
near the telomeres. These enzymes and host encoded lysophospholipases catabolize
phosphoatidylcholine. PlasmoDB lists the gene as minimally expressed in early
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schizonts and maximally expressed in late rings. We noticed the magnitude of upregulation was equal for D6 and D6.QHS2400x5. Perhaps this gene was ramping up to
maximum expression in our studies before DHA treatment and subsequent overexpression. This up-regulation may reflect a need to differentially remodel the parasite
niche in the dormant state or to prepare the parasite for eventual recovery. Also among
the strongly up-regulated genes was signal recognition particle (SRP, encoded by
PF14_0183). SRPs are responsible for targeting new translated proteins to the
endoplasmic reticulum. This protein also has ATP-dependent RNA helicase activity
(PlasmoDB). It may be that this protein is capable of shuttling between the nucleus and
cytoplasm where it interacts with secreted proteins. PF14_0183 exhibits minimum
expression in schizonts and maximum expression in ring stages. Therefore, this protein
may be involved in exporting proteins to the RBC surface as the parasite matures. In
terms of artemisinin exposure, perhaps dormant rings non-specifically required the upregulation of all secretion or they require an increased capacity to secrete a specific
cohort of remodeling proteins in order to divert into dormancy. The observed upregulated lysophospholipase may play a role in this remodeling. Natalang et al. (2008)
412

also noted that AS induced the expression of several secreted proteins, though this

could be related to antigenic switching. PFF0510w encodes a histone H3 protein, which
is normally minimally expressed in early rings and maximally expressed in max early
schizont. This reflects the protein‟s function in packaging and assembly of DNA into
merozoites before the next invasion cycle. We found the magnitude of up-regulation was
equal in parent and resistant D6 strains. Perhaps dormant parasites up-regulate this
protein to protect DNA while in survival mode, then when parasites emerging, there is
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intact DNA to continue gene expression in mature stages. We also identified upregulation of a glycophorin binding protein (PF14_0010), which is known to be
minimally expressed in gametocytes and maximally expressed in merozoites. This
reflects the need for merozoites to express proteins that recognize glycophorin on the
surface of RBCs during invasion. This gene was up-regulated at a higher level in D6
compared to D6.QHS2400x5. Also, genes encoding a rhoptry protein (PFB0680) and a
MSP-7-like protein (PF13_0193) were up-regulated in both strains. We currently do not
understand why merozoite/invasion-related proteins were up-regulated in both strains
after artemisinin pressure. Our transcriptional analysis also found MSP-1 was the highest
ranked down-regulated gene in D6 and D6.QHS2400x5. Our proteomic studies (above)
found merozoite-related proteins were up-regulated in resistant D6 and W2 compared to
parent strains. Also, other studies found merozoite proteins or transcripts were upregulated in response to an endoperoxide 429 or CQ 432,433. Interestingly the study by
Jiang et al. (2008) 432 found a rhoptry protein was up-regulated at the transcriptional level
in both CQ-resistant (>4-fold) and CQ-sensitive (>11-fold). This study, along with our
results, indicates that drug-susceptible parasites may have a greater need to induce
invasion-related genes, yet some are down-regulated. We also identified up-regulation of
a LAG1-containing protein (encoded by PFE0405c) in D6 and D6.QHS2400x5 (greater
magnitude in resistant parasite; data not shown). LAG1 domain proteins are part of the
LASS (longevity assurance) family of ceramide synthases 452. Deletion of LAG1 in yeast
resulted in increased replication 453, whereas over-expression of LAG1 in yeast had a
bimodal effect on longevity, with moderate expression resulting in increased longevity
and with higher expression curtailing life span 454. Ceramide synthases are important for
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sphingolipid metabolism (proteins that have roles in different eukaryotic cell functions).
Ceramide accumulates in response to cytotoxic agents or stress responses in eukaryotic
cells 455. Recently, a study found that an increase in the intracellular ceramide content
and an activation of parasite sphingomyelinase(s) in P. falciparum were associated with
the parasite death induced by artemisinin and mefloquine 456. Interestingly, PFE0405c is
usually minimally expressed in rings (PlasmoDB), yet it was over-expressed in
transcriptionally arrested dormant rings in our study. Perhaps the observed increased
ceramide content and expression associated with artemisinin treatment is a factor of the
parasite creating a protective stress response. Ceramide metabolism maybe important for
parasite survival as it was found that certain ceramide analogs can inhibit P. falciparum
in vitro 455.
Although we were more interested in genes that were up-regulated in dormancy
(which may be useful for molecular marker studies), down-regulated genes could indicate
ring-stage metabolic pathways that are normally important for progression through the
life cycle (but have been shut down after drug treatment). Notable genes that were downregulated in our transcriptional analysis included PF10_0327 and PF13_0088. These are
genes that encode proteins containing PfMyb domains, which are linked to DNA binding
and regulation of transcription 457. These genes are thought to both be minimally
expressed in late schizonts and maximally expressed in early rings (PlasmoDB).
PF13_0088 has a reported involvement in the transition from trophozoites to schizonts in
P. falciparum, with knockdown inducing mortality at the trophozoite stage 458. This gene
was down-regulated more in the resistant strain compared to the parental strain. It may
be that artemisinin treatment caused inhibition of these proteins, leading to a halt in
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progression of the life cycle. The effect of more down-regulation in D6.QHS2400x5 is
unknown. Interestingly, PF10_0327 is outside of the amplification region we identified
in D6 and W2 QHS-resistant parasites. Our analysis also found genes that encode
proteins involved in nucleic acid binding (PF10_0232, Chromodomain-helicase-DNAbinding protein 1 homolog; PF13_0035, U3_small_nucleolar_RNA-associated protein 6)
were down-regulated. PF10_0232 is normally minimally expressed in gametocytes and
maximally expressed in merozoites, whereas PF13_0035 has minimal expression in
gametocytes/maximal expression in early rings. These genes were down-regulated more
in D6 compared to D6.QHS2400x5. These may be housekeeping genes that were downregulated in response to DHA. We found two genes encoding ubiquitin-related proteins
(PF08_0020, MAL7P1.19) were down-regulated in both PTS and RTS. These proteins
are involved in modifying proteins that are targeted for degradation in parasite
proteasomes. A recent study by Hunt et al. (2010) 342 found that mutations in pcubp-1
(encodes a deubiquinating enzyme) are related to artemisinin resistance. It is expected
that mutations in this gene would lead to reduced de-ubiquitinating activity, having the
effect of increasing ubiquinated proteins destined for degradation. It is proposed that
artemisinin-resistant parasites may increase protein turnover or trafficking (ex. Pfmdr1 or
proteins damaged by oxidative stress) 341,342. We did not find a difference in expression
in parent vs. resistant parasites, and the fact that the genes were down-regulated points
toward protein preservation rather than degradation. Perhaps dormant parasites need to
prevent essential proteins from being degraded during or to maintain a variety of proteins
that are usually not needed if the normal life cycle proceeds. However, a gene in the
chromosome 10 amplification we identified (PF10_0298) in artemisinin resistant D6
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encodes a 26S regulatory proteasome subunit and Prieto et al. (2008) 434 found a 20S
proteasome beta subunit was up-regulated in artemisinin-treated 3D7. This may indicate
that increased protein degradation may be interesting to investigate as a potential
artemisinin-resistance mechanism.
PFF0450c (encodes a Zn+2or Fe+2 permease) was also down-regulated in our
study. This gene is normally minimally expressed in merozoites and maximally
expressed in early rings. The protein is responsible for heavy metal ion transport. We
found the degree of down-regulation of PFF0450c was greater in D6 compared to
D6.QHS2400x5. DHA may have shut down expression of this protein to basal levels for
entrance into dormancy, but it is not clear why it would be much more down-regulated in
D6. Another protein that is involved in heavy metal transport is Pfmdr2, which was
originally thought to be involved in CQ-resistance 402. The initial microarrays we
performed with AL and QHS-resistant W2 (Chapters One, Two) found pfmdr2 was
down-regulated after DHA exposure. The results of transcriptional analysis in D6 and
D6.QHS2400x5 also found pfmdr2 was down-regulated in both parasites (data not
shown). Therefore, heavy metal transport may be a pathway that could be important for
antimalarial drug discovery.
Dihydroartemisinin induces differential expression of genes in artemisinin
resistant and sensitive parasites. In addition to the description of the dormant
transcriptional state and induced/repressed genes associated with it, transcriptional
analysis identified genes that were differentially expressed in D6 vs. D6.QHS2400x5
(Table 3.8). Genes involved in DHA-induced dormancy or QHS resistance could
potentially be up-regulated in resistant parasites during dormancy or only after drug
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treatment. To explore this possibility, the microarray data were analyzed for genes that
were regulated with opposite effects for induction or repression (Table 3.8) in D6 versus
D6.QHS2400x5 synchronized cultures. There was differential regulation of cytochrome
c complex genes, as MAL13P1.55 (cytochrome c2 precursor, up-regulated in
D6.QHS2400x5 vs. D6), PF14_0038 (cytochrome c, putative, up-regulated in
D6.QHS2400x5 vs. D6) and PF10_0252 (cytochrome c oxidase copper chaperone, upregulated D6 vs. D6.QHS2400x5) were differentially regulated between the two strains
after drug treatment. Atovaquone is a known inhibitor of cytochrome bc1 complex of the
electron transport chain in Plasmodium spp., and resistance is mediated by mutations in
cytochrome genes. Artemisinin is also theorized to target mitochondrial function in
Plasmodium spp. 182,183. Unlike ATOV, which creates a loss of membrane potential and
reduction of electron transport chain (ETC) activity, artemisinin does not inhibit the ETC.
Instead, it exerts it effect through mediation of reactive oxygen species (ROS) or ROS
together with some other free radicals as a result of artemisinin reduction 183. A potential
resistance mechanism to artemisinin involving cytochrome genes or other elements of
parasite mitochondria is not described. The up-regulation of genes encoding cytochrome
c complex components in D6.QHS2400x5 seems to implicate mitochondrial function in
artemisinin mechanism of action and/or resistance. Wang et al. (2010) 183 theorized that
the mitochondrial ETC stimulates artemisinin's effect, most likely by activating it, then
the locally generated free radicals disrupt the normal function of mitochondria. Taking
this into consideration, perhaps artemisinin-sensitive and resistant parasites actually
induce artemisinin activity through up-regulation of cytochrome genes. This may cause
parasites to enter dormancy. The fact that D6 only up-regulated one of three
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mitochondria genes may reflect metabolic differences in the dormant states of the two
strains. Two genes that encode zinc finger proteins were differentially expressed after
DHA treatment. These proteins were encoded by PF11_0357 (down-regulated in D6, upregulated in D6.QHS2400x5) and PFC0510w (up-regulated in D6, down-regulated in
D6 .QHS2400x5). These proteins are involved in zinc ion and nucleic acid binding. The
differential expression exhibited in D6 strains may reflect different post-transcriptional
regulatory regimes in the two strains.
Constitutive transcription differences were identified between resistant and
sensitive strains. We also theorized that genetic determinant(s) of dormancy or
resistance may be constitutively up-regulated or down-regulated in the absence of drug
pressure. Indeed, our proteomic and sequencing results using D6 and W2 parasites
resistant to QHS identified putative resistance markers in the absence of drug pressure.
We identified constitutive transcriptional differences in D6 vs. D6.QHS2400x5 (Table
3.9). An important finding of this analysis was the detection of genes within
chromosome 10 that were expressed higher in the resistant strain compared to the parent
strain. These genes exist in the same reason of chromosome 10 that was amplified in
QHS-resistant D6 parasites described above. These genes included PF10_0281,
PF10_0282, PF10_0291, and PF10_0296. Not much is reported about these genes in the
literature. PF10_0281 encodes a merozoite TRAP (thrombospondin-related anonymous
protein) protein that is normally minimally expressed in late rings and maximally
expressed in late schizonts. Therefore, the gene is expressed during merozoite packaging
and down-regulated after invasion of a new RBC. PF10_0282 encodes a conserved
protein of unknown protein that has min expression at early rings and max expression in
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gametocytes. It exhibits similarity to a merozoite TRAP protein in P. chabaudi.
PF10_0291 encodes a RAP protein (rhoptry associated-protein) that has min expression
in gametocytes and max expression in early trophozoites. As discussed above, we found
merozoite proteins were up-regulated in W2.QHS200 vs. W2 and D6.QHS2400x2 vs. D6.
Other studies found merozoite proteins were up-regulated as well with or without
endoperoxide or CQ drug pressure. We found genes encoding MSPs can be highly
down-regulated or moderately up-regulated in both parent and resistant parasites during
dormancy. Perhaps there is a clear reason for merozoite genes to be involved in
dormancy and resistance, or maybe there are redundant pathways involving proteins
encoded by these genes that are necessary for response to artemisinins. Once parasites
have been exposed to artemisinins, these genes may be constitutively expressed for some
time. Maybe this gene has a definitive function in rings exposed to drug, or the gene is
unimportant and just amplified as part of the whole amplicon. PF10_0296 is another
conserved protein with unknown function, with min expression in late trophozoites and
max expression in gametocytes. It exhibits similarity to P. yoelii erythrocyte membrane
protein-3. This protein is unlikely to play a role in drug resistance as it may be related to
PfEMP1 (which is a variable antigen). We do not understand why all of the genes in the
chromosome 10 amplification were not over-expressed in our transcriptional analysis.
Perhaps parasites only up-regulate necessary genes in response to artemisinin as they
enter dormancy. Also, it would have been interesting to see how these genes are
regulated after parasites exit dormancy. Unfortunately, our data analysis has not
progressed to this point.
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Notably missing among our baseline transcriptional differences are other
candidate genes of interest postulated as being associated with artemisinin resistance (e.g.
pfatp6, tctp, pfubp-1), suggesting that if these genes are indeed causative for resistance
they do not exert their effect at the transcript abundance level. However, our analysis
focused on genes regulated before drug addition, so these genes may be expected to be
induced upon drug exposure (we did not find these genes as differentially expressed in
D6 vs. D6.QHS2400x5). Pfmdr1 is linked to MQ and QN resistance, and it is thought to
be associated with artemisinin resistance. Pfmdr1 was down-regulated in
D6.QHS2400x5 compared to D6. This reinforces other data from our lab that showed
this gene is not essential for artemisinin resistance in various parasite lines (Chavchich et
al., 2010; Chen et al, 2010; Tucker et al, unpublished results).
The three data sets we developed may allow particular insight into the progression
of events that occur during dormancy (and maybe resistance) in synchronized
parent/resistant cultures (PTS/RTS). If one focuses on particular genes/functions that we
have described above, there are some that overlap. Zinc finger proteins are involved in
DNA, protein, and zinc ion binding. A gene encoding a zinc finger protein (PF11_0357)
was up-regulated in PTS but down-regulated in RTS before drug exposure. This protein
was also found to be differentially regulated after DHA treatment (down-regulated in
PTS, up-regulated in RTS). Other genes encoding zinc finger proteins were either highly
down-regulated in RTS before drug exposure (PFD0765w, PF10_0273) or differentially
expressed after DHA-treatment (PFC0510w, up-regulated in D6, down-regulated in
D6.QHS2400x5). A gene encoding a Zn+2/Fe+2 permease (PFF0450c) was downregulated in dormancy in PTS and RTS. This may indicate that these types of proteins
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are not required for entrance into dormancy, but are employed in different ways in
response to drug pressure over time. Perhaps resistant parasites have a greater capacity to
up-regulate these proteins and survive. Lysophosopholipases (catalyze hydrolysis of 2lysophosphatidylcholine to glycerophosphocholine and a carboxylate) also were found in
the various data sets. PFI1775w (which encodes a putative lysophospholipase) was upregulated in both PTS and RTS at baseline, but the magnitude of regulation in PTS was
much greater. This gene is maximally expressed in merozoites, normally. A
lysophospholipase (encoded by PF14_0017) was up-regulated in both PTS and RTS
during dormancy (about equal magnitude). This gene is maximally expressed in late
rings, normally. A gene encoding a putative alpha/beta hydrolase (PF10_0020) was also
down-regulated during dormancy in both strains. Interestingly, a lysophospholipase of P.
falciparum was found to exhibit different sensitivities to antimalarial compounds 459.
This study found the enzyme was insensitive to MQ and the artemisinin derivative
arteether, it was weakly inhibited by CQ, and more inhibited by QN. Sulphydryl agents
p-hydroxymercuribenzoate (pHMB) and thimerosal were more potent than QN. When
the sulphhydryl compounds were present at 10 µM prior to invasion, they arrested growth
and re-invasion capacity of P. falciparum in vitro. Application of 5 µM thimerosal to
synchronized parasites dramatically decreased total parasitemia and after 4 days, the
capacity of surviving parasites to re-invade new RBCs was abolished. An important
question to ask based on this study and our data is if inhibition of the enzyme leads to
arrest after drug treatment, why are the genes up-regulated? Perhaps lysophospholipases
are necessary during invasion and in the early part of the life cycle. These enzymes may
also be necessary for entrance into dormancy. It is not clear why the parental parasite up-
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regulated PFI1775w so much. Like PfTrxR, plasmodial lysophospholipase may represent
a new target for anti-malarial chemotherapy that should be explored further.
A recurring theme in the data sets was the differential regulation of genes
involved in DNA replication, transcription, splicing, and translation. Genes encoding
proteins involved in DNA replication (PF10_0232, PFF1225c, PFL0580w, PFD0470c)
were down-regulated in PTS and RTS, yet some of these were up-regulated in RTS
(PF10_0232, PFF1225c) before DHA exposure. One of these (PF10_0232) was downregulated in PTS and RTS during dormancy. A gene encoding a DNA helicase
(PFI0480w) was down-regulated in dormancy in PTS and RTS. A gene encoding a
DNA-replication factor gene (PFA0545c) was down-regulated in D6 vs. D6.QHS2400x5
after DHA treatment. PFF0510w (encodes a histone protein) was up-regulated in PTS
and RTS in dormancy. Another histone-binding protein (encoded by PF14_0314) was
up-regulated after DHA treatment (D6.QHS2400x5 vs. D6). These data may indicate
that proteins of DNA replication machinery are unnecessary in both PTS and RTS during
dormancy, but histone proteins are still needed for accessing DNA. A reason separating
parent and resistant parasites in this regard is not clear. For transcription related genes,
PF11_0477 (encodes CCAAT-box DNA binding protein subunit B) was down-regulated
in PTS and RTS at baseline. During dormancy, PF14_0374 (encodes a putative CCAAT
binding transcription factor) was down-regulated in both PTS and RTS. Again,
transcription may not be important for rings at baseline, and during dormancy, a majority
of it is probably shut down. However, PF14_0469, which encodes a putative
transcription factor IIIb subunit was up-regulated in both PTS and RTS at baseline.
PlasmoDB lists its maximum expression in early rings, so maybe this protein is
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responsible for expressing early ring-stage proteins, and artemisinin drove this gene into
maximum efficiency.
A group of genes involved in RNA metabolism/processing was also present in the
data sets. Before drug pressure, PFF0100w (encodes a putative ATP-dependent RNA
Helicase) was down-regulated in PTS, but up-regulated in RTS. Also, PF13_0077
(encodes a putative DEAD box helicase) was up-regulated in PTS, but down-regulated in
RTS before DHA was added. PF10_0214, which encodes a putative RNA binding
protein, was up-regulated in both strains before DHA was added. During dormancy, a
few genes were down regulated in both D6 and D6.QHS2400x5. These included genes
encoding RNA binding proteins (PFI0820c, PF08_0086, PF13_0058), a u5 small nuclear
ribonucleoprotein specific protein (PFD1060w), and a putative cleavage stimulation
factor subunit 1-like protein (PFF1000w). After DHA was added, PFF0100w was upregulated in PTS, but down-regulated in RTS. PFL1200c, which encodes a putative
splicing factor 3b subunit, was down-regulated in PTS and up-regulated in RTS after
DHA was added. These results imply that the two strains differentially regulate these
proteins before and during DHA pressure. Perhaps there is redundancy in these pathways,
enabling selection of different proteins in strains. Importantly, genes of this class were
down-regulated in dormancy. This again indicates that nucleic acid machinery is
unnecessary during dormancy. Interestingly, the expression profile of PFF0100w in the
two strains changed from baseline to dormancy. The up-regulation in PTS while in
dormancy may indicate that particular helicase is important for artemisinin-sensitive
parasites. Another interesting point is that PF10_0294 (encodes a RNA helicase), which
is part of the chromosome 10 amplification in QHS-resistant D6 and W2, did not appear
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in our data analysis. Perhaps this gene is not as important as other helicase genes for the
resistant parasite or this gene is unimportant (just appears that way because of overall
amplicon).
The genes we found that encode translation-related proteins were mostly downregulated in both PTS and RTS in all our data sets. At baseline, a region that is antisense
to PF08_0018 (which encodes a translation initiation factor), was more down-regulated in
RTS. MAL8P1.27 (encodes a putative translation initiation factor IF-3) was also downregulated in both strains, but much more in PTS. The same was true for PFF0205w,
which encodes a putative mitochondrial ribosomal protein L41 precursor. During
dormancy, MAL7P1.93 (encodes a putative mitochondrial ribosomal protein S8
precursor) and PFD0770c (encodes a putative 60S ribosomal protein L15) were downregulated in both strains. After DHA treatment, PF07_0079 (encodes a putative 60S
ribosomal protein L11a) was down-regulated in PTS, but up-regulated in RTS. These
data substantiate the repression of DNA replication and transcription described above, as
protein machinery is probably unnecessary before drug and during dormancy. The fact
that protein machinery is active in RTS may indicate that resistant parasites are ramping
up proteins for exit from dormancy to progress through the life cycle. Interestingly, we
found DHA not only affected cytosolic translation genes, but also those involved in
mitochondrial translation. Therefore, artemisinins appear to affect mitochondria in other
ways then the proposed mechanism described above.
Our results are significant because other than the study by Witkowski et al. (2010)
360

, there is no previous molecular description of any growth arrest state in the cell cycle

of the malaria parasite. This remains true even despite multiple attempts to disturb the
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IDC with a variety of drugs and perturbations 441,442,460. This transcriptional arrest was
induced by DHA in both W2 and D6 in this study and in numerous P. falciparum strains
in previous studies (362; Kyle unpublished data), making it unlikely to be a strain-specific
phenomenon. We knew that parental and resistant parasites enter dormancy and we
hypothesized that transcription would be arrested at the ring stage. We found that ringstages of both D6 parasites enter dormancy with an arrested transcriptome, which refutes
the suggestion of Witkowski et al. (2010) 360 that only resistant parasites enter a dormant
state following exposure to artemisinin. Furthermore, our data provide evidence that
DHA-exposed parasites do not become dormant or arrest transcription at any other time
in the erythrocytic cycle other than ring stage. Again, we had already morphologically
confirmed this (Chapter One) but we had not molecular data to substantiate it.
Interestingly, expression of a select set of genes during dormancy provides unique insight
into cell cycle regulation and may introduce new strategies for antimalarial combination
therapy. More investigation into the nature and mechanisms of entry and exit from into
this dormancy state is merited, particularly in relation to our understanding of cell cycle
control mechanisms and new strategies for ACTs.
In the broader context our results describe the time course of induction of
dormancy that may prove very clinically relevant for better dosing schedules of ACTs
and provide some kinetic data for epidemiological predictions about the acquisition and
geographic spread of resistance. In addition, the differentially expressed genes in
dormant parasites and in QHS resistant parasites may serve as novel molecular markers
for monitoring drug efficacy and emergence of resistance in the field. Given the recent
emergence of clinically relevant resistance, confirmation of dormancy in vivo and
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correlation of the dormant parasite transcriptome provide new avenues to understanding
artemisinin resistance, which is the most pressing public health problem for malaria
control and elimination efforts.
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D6.QHS2400x3/D6

W2.QHS200/W2

Figure 3.1. 2-D DIGE of D6.QHS2400x3/D6 and W2.QHS200/W2 Identified Potential
Spots Representing Differentially Expressed Proteins. Separate gels were run for parent
and resistant parasites and different dyes labeled parent or resistant parasite proteins in
each comparison. The dyes have different excitation wavelengths (red vs. green for
resistant vs. parent) enabling two excitation images to be produced, then merged to
determine overlapping proteins of interest. For the D6 series, 29 potential protein spots
were identified, whereas 33 were identified for the W2 series. Thirteen spots were picked
from each gel for further analyses.
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Figure 3.2. Artemisinin Microarray Experimental Design. D6 (clone C11) and
D6.QHS2400x5 (clone C9) were expanded into both highly synchronous ring stage
cultures as well as asynchronous (mixed) stage cultures. When the synchronous cultures
were approximately at 8 hours post-invasion, 200 ng/ml DHS was added to half of each
culture (purple arrow). Six hours later, DHA was washed out (orange arrows). Untreated
controls were treated with DMSO and it was washed out 6 hours later (grey arrows). The
tick marks for each culture indicate samples hybridized against pool RNA on the
microarray. The figure here only shows a limited amount of time points. Untreated
cultures were discontinued after 48 hours, but treated/mixed cultures were followed up to
151 hours and treated/synchronized cultures were followed to 189 hours.
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A.

B.

Figure 3.3. Analysis of Spots From 2D-DIGE Reveals Differentially Regulated Proteins
for D6.QHS2400x3 vs. D6. The ratio of proteins expressed in resistant/parental strains
was determined for D6.QHS2400x3/D6. Computer analysis measured protein peaks and
ratios were calculated. An example of down-regulation (A.) and up-regulation in
D62400x3/D6 (B.) is displayed. Each panel shows a particular protein spot from the gel,
with D6 on left and D6.QHS2400x3 on right. Spot 1594 (A.) had decreased ratio of 1.53
in the resistant vs. parent parasite, whereas spot 2300 (B.) had increased ratio of 2.05 in
the resistant parasite. Surrounding protein peaks looked similar in the protein pairs.
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A.

B.

Figure 3.4. Analysis of Spots From 2D-DIGE Reveals Differentially Regulated Proteins
for W2.QHS200 vs. W2. The ratio of proteins expressed in resistant/parental strains was
determined for W2.QHS200/W2. Computer analysis measured protein peaks and ratios
were calculated. An example of down-regulation (A.) and up-regulation in
W2.QHS200/W2 (B.) is displayed. Each panel shows a particular protein spot from the
gel, with W2 on left and W2.QHS200 on right. Examples of differential regulation are
spot 439 (A.), which was decreased 2.75 fold in W2.QHS200 compared toW2, whereas
spot 788 (B.) was increased 1.88 fold in the resistant parasite. For the W2 series (Fig.
3.3), examples of differential regulation are spot 439, which was decreased 2.75 fold in
W2.QHS200 compared toW2, whereas spot 788 was increased 1.88 fold in the resistant
parasite.

291

A.
4.0

292

Average Copy Number Relative to D6

3D7
3.5

D6

3.0

D6.QHS80
D6.QHS120

2.5
D6.QHS200
2.0

D6.QHS300x2

1.5

D6.QHS340x3

1.0

D6.QHS2400x2
D6.QHS2400x4

0.5
0.0

D6.QHS2400x5

B.

293

Average Copy Number Relative to D6

4.0
3.5
3.0
2.5
2.0
1.5

3D7
W2
W2 (clone D7)
W2.QHS200

1.0
0.5
0.0

W2.QHS200x2

C.
2.0

294

Average Copy Number Relative to D6

1.8
1.6
1.4
1.2
1.0

3D7

0.8

TM91c235

0.6
0.4
0.2
0.0

TM91c235.AL240x2
TM91c235.AL280x2

D.

295

Average Copy Number Relative to D6

2.0
1.8

Cambodia 3
Cambodia 5

1.6

Cambodia 6
1.4

Cambodia 8

1.2

Cambodia 10
Cambodia 18

1.0

Cambodia 26
Cambodia 32

0.8

Cambodia 33

0.6

Thai 3

0.4

Thai 6

0.2
0.0
PF10_0275

PF10_0279

PF10_0292

PF10_0294

PF10_0295

PF10_0296

Figure 3.5. Chromosome 10 Genes are Amplified in Artemisinin-Selected D6 and W2
Strains. Average copy number of chromosome 10 genes (for PF10_0275 to PF10_0300)
in D6 lines (A.), W2 lines (B.), TM91c235 lines (C.), and Cambodia-Thai isolates (D.)
relative to D6. Each QPCR copy number assays was performed at least twice (except for
Thai-Cambodia assays, only performed once). Standard deviation is shown as error bars.
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Figure 3.6. D6.QHS2400x5 Recrudesces Before D6 After Exposure to 200 ng/ml
Dihydroartemisinin. D6 recovery assay prior to microarray study. Highly synchronous
clonal parental D6 (clone C11) and resistant D6.QHS2400x5 (clone C9) were exposed to
200 ng/ml DHA for 6 hours, then drug was washed out with RPMI. (A.) Parasitemia
counted from thin smears including dead, dormant, and normal parasites for all strains.
(B.) Percentage of normal/total parasites counted for all strains. (C.) Representative
photomicrographs of D6 and D6.QHS2400x5 parasites through 120 hours post-drug. (D.)
Percentage of dormant/total parasites counted for all strains.
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Figure 3.7. Pilot Microarray Experiment With W2 Strains Shows Dihydroartemisinin
Arrests Ring Stage Parasites. W2 was treated with 100 nM DHA for 6 hours, then drug
was washed out. RNA was isolated from parasites after 6 and 27 hours post-drug
exposure. The heat map has a gradient of color correlation of W2 parasites compared to
a reference intraerythrocytic development cycle (IDC) transcriptome of HB3 (see text).
The color gradient ranges from yellow to blue, which corresponds to high to low
correlation with the HB3 transcriptome (see below Figures). The right side of the map
indicates time points within the IDC (0-48 hours). There is a majority of yellow shading
in the areas corresponding to 12-13 hours post-invasion, indicating that at 6 and 27 hours
post-drug, parasites had a transcriptome that resembled ring-stage.
300
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Figure 3.8. Dihydroartemisinin Arrests Ring Stages in D6 Parental and Resistant
Parasites and D6.QHS2400x5 Exits Dormancy Before D6. D6 (clone C11) and
D6.QHS2400x5 (clone C9) were treated with 200 ng/ml DHA for 6 hours, then drug was
washed out. RNA was isolated from parasites at T0 and time points beyond 100 hours
post-drug exposure. Microarrays were performed with experimental and pooled
reference RNA. The heat map has a gradient of color correlation of D6 parasites
compared to a reference intraerythrocytic development cycle (IDC) transcriptome of HB3
(see text). The top of each heat map has time points from the experimental time course.
The right side of the map is divided into two 0-48 cycles that indicates time points within
the IDC (0-48 hours). The color gradient ranges from yellow to black (+0.8-0.0
correlation) and black to light blue (0.0 to -0.8 correlation), which corresponds to high to
low correlation with the HB3 transcriptome. There is a majority of yellow shading in the
areas corresponding to 12-13 hours post-invasion of experimental samples, indicating
that at 6 and 27 hours post-drug, parasites had a transcriptome that resembled ring-stage.
Panels A and B show Parent Untreated and Parent Treated cultures, respectively. Panels
C and D show Resistant Untreated and Resistant Treated cultures, respectively. In panels
A and C, there is progression from rings-schizonts through the 0-48 hour cycle indicated
by high correlation (yellow) of experimental time points and corresponding time points
within the HB3 IDC (and low correlation where time points do not correspond [i.e. 6
hours yellow for rings, but also blue in later times]). In panels B and D, there is high
correlation for experimental samples at ring stage (8-11 hours post invasion), indicating
arrest of the transcriptome after DHA treatment. In panel D, there is evidence of the
resistant parasite exiting dormancy before the parent (panel B) as the heat map changes at
68 hours post invasion.
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Figure 3.9. During Transcriptome Analysis, D6.QHS2400x5 Recrudesced Before D6 and
a Greater Percentage of Normal Parasites Were Present After Dormancy. Parasitemia
calculations from array experiment with clonal D6 parent and resistant strains. (A.)
Three independent counts for untreated groups for hours 0-48 post-drug. PUM (Parent
Untreated Mixed), PUS (Parent Untreated Synchronized), RUM (Resistant Untreated
Mixed), RUS (Resistant Untreated Synchronized). (B.) Three independent counts for
treated groups for hours 0-48 post-drug, then two counts for hours 57-117, then one count
for time points after 117 hours post-drug. PTM (Parent Treated Mixed), PTS (Parent
Treated Synchronized), RTM (Resistant Treated Mixed), RTS (Resistant Treated
Synchronized). PTM and RTM groups were terminated after 153 hours post-drug (over 6%
parasitemia in each). (C.) Percentage of dead-dormant/total parasites for parental and
resistant mixed-treated groups. (D.) Percentage of dead and dormant parasites/normal
parasites for parental and resistant synchronized-treated groups. (E.) Percentage of
normal/total parasites for parental and resistant synchronized-treated groups.
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Figure 3.10. Dihydroartemisinin Causes a Convergence on a Ring-like Transcriptome in
Asynchronous D6 Strains. D6 (clone C11) and D6.QHS2400x5 (clone C9) were treated
with 200 ng/ml DHA for 6 hours, then drug was washed out. RNA was isolated from
parasites at T0 and time points up to 48 hours post-drug exposure. The heat map has a
gradient of color correlation of D6 parasites compared to a reference intraerythrocytic
development cycle (IDC) transcriptome of HB3 (see text). The top of each heat map has
time points from the experimental time course. The right side of the map is divided into
two 0-48 cycles that indicates time points within the IDC (0-48 hours). The color
gradient ranges from yellow to black (+0.8-0.0 correlation) and black to light blue (0.0 to
-0.8 correlation), which corresponds to high to low correlation with the HB3
transcriptome. There is a majority of yellow shading in the areas corresponding to 12-13
hours post-invasion, indicating that at 6 and 27 hours post-drug, parasites had a
transcriptome that resembled ring-stage. Panels A and B show Parent Untreated and
Parent Treated cultures, respectively. Panels C and D show Resistant Untreated and
Resistant Treated cultures, respectively. In panels A and C, there is progression from
rings-schizonts through the 0-48 hour cycle indicated by high correlation (yellow) of
experimental time points and corresponding time points within the HB3 IDC (and low
correlation where time points do not correspond [i.e. 6 hours yellow for rings, but also
blue in later times]). In panels B and D, there is high correlation for experimental
samples at ring stage, indicating arrest of the transcriptome after DHA treatment. It
appears that the arrest occurred later in the parent (22 hours post-invasion) compared to
the resistant parasite (9 hours post-invasion).
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Table 3.1. Oligonucleotides Used for Sequencing and Real-Time QPCR
Primer Name
Sequence 5'-3'
Source/Reference
Sequencing
PF13_0238 seq1-F
new
GGAAGTAGTAGCGAGAATGATTC
This work
PF13_0238 seq1-R
new
CGTACTCTTTCCATTTCTAGTTCT
This work
PFF0275c seq1-F
PFF0275c seq1-R

TGATAAGATACTAGAGGCCATTG
TCATCCTCAACCATTAATATAGC

This work
This work

PFF0275c seq3-F
PFF0275c seq3-R

GGTTGAGGATGATTCTTATATGA
CATCTAAATCATACTCATCTCCA

This work
This work

PFF0275c seq4-F
PFF0275c seq4-R
Real-Time QPCR

CATTTGGTAAGTTACGATGATGT
CATTCATAACATCGGAACATATC

This work
This work

LDH-T1F

AGGACAATATGGACACTCCGAT

LDH-T1R

TTTCAGCTATGGCTTCATCAAA

Chavchich et al.,
2010 276
Chavchich et al.,
2010 276

PF10_0275 rt-2F
PF10_0275 rt-2R

CAAATGGAAAGACGCAATACC
CGTTCCAGTTATCCATCCAGA

This work
This work

PF10_0277F
PF10_0277R

TTTTTGAGGAAGCCTTTCTTTT
GCTGGAAAAATAACCGCAAA

This work
This work

PF10_0278F
PF10_0278R

TTTCACTGAAGACGCCATGA
TTCTTGTAGCTTGGGAGGTTG

This work
This work

PF10_0279F
PF10_0279R

ATCCGGCAAATTCTCACATC
GGAAGCGAAAAACCATAACG

This work
This work

PF10_0285F
PF10_0285R

TGAACAAACCGAAAAAGGAA
AGGGAGATATGTCCAGAAGGTG

This work
This work

PF10_0286F
PF10_0286R

GCCATTTCATCCATTTCGTT
CAACTTGAAGGATTTTCGTTCC

This work
This work

PF10_0292F
PF10_0292R

CTACATTGGAAGATATGGTTAATCT This work
TATAATTTAATAGAGCCGAAACATT This work
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Table 3.1 Continued
Primer Name
Sequence 5'-3'
Real-Time QPCR
PF10_0294 rt-2F
CGTCCTGAATATCCACCTGAA
PF10_0294 rt-2R
TCACACTCTGCATTTCTGACG

Source/Reference
This work
This work

PF10_0295 rt2-F
PF10_0295 rt2-R

GTAGAGACTTGGACACAACGA
AAGCTTCAGGACATACAGATG

This work
This work

PF10_0296F
PF10_0296R

AACATTTTCACGCGACTTCC
TGTGCGTTTTGCTCCAATAA

This work
This work

PF10_0299F
PF10_0299R

TTCATTGCATCCTTGATTGG
AATGCACCCTCACCAGGATA

This work
This work

PF10_0300 rt-1F
PF10_0300 rt-1R

CACAATATGGGAAAGGTACTGCT
TCATAATTTGCCCACACAGC

This work
This work
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Table 3.2. Spots Identified in Proteomic Analyses in D6 and W2 Strains with Indicated
Differential Expression
Protein
ID
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

Spot No.
107
129
54
140
780
788
795
913
1108
1276
1233
1197
1209
1224
1310
1656
1781
1730
1648
1594
2300
2310
2237
2343
2384
2414
2428
2477
2831

Ratio:
D6.QHS2400x3/D6
-1.51
-1.52
-2.14
-1.52
-1.56
-1.53
-1.55
-1.51
-1.53
1.63
-1.18
1.02
1.02
1.02
-1.32
-1.41
1.56
1.57
1.54
-1.53
2.05
2.00
1.53
1.24
1.70
1.56
1.74
1.76
-1.13

Protein
ID
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

310

Spot No.
95
206
281
424
439
571
712
719
721
724
849
788
1221
1230
1234
1236
1185
1365
1349
1717
1939
1960
2210
2213
2214
2360
2254
2306
2417
2413
2602
2776
2822

Ratio:
W2.QHS200x2/W2
1.43
2.00
1.51
1.68
-2.75
1.51
1.57
1.57
1.50
1.52
1.62
1.88
-1.24
-2.14
-1.62
-1.95
-1.38
1.38
-1.57
-1.00
-1.51
-1.51
-1.55
-1.72
-1.66
-1.56
-1.46
1.34
-1.58
-1.87
1.54
1.32
1.28

Table 3.3. Differentially Expressed Proteins in D6.QHS2400x3/D6 and W2.QHS200/W2
D6.QHS2400x3/D6
Protein MW

Protein PI

Peptide
Count

Expression
Ratio

Protein Score C.I.%

PF11_0098

PlasmoDB Name
Endoplasmic reticulumresident calcium binding
protein

39396.6

4.45

20

-1.41

100

PFI0265c

RhopH3

104789.2

6.25

20

1.57

100

PF14_0425

Fructose-bisphosphate aldolase
Conserved Plasmodium
protein, unknown function

40079.9

8.33

14

-1.53

100

24682.6

5.49

4

1.74

100

PlasmoDB Name
Heat shock protein 70 (HSP70)
homologue
Merozoite surface protein 1
precursor (MSP-1)

Protein MW

Protein PI

Peptide
Count

Expression Ratio

Protein Score C.I.%

72343

5.18

21

1.62

100

87991.8

8.13

16

1.88

100

Actin I
Merozoite Surface Protein 7
precursor (MSP-7)

41828.1

5.27

18

1.38

100

41298.1

4.71

8

1.54

100

PlasmoDB ID
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PFI1270w

W2.QHS200/W2
PlasmoDB ID
PFI0875w
PFI1475w
PFL2215w
PF13_0197

Table 3.4. Whole Genome Sequencing Produced a Preliminary Set of Single Nucleotide Polymorphisms in D6 and D6.QHS2400x2

D6 Base

D6.QHS
2400x2
Base

# D6
Reads

#D6.QHS
2400x2
Reads

312

D6 % SNP

D6.QHS
2400x2
% SNP

Plasmo DB ID

Description

C

C

T

59

31

100.0%

100.0%

PF13_0238

Glu->Lys

86

30

98.8%

100.0%

PFC0320w

G

86

3

98.8%

100.0%

PFD0900w

C

G

74

18

98.6%

94.4%

PFF0275c

T

T

C

68

15

98.5%

100.0%

PFE1155c

13

G

G

A

56

16

98.2%

100.0%

MAL13P1.298

1

A

A

G

12

13

66.7%

84.6%

PFA0675w

13

C

C

G

15

3

66.7%

100.0%

MAL13P1.316

kelch protein, putative
conserved Plasmodium protein,
unknown function
conserved Plasmodium protein,
unknown function
nucleoside diphosphate kinase,
putative
mitochondrial processing
peptidase alpha subunit, putative
conserved Plasmodium
membrane protein, unknown
function
RESA-like protein with DnaJ
domain, putative
conserved Plasmodium protein,
unknown function

3

A

A

T

4

A

A

6

C

5

3

G

G

T

4

10

50.0%

100.0%

PFC0770c

Asp->Glu

9

G

G

A

10

10

50.0%

90.0%

PFI0495w

14

T

C

T

12

7

58.3%

100.0%

PF14_0031

kinesin-like protein, putative
conserved Plasmodium protein,
unknown function
conserved Plasmodium protein,
unknown function

14

T

G

T

3

11

66.7%

100.0%

PF14_0404

13

A

T

A

4

5

75.0%

100.0%

PF13_0254

3

A

T

A

17

9

70.6%

100.0%

PFC1125w

14

T

G

T

72

84

58.3%

98.8%

PF14_0081

1

T

C

T

61

28

80.3%

96.4%

PFA0315w

14

C

T

C

58

11

98.3%

90.9%

PF14_0419

7

C

T

C

11

8

63.6%

87.5%

MAL7P1.102

8

A

C

A

45

58

53.3%

86.2%

MAL8P1.335

7

A

G

A

8

6

62.5%

83.3%

MAL7P1.170

Chrom

3D7
Base

13

D6 AA change

D6.QHS2400x2
AA change

Asn->Ile
Arg->Gly
Asp->His
Ser->Gly

Gly->Asp
Lys->Glu
Thr->Arg

Asp->Asn
Asn->Asp

TRAP-related protein
conserved Plasmodium
membrane protein, unknown
function
hypothetical protein, conserved
in P. falciparum

Ile->Ser

DNA repair helicase, putative
conserved Plasmodium protein,
unknown function
conserved Plasmodium protein,
unknown function
conserved Plasmodium protein,
unknown function
hypothetical protein, conserved
in P. falciparum
Plasmodium exported protein,
unknown function

Asp->Ala

Ile->Lys
Met->Leu

Cys->Arg
Val->Met
Gly->Asp
Ser->Arg
Asn->Asp

Table 3.4 Continued
D6 Base

D6.QHS
2400x2
Base

# D6
Reads

#D6.QHS
2400x2
Reads

G

A

G

10

7

T

C

T

6

C

T

12

G

3

A

Chrom

3D7
Base

8

D6 % SNP

D6.QHS
2400x2
% SNP

Plasmo DB ID

16

60.0%

81.3%

MAL8P1.335

22

21

54.5%

81.0%

MAL7P1.30

C

10

15

70.0%

80.0%

PFF0770c

A

G

4

10

75.0%

80.0%

T

A

3

5

66.7%

80.0%

D6 AA change

PFL1370w

Description
hypothetical protein, conserved
in P. falciparum
conserved Plasmodium protein,
unknown function
conserved Plasmodium protein,
unknown function
NIMA-related protein kinase,
Pfnek-1

PFC0485w

protein kinase,putative

Asn->Ile

Val->Ile
Asn->Ser
Asp->Asn
Trp->Stop

D6.QHS2400x2
AA change
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Table 3.5. Reduced List of Single Nucleotide Polymorphisms in D6 vs. D6.QHS2400x2.
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3D7 Base
G
C
A
T
C

D6 Base
G
C
A
T
C

D6.QHS2400(x2)
Base
A
T
T
C
G

D6 Coverage
68
76
98
83
82

D6.QHS2400(x2)
Coverage
22
36
41
27
24

D6 %
SNP
97
100
99
98
97

D6.QHS2400(x2) %
SNP
100
100
100
100
95

PlasmoDB_ID
MAL13P1.298
PF13_0238
PFC0320w
PFE1155c
PFF0275c

D6.QHS2400x2
AA-change
Gly->Asp
Glu->Lys
Asn->Ile
Ser->Gly
Asp->His

Table 3.6. Confirmation of Single Nucleotide Polymorphisms for D6 vs. D6 QHSResistant Progeny and 3D7/D6 vs.D6 QHS-Resistant Progeny.
Strain
PF13_0238
3D7
D6
D6 (clone C11)
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x4 C9
D6.QHS2400x5 C9

Nucleotide
D6 vs. 3D7 AAA-ACA (Lys-Thr)
at 1726463
A
C
C
C
C

D6 vs. D6.QHS2400 GAA-AAA
(Glu-Lys) at 1726407
G
G
G
A
A
A
A

W2

A

W2 (clone D7)

A

G

W2.QHS200

A

W2.QHS200x2 clone C5

A

PFF0275c-3
3D7
D6
D6 (clone C11)
D6.QHS2400x2
D6.QHS2400x4
W2

D6 vs. 3D7 AAA-AAG (Lys-Lys)
at 229836
A
G
G
G
G
A

PFF0275c-4
3D7
D6
D6 (clone C11)
D6.QHS2400x2
D6.QHS2400x4
W2

D6 vs. 3D7 AAA-CAA (Lys-Gln)
at 229481
A
C
C
C
C
A

PFF0275c-1
3D7
D6
D6 (clone C11)
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x4 C9
D6.QHS2400x5 C9

D6 vs. D6.QHS2400 GAT-CAT (Asp-His) at 230387
G
G
G
C
C
C
C

315

Table 3.7. List of Genes That are Either Up-Regulated or Down-Regulated in Both D6 and D6.QHS2400x5 During Dormancy

316

PlasmoDB ID

Description

PFI1475w
PF13_0276
PFF0450c
PFI0820c
PF13_0161
PF13_0198
PF11_0115
PFD0110w
PFE1400c
PF11_0291
PF08_0086
PF11_0267
PFB0305c-b
PF14_0252
PF08_0127
PF10_0242
PFI1470c
PFL1090w
MAL7P1.141
PFD0100c
PFL2235w

merozoite_surface_protein_1_precursor
membrane-associated_histidine_rich_protein_2__(MARHP2)
Zn2+_or_Fe2+_permease
RNA_binding_protein__putative
conserved_Plasmodium_protein__unknown_function
reticulocyte_binding_protein_2_homolog_A
conserved_Plasmodium_protein__unknown_function
reticulocyte-binding_protein_homologue_1
beta_adaptin_protein__putative
conserved_Plasmodium_protein__unknown_function
RNA_binding_protein__putative
kelch_protein__putative
PFB0305c-a
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
glideosome-associated_protein_45
conserved_Plasmodium_protein__unknown_function
surface-associated_interspersed_gene_4.1__(SURFIN4.1)
conserved_Plasmodium_protein__unknown_function
Chromodomain-helicase-DNAbinding_protein_1_homolog__putative
conserved_Plasmodium_protein__unknown_function
U3_small_nucleolar_RNA-associated_protein_6__putative
WD_domain__G-beta_repeat-containing_protein
neutral-sphingomyelinase_activation_factor_protein__putative
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function

PF10_0232
MAL13P1.268
PF13_0035
PFE1270c
PF11_0252
PF10_0179
PFF1295w

PTS
induction

RTS
induction

-4.0122758
-3.7714916
-3.1865042
-2.9411938
-1.9201665
-2.0618474
-3.2893106
-2.6834671
-2.8350515
-2.7022322
-3.0253363
-2.1881948
-1.1988956
-3.1564417
-2.4889283
-2.7487976
-2.0585974
-2.5617122
-1.9417168
-2.4074047
-2.6613861

-3.3474765
-1.1615676
-1.6664611
-1.7712682
-2.75545
-2.5750461
-1.2928555
-1.6734861
-1.4857174
-1.6080137
-1.2537849
-2.0906963
-3.0547098
-1.0424037
-1.6180217
-1.3016852
-1.9859202
-1.4119216
-2.0233553
-1.5015648
-1.2286429

-2.4074828
-2.3809854
-2.2029116
-1.772013
-2.234824
-2.2681419
-2.2753111

-1.4622105
-1.4654799
-1.6331854
-2.0598109
-1.5588927
-1.5091625
-1.4903569

Table 3.7 Continued

317

PlasmoDB ID
PF13_0091
PF08_0107
PFF1000w
PF13_0233
PFE0280c
PFD1060w
PF13_0058
PFL1235c
PFI1480w
PF10_0022
PF10_0180
PF14_0753
PF14_0201
PFL2225w
PF14_0374
PFE1250w
PF11_0218
PFE0320w
PF14_0308
PFB0145c
PF08_0003
MAL8P1.132
PF14_0578
PF10_0021
MAL7P1.19
PF13_0278
PFF0505c
MAL7P1.19
PFI1725w
PFI1180w

Description
conserved_Plasmodium_protein__unknown_function
erythrocyte_membrane_protein_1__PfEMP1
cleavage_stimulation_factor_subunit_1-like_protein__putative
myosin_A
conserved_Plasmodium_membrane_protein__unknown_function
u5_small_nuclear_ribonucleoprotein-specific_protein__putative
RNA_binding_protein__putative
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
Plasmodium_exported_protein_(PHISTc)__unknown_function
conserved_Plasmodium_protein__unknown_function
Plasmodium_exported_protein_(hyp13)__unknown_function
surface_protein__Pf113
myosin_A_tail_domain_interacting_protein
CCAAT-binding_transcription_factor__putative
acyl-CoA_synthetase__PfACS10
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
Kid_domain_containg_protein
tryptophan/threonine-rich_antigen
kinesin-like_protein__putative
conserved_Plasmodium_protein__unknown_function
Plasmodium_exported_protein_(PHISTc)__unknown_function
ubiquitin_transferase__putative
ran-binding_protein__putative
conserved_Plasmodium_protein__unknown_function
ubiquitin_transferase__putative
Plasmodium_exported_protein__unknown_function
patatin-like_phospholipase__putative

PTS
induction
-2.4429398
-2.6416198
-2.5973208
-1.7689914
-2.4344461
-2.5395158
-2.3498467
-2.6150319
-1.7485015
-2.3255101
-2.3178622
-2.1774114
-1.9919416
-1.9138166
-1.9621271
-2.0509691
-1.450218
-1.919224
-2.2109622
-1.6270989
-1.824834
-2.1945282
-2.0242004
-1.7513504
-2.0289881
-2.0315616
-1.5631063
-1.5027399
-1.0496104
-1.4538159

RTS
induction
-1.313989
-1.0811586
-1.0891824
-1.9009532
-1.2145255
-1.1089365
-1.2967036
-1.0292664
-1.8639976
-1.2869174
-1.251799
-1.3547956
-1.5215274
-1.5688659
-1.5079823
-1.4040629
-2.003737
-1.5266028
-1.2212551
-1.7895704
-1.5731558
-1.1771417
-1.3260126
-1.5687649
-1.2388211
-1.2259204
-1.6522202
-1.7102344
-2.1457842
-1.7365574

Table 3.7 Continued
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PlasmoDB ID
PF08_0137
PFD0385w
PF10_0244
PF10_0233
PFL0290w
PFI0685w
PF10_0327
PFI0095c
PF11_0111
PFC0700c
PF14_0223
PFD0835c
PFL0380c
MAL13P1.26
PF13_0088
PFI0700c
PFE1160w
PFF1005w
PF13_0215
PF10_0078
PFD1145c
MAL7P1.150
PFI1480w
PFI0480w
PFB0735c
PFD0770c
PF08_0020
PFD0290w
PFE1525w
PFD0830w

Description
Plasmodium_exported_protein_(PHISTc)__unknown_function
conserved_Plasmodium_protein__unknown_function
formin_2__putative
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
pseudouridylate_synthase__putative
Myb2_protein
Serine/Threonine_protein_kinase__FIKK_family
asparagine-rich_antigen
conserved_Plasmodium_protein__unknown_function
cyclophilin__putative
LETM1-like_protein__putative
tRNA_delta(2)-isopentenylpyrophosphate_transferase__putative
conserved_Plasmodium_protein__unknown_function
Myb1_protein
met-10+_like_protein__putative
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
histone_deacetylase__putative
reticulocyte-binding_protein_homologue_5
cysteine_desulfurase__putative
conserved_Plasmodium_protein__unknown_function
helicase_with_Zn-finger_motif__putative
conserved_Plasmodium_protein__unknown_function
60S_ribosomal_protein_L15__putative
Ubiquitination-mediated_degradation_component__putative
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_membrane_protein__unknown_function
bifunctional_dihydrofolate_reductase-thymidylate_synthase

PTS
induction
-1.65873
-1.7089599
-2.0759703
-1.9969651
-1.8251526
-1.839536
-1.5376157
-1.6836756
-1.5844931
-1.3806204
-1.5090967
-1.6133704
-1.5937552
-1.3559142
-1.0794496
-1.1615767
-1.7797424
-1.7195485
-1.6799098
-1.4841942
-1.1785154
-1.335683
-1.1419108
-1.4058756
-1.2763977
-1.2456682
-1.3515606
1.11542411
1.20835854
1.13848086

RTS
induction
-1.5218798
-1.4128193
-1.0308301
-1.0961442
-1.2248395
-1.2002081
-1.5017474
-1.2985878
-1.3962718
-1.5249683
-1.3956387
-1.2512641
-1.2358461
-1.46311
-1.7325195
-1.6284459
-1.0057264
-1.0444659
-1.080074
-1.2667114
-1.5710186
-1.3941081
-1.5050727
-1.2216186
-1.2850339
-1.2713336
-1.0947258
1.4730496
1.45335541
1.42145005

Table 3.7 Continued
PlasmoDB ID
PFB0680w
PF11_0128
PF13_0193
PF14_0073
PFA0395w
PFA0045c
PFI0385c
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PFA0650w
PFA0130c
MAL7P1.144
PF10_0020
MAL7P1.93
MAL13P1.470
PF11_0178
PF08_0001
PF14_0014
PF14_0017
PFC0360w
PF14_0438
PF14_0010
PF14_0180
PFF0510w
PF14_0183
PFI1170c
PFE0065w

Description
rhoptry_neck_protein_6
coq4_homolog__putative
MSP7-like protein
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
rifin
P1_nuclease__putative
surfaceassociated_interspersed_gene_pseudogene__(SURFIN)_pseudogene
Serine/Threonine_protein_kinase__FIKK_family__putative
Serine/Threonine_protein_kinase__FIKK_family
alpha/beta_hydrolase__putative
mitochondrial_ribosomal_protein_S8_precursor__putative
Plasmodium_exported_protein_(PHISTa)__unknown_function
conserved_Plasmodium_protein__unknown_function
Plasmodium_exported_protein__unknown_function
Plasmodium_exported_protein__unknown_function
lysophospholipase__putative
Activator_of_Hsp90_ATPase_homolog_1-like_protein__putative
conserved_Plasmodium_protein__unknown_function
glycophorin_binding_protein_family__Gbph
conserved_Plasmodium_protein__unknown_function
histone_H3
signal_recognition_particle__RNP__putative
thioredoxin_reductase
skeleton binding protein

PTS
induction
1.47303785
1.09236079
1.34046932
1.43318706
1.0216813
1.82509264
1.18473999

RTS
induction
1.19186476
1.10857838
1.32447335
1.72749487
1.82159222
1.14030954
1.74250712

1.43675223
1.63592879
1.495712
1.17075642
2.21703878
1.22671687
1.01390863
1.87317625
2.27287928
2.85952559
2.65478733
3.66638406
4.25363192
3.25933916
2.34188341
4.42940995
4.52840343
7.36566368

1.2129938
1.04883918
1.62882184
1.9159615
1.05482928
1.9985018
2.54695928
2.18749991
1.89517329
2.87223754
2.85218388
3.09545633
2.63414777
1.99953729
2.88776901
1.30698912
3.16225001
3.92378486

Table 3.8. List of Genes That are Differentially Expressed in D6 vs. D6.QHS2400x5 During Dihydroartemisinin Treatment
PlasmoDB ID
PF10_0252
PFD1150c
PF14_0735
PFI0975c
PFA0545c
PF11_0277
PFL2520w

320

No_ORFs
PFF1365c
PF14_0223
MAL8P1.92
PF07_0104
MAL13P1.7
PF14_0748
MAL7P1.17
PFF0100w
Multiple_ORFs
MAL7P1.171
PFC0510w
MAL13P1.309
PFB0320c
PFL0170w
MAL8P1.88
PFI1210w
MAL13P1.347
PFL2425w
PFD0400w
PFF0445w

Description
cytochrome_C_oxidase_copper_chaperone__putative
reticulocyte_binding_protein_homolog_4__Rh4
probable_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
replication_factor_c_protein__putative
conserved_Plasmodium_protein__unknown_function
reticulocyte-binding_protein_3_homologue
Control oligonucleotide to bifunctional dihydrofolate reductasethymidylate synthase(PFD0830w)
HECT-domain_(ubiquitin-transferase)__putative
cyclophilin__putative
ATPase__putative
kinesin-like_protein__putative
stevor
Plasmodium_exported_protein_(PHISTa)__unknown_function
conserved_Plasmodium_membrane_protein__unknown_function
ATP-dependent_RNA_Helicase__putative
pseudogene, P. falciparum-specific conserved gene family
Plasmodium_exported_protein__unknown_function
RING_zinc_finger_protein__putative
14-3-3_protein__putative
iron-sulfur_assembly_protein__putative
transporter__putative
conserved_Plasmodium_protein__unknown_function
conserved Plasmodium protein, unknown function
conserved_Plasmodium_protein__unknown_function
Adaptor related_protein_complex3__sigma_2_subunit__putative
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function

PTS
induction
1.63394168
1.9377158
1.70526971
1.72431216
1.94485287
1.9377158
0.65468142

RTS
induction
-1.7293658
-1.4167447
-1.6320825
-1.3863866
-1.0753358
-1.0548411
-2.323381

0.67189034
1.57410936
1.3192684
1.50061036
0.62914432
1.30543002
1.17385331
1.13018205
0.80114659
0.61496969
0.26711822
0.6922195
0.72930869
0.68211151
0.23021723
-0.6801625
-0.7885322
-0.4784996
-0.7182482
-0.9010357
-0.9945471

-2.1428645
-1.0059598
-1.2303327
-1.0117397
-1.8820465
-1.1642392
-1.2542606
-1.0386957
-1.2366027
-1.313552
-1.5967097
-1.1445609
-1.0252043
-1.0227192
-1.1489961
1.21307621
1.1218441
1.43249509
1.24491283
1.06660293
1.04164774

Table 3.8 Continued
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PlasmoDB ID
PFE1110w
PFL1200c
PF14_0540
PFL0430w
PF14_0314
MAL13P1.182
MAL13P1.55
PFF0175c
PFA0475c
PFE0175c
PF14_0100
PFB0095c
MAL13P1.68
MAL13P1.184
PF13_0136
PF11_0035
PFF0375c
PFD0545w
PF14_0038
PF11_0506
PF08_0044
PFC0695w
PF07_0079
PF10_0373a
PFF1260c
PF11_0357
PF11_0273
PF14_0121

Description
conserved_Plasmodium_protein__unknown_function
splicing_factor_3b_subunit__putative
conserved_Plasmodium_protein__unknown_function
tim10_homologue__putative
chromatin_assembly_factor_1_P55_subunit__putative
conserved_Plasmodium_protein__unknown_function
cytochrome_c2_precursor_putative
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
unconventional_myosin_pfm-b
cytidine_triphosphate_synthetase
erythrocyte_membrane_protein_3
peptidyl-prolyl_cis-trans_isomerase__putative
endopeptidase__putative
conserved_Plasmodium_protein__unknown_function
Plasmodium_exported_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
cytochrome_c__putative
Antigen_332__DBL-like_protein
protein_kinase_1
conserved_Plasmodium_protein__unknown_function
60S_ribosomal_protein_L11a__putative
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
zinc_finger_protein__putative
DNAJ_protein__putative
conserved_Plasmodium_protein__unknown_function

PTS
induction
-0.9369856
-0.9027705
-0.8054582
-0.7165572
-0.90478
-1.1691074
-0.7657609
-0.677744
-0.7498068
-1.2942585
-1.2958324
-0.5538473
-1.2144687
-0.8838423
-1.467772
-0.8038536
-1.1385198
-0.6997264
-1.4735048
-1.8903742
-1.840588
-0.8798918
-1.1331181
-2.0389976
-1.7398095
-1.7087687
-1.6011369
-1.8520665

RTS
induction
1.1071453
1.21178864
1.34564343
1.45290844
1.27814226
1.01649465
1.50796717
1.60759531
1.55514139
1.02248954
1.13885037
1.94036823
1.28329682
1.62952572
1.06456325
1.8773292
1.56913753
2.09387722
1.37974371
1.01385261
1.08346417
2.09127396
1.94007221
1.11186685
1.54249857
1.86705495
2.72544016
2.62650345
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PlasmoDB ID
PFI0900w

Description
conserved_Plasmodium_protein__unknown_function

mean PTS0
& PUS0
-0.0646314

MAL7P1.29
PFC1016w
PFF1260c
No_ORFs
PFD0765w
PF14_0751
PFC0820w
PFD0820w
No_ORFs
No_ORFs
PF14_0224
No_ORFs
No_ORFs
PF10_0337
No_ORFs
PFC0911c
PFD0470c
PFE1300w
PF10_0184
PF11_0357
PFI1390w
PF10_0273
PFI1465w
PFE0680w
PF11_0481
No_ORFs
MAL13P1.178

conserved_Plasmodium_membrane_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
antisense to PF08_0018 UTR Translation initiation factor
RING_zinc_finger_protein__putative
acyl-CoA_synthetase__PfACS1b
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
conserved Plasmodium protein, unknown function
yeast control oligonucleotide
serine/threonine_protein_phosphatase
antisense to PF10_0195 kinesin, putative intron
between mal7p1.82 and 83 conserved proteins
ADP-ribosylation_factor-like_protein
near Pfmc-2TM family pseudogene
conserved_Plasmodium_protein__unknown_function
replication_factor_a_protein__putative
conserved_Plasmodium_membrane_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
zinc_finger_protein__putative
conserved_Plasmodium_protein__unknown_function
DHHC-type_zinc_finger_protein__putative
procollagen_lysine_5-dioxygenase__putative
conserved_Plasmodium_protein__unknown_function
tubulin-tyrosine_ligase__putative
hypothetical protein
conserved_Plasmodium_protein__unknown_function

-0.3215103
-0.5151719
3E-09
-0.2947815
-0.3461112
-0.1443899
-0.5173232
-0.7258251
1.86835596
-0.2853273
-0.3362127
0.06635125
-0.3931467
2.15116404
-0.7331872
0.04864858
-0.2168114
-1.0024005
-0.2168114
1.29373122
-0.2780029
-0.2025324
-0.2561681
-0.4772346
0.36991925
-2.6196428
-0.4618822

mean RTS0
& RUS0
-5.7004397

Residual Resistant0.7478Parental0.2228
-5.4293083

-5.7004397
-5.7004397
-5.0874629
-4.7004397
-4.7004397
-4.0874629
-4.10147
-4.2329872
-2.2329872
-3.7004397
-3.7004397
-3.3939513
-3.7004397
-1.7935491
-3.8939513
-3.3089888
-3.5025004
-4.0874629
-3.440506
-2.280108
-3.440506
-3.3785116
-3.3785116
-3.5437314
-2.8930848
-5.1164005
-3.4902738

-5.2372143
-5.0923941
-4.8646629
-4.2572021
-4.2188178
-3.7566881
-3.4918158
-3.4674153
-3.4073438
-3.2642719
-3.2262198
-3.2207688
-3.1836446
-3.1793896
-3.1228739
-3.1225682
-3.1175688
-3.1150678
-3.0555744
-3.0247602
-3.0098154
-3.0042579
-2.9641491
-2.9640554
-2.9469104
-2.9346316
-2.9220783
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PlasmoDB ID
MAL7P1.92
PF11_0186
PFC0820w
PF11_0480
No_ORFs
PFD0462w
PF07_0096
No_ORFs
PF11_0359
No_ORFs
PF13_0233
No_ORFs
PF10_0139
PFB0423c
PFE0635c
MAL13P1.114
No_ORFs
PF14_0384
No_ORFs
PFE1060c
MAL13P1.301
PF14_0506
PFL1575w
PFC0415c
PF13_0077
No_ORFs
PF13_0204
MAL7P1.162
PFC0525c

Description
cysteine_repeat_modular_protein_2__putative
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
sporozoite_asparagine-rich_protein
outside PF14_0013 DNAJ protein
DNAJ_protein
conserved_Plasmodium_protein__unknown_function
hypothetical, plastid encoded
coatomer_delta_subunit__putative
antisense to PF14_0363 metacaspase-like protein
myosin_A
antisense to PF14_0392 serine/threonine protein kinase, putative
conserved_Plasmodium_protein__unknown_function
conserved_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
intron of PFL0115 dynein heavy chain, putative
allantoicase__putative
between PFD0560w and PFD0565c conserved and DEAD box ATPdependent RNA helicase, putative
conserved_Plasmodium_protein__unknown_function
guanylyl_cyclase
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
DEAD_box_helicase__putative
no orfs Chr 7
nuclear_movement_protein__putative
dynein_heavy_chain__putative
glycogen_synthase_kinase_3

mean PTS0
& PUS0
-0.3505549
0.23341
-0.4558458
-0.0687128
-0.9109185
-0.0687128
-0.1111962
-0.2473205
-0.1524273
-0.5184184
1.94005742
1.9574395
-0.4854268
-1.0171739
-0.6549277
-0.2969818
-0.2969818
-0.3318821

mean RTS0
& RUS0
-3.3939513
-2.940506
-3.440506
-3.1154772
-3.7407754
-3.0874629
-3.1154772
-3.1977926
-3.1154772
-3.3785116
-1.5305147
-1.5025004
-3.3089888
-3.6821591
-3.4092341
-3.0874629
-3.0874629
-3.0874629

Residual Resistant0.7478Parental0.2228
-2.9090064
-2.89225
-2.8768245
-2.8412938
-2.8367906
-2.8132795
-2.8095247
-2.7900463
-2.778692
-2.7680383
-2.7584896
-2.7434736
-2.7231866
-2.6987165
-2.6966792
-2.6425799
-2.6425799
-2.6164815

1.58496247
-1.083601
-0.2223924
-0.5368742
-0.4730434
-0.4427537
0.48906271
0.03316683
3E-09
-0.4850652
-0.7483934

-1.6280313
-3.60147
-2.940506
-3.1642355
-3.1154772
-3.0899234
-2.3827674
-2.7004397
-2.7004397
-3.0437314
-3.2329872

-2.5904662
-2.5683532
-2.5514009
-2.539961
-2.5389354
-2.5360321
-2.5256885
-2.5024418
-2.4776397
-2.4581997
-2.4505387
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PlasmoDB ID
PF14_0121
PFC0910w
No_ORFs
MAL7P1.100
No_ORFs
PF14_0155
MAL7P1.29
PF14_0458
PFD0520c
PF10_0254
PF14_0529
PFD0260c
PF14_0298
No_ORFs
PF11_0477
PFI0130c
PFI1100w
PF11_0506
PFD0872w
PFA0685c
PFE1150w
PFD0595w
PFC0950c
PFI0490c
PFL1135c
PFI1775w
PF14_0180
PF10_0390
PF14_0706
PFB0615c

Description
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
succinyl-CoA synthetase alpha subunit, putative
protein_kinase
near PFD0310w sexual stage-specific protein precursor
serine_C-palmitoyltransferase__putative
conserved_Plasmodium_membrane_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
gamma-adaptin__putative
sequestrin
conserved_Plasmodium_membrane_protein__unknown_function
antisense near PFD1105w asparagine-rich protein
CCAAT-box_DNA_binding_protein_subunit_B
Plasmodium_exported_protein_(PHISTb)__unknown_function
para-aminobenzoic_acid_synthetase
Antigen_332__DBL-like_protein
conserved_Plasmodium_protein__unknown_function
Plasmodium_exported_protein_(hyp4)__unknown_function
multidrug_resistance_protein
conserved_Apicomplexan_protein__unknown_function
peptidase__putative
ran-binding_protein__putative
conserved_Plasmodium_protein__unknown_function
lysophospholipase__putative
conserved_Plasmodium_protein__unknown_function
Pfmc-2TM_Maurer's_cleft_two_transmembrane_protein
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function

mean PTS0
& PUS0
1.58496245
-0.579436
-0.6198218
-0.5849625
-0.6064969
-0.6300807
-0.2433511
-0.2223924
-0.6713773
-0.4668244
0.41083136
-0.4852214
-0.3459389
-0.5946128
-2.0703893
-0.2355217
-0.3030627
-0.1744104
-0.5589514
-0.5318474
-0.4829498
-1.2660624
-0.7948818
-0.0339474
-0.1074898
4.06263989
-0.4954719
-0.3629125
0.19264508
0.17441797

mean RTS0
& RUS0
-1.4775063
-3.0945348
-3.1154625
-3.0874629
-3.10147
-3.1154772
-2.8089888
-2.7655348
-3.0874629
-2.9266355
-2.2699875
-2.9378391
-2.8318325
-3.0165075
-4.1154772
-2.7406511
-2.7699875
-2.6645618
-2.940506
-2.8930848
-2.8502199
-3.4351722
-3.0720232
-2.5025004
-2.5305147
0.59633267
-2.8089888
-2.7004397
-2.280108
-2.280108

Residual Resistant0.7478Parental0.2228
-2.4399412
-2.4384326
-2.4291597
-2.4272279
-2.4251317
-2.4215028
-2.4042109
-2.3764297
-2.362607
-2.3547442
-2.3544072
-2.3521906
-2.3503394
-2.3490561
-2.3444401
-2.341728
-2.3205573
-2.3113377
-2.2997222
-2.2725693
-2.26627
-2.2656108
-2.2548106
-2.2543145
-2.2273338
-2.2189094
-2.2156749
-2.2062537
-2.201368
-2.1877377
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PlasmoDB ID
PF11_0178
MAL13P1.301
PFL0045c
PFF0470w
PF13_0068
PF11_0342
PFE0540w
MAL7P1.162
PFL1645w
PFD0380c
MAL8P1.201
No_ORFs
MAL8P1.56
PF14_0406
PF08_0077
No_ORFs
PFI1145w
PFL0580w
PFF1120c
PFF0100w
PF14_0469
PFI1725w
PFL0205w
PFI1330c
PFB0150c
PFD0505c
PFI1180w
PFL1260w
PFB0161c
PFE1245w

Description
conserved_Plasmodium_protein__unknown_function
guanylyl_cyclase
Plasmodium_exported_protein_(PHISTc)__unknown_function
conserved_Plasmodium_protein__unknown_function
mitochondrial_ribosomal_protein_S35_precursor__putative
conserved_Plasmodium_protein__unknown_function
WD-repeat_protein__putative
dynein_heavy_chain__putative
conserved_Plasmodium_protein__unknown_function
conserved Plasmodium protein, unknown function
conserved_Plasmodium_protein__unknown_function
hypothetical protein
conserved_Plasmodium_membrane_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
GDP-mannose_4_6-dehydratase__putative
utr PFEMP1 pseudogene PFD1025w
MAC/Perforin__putative
DNA_replication_licensing_factor_MCM5__putative
conserved_Apicomplexan_protein__unknown_function
ATP-dependent_RNA_Helicase__putative
transcription_factor_IIIb_subunit__putative
Plasmodium_exported_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
protein_kinase__putative
protein_phosphatase__putative
patatin-like_phospholipase__putative
hydrolase_/_phosphatase__putative
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function

mean PTS0
& PUS0
-1.1265426
-0.140845
-0.4641745
-0.5212085
-0.260833
-0.6933999
0.06196615
0.52793152
2.36815108
-0.7495042
0.05781447
-1.0699652
-0.5260842
0.2175914
0.17186854
0.24616055
0.55101513
-0.2468585
-2.7655348
-0.5620567
1.52558879
2.53908099
-0.3250665
0.16046462
-1.774903
1.78722095
0.4681265
-0.6713773
-2.1523262
-2.2911138

mean RTS0
& RUS0
-3.2329872
-2.4902738
-2.7276535
-2.7512502
-2.5437314
-2.8646437
-2.2795419
-1.9175379
-0.5274436
-2.8502199
-2.2329872
-3.0720232
-2.6480247
-2.0874629
-2.10147
-2.0437314
-1.7935491
-2.3827674
-0.2620813
1.3867653
2.94888774
3.71492819
1.57634713
1.94260428
0.50325664
3.17168764
2.19288728
1.34635626
0.25835824
0.16066936

Residual Resistant0.7478Parental0.2228
-2.1677587
-2.1621499
-2.1577438
-2.1386905
-2.1258805
-2.1233192
-2.1030802
-2.0895251
-2.075547
-2.0669406
-2.0534209
-2.0491033
-2.031819
-2.0273777
-2.0071933
-2.0050103
-1.9827982
-1.9753666
2.0287856
2.02987128
2.03085245
2.03900342
2.04223187
2.04540883
2.05332914
2.05800381
2.06562228
2.0712122
2.0906678
2.09676425
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PlasmoDB ID
MAL8P1.27
PF11_0375
PFF1225c
MAL13P1.106
PFL0795c
PF11_0114a
MAL13P1.184
PFE0570w
PFD0320c
PF13_0161
MAL13P1.333
PFC0110w
PF11_0291
PFF0575c
PFB0790c
PF14_0589
PF14_0588
PFD0310w
PF14_0457
PFF0205w
PF14_0034
PF10_0214
PFL1530w
PFA0110w
PFB0105c
PFE1595c
PF13_0209
PFL1055c
PFD0310w
PF13_0173

Description
translation_initiation_factor_IF-3__putative
conserved_Plasmodium_protein__unknown_function
DNA_polymerase_1__putative
probable_protein__unknown_function
male_development_gene_1
conserved_Plasmodium_protein__unknown_function
endopeptidase__putative
RNA_pseudouridylate_synthase__putative
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
Cytoadherence_linked_asexual_protein_3.2
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_membrane_protein__unknown_function
valine-tRNA_ligase__putative
conserved_Plasmodium_protein__unknown_function
sexual_stage-specific_protein_precursor
conserved_Plasmodium_protein__unknown_function
mitochondrial_ribosomal_protein_L41_precursor__putative
translocation_associated_membrane_protein__putative
RNA_binding_protein__putative
asparagine-rich_protein__putative
DNAJ_protein__putative
Plasmodium_exported_protein_(PHISTc)__unknown_function
Plasmodium_exported_protein_(PHISTc)__unknown_function
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_membrane_protein__unknown_function
sexual_stage-specific_protein_precursor
conserved_Plasmodium_protein__unknown_function

mean PTS0
& PUS0
-3.0874629
0.65977888
-0.3048546
0.11119619
0.35418088
-0.3997411
0.92500801
-0.1961587
0.36512953
-0.3992687
0.16046462
-0.426399
-0.2613391
-0.0937293
3E-09
-0.8596559
-0.9668332
3.24522699
-1.5318474
-2.5025004
-0.2969818
2.02023711
1.48390977
0.91753989
1.04402155
-0.6385167
-3.8413023
1.09543797
3.27537595
-2.0730295

mean RTS0
& RUS0
-0.431807
2.37223713
1.65260255
1.97187102
2.15506387
1.59531044
2.6029861
1.79057292
2.22380075
1.65526603
2.07448523
1.63661517
1.77324487
1.91020047
1.98606084
1.38212096
1.30542056
4.45602015
0.9090856
0.1836988
1.86056505
3.60081118
3.20428487
2.78735698
2.88255829
1.63153651
-0.7547266
2.94944632
4.58399656
0.59634593

Residual Resistant0.7478Parental0.2228
2.09979771
2.10165448
2.1033728
2.11151851
2.11300741
2.11703682
2.13406511
2.16006042
2.17355688
2.17663918
2.17728978
2.17827631
2.19147427
2.20309127
2.20886083
2.24777164
2.2512184
2.25203941
2.27740105
2.27786859
2.30544802
2.31287788
2.31741714
2.32402065
2.32463897
2.33181927
2.34059929
2.35307781
2.35747043
2.36935736
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PlasmoDB ID
PF10_0344
PFB0080c
PFI1610c
PF10_0296
PF13_0044
MAL13P1.294
MAL13P1.179
PF10_0232
PF10_0291
MAL7P1.171
PF13_0011
PF10_0282
PFF0640w
PFD0750w
PF10_0281
MAL7P1.162
PF10_0258
PF14_0748
PF14_0745
PFL1750c
PFD1035w
PF14_0631
PFB0090c
PF14_0744
PF11_0512
PF14_0748
PFE1600w

Description
glutamate-rich_protein
Plasmodium_exported_protein_(PHISTb)__unknown_function
calcyclin_binding_protein__putative
conserved_Plasmodium_protein__unknown_function
carbamoyl_phosphate_synthetase
GTP_binding_protein__putative
conserved_Plasmodium_protein__unknown_function
Chromodomain-helicase-DNA-binding_protein_1_homolog__putative
RAP_protein__putative
Plasmodium_exported_protein__unknown_function
plasmodium_falciparum_gamete_antigen_27/25
conserved_Plasmodium_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
nuclear_cap-binding_protein__putative
merozoite_TRAP-like_protein__MTRAP
dynein_heavy_chain__putative
conserved_Plasmodium_protein__unknown_function
Plasmodium_exported_protein_(PHISTa)__unknown_function
probable_protein__unknown_function
conserved_Plasmodium_protein__unknown_function
steroid_dehydrogenase__putative
conserved_Plasmodium_protein__unknown_function
RESA-like_protein_with_PHIST_and_DnaJ_domains
Plasmodium_exported_protein__unknown_function
RESA-like_protein_with_PHIST_and_DnaJ_domains
Plasmodium_exported_protein_(PHISTa)__unknown_function
Plasmodium_exported_protein_(PHISTb)__unknown_function

mean PTS0
& PUS0
-2.6301497
-2.2160956
-2.5025004
-0.0512849
0.48261727
-1.8413023
-0.0104704
-0.774903
-1.2065225
0.86853691
4.69099559
-1.1805723
-4.0874629
-0.7258251
-1.3870232
-3.4262648
0.33688586
-0.5330144
2.41338379
2.54916173
0.18285487
-0.4022042
-2.0515725
-0.0703893
0.59242089
1.51244995
-5.5208296

PFB0085c

DNAJ_protein__putative

-4.4926061

mean RTS0
& RUS0
0.18786174
0.52498734
0.31414296
2.17247954
2.5895819
0.86941592
2.252071
1.70300298
1.44892203
3.01221909
5.88897695
1.50648246
-0.6185779
1.96541455
1.4713164
0.04277077
2.90870579
2.27748852
4.57243739
4.80953225
3.05921348
2.70996978
1.86236541
3.73427736
4.35894658
5.17173284
1.28308453

Residual Resistant0.7478Parental0.2228
2.37748771
2.40498362
2.40831275
2.43363038
2.4514807
2.46914177
2.4827008
2.50527547
2.57395953
2.58552719
2.60385044
2.61211442
2.66082685
2.73098653
2.73133233
2.82773158
2.87958254
2.89887668
2.99050899
3.12606911
3.1452746
3.23353812
3.61933132
4.0097145
4.13873424
4.26352277
5.6343609

2.41346422

5.99583505

Chapter Four:
Summary
During the past three decades, Plasmodium falciparum, the most lethal malaria
parasite infecting humans, has developed resistance to almost every commonly available
antimalarial drug. The emergence and spread of resistance to most antimalarial drugs has
made the effective treatment of malaria difficult, and there is an urgent need for new
antimalarial drugs and drug combinations. The ineffectiveness of drugs such as
chloroquine (CQ), sulfadoxine-pyrimethamine (SP), and mefloquine (MQ) has ushered in
the usage of artemisinin combination therapies (ACTs) as front line therapy where P.
falciparum exists. Although ACTs are very promising tools for treating and controlling
drug-resistant malaria, factors still exist that may serve to continue transmission of drugresistant parasites in endemic countries. These include affordability of drugs, availability
of sub-optimal/counterfeit drug regimens, sociocultural and behavioral barriers, and noncompliance to ACT recommendations. As a consequence of the decreased number of
effective antimalarials and proven vaccine candidates, the WHO has instituted a policy of
disease control rather than eradication. The lack of development of new drugs and
vaccines puts a burden on malaria prevention and control programs in endemic areas,
focusing on bed net distribution, case management, and proper drug regimens.
The development of new antimalarials has been slowed by the lack of financial
incentive and the high cost of effective drugs that must be administered in multi-drug
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resistant areas. Researchers still have a limited view of what occurs at the molecular
level in resistant parasites and these parasites are rapidly becoming the predominant
strains in malaria-endemic areas. Multi-drug therapies have been shown to be effective,
but due to the high cost and the complexity of combining drugs with the correct
pharmacodynamics, many poor countries will continue to use ineffective drug such as
CQ and MQ even in high areas of drug resistance.
Artemisinin (QHS) drugs have been used for the treatment of malaria for
centuries and these drugs are effective against all stages of Plasmodium spp. These drugs
provide rapid clearance of parasitemia and kill gametocytes, making them valuable drugs
for preventing transmission of malaria. ACTs take advantage of artemisinin‟s ability to
rapidly reduce parasite densities to low levels. The two components of an ACT seem to
have a synergistic effect as the artemisinin component reduces the chance that parasites
will be exposed to sub-optimal levels of the longer acting antimalarial, and the longer
acting antimalarial protects artemisinins from selection of a resistant mutant if adherence
is good. Importantly, the partner drug of choice must be one that still is highly
efficacious in a given area. Therefore, combination strategies must be tailored to each
malarious location/drug resistance profile, taking into account if combination drug effects
are potentiating for the area of administration (one of the drugs must be extremely
effective) 163.
Current Reports of Artemisinin Resistance
The use of artemisinins in ACTs has brought about concern that resistance may
potentially occur to this class of crucial antimalarials. Also, despite the implementation
of active malaria-control programs that include ACTs, a very high percentage of
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artemisinin monotherapies are still provided through the private sector (as in Cambodia)
320

. Until recently, clinical resistance to these drugs was not described. Historically, the

area of Southeast Asia and specifically the Thailand-Cambodian border has been a focus
of malaria drug resistance 280,461. Noedl et al. 2008 321 reported on a clinical study in the
western Cambodian province Battambang, which is located on the Thai-Cambodia border.
This study involved the administration of high-dose AS therapy (60 patients) or
quinine+tetracycline (QN+Tet) (34 patients) to patients with uncomplicated P.
falciparum malaria. Artemisinin resistance in patients was defined as: persistence of
parasites 7 days after the start of treatment or reemergence of parasites within 28 days
after the start of treatment; sufficient plasma concentrations of dihydroartemisinin (DHA);
prolonged time to parasite clearance; and reduced in vitro susceptibility to DHA. Two
patients who received AS were classified as having artemisinin-resistant infections,
according to the defined criteria. These patients had parasite-clearance times (PCTs) that
were prolonged (133 and 95 hours vs. 52.2 hours for patients who were cured), and
sufficient plasma drug concentrations after a first dose of drug. For these subjects, the
IC50s of DHA were up to 4 times the geometric mean for cured patients and almost 10
times that for the reference clone W2. The authors suggested that clinical and in vitro
data that allude to artemisinin resistance may not be the result of a sudden change in drug
sensitivity. Importantly, resistance did not appear to be mediated by the number of
copies of pfmdr1 or selected pfatp6 polymorphisms tested in this study. Dondorp et al.
(2009) 320 conducted a clinical trial where efficacies of AS and AS+MQ were determined
for uncomplicated malaria in Pailin, western Cambodia, and Wang Pha, northwestern
Thailand. An important finding was that an overall slower PCT was reported in Pailin for
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both AS monotherapy and AS+MQ (median 84 and 72 hours) compared to Wang Pha
(median 54 and 48 hours). Also, recrudescence occurred in more patients receiving AS
monotherapy in Pailin compared to Wang Pha. The different parasitologic responses
were not explained by differences in drug susceptibility; and again, no mutations,
amplifications, or deletions in pfmdr1 or pfatp6 were present in long clearance time
isolates. The extended period of often-suboptimal use and high use of monotherapy, and
the genetic background of parasites from this region, might contribute to the emergence
and subsequent spread of these new artemisinin-resistant parasites in western Cambodia.
In contrast, artemisinin derivatives have been used almost exclusively in combination
with MQ on the Thai-Burmese border, where parasitologic responses to artemisinins
remain good, even after 15 years of intensive use. Noedl et al., 2009 reported on the use
of a histidine-rich protein assay to assess artemisinin susceptibility in Thailand,
Cambodia, and Bangladesh. Blood samples were obtained from approximately 250
patients who presented with uncomplicated P. falciparum malaria from 2004-2006.
Compared to the reference W2 clone, samples from Eastern Thailand and Cambodia
displayed elevated susceptibility to DHA (as evidenced by IC50). Importantly, the
authors concluded that although these results point to artemisinin resistance, it is unlikely
that artemisinin resistance has spread across Thailand or into Bangladesh. Lim et al.
(2010) 390 also observed a trend of slightly elevated IC50s for QHS, MQ, CQ, and QN in
P. falciparum isolates from western Cambodia (vs. eastern Cambodia). Also, IC50s for
isolates from participants who failed AS+MQ therapy were significantly higher than
those for patients who were cured. In addition, Carrara et al (2009) 286 showed a
longitudinal increase in PCTs from 1995-2007 in northwestern Thailand (AS+MQ was

331

introduced at the Thai-Burmese border in 1995). The study also found AS and MQ
susceptibility increased from 1995-2001, but from 2002-2006, this trend reversed for AS.
However, as of 2007, it appears that AS efficacy has returned to levels before 1995. MQ
IC50s also rose between 2001-2004, but fell again in 2006–2007. In addition, the study
also found an increase in gametocyte carriage of treated patients from 1995-1997. These
data are important because the failing efficacy of AS could not be related to amplification
of pfmdr1 (which is usually associated with MQ resistance). Importantly, the increases in
PCT and concomitant gametocyte carriage may indicate a general failure of artemisinin
for malaria transmission control in this area.
Artemisinin Resistance in This Work
In our studies, we have attempted to characterize potential artemisinin
mechanisms of resistance. Our efforts have resulted in a set of drug resistant parasites
(from different parts of the world) that represent reagents that can be used for studies on
molecular markers of resistance, drug discovery, and cell function/metabolism. We
produced parasites that tolerate clinically relevant levels of artemisinin drugs and a strain
of D6 that tolerated concentrations of QHS that are beyond clinically relevant. By using
different recrudescence assays, we showed resistant D6 and W2 parasites recover faster
than respective parent strains. In vitro susceptibility testing (SYBR Green and
hypoxanthine) showed some separation between artemisinin sensitivity between parent
and resistant strains for some drugs (QHS, AL), but these results still may underestimate
the magnitude of resistance between strains. Other methods of characterization found
growth differences were related to merozoite number in some strains (D6), but not in all.
Through these methods of characterization, we defined an artemisinin resistant phenotype
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which will be useful for future resistance studies. Molecular analyses were performed on
a variety of resistant parasites to investigate putative molecular markers for resistance.
We identified potential molecular markers in D6 and W2 QHS-resistant parasites by
whole genome sequencing (SNPs in D6, chromosome 10 amplification in D6, W2).
Gene amplification was validated in both strains by QPCR, and it was found that the
amplification in D6 resistant strains occurred as early as 80 ng/ml. Interestingly, we did
not find amplifications in chromosome 10 genes in a set of isolates from Cambodia and
Thailand. Future experiments will focus on mining W2 resistant/parental cloned line
sequence data for SNPs (with comparison to D6 data) and determining at what resistance
level SNPs and gene amplifications occurred in both D6 and W2 resistant lines.
Transcriptional analysis also identified some genes that may be important in D6 parent
and resistant strains. The large data set produced from these microarrays justifies further
examination where we will attempt to find particular genes that are important for
resistance during the entire time course we designed. It will be interesting to analyze
artemisinin-induced transcriptional changes in other strains (W2, etc.) in a similar manner
as we did with D6. Also, we will correlate transcriptional changes with earlier
microarrays (low level QHS, AL-resistant W2 lines) and validate transcriptional changes
by RT-QPCR. Finally, we have different sets of field isolates from Thailand and
Cambodia (where artemisinin resistance is thought to be occurring) that are verified as
having reduced susceptibility to artemisinins. It will be interesting to analyze these
isolates for the molecular markers of artemisinin resistance we have identified.
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Dormancy and Resistance
Artemisinins are known to be associated with high rates of recrudescence when
used without a partner drug. We previously showed that ring-stage parasites enter a state
of dormancy after treatment with artemisinin drugs. A hypothesis we proposed is that
artemisinin-induced dormancy may lead to the frequent recrudescence observed in
patients. Dormancy is similar to the post-antibiotic effect where there is a delayed
growth of bacteria after complete removal of an antibiotic 462. Bacteria can remain
susceptible to an antibiotic over multiple exposures, but a degree of tolerance seems to
develop over time. During induction of resistance in the strains we describe, parasites
always entered a dormant state before recovery. We were able to adapt parasites to
increasing amounts of drug by discontinuously applying drug pressure. This indicated
that multiple rounds of parasite exposure to an artemisinin drug, followed by dormancy,
recovery, and growth, selects for parasites with reduced susceptibility to this class of
antimalarial drugs. Based on observations of dormancy and in vitro selection of
artemisinin resistance, it may be possible to implicate dormancy as an artemisininresistance mechanism.
It is tempting to speculate about the nature of artemisinin-induced dormancy as it
relates to an artemisinin resistance mechanism, as some lines of evidence point in this
direction. In the recovery assays we performed, QHS-resistant D6 and W2 strains both
recrudesced before respective parent strains. There was also an associated greater
percentage of dormant/total or dead-dormant/total parasites observed during the time
when most parasites were dormant or dead. Also, the increase in percentage of
normal/total parasites in resistant strains corresponded with the decrease of dormant/total
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or dead-dormant/total parasites. We believe these data given an indication that resistant
parasites are capable of exiting dormancy at a greater rate than parent strains. This may
be because dormant resistant parasites have a higher survival rate from dormancy; if a
greater number of dormant parasites existed in resistant cultures, recrudescence would
occur earlier.
Because artemisinin-exposed parasites enter dormancy and recrudesce over time,
this may not be a true resistance mechanism where parasites would survive levels of drug
without a significant decrease in parasitemia. During induction of resistance in the
strains we describe, parasites always entered a dormant state before recovery. Another
detractor to stating that dormancy is a resistance mechanism is that in vitro susceptibility
testing does not show a dramatic difference for parent vs. resistance strains. Although we
did find differences we believe are significant in resistant parasites for some drugs (QHS,
AL), this was not true for all artemisinin drugs. The reason for this may be that the
SYBR green assay we used is not appropriate for assessing resistance phenotypes. Ring
stage parasites enter dormancy and take an extended time to recover after exposure to
artemisinins, so by assessing viability at 72 hours after drug was added, we did not
capture parasites that recrudesce later. This point is echoed in patient studies that find
prolonged parasite clearance times of parasites but no reduction in IC50, making it
difficult to characterize these parasites as resistant (below). Our laboratory showed that
some population of parasites can withstand greater levels of drug early after drug
treatment, indicating they are unaffected by the drug, or become dormant only to
recrudesce 362. Based on these data, we investigated what may occur during the first 48
hours of artemisinin treatment in both parent and resistant strains (D6 and W2). From
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these hypoxanthine incorporation assays, our studies found that at high levels of DHA,
we were unable to determine a significant difference in recrudescence. However, at
lower levels of artemisinin drugs, resistant parasites tolerate more drug compared to
parental parasites. The greater incorporation of hypoxanthine we observed in resistant
parasites may indicate that a greater number of parasites were unaffected by drug.
Therefore, a greater number of resistant parasites progressed through the life cycle as
normal. The IC50 results indicating this were verified by blood smears. Also, it may be
that a greater percentage of dormant parasites were present after drug exposure. If this is
true, then resistant parasites have the ability to produce a greater number of dormant
parasites and/or exit dormancy faster than parent parasites. Therefore, this may be the
reason that in longer susceptibility assays and recovery assays that artemisinin-resistant
parasites recover at a higher rate than parent strains.
Although our laboratory has characterized dormancy in terms of recovery rates,
morphological observations, and flow cytometry, molecular characterization has not been
performed. Furthermore, studies have not focused on in vitro artemisinin-selected
parasites we generated in the laboratory. Based on the above results, we knew sensitive
and resistant parasites enter dormancy, yet we did not know what may occur at the
transcriptional level in terms of differential gene expression between parasites after drug
exposure. The microarray experiment we performed again found that QHS-resistant D6
recrudesced before the susceptible parent strain, possibly indicating that resistant
parasites are more capable of emerging from dormancy compared to the parent strain.
This was confirmed by morphological and correlogram analysis that showed resistant
parasites exited dormancy before the parental parasites. Perhaps the mechanism of
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resistance involves an increased ability to recover from dormancy following exposure to
drug. During the data analysis of microarray results, we searched for genes up-regulated
in resistant and/or susceptible parasites that might be important during dormancy. A
group of genes were up-regulated in both parent and resistant strains, with PFI1170c
(encoding thioredoxin reductase) being the most interesting gene. This indicated that
both sensitive and resistant parasites may employ similar mechanisms while dormant.
We also searched for differentially regulated genes after drug treatment, and found some
cytochrome genes were up-regulated in resistant vs. parent strains. Unfortunately, this
analysis did not produce obvious mechanisms of resistance that the QHS-resistant D6
parasite might employ. What was more interesting is that of a group of genes expressed
at baseline, a few on chromosome 10 were up-regulated in the resistant parasite compared
to D6. The genes coincided with genes within the amplification we found in D6 and W2
QHS-resistant parasites. Taking these data into consideration, it may be that the drug
selection pressure method we used caused genetic changes in the genome that exist to
resist effects of artemisinin. A key finding from this experiment is that parent and
resistant strains were both arrested after drug exposure, suggesting that dormancy may be
a hallmark of artemisinin treatment, rather than artemisinin resistance as has been
suggested by others 360.
If dormancy is not a true artemisinin-resistance mechanism, it may still play a
critical role in the malaria transmission because parasites may remain in patients for an
increased amount of time. In fact, increased PCTs in patients treated with artemisinin
drugs constitute the bulk of evidence for emerging resistance to artemisinins in the field.
In a study of almost 20,000 patients from different locations in the world with different
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malaria transmission intensities, Stepniewska et al., 2010 395 found that the main factor
affecting PCT in was parasite density on admission. Clearance rates were faster in hightransmission settings and with more effective partner drugs in artemisinin-based
combination treatments (ACTs). This is probably a factor of a greater number of
parasites carried by non-immunes in low-transmission settings 191,463. Perhaps with
increased parasitemia (and a higher dormant parasitemia), PCT becomes greatly
increased in these areas. Noedl et al. (2008) 322 found prolonged PCTs in the two cases
meeting their definition of AS resistance. Dondorp et al. (2009) 320 found resistance in
western Cambodia was characterized by slow PCT in vivo without corresponding
reductions on conventional in vitro susceptibility testing. Wongsrichanalai and Meshnick
(2008) 280 reviewed studies of AS+MQ treatment in Cambodia and Thailand and stated
that clinical and molecular evidence (amplification of pfmdr1) indicate AS+MQ failures
are occurring on the Cambodia–Thailand border. There was an associated extended PCT
in one of these studies from Pailin in 2004 298 where there was reduced efficacy of
AS+MQ. A study by Carrara et al. (2009) 286 found a reduction of PCT in northwestern
Thailand parasite clearance associated with increase in treatment failure rates. Although
they reported higher IC50s for AS from 2002-2006, AS appears to be re-gaining
effectiveness. Therefore, there is dissociation between in vitro susceptibility findings of
AS efficacy and PCT. As stated above, conventional in vitro testing may not be
appropriate for testing tolerance to artemisinins such as AS. Prolonged PCT in endemic
areas may be a result of dormant parasites causing recrudescence of malaria. If
dormancy and recrudescence are related, and parasites with reduced susceptibility to
artemisinin drugs are selected for, then these viable parasites could be responsible for
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increased PCT. Perhaps in resistant parasites, higher numbers of dormant parasites and
faster recovery allows recrudescence, then prolonged PCT could result from more
dormant parasites lasting and not being eliminated.
Utility of Molecular Markers for Field Studies
The use of molecular markers for parasite identification has been a major windfall
for the diagnosis of malaria, and these markers have enabled the detection of drugresistant infections. Some of the major molecular markers identified for antimalarial
resistance include polymorphisms in pfcrt for CQ resistance, polymorphisms in pfmdr1
that modulate resistance to CQ, artemisinins, QN, and MQ, polymorphisms in dhfr/dhps
responsible for pyrimethamine/sulfa drug resistance, and amplification of pfmdr1
responsible for reduced MQ efficacy. Molecular markers have been validated as tools for
surveillance of resistance and they have great value to for public health policy in terms of
controlling epidemics, guiding national malaria treatment policies, and the monitoring of
changes in parasite drug susceptibility (which is integral for making changes in malaria
drug treatment policy) 464. Still, the global P. falciparum drug resistance situation is such
that these molecular markers cannot do anything to preserve drugs that have lost efficacy
such as CQ and SP. As stated above, the ineffectiveness of these drugs, described by
emergence and spread of resistance, has led to recommendations that they be replaced
with ACTs. If the artemisinin resistance reported by the studies above were to spread
from the defined area it is in now, the results would be devastating for malaria control.
An alarming fact is that with the failure of artemisinin drugs, gametocyte carriage would
increase and transmission of resistant parasite would occur before the phenomenon could
be detected. This occurred with SP resistance in Southern Africa, even before any
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discernable effect on cure rates was noticed 465. Several public health strategies to
interrupt the spread and prevent further emergence of artemisinin resistance are under
consideration, and recently a containment program designed to stop the emergence of
artemisinin resistance in western Cambodia and eastern Thailand was formed 466. The
proposed program involves a comprehensive approach, including early diagnosis and
appropriate treatment of malaria, decreasing the drug pressure, optimizing insect vector
control, targeting the mobile population, strengthening disease management and
surveillance systems, and operations research 463. Unfortunately, most countries that
conduct drug resistance surveillance rely only on therapeutic efficacy testing. Although
this is applicable for most national malaria control programs and can identify areas where
intensive drug resistance studies are needed, these tests have limited usefulness as an
early warning system for artemisinin resistance 189. Importantly, at the genetic level,
artemisinin resistance may be multifactorial where an accumulation of genetic changes
leads to resistance (like SP resistance). Therefore, if resistance develops gradually
through sequential mutations and/or gene amplifications, treatment failure may not
manifest until late in this process. Unfortunately, because of the lack of molecular
markers for artemisinin resistance, clinical monitoring may be the most important facet of
the artemisinin resistance containment program. To ensure that the utility of ACTs is not
compromised, the above approach could greatly benefit from reliable markers for
artemisinin resistance. The recent establishment of the World Antimalarial Resistance
Network (WARN) will help integrate molecular markers for resistance with drug efficacy
trials and in vitro susceptibility testing 464. This can help monitor and deter resistance and
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to guide malaria treatment and prevention policies. If markers for ACT or artemisinin are
identified, WARN will include these to help control resistance in real-time.
Because markers linked to artemisinin resistance (pfmdr1, pfatp6, tctp, pfubp-1,
pfcrt) are reported to be unassociated with clinical resistance 320,321,329, there is a dire need
to develop and validate new markers. We believe genes that are amplified on
chromosome 10 may be strong indicators of resistance in certain strains, but not all. We
showed that in vitro QHS-selected parasites from Africa (D6) and Asia (W2) contained
amplified genes, yet resistant progeny of an isolate from Asia (TM91c235) did not have
these amplifications. Also, field isolates from Thailand and Cambodia did not have
genes amplified in chromosome 10 (particularly regions that overlapped with W2,
another parasite from Asia). It remains to be seen if the high-probability SNPs we
detected in D6.QHS2400x2 are found in W2-QHS resistant strains, TM91c235-AL
resistant strains, and any isolates from Thailand and Cambodia. Also, it may be
interesting to see if these putative markers of artemisinin resistance are found in any other
African parasites, as there may be tremendous selection pressure with high ACT use.
The spread of artemisinin resistance could have a devastating effect on global
malaria control efforts. The studies above suggest artemisinin resistance has emerged
and they avoid long-standing arguments over whether potential ACT resistance may
occur as a result of inefficacy of ACT partner drugs. This is demonstrated by longer
PCTs for both ACTs and AS administered as a monotherapy. It is possible that
artemisinin-induced dormancy and re-emergence is responsible for extended parasite
clearance times in patients. Ring-stage parasites of parent and resistant lines seem to
enter dormancy, so perhaps dormancy is not a sole mechanism of artemisinin resistance.
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We hypothesize that induction and selection of artemisinin resistant parasites could
enhance recrudescence rates (i.e., treatment failure) and explain a mechanism where an
increased the proportion of parasites recover from dormancy following the removal of
drug pressure, by decreasing the duration of dormancy, or both. A better understanding
of dormant parasites and their susceptibility to combination drug partners may allow the
design of optimal dosage regimens and help prevent the emergence of resistance to
artemisinins and other new antimalarial drugs in the future. Our studies on molecular
markers for artemisinin resistance may provide an important advance in public health, but
future work is necessary to validate these markers in a variety of isolates to determine
their worth.
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Appendix A: Extra Tables
Table A-1. Summary of Merozoite Characterization for Parental and Resistant Strains

Strain
D6
D6.QHS2400x5

Standard
Mean Deviation
19.3 2.58
16.3 2.24

Min
14
12

Max
24
22

Median
20
16

Mode
18
16

95%
Confidence
Interval
18.6-20.0
15.7-16.9

W2
W2.QHS200x2

15.3
19.7

2.38
2.66

12
14

22
26

15
20

14
20

14.7-15.9
19.1-20.4

TM91c235
TM91c235.AL280x2

20.7
19.7

2.26
2.16

16
16

26
24

20
20

20
18

20.1-21.3
19.1-20.2
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Table A-2. Real Time QPCR Copy Number Results for PFE1050w, PF11_0466, pfmdr2,
and pfmdr1

Strain
PFE1050w
3D7
D6
D6.QHS80
D6.QHS120
D6.QHS200
D6.QHS300x2
D6.QHS340x3
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x5
W2
W2 (clone D7)
W2.QHS200
W2.QHS200x2
TM91c235
TM91c235.AL80
TM91c235.AL240x2
TM91c235.AL280x2
PF11_0466
3D7
D6
D6.QHS80
D6.QHS120
D6.QHS200
D6.QHS300x2
D6.QHS340x3
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x5
W2
W2 (clone D7)
W2.QHS200
W2.QHS200x2
TM91c235
TM91c235.AL80
TM91c2325.AL240x2
TM91c235.AL280x2

Mean
CN

Standard
Deviation

Number
of Assays

95% confidence
interval

1.09
1.00
0.98
1.05
1.05
1.05
0.96
1.05
1.13
0.98
1.07
1.15
1.10
1.12
1.08
1.01
1.12
1.12

0.12
0.01
0.06
0.01
0.01
0.05
0.04
0.05
0.03
0.07
0.16
0.09
0.08
0.09
0.02
0.13
0.03
0.01

5
6
2
2
2
3
2
2
2
3
5
6
5
4
3
2
2
2

0.99
1.00
0.89
1.04
1.03
1.00
0.91
0.98
1.09
0.91
0.93
1.08
1.03
1.04
1.06
0.83
1.08
1.10

1.19
1.01
1.06
1.05
1.07
1.11
1.00
1.11
1.17
1.05
1.20
1.22
1.16
1.21
1.09
1.19
1.16
1.14

1.08
1.00
0.96
1.21
1.10
1.05
1.08
1.20
1.02
0.90
1.10
1.32
1.01
1.11
1.16
1.21
1.00
1.08

0.12
0.01
0.15
0.06
0.12
0.05
0.07
0.04
0.19
0.02
0.17
0.08
0.10
0.01
0.17
0.16
0.08
0.13

5
6
2
2
2
3
2
2
2
3
4
3
3
2
5
3
2
3

0.98
0.99
0.75
1.12
0.93
0.99
0.98
1.14
0.75
0.88
0.93
1.24
0.90
1.10
1.01
1.03
0.89
0.94

1.19
1.01
1.16
1.29
1.26
1.10
1.18
1.26
1.28
0.92
1.27
1.41
1.13
1.11
1.31
1.39
1.10
1.23
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Table A-2 Continued
Strain
pfmdr2
3D7
D6
D6.QHS80
D6.QHS120
D6.QHS200
D6.QHS300x2
D6.QHS340x3
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x5
W2
W2 (clone D7)
W2.QHS200
W2.QHS200x2
TM91c235
TM91c235.AL80
TM91c235.AL240x2
TM91c235.AL280x2
pfmdr1
3D7
D6
D6.QHS80
D6.QHS120
D6.QHS200
D6.QHS300x2
D6.QHS340x3
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x5
W2
W2 (clone D7)
W2.QHS200
W2.QHS200x2
TM91c235
TM91c235.AL80
TM91c235.AL240x2
TM91c235.AL280x2

Mean
CN

Standard
Deviation

Number
of Assays

95% confidence
interval

1.05
1.00
1.06
1.06
1.11
1.06
1.14
1.04
1.22
1.12
0.99
1.20
1.14
1.20
1.00
1.00
1.03
1.16

0.10
0.00
0.10
0.02
0.14
0.15
0.13
0.03
0.07
0.05
0.08
0.11
0.03
0.08
0.08
0.10
0.16
0.16

4
7
3
3
3
3
3
3
3
3
3
4
5
3
4
3
3
3

0.95
1.00
0.95
1.04
0.95
0.89
1.00
1.01
1.14
1.07
0.90
1.09
1.11
1.11
0.92
0.89
0.85
0.98

1.15
1.01
1.17
1.08
1.27
1.24
1.28
1.07
1.30
1.17
1.08
1.30
1.17
1.29
1.08
1.12
1.22
1.34

1.14
1.01
0.99
1.03
1.16
0.96
1.16
1.02
1.03
1.10
1.18
1.21
2.24
2.55
2.20
2.82
3.60
3.56

0.08
0.01
0.09
0.10
0.09
0.00
0.11
0.07
0.09
0.04
0.11
0.10
0.17
0.07
0.17
0.19
0.33
0.13

14
15
3
3
2
2
3
3
3
3
13
9
8
5
7
4
5
3

1.10
1.00
0.89
0.92
1.03

1.18
1.01
1.09
1.15
1.28

1.03
0.94
0.93
1.06
1.11
1.14
2.12
2.49
2.07
2.63
3.31
3.41

1.29
1.10
1.14
1.15
1.24
1.27
2.35
2.61
2.32
3.01
3.88
3.71
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Table A-3. Real Time QPCR Copy Number Results for Chromosome 10 Genes

Strain
PF10_0275
3D7
D6
D6.QHS80
D6.QHS120
D6.QHS200
D6.QHS300x2
D6.QHS340x3
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x5
W2
W2 (clone D7)
W2.QHS200
W2.QHS200x2
TM91c235
TM91c235.AL240x2
TM91c235.AL280x2
Cambodia 18
PF10_0277
3D7
D6
D6.QHS80
D6.QHS120
D6.QHS200
D6.QHS300x2
D6.QHS340x3
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x5
W2
W2 (clone D7)
W2.QHS200
W2.QHS200x2
TM91c235
TM91c235.AL240x2
TM91c235.AL280x2

Number
of
95% confidence
Assays interval

Mean
CN

Standard
deviation

0.983
1.002
1.070
1.015
1.100
1.105
1.070
1.000
1.087
1.070
1.115
1.015
1.110
1.203
1.090
1.100
1.040
0.92

0.128
0.004
0.113
0.049
0.085
0.191
0.089
0.090
0.047
0.101
0.106
0.120
0.057
0.184
0.014
0.071
0.028

4
5
2
2
2
2
3
3
3
3
4
4
4
4
2
2
2
1

0.857
0.998
0.913
0.946
0.982
0.840
0.969
0.898
1.033
0.955
1.011
0.897
1.055
1.023
1.070
1.002
1.001

1.108
1.006
1.227
1.084
1.218
1.370
1.171
1.102
1.140
1.185
1.219
1.133
1.165
1.384
1.110
1.198
1.079

0.965
0.998
1.015
0.977
1.055
1.113
1.145
1.040
1.028
1.065
1.080
1.170
1.215
1.120
1.205
1.055
1.150

0.035
0.004
0.007
0.042
0.035
0.122
0.035
0.014
0.150
0.064
0.014
0.028
0.127
0.014
0.110
0.007
0.053

2
5
2
3
2
3
2
2
4
2
2
2
2
2
4
2
3

0.916
0.994
1.005
0.930
1.006
0.975
1.096
1.020
0.881
0.977
1.060
1.131
1.040
1.100
1.097
1.045
1.090

1.014
1.002
1.025
1.024
1.104
1.252
1.194
1.060
1.174
1.153
1.100
1.209
1.390
1.140
1.313
1.065
1.210
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Table A-3 Continued

Strain
PF10_0278
3D7
D6
D6.QHS80
D6.QHS120
D6.QHS200
D6.QHS300x2
D6.QHS340x3
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x5
W2
W2 (clone D7)
W2.QHS200
W2.QHS200x2
TM91c235
TM91c235.AL240x2
TM91c235.AL280x2
PF10_0279
3D7
D6
D6.QHS80
D6.QHS120
D6.QHS200
D6.QHS300x2
D6.QHS340x3
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x5
W2
W2 (clone D7)
W2.QHS200
W2.QHS200x2
TM91c235
TM91c235.AL240x2
TM91c235.AL280x2
Cambodia 3
Cambodia 5

Mean
CN

Standard
deviation

Number
of
95% confidence
Assays interval

1.020
0.988
1.027
1.063
1.107
1.170
1.035
1.160
0.990
0.947
1.225
1.155
1.125
1.190
1.295
1.240
1.100

0.105
0.027
0.127
0.090
0.118
0.113
0.035
0.042
0.099
0.084
0.007
0.134
0.106
0.069
0.078
0.040
0.070

3
5
3
3
3
4
2
2
2
3
3
3
3
3
2
3
3

0.901
0.964
0.883
0.962
0.973
1.059
0.986
1.101
0.853
0.852
1.217
1.003
1.005
1.112
1.187
1.195
1.021

1.139
1.012
1.170
1.165
1.241
1.281
1.084
1.219
1.127
1.042
1.233
1.307
1.245
1.268
1.403
1.285
1.179

1.086
1.000
2.105
2.165
2.090
2.123
2.120
2.203
2.110
2.020
1.333
1.278
1.233
1.360
1.355
1.393
1.227
1.18
1.27

0.121
0.000
0.338
0.281
0.200
0.155
0.135
0.222
0.190
0.058
0.062
0.073
0.096
0.036
0.035
0.038
0.032

5
7
4
4
3
3
3
3
3
4
5
5
5
5
2
3
3
1
1

0.980

1.192

1.773
1.890
1.864
1.948
1.967
1.952
1.895
1.963
1.278
1.214
1.149
1.328
1.306
1.350
1.190

2.437
2.440
2.316
2.299
2.273
2.454
2.325
2.077
1.387
1.342
1.318
1.392
1.404
1.436
1.263
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Table A-3 Continued

Strain
PF10_0279
Cambodia 8
Cambodia 10
Cambodia 26
Cambodia 32
Cambodia 33

Mean
CN

Standard
deviation

1.32
1.03
1.26
1.28
1.25

Number
of
Assays

95% confidence
interval

1
1
1
1
1

PF10_0285
3D7
D6
D6.QHS80
D6.QHS120
D6.QHS200
D6.QHS300x2
D6.QHS340x3
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x5
W2
W2 (clone D7)
W2.QHS200
W2.QHS200x2
TM91c235
TM91c235.AL240x2
TM91c235.AL280x2

1.045
0.993
1.987
2.217
1.980
2.197
2.295
1.980
2.010
1.995
1.175
1.020
1.165
1.145
1.077
1.060
0.995

0.104
0.016
0.246
0.158
0.159
0.214
0.205
0.014
0.042
0.191
0.148
0.085
0.021
0.049
0.210
0.226
0.205

4
6
3
3
3
3
2
2
2
2
2
2
2
2
3
3
2

0.943
0.980
1.708
2.038
1.800
1.955
2.011
1.960
1.951
1.730
0.969
0.902
1.136
1.076
0.839
0.804
0.711

1.147
1.006
2.265
2.396
2.160
2.438
2.579
2.000
2.069
2.260
1.381
1.138
1.194
1.214
1.315
1.316
1.279

PF10_0286
3D7
D6
D6.QHS80
D6.QHS120
D6.QHS200
D6.QHS300x2
D6.QHS340x3
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x5
W2
W2 (clone D7)

0.985
1.003
1.935
2.110
2.060
2.100
2.070
2.170
2.070
1.820
1.160
1.185

0.110
0.005
0.078
0.057
0.141
0.071
0.283
0.297
0.134
0.081
0.085
0.064

4
2
2
2
2
2
2
2
3
4
2
2

0.877
0.996
1.827
2.032
1.864
2.002
1.678
1.758
1.918
1.740
1.042
1.097

1.093
1.009
2.043
2.188
2.256
2.198
2.462
2.582
2.222
1.900
1.278
1.273
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Table A-3 Continued
Mean
CN

Standard
deviation

Number
of
Assays

1.010
1.143
1.060
1.120
0.945

0.042
0.096
0.014
0.014
0.007

2
3
2
2
2

0.951
1.035
1.040
1.100
0.935

1.069
1.252
1.080
1.140
0.955

PF10_0292
3D7
D6
D6.QHS80
D6.QHS120
D6.QHS200
D6.QHS300x2
D6.QHS340x3
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x5
W2
W2 (clone D7)
W2.QHS200
W2.QHS200x2
TM91c235
TM91c235.AL240x2
TM91c235.AL280x2
Cambodia 3
Cambodia 5
Cambodia 6
Cambodia 8
Cambodia 10
Cambodia 26
Cambodia 32
Cambodia 33
Thai 3
Thai 6

0.994
1.018
2.493
1.985
1.860
2.175
2.175
2.495
2.090
1.930
3.463
2.176
2.970
3.575
1.207
1.133
1.130
1.04
1.13
1.05
1.06
1.16
1.02
1.03
1.07
1.07
1.14

0.062
0.031
0.060
0.136
0.127
0.149
0.150
0.197
0.070
0.136
0.152
0.069
0.184
0.021
0.075
0.131
0.113

5
8
4
4
2
4
4
4
2
4
6
5
2
2
3
3
2
1
1
1
1
1
1
1
1
1
1

0.940
0.996
2.434
1.851
1.684
2.029
2.028
2.302
1.993
1.797
3.341
2.115
2.715
3.546
1.122
0.986
0.973

1.048
1.039
2.551
2.119
2.036
2.321
2.322
2.688
2.187
2.063
3.585
2.237
3.225
3.604
1.292
1.281
1.287

PF10_0294
3D7
D6

1.102
1.002

0.108
0.004

5
6

1.008
0.998

1.196
1.005

Strain
PF10_0286
W2.QHS200
W2.QHS200x2
TM91c235
TM91c235.AL240x2
TM91c235.AL280x2
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Table A-3 Continued

Strain
PF10_0294
D6.QHS80
D6.QHS120
D6.QHS200
D6.QHS300x2
D6.QHS340x3
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x5
W2
W2 (clone D7)
W2.QHS200
W2.QHS200x2
TM91c235
TM91c235.AL240x2
TM91c235.AL280x2
Cambodia 5
Cambodia 33
PF10_0295
3D7
D6
D6.QHS80
D6.QHS120
D6.QHS200
D6.QHS300x2
D6.QHS340x3
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x5
W2
W2 (clone D7)
W2.QHS200
W2.QHS200x2
TM91c235
TM91c235.AL240x2
TM91c235.AL280x2
Cambodia 3
Cambodia 5

Number
of
95% confidence
Assays interval

Mean
CN

Standard
deviation

2.035
1.975
1.975
2.090
2.020
1.977
2.063
1.967
3.045
2.173
2.867
3.070
1.260
1.195
1.140
1.32
1.03

0.049
0.064
0.106
0.042
0.125
0.040
0.153
0.085
0.302
0.085
0.146
0.028
0.014
0.191
0.185

2
2
2
2
3
3
3
3
4
3
3
2
2
2
3
1
1

1.966
1.887
1.828
2.031
1.879
1.931
1.890
1.870
2.749
2.077
2.701
3.031
1.240
0.930
0.930

2.104
2.063
2.122
2.149
2.161
2.022
2.237
2.063
3.341
2.270
3.032
3.109
1.280
1.460
1.350

0.970
1.004
2.000
2.143
1.937
2.040
1.983
2.230
2.220
2.025
1.135
1.147
2.964
3.495
1.065
1.123
1.103
1.01
1.11

0.042
0.009
0.174
0.280
0.137
0.141
0.162
0.279
0.184
0.035
0.021
0.032
0.352
0.007
0.064
0.146
0.121

2
5
3
3
3
3
3
3
2
2
2
3
5
2
2
4
4
1
1

0.911
0.996
1.803
1.826
1.782
1.880
1.800
1.915
1.965
1.976
1.106
1.110
2.656
3.485
0.977
0.979
0.984

1.029
1.012
2.197
2.460
2.091
2.200
2.166
2.545
2.475
2.074
1.164
1.183
3.272
3.505
1.153
1.266
1.221
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Table A-3 Continued

Strain
PF10_0295
Cambodia 8
Cambodia 10
Cambodia 26
Cambodia 32
Cambodia 33

Mean
CN

Standard
deviation

1.05
1.09
1.05
0.91
0.89

Number
of
95% confidence
Assays interval
1
1
1
1
1

PF10_0296
3D7
D6
D6.QHS80
D6.QHS120
D6.QHS200
D6.QHS300x2
D6.QHS340x3
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x5
W2
W2 (clone D7)
W2.QHS200
W2.QHS200x2
TM91c235
TM91c235.AL240x2
TM91c235.AL280x2
Cambodia 3
Cambodia 8
Cambodia 10
Cambodia 26
Cambodia 32

0.985
1.000
2.175
2.270
2.005
2.115
2.165
2.173
2.113
1.967
1.163
1.073
3.068
3.610
1.173
1.200
1.180
1.32
1.29
1.04
0.97
1.08

0.090
0.000
0.106
0.127
0.092
0.120
0.092
0.137
0.116
0.093
0.167
0.085
0.205
0.042
0.131
0.075
0.157

6
7
2
2
2
2
2
3
4
3
4
3
5
2
4
3
3
1
1
1
1
1

0.913

1.057

2.028
2.094
1.878
1.948
2.038
2.019
1.999
1.862
0.999
0.977
2.888
3.551
1.044
1.115
1.002

2.322
2.446
2.132
2.282
2.292
2.328
2.226
2.072
1.326
1.170
3.247
3.669
1.301
1.285
1.358

PF10_0299
3D7
D6
D6.QHS80
D6.QHS120
D6.QHS200
D6.QHS300x2
D6.QHS340x3

0.975
1.002
2.285
2.115
2.210
2.135
2.095

0.068
0.004
0.134
0.007
0.127
0.134
0.049

4
5
2
2
2
2
2

0.909
0.998
2.099
2.105
2.034
1.949
2.026

1.041
1.006
2.471
2.125
2.386
2.321
2.164
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Table A-3 Continued

Strain
PF10_0299
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x5
W2
W2 (clone D7)
W2.QHS200
W2.QHS200x2
TM91c235
TM91c235.AL240x2
TM91c235.AL280x2
PF10_0300
3D7
D6
D6.QHS80
D6.QHS120
D6.QHS200
D6.QHS300x2
D6.QHS340x3
D6.QHS2400x2
D6.QHS2400x4
D6.QHS2400x5
W2
W2 (clone D7)
W2.QHS200
W2.QHS200x2
TM91c235
TM91c235.AL240x2
TM91c235.AL280x2

Mean
CN

Standard
deviation

Number
of
95% confidence
Assays interval

2.260
2.045
1.970
1.250
1.205
1.210
1.150
1.160
1.243
1.125

0.028
0.219
0.028
0.042
0.092
0.127
0.014
0.028
0.090
0.035

2
2
2
2
2
2
2
2
3
2

2.221
1.741
1.931
1.191
1.078
1.034
1.130
1.121
1.141
1.076

2.299
2.349
2.009
1.309
1.332
1.386
1.170
1.199
1.345
1.174

1.000
1.000
1.025
1.040
1.050
1.120
1.015
1.060
1.025
0.990
1.025
1.050
1.145
1.035
1.040
1.075
1.040

0.057
0.000
0.092
0.099
0.071
0.099
0.035
0.000
0.035
0.071
0.007
0.042
0.007
0.021
0.099
0.021
0.014

2
4
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

0.922

1.078

0.898
0.903
0.952
0.983
0.966

1.152
1.177
1.148
1.257
1.064

0.976
0.892
1.015
0.991
1.135
1.006
0.903
1.046
1.020

1.074
1.088
1.035
1.109
1.155
1.064
1.177
1.104
1.060
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